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This book considers mainly etiology, pathogenesis, and pathophysiology of aortic 
aneurysms (AA) and aneurysm rupture and addresses anyone engaged in treatment 
and prevention of AA. Multiple factors are implicated in AA pathogenesis, and are 
outlined here in detail by a team of specialist researchers. Initial pathological events in 
AA involve recruitment and infiltration of leukocytes into the aortic adventitia and 
media, which are associated with the production of inflammatory cytokines, 
chemokine, and reactive oxygen species. AA development is characterized by elastin 
fragmentation. As the aorta dilates due to loss of elastin and attenuation of the media, 
the arterial wall thickens as a result of remodeling. Collagen synthesis increases 
during the early stages of aneurysm formation, suggesting a repair process, but 
resulting in a less distensible vessel. Proteases identified in excess in AA and other 
aortic diseases include matrix metalloproteinases (MMPs), cathepsins, chymase and 
others. The elucidation of these issues will identify new targets for prophylactic and 
therapeutic intervention.  
 









Etiology and Pathogenesis of  
Aortic Aneurysms 
Carl W. Kotze and Islam G. Ahmed 
University College London 
United Kingdom 
1. Introduction  
The introduction of aneurysm screening programmes in North America and Europe has led 
to a significant increase in the number of new diagnoses. The pathobiology of aortic 
aneurysm (AA) is both complex and multifactorial, and is associated with several significant 
developmental risk factors. Understanding current concepts in the etiology and 
pathogenesis of AA is therefore imperative in fueling future research studies and in aiding 
the development of treatment guidelines.  
In 2001, the Vascular Biology Research Program of the National Heart, Lung and Blood 
institute (Wassef et al, 2001) summarised abdominal aortic aneurysm (AAA) pathogenic 
mechanism into four broad areas: proteolytic degradation of the aortic wall connective 
tissue, inflammation and immune response, molecular genetics and biomechanical wall 
stress. More recently Nordon and colleagues investigated three possible models of AAA 
pathogenesis not mutually exclusive: AAAs secondary to a local disease process confined to 
the abdominal aorta resulting from atherosclerosis; a systemic dilating diathesis primarily 
governed by genotype; and diseased vascular tree as a consequence of a chronic 
inflammatory process. They concluded that the evidence suggest AAA disease being a 
systemic disease of the vasculature, with a predetermined genetic susceptibility leading to a 
phenotype governed by environmental factors. AAAs are therefore referred to by some 
researchers as a degenerative disease (Nordon et al, 2011). 
AAAs are associated with atherosclerosis, transmural degenerative processes, 
neovascularization, degeneration of vascular smooth muscle cells, and a chronic 
inflammation, mainly located in the outer aortic wall. Literature describes the relevant 
mechanisms of the formation and progression of idiopathic ascending aortic aneurysm as 
destructive remodeling of the aortic wall, inflammation and angiogenesis, biomechanical 
wall stress, and molecular genetics. Aneurysm occurrence and expansion could be further 
influenced by the variability of local hemodynamic factors and factors intrinsic to the 
arterial segment along the aorta (Kirsch et al, 2006). Observational evidence now suggests 
that the intraluminal thrombus (ILT), together with adventitial angiogenic and immune 
responses, play important roles in the evolution of atherothrombosis from the initial stages 
through to clinical complications, which include the formation of aneurysms (Michel et al, 
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Uncertainty exists as to the impact of reported AA risk factors since the incidence of AAA is 
increasing despite a general reduction in tobacco use and an ever-increasing incidence of 
diabetes, which has been shown to have a protective influence. A number of other factors 
have also been commonly associated with aneurysm formation. They include family history, 
advanced age, male sex, hypertension, aortic dissection and arteriosclerosis. The significance 
of AA risk factors will be further explored in subsequent chapters. 
2. Structural considerations in AA 
Multiple factors rather than a single process are implicated in AA pathogenesis. These result 
in the destructive changes in the connective tissue of the media and adventitia of the aortic 
wall and ultimately lead to aneurysm formation and eventual rupture. The media is 
composed of multiple elastic laminae alternating with circularly oriented vascular smooth 
muscle cells (VSMCs) and surrounded by a copious ground substance. The adventitia lacks 
lamellar architecture but is composed of loose connective tissue with fibroblasts and 
associated collagen fibers and vasa vasorum. Integrity of the aortic wall is dependent on 
balanced remodelling of the extracellular matrix (ECM), predominantly of elastin, collagen 
and VSMCs.  (Dobrin & Mrkvicka, 1994; Tilson, 1988).  
2.1 Elastin 
The chief component of the media is elastin, a lamellar ECM protein consisting of soluble 
tropoelastin monomers. Elastin production by the VSMCs ceases when a patient reaches 
maturity, therefore these soluble tropoelastin monomers, which are cross-linked by lysine 
residues, have a half life of 40 to 70 yrs (Rucker & Tinker, 1977). This could explain the 
elderly predisposition to AA formation. Normally, more than 99% of total elastin in arteries 
is found in an insoluble cross-linked form that can be stretched as much as 70% of its initial 
length (Stromberg & Wiederhielm, 1969). Elastin is responsible for the load bearing property 
that behaves uniformly in both the circumferential and longitudinal directions at different 
locations across the wall thickness (Dobrin, 1999), thereby absorbing oscillating arterial 
shock waves, providing recoil and maintaining arterial structure.  
2.2 Collagen 
Collagen is the primary structural component of the arterial adventitia and has been 
identified in smaller quantities in the media. It is a stable triple helix composed of three 
polypeptide chains with repeating tripeptide sequences (Prockop, 1990) and is responsible 
for tensile strength and resistance of the arterial wall. In contrast to elastin, collagen is 
synthesized on a continual basis throughout life, thereby collagen content represents the net 
effect of synthesis and degradation. Type 1 fibrillar collagen accounts for aortic wall load 
bearing capability (over 20 times greater than that of elastin), while Type 3 collagen 
provides some extensile stretch (Menashi et al, 1987). Arterial distension in response to 
increasing intraluminal pressures are limited through the recruitment of inextensible 
collagen fibers (Dobrin, 1978). Structural damage occurs when collagen is extended beyond 
2–4% from its uncoiled form (Dobrin, 1988). 
2.3 Vascular Smooth Muscle Cells (VSMCs) 
VSMCs as part of the ECM form an important structural element and perform a mediator 
role in AA disease by producing TGF-beta1, ECM and inhibitors of proteolysis (O’Callaghan 
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& Williams, 2000). Transition of VSMCs from a contractile to a synthetic phenotype is 
characterized by a change in cell morphology, resulting in the production of substances such 
as components of the ECM, growth factors, and proteases, which are important in 
remodeling the vascular wall (Lesauskaite et al, 2003). This was verified by an experimental 
study that reported cultured VSMCs from AAAs exhibited greater elastolytic activity than 
VSMCs from Aortic Occlusive Disease (AOD) (Patel et al, 1996). VSMC density depends on 
patient age, patient gender and the location of quantification in non-atherosclerotic 
aneurysms. Conversely, loss of VSMCs is a characteristic of atherosclerotic aortic aneurysms 
(Sakalihasan et al, 2005; Kirsch et al, 2006). In particular VSMC apoptosis has been 
associated with fibrous cap thinning, enlargement of the necrotic core, plaque calcification, 
medial expansion and degeneration, elastin breaks, and failure of outward remodeling. In 
addition, chronic VSMC apoptosis may mimic multiple features of medial degeneration 
seen in a variety of human pathologies (Clarke et al, 2008). 
2.4 Experimental and clinical studies 
Histological examination of aneurysms reveals a thinning of the media, disruption of the 
medial connective tissue structure, and the loss of elastin (Campa et al, 1987) culminating in 
the effacement of the lamellar architecture (White et al, 1993). The role of the aortic media in 
contributing to wall stability is emphasized through studies demonstrating AA formation 
following media destruction with surgical resection, freezing, or the injection of acetrizoate 
or other noxious agents (Economou et al, 1960). Other studies confirmed that both elastin 
and collagen content is decreased in AA walls with increased collagen cross-links (Carmo et 
al, 2002) and an increased collagen to elastin ratio. (Cohen et al, 1988)  Loss of elastin 
appears to be accompanied by an increase in the collagen content of the arterial wall, 
resulting in an overall decrease in the elastin to collagen ratio (Halloran & Baxter, 1995). This 
reflects in experimental studies that suggest that aortic elastase is significantly higher in 
patients with AAAs, multiple aneurysms, and ruptured AAAs compared with AOD. Also 
elastase and its major serum inhibitor, alpha 1-antitrypsin, are significantly altered in the 
aortic wall in different types of infrarenal aortic disease (Cohen et al, 1988). 
AA development is characterised by intial elastin fragmentation responsible for aneurysmal 
elongation and tortuosity. There is consensus that as the aorta dilates due to loss of elastin 
and attenuation of the media, the arterial wall thickens as a result of remodeling. Collagen 
synthesis increases during the early stages of aneurysm formation, suggesting a repair 
process (Shimizu et al, 2006). As the load bearing increases, more uncoiled collagen is 
recruited to load bear circumferentially (Goodall et al, 2002) resulting in a less distensible 
vessel. Collagen, because of its structural properties, must fail for significant dilatation and 
rupture to occur. This is confirmed as patients who are post aortic endarterectomy rarely 
incur AA disease.  Dobrin et al. concluded that both elastin and collagen are possibly critical 
in AA dilatation with collagen failure resulting in gross expansion and rupture (Dobrin et al, 
1994). This work confirmed experimental studies demonstrating that treatment with elastase 
leads to arterial dilatation and stiffening at physiologic pressures, whereas treatment with 
collagenase leads to arterial rupture without dilatation (Cohen et al, 1988). Cohen suggested 
that elastin degradation is a key step in the development of aneurysms, but that collagen 
degradation is ultimately required for aneurysm rupture. The integral role of VSMCs in AA 
disease is confirmed by an animal study that observed AAA prevention and regression after 
infusion with VSMCs (Allaire et al, 2002). 
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2.5 Structural considerations in TAA 
Elastin lamellar units are found less frequently in AAA as compared to TAA, with an even 
more marked difference infrarenally. This relative paucity of elastin and collagen is thought 
to play a role, amongst other factors, in the predisposition for aneurysm development in the 
infrarenal aorta. The microscopic findings in TAAs are predominantly described as cystic 
medial degeneration, reflecting a non-inflammatory loss of medial VSMCs, fragmentation of 
elastic lamellae, and mucoid degeneration. In contrast, the histopathologic features of AAAs 
are characterized by severe intimal atherosclerosis, chronic transmural inflammation, 
neovascularization, and destructive remodeling of the elastic media (Diehm et al, 2007). 
Furthermore, ascending TAAs are associated with an underlying bicuspid aortic valve 
(BAV) with an estimated 75 % of patients who underwent BAV replacement demonstrating 
cystic medial necrosis on biopsy, compared to 14 % in patients who had tricuspid valve 
replacement.  Inadequate levels of firillin-1 may be responsible for this weakness in aortic 
wall leading to BAV (Huntington et al, 1997). 
 
 Ascending aorta Abdominal aorta Consequences 
Elastin lamellae – number decreased/diameter less provisional ECM 
elastin/collagen – decreased modified biomechanical properties 
Embryonic origin of 
VSMCs Neur-ectoderm mesoderm 
differences in responses 
to TGF-beta 
Shear stress – decreased control of inflammation 
Thrombus in 
aneurysms no yes 
neutrophils adsoption 
and protease release 
VSMCs in 




Table 1. Structural differences between TAA and AAA (Courtesy of Allaire, et al, 2009). 
3. Molecular genetics in AA 
Aortic aneurysms are a complex multi-factorial disease with genetic and environmental 
risk factors. Genetic factors have been shown to play a role in the etiology of TAA and 
AAA even though they are not associated aortic syndromes (Kuivaniemi et al, 2008). The 
genetic basis of aortic aneurysms was reviewed in 1991 (Kuivaniemi et al, 1991). The 
major determining factor in the appearance of aortic aneurysms may be an inborn defect 
of collagen type III or of another component of the connective tissue matrix. At least 20% 
of aneurysms result from inherited disorders (Verloes et al, 1995). Medial necrosis of the 
proximal aorta in aneurysms or dissections is associated with a number of conditions, 
including inherited connective tissue disorders such as Marfan syndrome and Ehlers—
Danlos syndrome type IV. It can also present along with bicuspid aortic valve, coarctation 
of the aorta, adult polycystic kidney disease and Turner syndrome (Caglayan & Dundar, 
2009). 
 




3.1.1 Genetic considerations in AAA 
Screening studies suggest that having a first-degree relative with a AAA is associated 
with an odds ratio of 1.9 to 2.4 of developing a similar problem. AAAs develop in 20% of 
brothers of patients with the condition (Rizzo et al, 1989). These and other findings 
including the presence of multiple aneurysms and systemic abnormalities in aneurysm 
patients e.g., increased connective tissue laxity; all emphasize a role for genetic factors in 
AAAs. 
A small number of studies have concentrated on multiplex AAA families (with at least  
2 affected members) (Platsoucas et al, 2006; Oleszak et al, 2004). Genome-wide scans of 
these patients have suggested a role for genes located on chromosome 19q13 and  
4q31.47. Candidate genes in these regions include interleukin (IL)-15, endothelin receptor 
A, programmed cell death 5, and LDL receptor-related protein 3.47 (Kuivaniemi et al, 
2008). 
3.2 TAA 
Since more than 40% of patients with TAA are asymptomatic at the time of diagnosis, such 
aneurysms are typically discovered accidentally through routine examination or when 
complications arise. Once one aneurysm has been discovered, the patient is at increased risk 
for developing another aneurysm (Lawrie et al, 1993; Crawford et al, 1989). Therefore, 
lifelong follow-up is required in these patients. If any mutation is found in the patients 
affected, the mutation should then be investigated in their relatives, and hence genetic 
counseling should be given. Because of this increased risk, according to target diseases, 
chromosomal and gene analysis are essential in selected cases with aneurysms or 
dissections, especially in inherited forms (Caglayan & Dundar, 2009). 
3.2.1 Genetic considerations in TAA  
Although AAA’s have been well characterized in terms of familial clustering, risk factors, 
growth rates, and possible modes of inheritance, less is known about thoracic aortic 
aneurysm (TAA). Rapid advances are being made in the understanding of TAA disease at 
the molecular genetic level. In pedigrees with several generations of multiply affected 
family members, chromosomal loci have been identified. These relate to the TAA phenotype 
by using the methods of linkage analysis and gene sequencing. Thus far, these loci have 
been mapped to the 5q13-14, 11q 23.2-24, and 3p24-25 chromosome sites (Vaughan et al, 
2001; Hasham et al, 2002; Kakko et al, 2003). Most recently, important work has localized the 
mutation on the 3p24-25 chromosome to the transforming growth factor-receptor type II 
(Pannu et al, 2005). Albornoz and his colleagues evaluated 88 familial pedigrees with TAA 
and found that 70 (79.5%) had an inheritance pattern that was most consistent with a 
dominant mode of inheritance: 30 were autosomal dominant, 24 were autosomal dominant 
versus X-linked dominant, 15 were autosomal dominant with decreased penetrance, and 
there was one pair of monozygotic probands with a likely autosomal dominant spontaneous 
mutation. The other 18 pedigrees (20.5%) were most consistent with a recessive inheritance 
pattern, eight being autosomal recessive versus X-linked recessive, five autosomal recessive, 
and five autosomal recessive versus autosomal dominant with decreased penetrance. 
(Albornoz et al, 2006). 
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type IV Autosomal dominant COLA3A1 
Ascending Marfan Syndrome Autosomal dominant FBN1 TGFβR2 
 Turner Syndrome Chrosomal  
 Osteogenesis imperfecta Autosomal dominant COLA1A1 
Thoracic Autosomal dominant adult polycystic kidney disease Autosomal dominant PKD1,PKD2 
Abdominal Homocystinuria Autosomal recessive CBS 
 Pseudoxanthoma elasticum Autosomal recessive ABCC6 
Table 2. Genetic diseases and Aortic Aneurysms  
3.3 General behaviour of familial aneurysms  
3.3.1 Aneurysm expansion  
TAA is a lethal disease and the size of the aneurysm has a profound impact on aortic 
dissection and death (Coady et al, 1999). The growth rate of TAA is highly variable ranging 
from 0.03 to 0.22 cm per year. Genetic factors may play an important role in aortic growth 
rates. The data suggests that genetic etiology permits more rapid aortic dilatation, thus 
increasing the risk for aortic dissection. Physicians must know how to distinguish between 
syndromic and non-syndromic forms of aortic aneurysm and dissection. As a result family 
history is a most important factor in evaluating the patients who have aortic aneurysms or 
dissection (Caglayan & Dundar, 2009). 
Aneurysms affecting the thoracic aorta in patients with Marfan syndrome behave more 
aggressively than TAA in patients without Marfan syndrome. However, the natural history of 
TAA in patients who do not have Marfan syndrome but who demonstrate a family history 
that is positive for aortic aneurysms has not been not well-described (Coady et al, 1997). It has 
also been reported that the presence of an aortic dissection significantly increases the 
aneurysm growth rate (Coady et al, 1997). Coady and colleagues clearly demonstrated that 
patients with familial nonsyndromic aneurysms and superimposed aortic dissections display a 
faster rate of aneurysmal growth (0.33 cm/y,) when compared with the overall growth rate of 
aortic dissections alone. The reasons for faster growth rates in patients exhibiting familial 
patterns and with concomitant aortic dissections are not clear, but may reflect a compounded 
environmental insult on a genetically weakened aortic wall (Coady et al, 1999).  
3.3.2 Dissection  
In most adults, the risk of aortic dissection or rupture becomes significant when the 
maximal aortic dimension reaches about 5.5 cm. However, in individuals with TGFBR2 
mutations, dissection of the aorta may occur before the aorta extends to 5.0 cm (Loeys et al, 
2005). Even patients with Loeys-Dietz syndrome (LDS) syndrome, both transforming 
growth factor, beta receptor 1 (TGFBR1) and two mutations have been described and 
dissections may occur under 5.0 cm (Caglayan & Dundar, 2009). 
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In the near future, new genetic studies such as single nucleotide polymorphisms (SNP) and 
RNA expression studies may help underlie genetic based therapies and develop more 
useful, simple and cheap diagnostic genetic tests for susceptible patients.  
4. Haemodynamic factors and biomechanical wall stress considerations  
in AA 
The pathobiology of AA is thought to be a multifactorial process that includes biological, 
biomechanical, and biochemical processes. Contrary to current understanding of biological 
and biochemical factors, the role of biomechanical factors in AA pathobiology is poorly 
understood. It is generally recognized that AAAs can continuously expand, dissect and even 
potentially rupture when the stress acting on the wall exceeds the strength of the wall. Wall 
stress simulation based on a patient-specific AAA model appears to give a more accurate 
rupture risk assessment than AAA diameter alone (Li et al, 2010).  
4.1 Haemodynamic forces  
The artery wall is subject to three distinct fluid-induced forces: (1) pressure created by 
hydrostatic forces, (2) circumferential stretch exerting longitudinal forces, and (3) shear 
stress created by the movement of blood. The net force includes a component perpendicular 
to the wall, the pressure; and a component along the wall, the shear stress. Disturbed flow 
conditions, such as turbulence, contribute to aneurysm growth by causing injury to the 
endothelium and accelerating degeneration of the arterial wall. Areas of flow oscillation and 
extremes in shear stress (high or low) correlate with development of atherosclerosis in the 
aorta (Ku et al, 1985). Although clinical studies show that flow within AAAs can be smooth 
and laminar or irregular and turbulent, little information is available on effects of wall shear 
stress in aneurysms (Miller, 2002). 
Intra-aneurysmal flow is affected by the geometry of the aneurysm sac and surrounding 
vasculature; including the existence, size, and symmetry of branches arising near the 
aneurysm; and the position of the aneurysm sac relative to the parent vessel (e.g. sidewall, 
terminal, or bifurcation). Effort has been made to correlate rupture with these various 
geometric features. (Zeng et al, 2011)  
4.2 Effect on aneurysm expansion  
Vascular endothelial cells are constantly exposed to fluid shear stress, the frictional force 
generated by blood flow over the vascular endothelium. The importance of shear stress in 
vascular biology and pathophysiology has been highlighted by the focal development patterns 
of atherosclerosis in hemodynamically defined regions. For example, the regions of branched 
and curved arteries exposed to disturbed flow conditions, including oscillatory and low mean 
shear stresses (OS), correspond to atheroprone areas. In contrast, straight arteries exposed to 
pulsatile high levels of laminar shear stress (LS) are relatively well protected from 
atherosclerotic plaque development (Zarins et al, 1983). Changes in blood flow have been 
shown to be a critical factor inducing arterial remodeling (Manu & Plattet, 2006).  
The increase in shear stress is also associated with a reduction in reactive oxidative stress 
(ROS). The flow-mediated increase in shear stress does not decrease oxidative stress in AAAs 
by reducing the inflammatory cell infiltrate, but through the expression of hemeoxygenase 
(HO-1) in macrophages. Activation of HO-1 expression is an adaptive cellular response to 
survive exposure to environmental stresses (Immenschuh & Ramadori, 2000). HO-1 has anti-
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inflammatory effects and may play a beneficial role in reducing oxidative reactions through 
the production of the antioxidants biliverdin and bilirubin (Miller, 2002). 
Because of limitations in studying hemodynamics in vivo, in vitro models of AAAs have 
often been used to analyze pressure and flow patterns. However, these biomechanical 
designs often use an axisymmetric model, whereas AAAs, particularly in advanced stages, 
are asymmetric, resulting in growth away from the lumen’s centerline. Interpretation of 
mechanical models can also be limited if they neglect effects of branch arteries, or by their 
use of steady flow, rigid walls; and homogenous and incompressible fluid. Understanding 
the biology of AAA development and expansion requires experiments in animal models. 
Unfortunately, in vivo studies are complicated by controversy regarding appropriate animal 
models of human AAAs (Miller, 2002).  
4.3 Effect on aneurysm rupture  
Rupture of the aneurysm can be seen as a structural failure when the induced mechanical 
stresses acting on the weakened AAA wall exceed its local mechanical failure strength. The 
external forces include blood pressure and wall shear stress. Stress in the AAA wall is due to 
the influence of other concomitant factors, including the shape of the aneurysm, the 
characteristics of the wall material, the shape and characteristics of the intraluminal 
thrombus (ILT) when present, the eccentricity of the AAA, and the interaction between the 
fluid and solid domains (Li et al, 2010).  
4.4 Haemodynamic factors and biomechanical wall stress considerations in TAA 
The influence of biomechanical factors in TAA is scarcely reported, therefore the role that 
haemodymic factors play in TAA pathobiology remains unknown. Nevertheless, weakening 
of the aortic wall is compounded by increased shear stress, especially in the ascending aorta 
(Ramanath et al, 2009). An experimental study of a cylindrical model of TAA demonstrates 
that mean circumferential stress depends on the aortic diameter and systolic blood pressure 
but not on age or clinical diagnosis supporting the clinical importance of blood pressure 
control and serial evaluation of aortic diameter in these patients (Okamoto et al, 2003). 
Considering the functional complexity and structural differences of TAA compared to 
AAA, several hemodynamic factors might contribute to the development of TAA. However 
the predilection of aneurysm formation infrarenally suggests other factors may overrule 
haemodynamic factors in AA pathogenesis.   
4.5 Current limitations  
Although rupture is determined by the comparison of wall stress and wall strength, 
accurate wall strength measurement in vivo is currently not possible. Therefore, computed 
wall stresses at one time point may not necessarily provide an estimation of the risk of 
rupture without knowing the strength value at that time point. However, by following up 
patients and performing wall stress analysis based on follow-up images, the change in wall 
stresses may be more useful in identifying aneurysm stability (Li et al, 2010). 
5. Enzymatic activity in AA  
Proteolytic degeneration is known to cause AA formation and lead to disease progression. 
Proteases identified in excess in AA and other aortic diseases includes matrix 
metalloproteinases (MMPs), cathepsins, chymase and tryptase, neutrophil-derived serine 
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elastase and the enzymes of the plasmid pathway, tissue plasminogen activator (tPA), 
Urokinase-type Plasminogen Activator (uPA) and plasmin (Choke et al, 2005). These 
proteolytic enzymes are involved in regulating and remodeling the ECM.  
5.1 Experimental and clinical studies  
Pioneering work in animal models has demonstrated the role of proteolysis in AA. These 
experimental studies showed elongation and dilatation following treatment with elastase, 
and rupture post collagenase infusion. More recently, an in vivo study of aortic wall 
treated with doxycycline loaded, controlled-release, biodegradable fiber led to 
preservation of elastin content, decreased MMPs (most notably MMP-2 and MMP-9) and 
increased tissue inhibitor of metalloproteases (TIMP-1) (Yamawaki-Ogata et al, 2010). A 
number of MMPs, including elastases, collagenases, gelatinases and stromelysin, are 
found in increased concentrations in the media of the AAA and are normally inhibited by 
TIMP. 
MMPs and other proteinases derived from macrophages and VSMCs are secreted into the 
extracellular matrix in response to stimulation by the products of elastin degradation 
(Ailawadi et al, 2003). Inflammatory infiltrates and invading neovessels are relevant sources 
of MMPs in the AAA wall and may substantially contribute to aneurysm wall instability 
(Reeps et al, 2009). In AA disease evidence suggests that the balance of vessel wall 
remodeling between MMPs, TIMPS, and other protease inhibitors favors elastin and 
collagen degradation with the net pathological effect of ECM destruction.  
5.1.1 MMP-9 (92-kd gelatinase) 
MMP-9 predominantly secreted by macrophages, monocytes and VSMCs is the most 
comprehensively studied of the metalloproteases. MMP-9 concentrations are higher in 
patients with AAA compared to subjects without AAA or AOD. Interestingly, Takagi 
observed that increased MMP-9 serum levels return to normal after aneurysm repair (Hisato 
Takagi et al, 2009). Furthermore, an experimental study showed that targeted gene 
disruption of MMP-9 prevented aneurysmal degeneration in murine models (Pyo et al, 
2000). Recently, a correlation was found between AAA rupture and elevated plasma levels 
of MMP-9 and MMP-1 (Wilson et al, 2008).  
5.1.2 MMP-2 (72-kd gelatinase)  
Evidence suggests MMP-2 may be the most integral protease in ECM degeneration. MMP-2 
sourced by adventitial VSMCs and fibroblasts is uniquely activated by membrane type 
(MT)-MMPs. MMP-2 has the ability to degrade both elastin and collagen, and possibly plays 
a role in early AA development. MMP-2 complements and facilitates the degenerative 
activity of MMP-9 in transgenic murine models, however some studies suggest that MMP-2 
has greater elastolytic activity compared to MMP-9. MMP-2 levels are increased in subjects 
with AA compared to those with AOD or without AA disease. It is found predominantly in 
its active form (62-kd), which is closely associated with its substrates, which provide 
additional support of its role in ECM degradation. Convincing evidence from a rat 
aneurysm model demonstrated that the inhibition of AA formation following TIMP-1 over-
expression, resulted in an activation blockade of both MMP-2 and MMP–9. Furthermore, 
Wilton concluded patients with larger aortic diameters have increased MMP-2/TIMP-1 
ratios (Wilton et al, 2007).  
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5.1.3 MMP- 3  
Matrix metalloproteinase-3 (MMP-3) degrades the ECM and may lead to the development of 
dilatative pathology of the ascending thoracic aorta (Lesauskaite et al, 2008). MMP-3 gene 
inactivation in mice demonstrated MMP-3 possibly causes degradation of matrix 
components, and promotes aneurysm formation by degradation of the elastica lamina 
(Silence et al, 2001).  
5.1.4 MMP-12 (54-kd macrophage metalloelastase)  
MMP-12 is involved in AA pathogenesis and shows a high affinity for elastin. In its active 
form the 22-kd enzyme degrades elastin (Longo et al, 2005). AA development in 
apolipoprotein E-knockout mice reported MMP-12 predominance in elastolytic activity. 
Deficiency of MMP-12 in the mice conferred protection against medial destruction and 
ectasia (Luttun et al, 2004).  
5.1.5 Collagenases  
Increasing collagenolytic activity has been identified in AAs, however collagen proteolysis is 
mostly associated with the terminal event of AA rupture. This is confirmed by greater levels 
of activity measured in specimens of ruptured aneurysms. (Busuttil et al, 1980).  
5.1.6 MMP-1 (Collagenase-1)  
MMP-1 localises within the mesenchymal cells (VSMCs, fibroblasts and endothelial cells) 
and is up-regulated by inflammatory mediators, however macrophage involvement has 
been described.  Increased pro MMP-1, MMP-1 protein and mRNA levels have been 
reported in AAA compared to healthy aorta (Irizarry et al, 1993).  
5.1.7 MMP-8 (Collagenase-2) (Matrilysin)  
Studies report inconsistent expression of MMP-8 in AOD and AAA tissue, however, MMP-8 
is stored as pre-formed protein in granules. Therefore MMP-8 mRNA may not accurately 
reflect protein concentration. Prominent expression of MMP-8 has been described in acute 
aortic dissection (Li et al, 2010).  
5.1.8 MMP-13 (Collagenase-3)  
MMP-13 is localised to VSMCs in close spatial proximity to collagen. Increased expression of 
MMP-13 in AAA compared to AOD tissue has been documented (Mao et al, 1999).  
5.1.9 Inhibition of MMPs  
Primary control of the activity of MMPs is achieved through tissue inhibitor of 
metalloproteinase (TIMP), by the formation of non-covalent complexes (Choke et al, 2005). 
TIMP-2, a broad-spectrum MMP inhibitor, and PAI-1, an inhibitor of tPA and uPA, are less 
expressed in AAA walls than in AOD, suggesting that ECM destruction is caused by a 
decrease in inhibitors and an increase in proteases (Allaire et al, 2009). Alpha-1-antitrypsin and 
Alpha-2-macroglobulin may suppress elastolysis, which is responsible for 90% of the 
inhibition of circulating MMPs, (Cohen et al, 1990). Treatment with atorvastatin decreases 
MMP expression and activity and leads to a reduction of TGF-beta signaling in the central region 
of human AAAs (Schweitzer et al, 2010). Ezetimibe combination therapy reduces aortic wall 
proteolysis and inflammation, key processes that drive AAA expansion (Dawson et al, 2011).  
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5.2 Proteolytic consideration in TAA  
The hypothetical model of AAA cellular pathogenesis cannot completely explain the 
formation of dilatative pathology of the ascending thoracic aorta. The cellular expression of 
MMP-9 and their tissue inhibitors TIMP-1, TIMP-2, and TIMP-3 differ in the dilatative 
pathology of abdominal and thoracic aortas (Lesauskaite et al, 2006). 
Overall a diminished expression of MMPs and tissue inhibitors relative to aged control 
AAAs in TAA, is documented. This may represent a loss of VSMCs in non-atherosclerotic 
TAA. Also, MT1-MMP plays a dynamic multifunctional role is TAA development (Jones et 
al, 2010). In Marfans syndrome MMP-2 and MMP-9 are found to be upregulated in TAA 
(Chung et al, 2007). Furthermore, animal studies show elevated MMP-9, MMP-2 and 
disintegrin and metalloproteinase domain-containing proteins 10 and 17 (ADAM-10 and -
17) expressed in calcium chloride induced TAAs. Murine studies depleted of MMP-9 gene 
have demonstrated attenuated TAA formation (Ikonomidis et al, 2005).  
6. Inflammatory changes in AA  
AA is best described as a chronic inflammatory condition with an associated proteolytic 
imbalance. The most important pathological feature of human AA is probably the infiltration 
of inflammatory cells. The chronic infiltration consists mainly of macrophages, lymphocytes 
and plasma cells. It is suggested that these inflammatory cells and others play a regulatory role 
through release of a cascade of cytokines. This process results in the expression of cell 
adhesion molecules, increased protease expression, and the release of reactive oxygen species 
causing degradation of the ECM through the activation of MMPs and TIMP (Shah, 1997). 
The recruitment of macrophages by chemotactic agents is possibly triggered by exposed 
elastin degradation products.  Lymphocyte activation may be mediated by micro-organisms 
as well as by auto-antigens from structural degradation. TNF-alpha and INF-gamma appear 
to be the most consistently upregulated cytokines in patients with large AAAs. (Golledge et 
al, 2009). These inflammatory cytokines play multiple roles in regulating mesenchymal cell 
matrix metabolism, endothelial cell growth and proliferation, lymphocyte activation, 
antigen presenting cell (APC) function, major histocompatibility (MHC) class II molecule 
expression, vascular adhesion molecule expression, and even matrix degrading protease 
expression of surrounding cells (Wills et al, 1996). 
Although AA and AOD are characterised by underlying inflammation, immunohistological 
studies have concluded that T- and B-cell predominance is localised to the outer media and 
adventitia in AA; compared to largely T–cell involvement localised to the intima and inner 
media in AOD. Furthermore, an autoimmune component to AA disease has been suggested 
after localisation of B lymphocytes in the media and considerable deposits of 
immunoglobulins (IgG) and complement in the wall of AA. (Lindholt & Shi, 2006).   
6.1 Experimental and clinical studies  
Key features of human AA include intense inflammation, increased expression of MMP-2 and 
MMP-9, and local ECM destruction. It became evident that inflammation plays an integral role 
in aneurysm pathogenesis following novel experimental animal models that demonstrated key 
features of human aneurysm following transmural chemical injury induced by calcium 
chloride treatment of vessel adventitia. Interestingly, aneurysm formation only developed 
after the inflammatory response was present, suggesting that inflammation occurring in 
response to chemical and mechanical injury is responsible for aneurysm development, rather 
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than direct elastolysis. The calcium chloride murine model further indicates that CD4+ 
lymphocytes may be central in orchestrating production of MMP-2 and MMP-9 through 
interferon gamma (Xiong et al, 2004; Gertz et al, 1988). Anidjar and Dobrin recognized that 
exposure of the aorta caused destruction of elastic lamellae with up to a 4-fold increase in AA 
diameter at 6 days following elastase treatment. This increase was also associated with media 
infiltration of a large number of activated macrophages and T-cells (Anidjar et al, 1994). 
Characteristics of the elastase infusion model demonstrated that inflammatory cell infiltrate is 
accompanied by an increase in MMP-2 and MMP-9. Interestingly, the infiltration of 
macrophages and T-lymphocytes is not the prominent feature in the ruptured edges of AAAs 
and is even less prominent in non-ruptured areas or walls of the same AAAs. Rather, ruptured 
areas present significantly increased amounts of immature micro-vessels, with an excess of 
total and activated MMPs (Choke et al, 2006). Furthermore, prostaglandins (PG) and 
leukotrienes may also contribute to AAA in that the deficiency of 5-lipoxygenase attenuates 
aneurysm formation of atherosclerotic apolipoprotein E-deficient mice, suggesting a role for 
the 5-LO pathway in AAA formation (Shimizu et al, 2006).  
6.2 Inflammatory cells involved in AA  
6.2.1 Lymphocytes  
It is suggested that Th1 and Th2-restricted T lymphocyte are the most commonly found 
infiltrates in AAA walls and are activated by antigen presenting cells such as macrophages, 
VSMCs, and endothelial cells. These inflammatory cells are integral for the regulation of the 
immune response in AAA. However, the specific regulatory traits of components of the 
inflammatory cascades and of proteases that cause aneurysmal growth remain largely 
unresolved. This reflects in earlier mouse studies which designated AAA disease as a T-
helper (Th)-2-type inflammatory disease and identified T-helper(Th)-2-restricted CD3C T as 
the dominant influx. Later human studies suggested differently with AAA disease labeled 
as Th1-dominated or as a general pro-inflammatory condition (Abdul-Hussein et al, 2010). 
Local production of Th1 cytokines (Interferon-gamma (IFN-gamma), Interleukin-2 (IL-2),  
IL-12, IL-15 and IL-18 possibly enhances macrophage expression of MMPs, whereas Th2 
cytokines (IL-4, 5, 8, and 10, Tumor necrosis factor-alpha (TNF-alpha), INF-gamma and 
CD40 ligand) appear to suppress macrophage MMP production and limit disease 
progression (Lindholt & Shi, 2006). In addition T-helper (Th)-2 cells secrete an FAS-ligand 
and FAP-1 resulting in apoptosis of  VSMCs and Th1 cells (Shonbeck et al, 2002). Cytokines 
TNF-alpha and IL-8 cause inflammatory cell recruitment that is responsible for stimulating 
neoangiogenesis. INF-gamma stimulates cathepsin production for further Th2 activation, B-
cell differentiation and Ig secretion. 
In most cases, the default pathway will be a Th1-dominant for stenotic arterial lesions; 
however, when the local environment is skewed toward Th2 predominance, aneurysms will 
develop (Shimizu et al, 2006). More recently a study comparing inflammatory and 
proteolytic processes in AAA and popliteal artery aneurysm, characterized degenerative 
aneurysmal disease as a general inflammatory condition that is dominated by profound 
activation of the nuclear factor-kappa-B and activator protein-1 pathways. There is also 
hyperexpression of IL-6 and IL-8, and neutrophil involvement (Adul-Hussein et al, 2010).  
6.2.2 Macrophages  
Inflammation is characterised by macrophage migration from the onset of AA formation. 
Elastin degradation products are possibly responsible for the recruitment of macrophages 
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by chemotactic agents. Heamodynamic forces may regulate macrophage adhesion, 
transmural migration and survival (Sho et al, 2004). A recent animal study confirmed that 
MT1-MMP acts directly to regulate macrophage secretion (Xiong et al, 2009). This antigen 
presenting cell is suggested to be a central role player in the immune response and 
subsequent ECM destruction. It is mostly localised in the adventitia of the AA wall. 
Through the secretion of cytokines  (IL-1b, IL-6, IL-8, and TNF-alpha) and proteases (in 
particular MMP-9) these macrophages recruit inflammatory cells and stimulate cytokine 
production, protease production, B-cell differentiation, Ig secretion, cytotoxic T-cell 
differentiation and neovascularization. (Lindholt & Shi, 2006). In addition to producing 
cytokines and proteases, these cells also produce TIMP, confirming the governing role of 
macrophages in AA immune response. Animal studies confirmed the paramount role of 
macrophages in AA inflammatory response by demonstrating human-like aortic 
aneurysmal degradation without further manipulation following the application of 
macrophages and plasmin to the aorta (Werb et al, 2001). 
6.2.3 Endothelial cells  
Endothelial cells have been localised in AA and are found in approximation to 
neovascularisation. A prominent role for endothelial cells in the inflammatory response has 
been suggested following histological study reports of a positive association between the 
degree of inflammation and the degree of neovascularisation. It is suggested that these 
inflammatory cells play a role in ECM remodeling through the secretion of IL-1b and IL-8, 
which stimulate intercellular adhesion molecule-1 (ICAM-1) presentation, thus causing 
recruitment of additional inflammatory cells, attraction of lymphocytes, stimulation of 
endothelial proliferation, stimulation of B-cell differentiation and Ig secretion. In addition, 
like macrophages, the proliferating endothelium also produces various MMPs and TIMP 
(Lindholdt & Shi, 2006). To this end an experimental study has demonstrated that 
doxycycline not only inhibits MMP-8 and MMP-9 activity, but also the synthesis of MMPs in 
human endothelial cells (Hanemaaijer et al, 1998).  
6.2.4 Fibroblasts  
Although fibroblasts are commonly identified in the adventitia of AAA and have a 
recognized function in atherosclerosis, the role of the fibroblast in aneurysm pathogenesis is 
uncertain. Fibroblasts secrete cytokine IL-6 which is suggested to cause a stimulatory 
cascade of B-cell and cytotoxic T-cell differentiation and MMP stimulation (Thompson & 
Parks, 1996).  
6.3 Infection and AA  
An infectious cause of aneurysm formation has also been suggested. Between 30% and 50% of 
AAAs are associated with Chlamydia and Herpes virus infections.  Chlamydia has been shown to 
induce AAA in rabbits and antichlamydial antibodies are commonly detected in AAA 
patients, however a causal relationship remains to be established. Studies have suggested that 
these infections play a role in elastolysis, possibly creating and augmenting an autoimmune 
response through particle mimicking. Lindholt et al. found that serum antibodies against  
C. Pneumonia have been associated with AAA expansion and cross-reaction with AAA 
structural proteins. Thus, immune responses mediated by microorganisms and autoantigens 
may play a pivotal role in AAA pathogenesis (Lindholt et al, 1999).  
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Fig. 1. Schematic diagram of the mechanisms implicated in abdominal aortic aneurysm, 
which primarily involve two main processes: inflammation and extracellular matrix 
turnover (Courtesy of Hellenthal et al, 2009). 
6.4 Reactive oxygen species and AA  
Reactive oxygen species such as superoxide (O2-) have also been shown to be raised in 
human AAAs. Elastase infusion in animal models has been shown to increase nitric oxide 
synthase expression and decrease the expression of the antioxidant, superoxide dismutase. 
O2- levels in human aneurysmal tissue are 2.5-fold higher than in adjacent nonaneurysmal 
aortic tissue and 10-fold higher than in control aorta (Miller et al, 2002).  
6.5 Inflammation considerations in TAA  
Developmental variation between TAA and AAA leads to differences in cellular responses 
to similar biological responses (El-Hamansy & Yacoub, 2009).  Similar to AAA, histological 
studies demonstrate inflammatory cells in the adventitia and media of the aortic wall. In 
particular TAA infiltrate consistently shows CD3+, CD45+, CD68+ cells in the adventitia 
along with a prominent vasovasorum (possibly suggesting its role as conduit) and local 
endothelial activation (El-Hamansy & Yacoub 2009). Immunohistochemical staining showed 
that T- lymphocytes followed by macrophages were the predominant inflammatory cell in 
sporadic TAA (Guo et al, 2000). A Th1-type immune response is predominant in TAA as 
mRNA levels of INF-y are significantly increased compared to controls. Specific 
inflammatory pathways implicated in TAA formation remain unknown. However, 
transforming growth factor Beta (TGF-B), a cytokine, is recognized to be central in TAA 
pathogenesis causing ECM degeneration through the production of plasminogen activators 
and the release of MMP-2 and MMP-9. Reduced or mutated forms of fibrillin 1 release active 
 
Etiology and Pathogenesis of Aortic Aneurysms 
 
15 
TGF-B, which in turn activates mitogen kinase activated pathways in VSMCs. Emilin 1, 
however, inhibits TGF-B signaling (El-Hamamsy & Yacoub 2009). ‘Mycotic’ aneurysms are 
found in less than 1% of patients with TAA. Salmonella, Staphylococcus and 
Mycobacterium species are mostly identified in blood cultures and tissue samples of 
subjects with AA disease (Koeppel et al, 2000). The role of oxidative stress is well described 
in AAA, however this remains to be established in TAA disease.  
7. Implications for AA management  
Current treatment of AA targets risk factors and the reduction of inflammation and 
proteolysis in AA walls. To this extent AA repair (open or endovascular) is currently 
practiced when aneurysms reach the recommended size for intervention or become 
symptomatic. The role of in vivo imaging techniques in vascular inflammation, such as 
Hybrid Positron Emmission Tomography / CT, that reflects the macrophage metabolic 
activity, may help to clarify the role of inflammation in AA pathogenesis and aid in the 
evaluation of treatment response. Currently, the potential role of pharmacotherapy in 
attenuation of AA growth is under investigation. Evidence suggests that smoking cessation 
may slow aneurysm growth and reduce the risk of rupture; therefore all AA patients should 
be counseled on the risks of smoking. 
Antihypertensive medication has been investigated in the past, as hypertension is regarded 
as a potential significant risk factor for AA disease. A meta-analysis did suggest a 
significantly attenuated growth rate by β-blockers, however randomised control trials 
reported no benefit in the β-blocker (propanolol) group (Guessous et al, 2008) and a 
greater stroke and all-cause mortality with a short peri-operative course of β-blockers. 
Angiotensin converting enzyme (ACE) inhibitors have been demonstrated to cause AA 
attenuation in animal models, however no clinical trial has been conducted to confirm this. 
The exact mechanism by which ACE inhibitors restrict aneurysm growth is unknown; 
however its ability to bind zinc, an important cofactor for MMP activity, has been suggested. 
Nevertheless, a population based study suggested that patients taking ACE inhibitors were 
less likely to present with rupture (Hackman et al, 2006). TGF-β antagonists such as TGF-β–
neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan, have 
demonstrated prevention of AA in a mouse model of Marfan Syndrome (Habashi et al, 
2006) but no significant proven effect in human AAA. Distinguishing TAA from AAAs 
might explain the differential findings regarding the beneficial effects of angiotensin II type 
1 receptor (AT1) blocker on various aortic aneurysmal pathologies. 3-Hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors (statins) restrict aneurysm growth through 
reduction of IL6 and MMPs (in particular MMP-9) in experimental models. However, a 
recent meta-analysis concluded that reduction in AAA expansion rate due to statins is not 
significant (Twine & Williams, 2010). Tetracyclines such as doxicycline, inhibit MMPs in 
animal models and have been shown to significantly reduce the growth of AAA. This has 
been confirmed clinically by a small scale, randomised, placebo controlled pilot study 
(Mosorin et al, 2001). Furthermore a macrolide antibiotic (Roxithromycin) used in a small 
randomised clinical trial reported a 44% reduction in AAA growth over 12 months, with the 
effect gradually tailing off up to 5 years (Vammen et al, 2001). Non-steroidal anti-
inflammatory drug, Indomethacin prevents elastase induced AAA in animal models 
through CoX 2 inhibition, leading to reduction of MMP-9 and PGE2 (Miralles et al, 1999). 
More recently, the antioxidant properties of Vitamin E have been investigated in AAA 
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models. It has been shown to block the induction of AAA in Angiotensin II-infused Apo-E 
knockout mice via reduction of macrophage infiltration and reduction of a chemotactic 
cytokine, suggesting that inhibition of oxidative stress in aneurysm tissue may play a 
significant role in AA pathobiology and be a possible treatment target (Gavrilla et al, 2005).  
8. Conclusion 
Interaction of multiple factors rather than a single process is responsible for the failure of the 
integrity of the aortic wall, which result in AA formation and progression. Despite several 
similarities in etiology and pathogenic mechanisms, it appears that TAA differs in many 
ways from AAA. Current areas of interest include proteolytic degradation of the arterial 
wall, inflammation and the immune response, biomechanical wall stress, and molecular 
genetics. Knowledge of the pathobiology of AA has lead to more targeted imaging methods 
and treatment trial design to investigate various pathobiological mechanisms of AA 
progression. Although some agents show promise, large controlled trials are needed to 
demonstrate clinically significant benefits. Future research should take into consideration 
knowledge gained of the differences between TAA and AAA pathobiology when designing 
clinical trials, in order to unravel the specificities of these different events in AA. As it stands 
surgical treatment of AA disease continues to be the most effective means of addressing the 
majority of factors involved in AA formation and progression. 
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1. Introduction  
Despite numerous studies focusing on the aortic aneurysm pathogenesis, the mechanism of 
aneurysm formation, especially – initiation of this process, remains unclear. The research 
concerning both, structural and molecular studies, is based on two main data sources. The 
first source of information are patients with already formed aneurysm, and with well 
defined biochemical and morphological changes in aortic wall architecture. The other source 
of data are experimental studies based on laboratory animals with artificially induced 
aneurysms. This approach enables verification of various hypotheses concerning 
pathogenesis of aortic aneurysm. Regrettably, animal aneurysm models, although similar, 
are not exactly the same, as human pathology. Thus, since the link between both mentioned 
data sources is still lacking, the knowledge achieved to date, even being highly profound, is 
not sufficient to fully understand this disease. Besides well defined factors, predisposing to 
formation of aortic aneurysm (patient’s age, cigarette smoking, arterial hypertension, 
atherosclerosis, as well as the Marfan’s and the Ehlers-Danlos’s syndrome-associated 
mutations), increasing popularity is currently being gained by the hypothesis concerning the 
pivotal role of proteolytic enzymes - matrix metalloproteinases (MMPs) in aortic wall 
destruction. The involvement of MMPs in extracellular matrix damage in aortic aneurysm is 
doubtless. However, it needs to be elucidated, what the sequence of events is and what the 
exact role of MMPs is in these events. MMPs could play a role of “executioners”, that are 
produced and activated in the aortic wall as constituents of inflammatory reaction, in 
response to some yet poorly defined triggers. On the other hand, it is plausible, that aortic 
wall destruction, followed by inflammatory response to tissue degradation products, results 
from primary local overproduction and/or activation of proteases. It could be due to some 
mutations or polymorphisms of MMP genes, or some impairment in their controlling 
mechanisms. In that circumstance MMPs could rather be considered as “executors”, with 
causative role in aortic aneurysm pathogenesis. Although the majority of studies suggest the 
first scenario as being more possible, there is some evidence, that could support the second 
alternative, too. 
2. Chronic inflammation – where the chaos begins… 
The histopathological assessment of aneurismal aortic wall specimens reveals widespread 
chronic inflammatory reaction. This reaction is associated with extensive destruction of 
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first source of information are patients with already formed aneurysm, and with well 
defined biochemical and morphological changes in aortic wall architecture. The other source 
of data are experimental studies based on laboratory animals with artificially induced 
aneurysms. This approach enables verification of various hypotheses concerning 
pathogenesis of aortic aneurysm. Regrettably, animal aneurysm models, although similar, 
are not exactly the same, as human pathology. Thus, since the link between both mentioned 
data sources is still lacking, the knowledge achieved to date, even being highly profound, is 
not sufficient to fully understand this disease. Besides well defined factors, predisposing to 
formation of aortic aneurysm (patient’s age, cigarette smoking, arterial hypertension, 
atherosclerosis, as well as the Marfan’s and the Ehlers-Danlos’s syndrome-associated 
mutations), increasing popularity is currently being gained by the hypothesis concerning the 
pivotal role of proteolytic enzymes - matrix metalloproteinases (MMPs) in aortic wall 
destruction. The involvement of MMPs in extracellular matrix damage in aortic aneurysm is 
doubtless. However, it needs to be elucidated, what the sequence of events is and what the 
exact role of MMPs is in these events. MMPs could play a role of “executioners”, that are 
produced and activated in the aortic wall as constituents of inflammatory reaction, in 
response to some yet poorly defined triggers. On the other hand, it is plausible, that aortic 
wall destruction, followed by inflammatory response to tissue degradation products, results 
from primary local overproduction and/or activation of proteases. It could be due to some 
mutations or polymorphisms of MMP genes, or some impairment in their controlling 
mechanisms. In that circumstance MMPs could rather be considered as “executors”, with 
causative role in aortic aneurysm pathogenesis. Although the majority of studies suggest the 
first scenario as being more possible, there is some evidence, that could support the second 
alternative, too. 
2. Chronic inflammation – where the chaos begins… 
The histopathological assessment of aneurismal aortic wall specimens reveals widespread 
chronic inflammatory reaction. This reaction is associated with extensive destruction of 
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elastic fibers in the tunica media layer, and infiltration of both, media and adventitia, by 
macrophages and lymphocytes, mainly the Th2 subset. Moreover, as has been found 
recently, outer media and adventitia of human aortic aneurysm samples contain 
numerous mast cells (Miyake & Morishita, 2009; Michel et al., 2011). In addition to the 
previously mentioned lymphocytes and macrophages, mast cells are currently recognized 
as a third considerable source of pro-inflammatory cytokines, including tumor necrosis 
factor (TNF), various chemokines, and interleukins. Furthermore, in cooperation with 
macrophages, mast cells produce and release large quantities of various proteases and, 
thus, they are also actively engaged in aortic wall destruction (Tsuruda et al., 2008). 
However, a trigger of inflammatory reaction still remains to be a missing component of 
this scenario. 
2.1 Chronic proteolytic atherothrombosis – a new concept 
Recently, it has been proposed, that the aneurysm pathogenesis could be explained, at least 
to some extent, by the model of chronic proteolytic atherothrombosis (Michel et al., 2011). 
This model is based on the observation that the development of aortic aneurysms is 
accompanied by the formation of chronic intraluminal thrombus inside the aneurysmal sac. 
It has been shown that the presence of intraluminal thrombus is associated with widespread 
degradation of elastic fibers, increased apoptosis and loss of vascular smooth muscle cells 
(VSMC) in tunica media, and with extensive inflammatory reaction in adventitia. It may 
suggest, that the thrombus rather, than the aortic wall, could be the primary source of 
various pro-inflammatory factors, including proteolytic enzymes (Michel et al., 2011). On 
the other hand, one can argue that formation of thrombus on the inner, luminal surface of 
the aortic wall could be secondary to already existing aortic wall inflammation, due to the 
damage of endothelium and tunica intima. Nevertheless, it is plausible, that independently 
of the sequence of events, the thrombus-aortic wall  interface may be “the place, where the 
chaos begins”… 
The pathophysiological role of intraluminal thrombus may be described by various 
activities of its components. The first activity could be a generation of free radicals and 
induction of oxidative stress reaction, mainly due to a degradation of red blood cells and 
release of the potent pro-oxidant mediator – iron-rich hemoglobin. The oxidative stress leads 
to the production of reactive oxygen and reactive nitrogen species, which are both 
components of a self-augmenting mechanism (Miyake & Morishita, 2009). Reactive oxygen 
and nitric oxide increase expression of pro-inflammatory cytokines, followed by further up-
regulation of reactive oxygen species production, peroxidation of membrane phospholipids 
and generation of eicosanoids and pro-apoptotic ceramides. Finally, reactive oxygen species 
induce activation of nuclear factor kappa-B (NF-κB), that leads to additional increase in 
MMPs expression and initiates the apoptosis of VSMC in the aortic wall. In addition to 
erythrocytes, intraluminal thrombus consists of an approximately 12-fold higher number of 
neutrophils, as compared to circulating blood (Michel et al., 2011). These cells produce a 
large number of proteinases, including elastase, cathepsin, MMP-8 and -9. Moreover, strong 
proteolytic activity between the thrombus and the adjacent aneurysm wall is revealed by the 
plasmin. This activity, although originally aimed at the thrombus fibrin network, may also 
contribute to aortic wall destruction. It may occur mainly through degradation of 
fibronectin, thus resulting in mesenchymal cells detachment and apoptosis, as well as direct 
activation of pro-MMPs. 
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2.2 Chlamydia pneumoniae and MMPs in aortic aneurysm 
According to “infection hypothesis”, the chronic inflammatory reaction, which takes place 
in the aortic wall, may be initiated by some pathogens. However, studies focusing on the 
presumed importance of various Chlamydia species, Helicobacter pylori, Borrelia burgdorferi, 
Cytomegalovirus, Herpes simplex virus, and most recently, some comensal, or weak pathogenic 
bacteria from the oral cavity, including Porphyromonas gingivalis and Streptococcus mutans, 
have failed to reveal a direct relationship between the presence of pathogen and aneurysm 
formation. Nevertheless, there is still no consensus in the debate concerning the significance 
of intracellular bacteria Chlamydia (Chlamydophila) pneumoniae in that event. It has been 
shown that almost half of aortic aneurysm specimens contained this pathogen. Moreover, a 
high prevalence of C. pneumoniae seropositivity and the presence of C. pneumoniae-reactive T 
lymphocytes in aortic aneurysm-suffering individuals, seemed to further support this 
hypothesis. Strong evidence was also provided by the results of experimental studies 
indicating, that in animal models C. pneumoniae antigens stimulated an elastin degradation 
followed by dilatation of aorta (Petersen et al., 2002). It is plausible that C. pneumoniae 
infection may reveal such destructive influence on the aortic wall due to activation of 
inflammatory reaction, mainly by stimulation of tissue macrophages with C. pneumoniae 
heat shock protein 60. This stimulation could lead to the release of a variety of pro-
inflammatory molecules, eicosanoids, cytokines and several MMPs. Thus, although the 
exact role of C. pneumoniae in pathogenesis of aortic aneurysm remains to be clarified, the 
results of several prospective clinical trials could provide some contribution to this matter. It 
has been proven, that antibiotics effective against C. pneumoniae – tetracyclines (doxycyclin) 
and macrolides (roxithromycin, but not azithromycin), may reduce the progression of small 
aortic aneurysm (Høgh et al., 2009, see also chapter 3.5.2.2). Based on mentioned 
observations one can expect a direct correlation between the presence of C. pneumoniae and 
tissue levels of MMPs in aneurismal aortic wall specimens. This hypothesis was tested by 
Petersen and coauthors (Petersen et al., 2002). Surprisingly, the authors found, that mean 
levels of MMP-2 and MMP-9 in C. pneumoniae-positive aortic wall specimens were lower, 
than in C. pneumoniae-negative samples. This astonishing result was explained by the 
authors as a consequence of possible irregular distribution of bacteria in the aortic wall. 
Since the C. pneumoniae detection and determination of MMPs activity were done using 
specimens from different locations, some of them could possibly display false negative 
results. It is noteworthy, that problems with detection of C. pneumoniae DNA in tissue 
specimens of Chlamydia-seropositive patients with abdominal aortic aneurysms have also 
been reported by other authors (Falkensammer et al., 2007). An additional cause behind 
such results in Petersen’s study could be the relatively small patient groups (28 individuals, 
divided into 4 groups, 7 patients in each). Moreover, the results of gelatin zymography 
could be affected by components of the extraction buffer used for analysis of MMP activity, 
especially EDTA and potent proteinase inhibitor – phenyl methylsulphonylfluoride (PMSF). 
Finally, authors suggested that C. pneumoniae infection may result in activation of some 
other, different from MMP-2 or MMP-9, proteolytic enzymes, e.g. neutrophil- or mast cells-
derived proteinases, like cathepsins G, or chymase. These enzymes can also reveal elastolytic 
activity, and therefore may directly contribute to the aortic wall destruction (Miyake & 
Morishita, 2009; Michel et al., 2011). Furthermore, it has been demonstrated, that mast cell-
derived chymase could activate pro-enzyme forms of MMP-2 and -9 in aneurysm tissue. 
However, although these observations could confirm the association of C. pneumoniae with 
MMPs activation in pathogenesis of aortic aneurysm, this issue still requires further studies. 
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3. Matrix metalloproteinases – the dark side of the Force… 
Matrix metalloproteinases (MMPs), also known as matrix metallopeptidases, or matrixins, 
belong to the large and still expanding family of zinc endoproteinases. The members of this 
evolutionarily ancient group were found in various organisms, from bacteria and plants, 
through hydra and worms, to humans. So far, at least 25 distinct MMPs have been identified 
in vertebrates. In humans a presence of 23 proteins, encoded for 24 distinct genes, has been 
confirmed. This discrepancy is due to the fact that human MMP-23 was found to be encoded 
by two identical genes located on chromosome 1. Together with the astacins, the 
adamalysins, and large bacterial proteinases – serralysins, MMPs constitute a huge 
superfamily of enzymes, called metzincins, which are characterized by the presence of the 
zinc-binding motif, with a conserved methionine nearby. 
MMPs play a crucial role in extracellular matrix (ECM) turnover. They are able to cleave 
main ECM components, including collagens, elastin, fibronectin, gelatin and aggrecan, as 
well as a variety of non-ECM molecules – transforming growth factor (TGF)-β, pro-IL-1β, 
pro-IL-8, Fas ligand, and pro-TNF. Moreover, MMPs are responsible for the release of 
cryptic fragments and neo-epitopes from extracellular matrix and non-ECM 
macromolecules, which may reveal bioactivities different from those of the parent 
molecules. Furthermore, MMPs may liberate numerous growth factors (e.g. vascular 
endothelial growth factor – VEGF and TGF-β) and cytokines, which are embedded in 
extracellular matrix and require proteolytic release from binding proteins for their 
activation. Finally, MMPs may modify cells’ attachment to the ECM by processing of 
syndecans, dystroglycan and other adhesion molecules (Endo et al., 2003; Yamada et al., 
2001; Mott & Werb, 2004). These properties of MMPs make them key players in the majority 
of physiological conditions (e.g. pregnancy, embryogenesis, wound healing), but also in 
various pathologies, including cancer progression with metastases, liver fibrosis, 
periodontal disease, multiple sclerosis and vascular diseases, especially atherosclerosis and 
aortic aneurysm (Hadler-Olsen et al., 2011). 
As mentioned previously, MMPs should not only be recognized as typical 
effector/”executioner” molecules, but also, at least in some circumstances, they may be 
considered as real causative factors/”executors”. This status may be supported by results of 
studies concerning the genetic polymorphisms of MMP genes. The polymorphisms are 
natural differences in DNA sequence that occur in more than 1% of the entire population. 
The vast majority of them concern variability of single nucleotides and are known as single 
nucleotide polymorphisms (SNPs). The effect of particular SNP is determined by its position 
in a gene structure. Most SNPs are functionally neutral. However, some of them may lead to 
an amino acid substitution, thus influencing the structure and properties of encoded 
protein. Furthermore, some SNPs located in a promoter region may alter the level of gene 
transcription. There is the reason, for which functional SNPs may contribute to the 
individual susceptibility to common diseases, including aortic aneurysms. In this chapter 
authors will shortly review several polymorphisms of selected MMP genes, which have 
been suspected of being involved in aortic aneurysm development. 
3.1 MMPs structure 
The overall scheme of a protein structure is common among all MMPs, with more or less 
significant differences between particular groups (Fig. 1). 
 





Fig. 1. The schematic structure of MMPs family 
In general, on its N-terminus the MMP molecule contains a signal sequence, which directs 
the protein to the secretory pathway, and is removed during insertion of the protein into an 
endoplasmic reticulum. The signal sequence is followed by the propeptide composed of 
approximately 80 amino acid residues, that contains a characteristic conserved PRCGXPD 
motif, known as “cysteine-switch”. The role of this sequence is to block a catalytic zinc and 
thus maintain the latent form of an enzyme. The next, the catalytic domain, has a sphere-like 
shape with an active site containing two atoms of zinc inside a large, shallow cleft. The 
catalytic domain is composed of approximately 160-170 amino acids, with a unique 
HEXXHXXGXXH sequence, that binds zinc ions. The last, approximately 200 amino acid 
residues-long C-terminal domain, called the hemopexin-like domain is found in all MMPs 
except for MMP-7, -23 and -26. In most MMPs the hemopexin-like domain is linked to a 
catalytic domain through a short, approximately 10-30 amino acid residues-containing hinge 
region. Exceptionally, the hinge region of MMP-9 is 64 amino acids-long, and is strongly O-
glycosylated. Furthermore, six representatives of the membrane type (MT) MMPs subgroup 
hold either a type I transmembrane domain with a short intracellular segment (MT1, -2, -3 
and -5-MMP) or a cell membrane-anchoring glycosylphosphatidylinositol (GPI) moiety 
(MT4- and -6-MMP). 
Unlike other MMPs, in the MMP-23 molecule, a cystein-rich segment with an 
immunoglobulin-like domain is present, instead of the hemopexin-like domain on C-
terminus, whereas the N-terminal signal peptide has been replaced by an N-terminal type II 
transmembrane domain. In addition to the previously mentioned common components, 
other elements, attached to the catalytic domain are fibronectin II-like inserts, which are 
found in MMP-2 and -9 molecules exclusively. Furthermore, three of the secreted MMPs 
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sequence R(X/R)KR between the prodomain and the catalytic domain. This motif is 
recognized and cleaved by a serine proteinase – furin, that results in removal of prodomain 
from the active site of the catalytic domain, followed by intracellular activation of 
mentioned MMPs (Fanjul-Fernandez et al., 2010).  
3.2 Classification of MMPs 
Traditionally, MMPs were classified into 6 main groups – collagenases, gellatinases, 
stromelysins, matrilysins, membrane type MMPs and others, unclassified to former groups. 
However, increasing knowledge, concerning the molecular structure, substrate specificity 
and mechanism of MMPs activation contributed to an arrangement of their new 
classification. According to this classification, MMPs are divided into four groups: 
archetypal MMPs, matrilysins, gelatinases and furin-activated MMPs (Fanjul-Fernandez et 
al., 2010, Hadler-Olsen et al., 2011) 
3.2.1 Archetypal MMPs 
Archetypal MMPs have the structure typical for all MMPs. They are further divided into 
three subgroups: collagenases, stromelysins and other archetypal MMPs. 
3.2.1.1 Collagenases 
This subgroup of archetypal MMPs is represented by three enzymes: collagenase-1 (MMP-
1), collagenase-2 (MMP-8), and collagenase-3 (MMP-13). Their main common feature is the 
ability to cleave native collagens into characteristic N-terminal ¾ and C-terminal ¼ 
fragments (Fanjul-Fernandez et al., 2010). Since the triple helix conformation of native 
collagens is highly resistant to cleavage mediated by other proteinases, collagenases are 
crucial enzymes for initiation of collagen degradation. After the cleavage mediated by 
collagenases, the native collagens rapidly denature to gelatin and thus they become 
susceptible to degradation by other MMPs. 
Besides the native fibrillar collagens (types I, II, III, V, and XI), the other targets for 
collagenases are numerous extracellular matrix components, as well as non-ECM molecules, 
including IL-8, pro-TNF, protease-activated receptor-1, several insulin-like growth factor-
binding proteins (IGFBPs), etc… (Gearing et al., 1994; Boire et al., 2005; Amalinei et al., 
2007). 
The activation of MMP-1 requires a presence of active MMP-3 or plasminogen 
activator/plasmin system. The main sources of collagenases are stimulated fibroblasts 
(MMP-1), neutrophils (MMP-8) and VSMC (MMP-1 and MMP-13). Increased levels of 
mRNA and proteins for collagenases were found in aortic aneurysm tissue (Kadoglou & 
Liapis, 2004). Moreover, they are supposed to be involved in aneurysm rupture. 
The studies focused on a presumable connection between aortic aneurysm formation and 
known SNPs in genes encoding for collagenases, including potentially clinically relevant 
SNP in MMP-1 promoter region (-1607 G/GG), did not reveal any significant correlation 
(Ogata et al., 2004; Sandford et al., 2007; Saratzis et al., 2011). 
3.2.1.2 Stromelysins 
The members of this group are stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10). Both 
stromelysins have a structure analogous to that of collagenases, however, in contrast to 
those enzymes, stromelysins are not able to cleave native collagen. Their substrates 
include processed collagen types III, IV, V, IX and X, laminin, gelatin, fibronectin, 
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proteoglycans and several other molecules, e.g. plasminogen, fibrinogen and IL-1β 
(Amalinei et al., 2007). Although both stromelysins display similar substrate specificity, 
MMP-3 reveals a grater proteolytic activity, as compared to MMP-10. Furthermore, MMP-
3 is known to activate various pro-MMPs (collagenases and gelatinases) by removal of 
their pro-domain, and therefore it is crucial for their activation (Suzuki et al., 1990; Visse 
& Nagase, 2003). Stromelysins may be produced by fibroblasts and epithelial cells, 
however, in aortic aneurysm tissue their main source seem to be macrophages (Fanjul-
Fernandez et al., 2010). 
The possible clinical relevance of nucleotide polymorphism in promoter region of genes 
encoding for both, MMP-3 and MMP-10, has been studied by several authors (Sandford et 
al., 2007; Saratzis et al., 2011). It has been found, that in the MMP-3 promoter, at the position 
-1171, corresponding to the transcriptional start site, two variants – one of them, containing 
5 adenosines (5A) and the other one with 6 adenosines (6A), may be present. In vitro tests 
have shown, that the 5A allele has nearly two fold higher activity, than the 6A variant. 
Presumably, this could be due to the higher affinity of the transcriptional repressor p50/p50 
to 6A, than to the 5A allele. Epidemiological studies have shown, that the mentioned 5A/6A 
polymorphism of MMP-3 promoter may be associated with various cardiovascular diseases. 
It was revealed that 5A/5A homozygotic individuals are significantly more susceptible to 
hypertension, myocardial infarction and coronary artery aneurysms. 
Interestingly, the 6A/6A variant carriers displayed a higher growth rate of atherosclerotic 
plaque, which, on the other hand, was more stable, than in patients with the 5A allele. Yoon 
and coauthors have observed a trend (p=0.06) for a higher 5A allele frequency in a small 
cohort of 47 Finnish patients with abdominal aortic aneurysm (Yoon et al., 1999). The higher 
5A allele frequency among aortic aneurysm-suffering patients compared to a control group 
was also confirmed in a British population (Ye, 2006). 
In contrast to MMP-3, studies concerning the presumable role of MMP-10 gene 
polymorphisms, including -180 A/G SNP, have failed to reveal any significant correlation 
with a prevalence of aortic aneurysm (Ogata et al., 2005). 
3.2.1.3 Other archetypal MMPs 
This subgroup of archetypal MMPs includes four enzymes: MMP-12, MMP-19, MMP-20 and 
MMP-27. The representative of this subgroup – MMP-12, also known as macrophage 
metalloelastase, is mainly expressed and secreted by activated macrophages and is 
necessary for its migration (Visse & Nagase, 2003; Kadoglou & Liapis, 2004). The main 
substrate for MMP-12 is elastin, but the enzyme may cleave some other ECM molecules, 
including aggrecan, fibronectin, laminin, and type IV collagen. 
The increased expression of MMP-12 was found exclusively in aortic aneurysm wall, but not 
in the control, or atherosclerotic aorta specimens. Immunohistochemical studies have 
localized MMP-12 within the media of aortic aneurysms, predominantly in zones adjacent to 
non-dilated aorta. However, although MMP-12 is recognized as a key player in aneurysm 
formation, its prominent role has been neglected in the elastase-induced aneurysm animal 
model. Interestingly, it has been found that MMP-12-deficient mice revealed aortic 
dilatation similar to that of wild type animals, whereas mice lacking MMP-9 were resistant 
to aneurysm induction. Therefore, it was suggested that MMP-12 role is restricted rather to 
supporting other MMPs in aneurysm formation (Kadoglou & Liapis, 2004). 
The analysis of polymorphic sites in the MMP-12 gene and in vitro studies suggested the 
possible connection between A to G substitution in -82 position of the promoter and the 
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sequence R(X/R)KR between the prodomain and the catalytic domain. This motif is 
recognized and cleaved by a serine proteinase – furin, that results in removal of prodomain 
from the active site of the catalytic domain, followed by intracellular activation of 
mentioned MMPs (Fanjul-Fernandez et al., 2010).  
3.2 Classification of MMPs 
Traditionally, MMPs were classified into 6 main groups – collagenases, gellatinases, 
stromelysins, matrilysins, membrane type MMPs and others, unclassified to former groups. 
However, increasing knowledge, concerning the molecular structure, substrate specificity 
and mechanism of MMPs activation contributed to an arrangement of their new 
classification. According to this classification, MMPs are divided into four groups: 
archetypal MMPs, matrilysins, gelatinases and furin-activated MMPs (Fanjul-Fernandez et 
al., 2010, Hadler-Olsen et al., 2011) 
3.2.1 Archetypal MMPs 
Archetypal MMPs have the structure typical for all MMPs. They are further divided into 
three subgroups: collagenases, stromelysins and other archetypal MMPs. 
3.2.1.1 Collagenases 
This subgroup of archetypal MMPs is represented by three enzymes: collagenase-1 (MMP-
1), collagenase-2 (MMP-8), and collagenase-3 (MMP-13). Their main common feature is the 
ability to cleave native collagens into characteristic N-terminal ¾ and C-terminal ¼ 
fragments (Fanjul-Fernandez et al., 2010). Since the triple helix conformation of native 
collagens is highly resistant to cleavage mediated by other proteinases, collagenases are 
crucial enzymes for initiation of collagen degradation. After the cleavage mediated by 
collagenases, the native collagens rapidly denature to gelatin and thus they become 
susceptible to degradation by other MMPs. 
Besides the native fibrillar collagens (types I, II, III, V, and XI), the other targets for 
collagenases are numerous extracellular matrix components, as well as non-ECM molecules, 
including IL-8, pro-TNF, protease-activated receptor-1, several insulin-like growth factor-
binding proteins (IGFBPs), etc… (Gearing et al., 1994; Boire et al., 2005; Amalinei et al., 
2007). 
The activation of MMP-1 requires a presence of active MMP-3 or plasminogen 
activator/plasmin system. The main sources of collagenases are stimulated fibroblasts 
(MMP-1), neutrophils (MMP-8) and VSMC (MMP-1 and MMP-13). Increased levels of 
mRNA and proteins for collagenases were found in aortic aneurysm tissue (Kadoglou & 
Liapis, 2004). Moreover, they are supposed to be involved in aneurysm rupture. 
The studies focused on a presumable connection between aortic aneurysm formation and 
known SNPs in genes encoding for collagenases, including potentially clinically relevant 
SNP in MMP-1 promoter region (-1607 G/GG), did not reveal any significant correlation 
(Ogata et al., 2004; Sandford et al., 2007; Saratzis et al., 2011). 
3.2.1.2 Stromelysins 
The members of this group are stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10). Both 
stromelysins have a structure analogous to that of collagenases, however, in contrast to 
those enzymes, stromelysins are not able to cleave native collagen. Their substrates 
include processed collagen types III, IV, V, IX and X, laminin, gelatin, fibronectin, 
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proteoglycans and several other molecules, e.g. plasminogen, fibrinogen and IL-1β 
(Amalinei et al., 2007). Although both stromelysins display similar substrate specificity, 
MMP-3 reveals a grater proteolytic activity, as compared to MMP-10. Furthermore, MMP-
3 is known to activate various pro-MMPs (collagenases and gelatinases) by removal of 
their pro-domain, and therefore it is crucial for their activation (Suzuki et al., 1990; Visse 
& Nagase, 2003). Stromelysins may be produced by fibroblasts and epithelial cells, 
however, in aortic aneurysm tissue their main source seem to be macrophages (Fanjul-
Fernandez et al., 2010). 
The possible clinical relevance of nucleotide polymorphism in promoter region of genes 
encoding for both, MMP-3 and MMP-10, has been studied by several authors (Sandford et 
al., 2007; Saratzis et al., 2011). It has been found, that in the MMP-3 promoter, at the position 
-1171, corresponding to the transcriptional start site, two variants – one of them, containing 
5 adenosines (5A) and the other one with 6 adenosines (6A), may be present. In vitro tests 
have shown, that the 5A allele has nearly two fold higher activity, than the 6A variant. 
Presumably, this could be due to the higher affinity of the transcriptional repressor p50/p50 
to 6A, than to the 5A allele. Epidemiological studies have shown, that the mentioned 5A/6A 
polymorphism of MMP-3 promoter may be associated with various cardiovascular diseases. 
It was revealed that 5A/5A homozygotic individuals are significantly more susceptible to 
hypertension, myocardial infarction and coronary artery aneurysms. 
Interestingly, the 6A/6A variant carriers displayed a higher growth rate of atherosclerotic 
plaque, which, on the other hand, was more stable, than in patients with the 5A allele. Yoon 
and coauthors have observed a trend (p=0.06) for a higher 5A allele frequency in a small 
cohort of 47 Finnish patients with abdominal aortic aneurysm (Yoon et al., 1999). The higher 
5A allele frequency among aortic aneurysm-suffering patients compared to a control group 
was also confirmed in a British population (Ye, 2006). 
In contrast to MMP-3, studies concerning the presumable role of MMP-10 gene 
polymorphisms, including -180 A/G SNP, have failed to reveal any significant correlation 
with a prevalence of aortic aneurysm (Ogata et al., 2005). 
3.2.1.3 Other archetypal MMPs 
This subgroup of archetypal MMPs includes four enzymes: MMP-12, MMP-19, MMP-20 and 
MMP-27. The representative of this subgroup – MMP-12, also known as macrophage 
metalloelastase, is mainly expressed and secreted by activated macrophages and is 
necessary for its migration (Visse & Nagase, 2003; Kadoglou & Liapis, 2004). The main 
substrate for MMP-12 is elastin, but the enzyme may cleave some other ECM molecules, 
including aggrecan, fibronectin, laminin, and type IV collagen. 
The increased expression of MMP-12 was found exclusively in aortic aneurysm wall, but not 
in the control, or atherosclerotic aorta specimens. Immunohistochemical studies have 
localized MMP-12 within the media of aortic aneurysms, predominantly in zones adjacent to 
non-dilated aorta. However, although MMP-12 is recognized as a key player in aneurysm 
formation, its prominent role has been neglected in the elastase-induced aneurysm animal 
model. Interestingly, it has been found that MMP-12-deficient mice revealed aortic 
dilatation similar to that of wild type animals, whereas mice lacking MMP-9 were resistant 
to aneurysm induction. Therefore, it was suggested that MMP-12 role is restricted rather to 
supporting other MMPs in aneurysm formation (Kadoglou & Liapis, 2004). 
The analysis of polymorphic sites in the MMP-12 gene and in vitro studies suggested the 
possible connection between A to G substitution in -82 position of the promoter and the 
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aortic aneurysm expansion. However, none of the clinical trials have confirmed the expected 
correlation to date (Sandford et al., 2007; Saratzis et al., 2011). 
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3.2.2 Matrilysins  
Matrilysins are represented by matrilysin-1 (MMP-7) and matrilysin-2 (MMP-26, or 
endometase). The most prominent feature of matrilysins group members is the lack of the 
hemopexin domain. MMP-26 is the smallest known MMP; it is composed of only 261 amino 
acids and may activate itself by autocatalysis. Matrilysins play an important role in 
degradation of ECM molecules, including type IV collagen, laminin, entactin, as well as 
several cell surface molecules, e.g. Fas ligand, E-cadherin and syndecan-1 (Fanjul-Fernandez 
et al., 2010). Due to a shedding of membrane-bound Fas ligand and generation of its soluble 
form, matrilysins may stimulate apoptosis. Furthermore, while cleaving plasminogen to 
produce an angiostatin fragments, matrilysins are involved in inhibition of angiogenesis. 
Interestingly, MMP-26 has an ability to activate pro-MMP-9 in a specific site, that results in 
better stability of MMP-9 (Zhaoet al., 2003; Amalinei et al., 2007). Moreover, intracellular 
MMP-26 was found to process the estrogen receptor β, therefore in patients with breast 
cancer an increased MMP-26 level was found to correlate with longer survival (Hadler-
Olsen et al., 2011 ) 
3.2.3 Gelatinases 
The group of gelatinases consists of two members: gelatinase A (MMP-2) and gelatinase B 
(MMP-9). Both of them are constitutively expressed by many cells, including fibroblasts, 
keratinocytes, endothelial cells, polymorphonuclear leukocytes, monocytes, alveolar 
macrophages and osteoclasts. When compared to other MMPs, the most significant 
difference in the structure of gelatinases is the presence of three type II fibronectin-like 
repeats within the catalytic domain. They are responsible for recognition and binding of 
denatured collagen and gelatin molecules (Visse & Nagase, 2003). Gelatinases may cleave 
various extracellular matrix molecules, e.g. collagen types I, IV, V, VII, IX, X, elastin, 
fibronectin, aggrecan, vitronectin, laminin, as well as numerous non-ECM molecules, 
including pro-TNF, TGF-β, pro-IL-1β and pro-IL-8 (Fanjul-Fernandez et al., 2010). Moreover, 
they are involved in generation of several pro- and anti-angiogenic factors, which may 
originate from both, ECM and non-ECM substrates (Mott & Werb, 2004). 
Gelatinases are considered the most important members of the MMPs family, involved in 
pathogenesis of aortic aneurysm. The amounts of mRNA and specific proteins in the 
aneurysm wall, as well, as plasma levels of both, MMP-2 and MMP-9, were statistically 
significantly higher in patients with aortic aneurysms, as compared to healthy controls. 
Moreover, it has been found that plasma levels of gelatinases noticeably correlate with 
aneurysm expansion rate and therefore they were suggested as presumable predictors of the 
aneurysm rupture risk. In an animal experimental study it was proven, that infusion of 
gelatinases resulted in development of aortic aneurysms. Interestingly, MMP-2- and/or 
MMP-9-deficient mice were resistant to aneurysm formation in this model (Longo et al., 
2002; Baxter, 2004; Kadoglou & Liapis, 2004). 
Recently, it has been postulated, that, in addition to elastin degradation, gelatinases may 
also be engaged in the pathogenesis of aortic aneurysm in a proteolysis-independent 
fashion. This hypothesis is based on the observation, that both, MMP-2 and MMP-9, may 
display some inhibitory influence on the calcium-dependent contraction of VSMC isolated 
from the aortic wall (Raffetto & Khalil, 2008). In addition to maintenance of aortic wall 
integrity, the contraction of those cells is considered as a counterbalance of hemodynamic 
forces, that protects the aorta against dilatation during each cardiac cycle. Thus, the MMP-
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aortic aneurysm expansion. However, none of the clinical trials have confirmed the expected 
correlation to date (Sandford et al., 2007; Saratzis et al., 2011). 
 






Collagens (I, II, III, VII, 
VIII and X), gelatin, 







Collagens (I, II, III, V, VII, 






Collagens (I, II, III, IV, IX, 
X, XIV), gelatin, aggrecan, 






Collagens (III, IV, V and 
IX), gelatin, aggrecan 
versican, hyaluronidase-
treated versican, perle- 
can, decorin, proteoglycan 






substance P, IL-1β, 
serum amyloid A, 
IGFBP-3, fibrinogen 
and cross- linked 





Collagens (III, IV and V), 
gelatin, casein, aggrecan, 






Collagen IV, gelatin, 








MMP-19 RASI Gelatin ND 
MMP-20 Enamelysin Amelogenin ND 
MMP-27              -                                                     ND 
Matrilysins 
MMP-7 Matrilysin 
Collagens IV and X, 
gelatin, aggrecan, decorin, 
proteoglycan link protein, 
fibronectin, laminin, 
insoluble fibronectin 
fibrils, entactin, large and 
small tenascin-C, 
osteonectin, β4 integrin, 
elastin, casein, transferrin









Matrix Metalloproteinases in Aortic Aneurysm – Executors or Executioners? 
 
33 
3.2.2 Matrilysins  
Matrilysins are represented by matrilysin-1 (MMP-7) and matrilysin-2 (MMP-26, or 
endometase). The most prominent feature of matrilysins group members is the lack of the 
hemopexin domain. MMP-26 is the smallest known MMP; it is composed of only 261 amino 
acids and may activate itself by autocatalysis. Matrilysins play an important role in 
degradation of ECM molecules, including type IV collagen, laminin, entactin, as well as 
several cell surface molecules, e.g. Fas ligand, E-cadherin and syndecan-1 (Fanjul-Fernandez 
et al., 2010). Due to a shedding of membrane-bound Fas ligand and generation of its soluble 
form, matrilysins may stimulate apoptosis. Furthermore, while cleaving plasminogen to 
produce an angiostatin fragments, matrilysins are involved in inhibition of angiogenesis. 
Interestingly, MMP-26 has an ability to activate pro-MMP-9 in a specific site, that results in 
better stability of MMP-9 (Zhaoet al., 2003; Amalinei et al., 2007). Moreover, intracellular 
MMP-26 was found to process the estrogen receptor β, therefore in patients with breast 
cancer an increased MMP-26 level was found to correlate with longer survival (Hadler-
Olsen et al., 2011 ) 
3.2.3 Gelatinases 
The group of gelatinases consists of two members: gelatinase A (MMP-2) and gelatinase B 
(MMP-9). Both of them are constitutively expressed by many cells, including fibroblasts, 
keratinocytes, endothelial cells, polymorphonuclear leukocytes, monocytes, alveolar 
macrophages and osteoclasts. When compared to other MMPs, the most significant 
difference in the structure of gelatinases is the presence of three type II fibronectin-like 
repeats within the catalytic domain. They are responsible for recognition and binding of 
denatured collagen and gelatin molecules (Visse & Nagase, 2003). Gelatinases may cleave 
various extracellular matrix molecules, e.g. collagen types I, IV, V, VII, IX, X, elastin, 
fibronectin, aggrecan, vitronectin, laminin, as well as numerous non-ECM molecules, 
including pro-TNF, TGF-β, pro-IL-1β and pro-IL-8 (Fanjul-Fernandez et al., 2010). Moreover, 
they are involved in generation of several pro- and anti-angiogenic factors, which may 
originate from both, ECM and non-ECM substrates (Mott & Werb, 2004). 
Gelatinases are considered the most important members of the MMPs family, involved in 
pathogenesis of aortic aneurysm. The amounts of mRNA and specific proteins in the 
aneurysm wall, as well, as plasma levels of both, MMP-2 and MMP-9, were statistically 
significantly higher in patients with aortic aneurysms, as compared to healthy controls. 
Moreover, it has been found that plasma levels of gelatinases noticeably correlate with 
aneurysm expansion rate and therefore they were suggested as presumable predictors of the 
aneurysm rupture risk. In an animal experimental study it was proven, that infusion of 
gelatinases resulted in development of aortic aneurysms. Interestingly, MMP-2- and/or 
MMP-9-deficient mice were resistant to aneurysm formation in this model (Longo et al., 
2002; Baxter, 2004; Kadoglou & Liapis, 2004). 
Recently, it has been postulated, that, in addition to elastin degradation, gelatinases may 
also be engaged in the pathogenesis of aortic aneurysm in a proteolysis-independent 
fashion. This hypothesis is based on the observation, that both, MMP-2 and MMP-9, may 
display some inhibitory influence on the calcium-dependent contraction of VSMC isolated 
from the aortic wall (Raffetto & Khalil, 2008). In addition to maintenance of aortic wall 
integrity, the contraction of those cells is considered as a counterbalance of hemodynamic 
forces, that protects the aorta against dilatation during each cardiac cycle. Thus, the MMP-
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mediated reversible inhibition of vascular myocytes contraction could promote aneurysm 
progression. However, this issue requires further elucidation. 
3.2.3.1 MMP-2 (Gelatinase A) 
MMP-2, or gellatinase A, is constitutively expressed by vascular myocytes, however, it may 
be produced in small amounts by macrophages and fibroblasts, too. As described in  chapter 
3.4, the activation of MMP-2 occurs mainly by its interaction with MT1-MMP/TIMP-2. Due 
to its elastolytic activity, MMP-2 is believed to play a pivotal role in aortic aneurysm 
development. It was found, that VSMC isolated from aortic aneurysm tissue produced 
higher amounts of MMP-2, as compared to those from atherosclerotic, or normal aortic wall. 
Surprisingly, the activity of MMP-2 negatively correlated with aneurysms diameter. This 
observation could support the opinion, that MMP-2 may be essential in the early stages of 
aneurysm development. Besides weakness of the aortic wall, MMP-2-mediated degradation 
of elastic fibers may lead to production of elastin-derived peptides, which have a great 
chemotactic potential. These peptides may promote recruitment of inflammatory cells and 
enhance further proteolysis. Moreover, MMP-2 liberates TGF-β from an inactive 
extracellular complex consisting of TGF-β, latent TGF-β binding protein and TGF-β-latency 
associated protein, which may stimulate various MMPs expression and results in further 
progression of the disease (Rizas et al., 2009). 
Among 18 polymorphisms found in the MMP-2 gene, the SNP located in a promoter (-1306 
C/T) was initially considered as clinically relevant. The studies focusing on the influence of 
this particular SNP on promoter function have shown, that the presence of C allele was 
associated with a higher promoter activity (Price et al., 2001). However, none of clinical 
studies, addressed at verifying a possible correlation between -1306 C/T SNP and aortic 
aneurysm prevalence, has revealed such a connection (Eriksson et al., 2005; Ogata et al., 
2005; Sandford et al., 2007; Saratzis et al., 2011). 
3.2.3.2 MMP-9 (Gelatinase B) 
MMP-9, or gellatinase B, is mainly produced by macrophages and neutrophils. 
Subsequently to proteolytic activation by a variety of factors, including plasminogen 
activators and other MMPs (MMP-2, -3, -12), MMP-9 displays elastolytic, collagenolytic and 
gelatinolytic activity. The leader position of MMP-9 in the pathogenesis of aortic aneurysm 
may be confirmed by several observations. Animal studies have shown, that MMP-9-
deficient mice were resistant to experimentally induced aortic dilation and they did not 
reveal elastin degradation despite the presence of inflammatory cell in the aortic wall 
(Kadoglou & Liapis, 2004; Baxter, 2004). On the other hand, among all metalloproteinases, 
MMP-9 is the most abundantly expressed enzyme in aortic aneurysm wall, in contrast to 
normal aortic tissue, where it was not present. Also, huge amounts of MMP-9 are released 
by neutrophils trapped in the intraluminal thrombus (see also chapter 2.1). Furthermore, 
high MMP-9 concentrations were detected in ruptured aneurysms. However, although 
patients with an aortic aneurysm have significantly higher levels of MMP-9, than control 
individuals, there is no consensus regarding a direct correlation between MMP-9 plasma 
levels and aneurysm progression and rupture risk to date (Takagi et al., 2009; Eugster et al., 
2005). Therefore, this issue still requires further elucidation. 
Several polymorphisms have been found in the MMP-9 gene. Most of the studies have 
focused on -1562 C/T polymorphism in a promoter region. It has been proven that a 
common T to C substitution in -1562 position of the MMP-9 promoter is associated with 
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approximately 50% increase of the promoter activity. A clinical study by Medley and 
coauthors has shown that mRNA level, protein concentration, as well as enzymatic activity 
of MMP-9 in aortic aneurysm tissues of -1562 T allele carriers were significantly higher, as 
compared to those with the -1562 C variant. Also, plasma levels of MMP-9 were much 
higher in -1562 T carriers, than in patients with -1562 C allele (Medley et al., 2004). 
Furthermore, Jones and coauthors have also reported a higher frequency of the -1562 T 
variant in a group of patients with aortic aneurysm (n=414), in comparison to individuals 
with atherosclerotic peripheral vascular disease (n=172, adjusted odds ratio 2.94), or healthy 
control subjects (n=203, adjusted odds ratio 2.41) (Jones et al., 2003). 
Interestingly, subsequent studies, independently conducted by Ogata and Eriksson on large 
groups of aortic aneurysm-suffering individuals (n=387 and n=455, respectively) have failed 
to confirm this association (Ogata et al., 2005; Eriksson et al., 2005). In a large study by 
Smallwood and coauthors, carried out on 678 patients with aortic aneurysms and 659 
healthy controls, no statistically significant association between occurrence of the -1562 T 
allele and development of aortic aneurysm was found (Sandford et al., 2007; Smallwood et 
al., 2008; Saratzis et al., 2011). 
It is noteworthy, that although recent studies have negated the direct involvement of -1562 
C/T polymorphism in pathogenesis of aortic aneurysm, the potential importance of other 
functional polymorphisms in the MMP-9 gene cannot be excluded. Presumably, two 
additional functional SNPs – the first located in the exon encoding for catalytic domain 
(Q279R), and the next relating to the sequence encoding for hemopexin domain (P574R), 
could be considered as attractive candidates for further studies. 
3.2.4 Furin-activated MMPs 
The members of this group are characterized by the presence of an unique RXKR or RRKR 
sequence, inserted between the prodomain and the catalytic domain. This site is recognized 
and cleaved by pro-protein convertases or serine proteinases – furins, thus resulting in an 
activation of enzyme. The furin-activated MMPs are further divided into small subgroups: 
secreted MMPs, membrane-type I and type II MMPs and GPI-anchored MMPs (Fu et al., 
2008; Fanjul-Fernandez et al., 2010). 
The furin-activated secreted MMPs include MMP-11, MMP-21 and MMP-28. In contrast to 
other secreted MMPs, members of this subgroup undergo intracellular processing by furin, 
or furin-like proteases and therefore they are secreted already in active form (Fanjul-
Fernandez et al., 2010). 
3.2.4.1 Membrane type MMPs 
All the membrane type MMPs (MT-MMPs) contain a hydrophobic component that enables 
their insertion in the cell membrane. They control the close neighborhood of both, normal 
and pathological cells, thus being involved in promoting of cell migration, invasion, 
experimental metastasis and angiogenesis (Hernandez-Barrantes et al., 2002). 
Type I transmembrane MMPs include: MT1-, MT2-, MT3-, and MT5-MMP (MMP-14, -15, -
16, and -24, respectively). They are characterized by a long hydrophobic transmembrane 
sequence followed by a short cytoplasmic tail, which could participate in several signaling 
pathways. The main representative of this subgroup, MT1-MMP (MMP-14) may be 
expressed on the cell surface of various cells, however, activated macrophages and VSMC 
are considered as its most important producers. It may cleave native type I collagen into  
¾ – ¼ fragments in a collagenase-specific fashion. Apart from collagen I, MT1-MMP is able 
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mediated reversible inhibition of vascular myocytes contraction could promote aneurysm 
progression. However, this issue requires further elucidation. 
3.2.3.1 MMP-2 (Gelatinase A) 
MMP-2, or gellatinase A, is constitutively expressed by vascular myocytes, however, it may 
be produced in small amounts by macrophages and fibroblasts, too. As described in  chapter 
3.4, the activation of MMP-2 occurs mainly by its interaction with MT1-MMP/TIMP-2. Due 
to its elastolytic activity, MMP-2 is believed to play a pivotal role in aortic aneurysm 
development. It was found, that VSMC isolated from aortic aneurysm tissue produced 
higher amounts of MMP-2, as compared to those from atherosclerotic, or normal aortic wall. 
Surprisingly, the activity of MMP-2 negatively correlated with aneurysms diameter. This 
observation could support the opinion, that MMP-2 may be essential in the early stages of 
aneurysm development. Besides weakness of the aortic wall, MMP-2-mediated degradation 
of elastic fibers may lead to production of elastin-derived peptides, which have a great 
chemotactic potential. These peptides may promote recruitment of inflammatory cells and 
enhance further proteolysis. Moreover, MMP-2 liberates TGF-β from an inactive 
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approximately 50% increase of the promoter activity. A clinical study by Medley and 
coauthors has shown that mRNA level, protein concentration, as well as enzymatic activity 
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Type I transmembrane MMPs include: MT1-, MT2-, MT3-, and MT5-MMP (MMP-14, -15, -
16, and -24, respectively). They are characterized by a long hydrophobic transmembrane 
sequence followed by a short cytoplasmic tail, which could participate in several signaling 
pathways. The main representative of this subgroup, MT1-MMP (MMP-14) may be 
expressed on the cell surface of various cells, however, activated macrophages and VSMC 
are considered as its most important producers. It may cleave native type I collagen into  
¾ – ¼ fragments in a collagenase-specific fashion. Apart from collagen I, MT1-MMP is able 
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to process various components of extracellular matrix, including collagens type II and III, 
gelatin, fibronectin, as well, as non-ECM molecules, e.g. hyaluronan receptor (CD44), 
myelin-inhibitory protein and α-2 macroglobulin (Fanjul-Fernandez et al., 2010). 
Furthermore, as previously mentioned, MT1-MMP plays a key role in the proteolytic 
activation of pro-MMP-2 (see chapter 3.4). 
 
Group Subgroup MMP Common name 
Substrates 
Extracellular matrix (ECM) Non-ECM 
Gelatinases 
MMP-2 Gelatinase A
Collagens (I, IV, V, VII, X, XI 
and XIV), gelatin, elastin, 
fibronectin, laminin-1, laminin-
5, galectin-3, aggrecan, decorin, 
hyaluronidase-treated versican, 








Collagens (IV, V, VII, X and 
XIV), gelatin, elastin, galectin-3, 
aggrecan, fibronectin, 
hyaluronidase-treated versican, 









Casein, laminin, fibronectin, 




MMP-21 XMMP ND 




Collagens (I, II and III), casein, 
elastin, fibronectin, gelatin, 






Large tenascin-C, fibronectin, 
laminin, entactin, aggrecan, 
perlecan 
MMP-2 
MMP-16 MT3-MMP Collagen-III, gelatin, casein, fibronectin MMP-2 
MMP-24 MT5-MMP ND 
GPI-anchored 
MMP-17 MT4-MMP ND 




23A - ND 
MMP-
23B - ND 
ND – not determined 
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Recently, it was found, that mRNA and protein levels of MT-MMP-1 were significantly 
higher among patients with an aortic aneurysm, than in healthy controls or atherosclerosis-
suffering subjects. Therefore, it is suggested, that MT-MMP-1 may also be important in 
pathogenesis of aortic aneurysm, especially due to its multidirectional action. Besides direct 
destruction of extracellular matrix components, MT1-MMP activates MMP-2 and facilitates 
migration of macrophages, thus promoting inflammatory infiltration of the aortic wall 
(Kadoglou & Liapis, 2004). 
Type II transmembrane MMPs are represented by enzymes: MMP-23A and MMP-23B, 
which, despite being encoded by two different genes, actually have an identical amino acid 
sequence. Their structure is significantly distinct from other MMPs, since they lack the 
signal peptide, the cysteine-switch motif and the hemopexin domain. Moreover, opposite to 
type I MT-MMPs, they have a transmembrane domain located in their N-terminal tail, 
whereas C-terminus contains a cysteine array and immunoglobulin-like domains (Fanjul-
Fernandez et al., 2010). 
The last subgroup of MT-MMPs includes MT4-MMP and MT6-MMP (MMP-17 and -25, 
respectively). Both of them have the glycosylphosphatidylinositol (GPI) anchor instead of a 
transmembrane domain on their C-terminus, that enables binding of the MMP molecule to 
the cell membrane. To date, little is known about the presumable role of other MT-MMPs in 
pathogenesis of aortic aneurysm, with the exception of MT1-MMP, therefore, this subject 
still requires further studies. 
3.3 Regulation of expression 
The critical role of MMPs in physiology, as well as their involvement in various pathological 
conditions decipher the tight control of production and activation of these enzymes. Among 
all MMPs, only MMP-2 and MMP-9 were found to be expressed constitutively, whereas the 
expression of the remaining members of the MMP family has to be induced, e.g. in response 
to a tissue remodeling, or inflammatory reaction. Numerous factors, including pro-
inflammatory cytokines (IL-1β, IL-6, TNF, etc.), growth factors (platelet-derived growth 
factor – PDGF; epidermal growth factor – EGF; TGF-β; etc.) and corticosteroids are involved 
in the control of MMPs gene expression Kadoglou & Liapis, 2004; Diehm et al., 2007). The 
common feature of the majority of inducible genes, including these encoding for MMPs, is 
the presence of the binding sites for transcription factors AP-1 and/or NF-κB in their 
promoter region. AP-1 transcription factors are heterodimer complexes, composed of two 
proto-oncogene family proteins – Jun and Fos. Together with NF-κB, a p50/p65 
heterodimer, which controls the expression of numerous immune response- and 
inflammation-engaged molecules, AP-1 complexes interconnect a number of growth factor- 
and cytokine-mediated pathways. Another group of transcription factors involved in 
regulation of MMPs expression are members of Ets family. They recognize and bind to the 
conserved polyomavirus enhancer activator protein-3 (Pea3) binding site, which is found in 
MMP promoters. Since the Pea3 binding site is located contiguously to at least one AP-1 
element, the interaction between both transcription factors will presumably modulate 
promoter response to various stimuli. Most recently, it was suggested that, in addition to the 
formerly discussed, the modification of chromatin structure through its acetylation-
deacetylation could be another mechanism, involved in the regulation of MMP genes 
expression. Interestingly, it has been found that inhibition of histone deacetylase (HDAC) 
results in enhanced MMP-3, but decreased MMP-1 and MMP-9 expression in response to 
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stimulation with IL-1β or TNF (Clark et al., 2007; Clark et al., 2008). Therefore, this aspect of 
MMPs expression control remains unclear and requires further studies. The next issue to be 
clarified is the role of mechanotransduction and the involvement of putative 
mechanoreceptors or mechano-responsive elements in MMPs expression control. This 
pathway seems to be of great importance especially in tissues permanently exposed to 
dynamic stress, like joint cartilage chondrocytes or VSMC in blood vessels (Blain, 2007). 
Finally, it is noteworthy, that besides transcriptional level, MMPs expression in response to 
various stimuli, including cytokines and growth factors, may also be controlled by the 
modulation of specific mRNA stability (Chakraborti et al., 2003). 
Most recently, it has been found that MMP-2 activity may also be modulated by protein 
kinase C–mediated phosphorylation at the post-translational level (Sariahmetoglu et al., 
2007). This modification may involve at least 5 amino acid residues from active site of 
catalytic domain and may result in modulation of its activity. Possibly, 3′-5′ cyclic adenosine 
monophosphate (cAMP) pathway may be involved in this step, too. 
3.4 Activation of MMPs 
As mentioned previously, all MMPs are produced and secreted in an inactive zymogen 
form. This status is maintained due to the presence of the “cysteine-switch”, the particular 
interaction between the thiol group of the prodomain cysteine and the zinc ion from the 
catalytic domain. The disruption of this interaction is essential for enzyme activation and 
may occur in two different manners (Fig. 2). 
The first mode is an alteration of the cysteine thiol group by some physiological factors, 
including disulfides, oxidants and electrophiles, as well as non-physiological compounds, 
among them denaturing surfactants with sodium dodecyl sulphate (SDS), alkylating 
agents, organomercurials with 4-aminophenylmercuric acetate (APMA), and heavy metal 
ions. This alteration results in some allosteric changes in MMP structure, followed by an 
exposure of the catalytic site of the enzyme. It may lead to the auto-cleavage and removal 
of prodomain, and thus is associated with reduction of enzyme molecular size. On the 
other hand, the prodomain may stay attached to the active enzyme and thus the 
molecular weight of activated MMP remains unchanged (Fu et al., 2008; Hadler-Olsen et 
al., 2011) (Fig. 2A). 
The second mechanism of MMPs activation is direct cleavage of their prodomain by another 
proteolytic enzyme. It has been shown that proteolytic activation of MMPs may be 
conducted by other MMPs, as well as a broad spectrum of extracellular serine-, cysteine- or 
aspartate-proteinases. Moreover, this mechanism is also utilized during an intracellular 
activation of MMPs by furin, the subtilisin-like serine proteinase from the trans-Golgi 
network (Fig. 2A). 
An interesting combination of both, allosteric and proteolytic mode of action, represents 
activation of MMP-2 by the membrane type 1-MMP (MT1-MMP, or MMP-14) in the 
presence of the endogenous MMP inhibitor – the tissue inhibitor of MMPs (TIMP)-2. The 
TIMP-2 molecule serves as a link between MMP-2 and MMP-14, where the N-terminal 
part of TIMP-2 inactivates MMP-14 and its C-terminal part binds to the hemopexin 
domain of pro-MMP-2 (Fig. 2B). The prodomain of immobilized MMP-2 is then cleaved 
by another recruited MMP-14 molecule, thus resulting in proteolytic activation of MMP-2. 
Remarkably, other membrane type MMPs: MT2-MMP and MT3-MMP are able to activate 
pro-MMP-2 without involvement of TIMP (Hadler-Olsen et al., 2011, Klein & Bischoff, 
2010). 
 





Fig. 2. The MMP activation pathways (a detailed description in text) 
3.5 Inhibition of MMPs 
When firmly supervised, matrix metalloproteinases control various physiological reactions 
very precisely. However, if this supervision appears incompetent, MMPs reveal their “dark 
side of the Force” and become highly dangerous molecules, which are engaged in many 
pathologies, including the development of an aortic aneurysm. Therefore, mechanisms 
responsible for this regulation and factors participating in these mechanisms are potentially 
useful in some therapeutic approaches.  
Standard mechanisms of MMPs silencing include interaction with the specific tissue 
inhibitors of metalloproteinases and other endogenous inhibitors, such as α2-macroglobulin, 
reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and tissue-factor-
pathway-inhibitor 2 (TFPI2) (Maskos & Bode, 2003). 
Surprisingly, although reactive oxygen species are known to activate autolytic cleavage of 
MMPs due to disruption of their “cysteine switch”, it has been suggested that oxidants may 
also inactivate MMPs by modification of some amino acids critical for their catalytic activity 
(Fu et al., 2008). 
3.5.1 TIMPs 
Tissue inhibitors of metalloproteinases are secreted by different types of cells, including 
macrophages, VSMC and platelets. The basically defined function of TIMPs is a suppression 
of the MMPs activity by biding to their catalytic domain and blocking enzymatic activity. 
Based on in vitro studies, TIMPs are recognized as highly efficient MMPs inhibitors (with Ki 
at the level of 10-11 M for TIMP-1/MMP-1 interaction). The affinity of various TIMPs to 
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other TIMPs are generally less selective. However, a direct interaction between TIMPs and 
active MMPs may be difficult to observe in vivo, mainly due to a presence of α2-
macroglobulin, a common MMP-neutralizing agent (Fu et al., 2008). On the other hand, as 
clearly shown for TIMP-2, as well as for other TIMPs, their binding to the hemopexin 
domain of pro-MMP-2 is actually necessary for the activation of this enzyme by MT1-MMP 
(Hadler-Olsen et al., 2011). 
It is plausible, that functional polymorphisms in genes encoding for TIMPs could influence 
the activity of MMPs in the aneurysm wall. Thus, several SNPs supposed to affect the level 
of TIMP transcription, were assessed in patients with aortic aneurysms. It is noteworthy, 
that the genotyping results were analyzed for male and female patients separately due to 
the fact, that TIMP-1 gene is located on the X chromosome. To date, the association with 
aortic aneurysm has been suggested for two polymorphisms in gene for TIMP-1 (434 C/T 
and rs2070584 T/C) (Ogata et al., 2005) and two in TIMP-2 (a promoter SNP -479 C/T, and 
573 G/A, but in male patients group only) (Wang et al., 1999; Hinterseher et al., 2007). 
Nevertheless, since the mentioned analyses concerned relatively small groups, this issue still 
requires additional investigation (Sandford et al., 2007; Saratzis et al., 2011). 
3.5.2 Pharmacological modulation of MMPs 
Since the modulation of MMPs activity by endogenous inhibitors in pathology seems to be 
inefficient, several strategies with exogenous MMP modulators have been developed. It is 
noteworthy, that some of these modulators are already used in clinical practice, although 
the primary indication for their application did not concern inhibition of MMPs. 
An interesting approach may be the use of MMP-specific antibody-based inhibitors. The 
experimental model with neutralizing antibodies directed against MMP-2 has shown their 
protective influence on a heart exposed to ischemia/reperfusion injury (Cheung et al., 2000). 
However, the verification, whether this procedure would be useful in management of aortic 
aneurysms, needs further studies. Apart from endogenous inhibitors, various 
pharmacological agents may reveal inhibitory activity against MMPs. The small 
hydroxamate-based zinc-chelating synthetic agents, such as batimastat, marimastat or 
ilomastat (galardin), were first used in oncology, to suppress MMPs-dependent metastasis 
and tumor invasion. However, due to non-selective, generalized inhibition of MMPs activity 
with numerous adverse events, accompanied by relatively poor effectiveness, their clinical 
career was ended very soon (Baxter, 2004). 
3.5.2.1 Tetracyclines 
Tetracyclines are natural antibiotics derived from Streptomyces. They are known for many 
non-antibiotic properties, including inhibition of proteolysis, or anti-apoptotic and anti-
inflammatory activity. The most intensively tested representative of tetracyclines – 
doxycycline, has been shown to prevent formation of aortic aneurysm in several animal 
models. Also, the results of three small clinical trials in humans have shown that 
doxycycline in a well tolerated dose 150-200 mg/day significantly reduced aneurysm 
expansion rate. It has been suggested, that doxycycline inhibits MMPs directly, by binding 
to their catalytic site. Furthermore, it may reduce the MMP expression attenuating the 
inflammatory cascade. However, the results of the studies on putative effects of tetracyclines 
on MMP-9 are not fully consistent. The first published study by Cruci and coauthors has 
shown that doxycycline treatment in a dose 200 mg/day resulted in a 2.5-fold reduction of 
MMP-9 protein levels and 82% reduction of MMP-9 mRNA expression (Cruci et al., 1998). 
 
Matrix Metalloproteinases in Aortic Aneurysm – Executors or Executioners? 
 
41 
Surprisingly, in a subsequent placebo-controlled study Ding and colleagues did not observe 
any effect of 1 month 100 mg/day doxycycline therapy on MMP-9 mRNA, or protein 
expression (Ding et al., 2005). Finally, Lindeman and coauthors have shown that 2-weeks 
doxycycline treatment decreased MMP-9 protein levels (p<0.0026), but did not affect mRNA 
expression level (p=0.206). The authors have concluded, that the beneficial effect of 
doxycycline on aneurysm progression might be due to the reduction of aneurysm wall 
infiltration by neutrophils and T CD8-positive lymphocytes rather, than the decrease of 
MMP-9 gene expression (Lindeman et al., 2009). 
3.5.2.2 Macrolides 
The beneficial influence of tetracyclines on aneurysm expansion rate may be 
multidirectional, including their antimicrobial activity against Chlamydia pneumoniae, and 
thus, indirect MMPs modulation (also discussed in chapter 2.2). This concept led to the 
introduction of macrolides, other antibiotics with potent Chlamydia-killing activity, to the 
arsenal of anti-aneurysm agents. In a randomized trial by Vammen and coauthors, the aortic 
aneurysm expansion rate in patients treated with roxithromycin was 1.56 mm/year, in 
comparison to 2.75 mm/year in the placebo-receiving control group. Interestingly, no 
significant correlation between C. pneumoniae titers and roxithromycin ability to suppress 
the aneurysm expansion was observed (Vammen et al., 2001) . 
The mechanism of anti-aneurysm protective action of macrolides remains unclear. 
Recently, another macrolide derivative, rapamycin, was tested in animal aortic aneurysm 
model. Due to its strong anti-inflammatory and immunosuppressive properties, 
rapamycin is commonly used to prevent transplanted organ rejection. It has been found, 
that rapamycin administration in experimentally induced aortic aneurysms in rat 
significantly inhibits activation of NF-κB and, subsequently, MMP-9 expression thus 
resulting in 40% decrease of aneurysm expansion rate, as compared to control animals 
(Lawrence et al., 2004). 
3.5.2.3 Statins 
The inhibitors of hydroxymetylglutaryl-coenzyme A reductase, better known as statins, are 
widely used in a treatment of patients with cardiovascular diseases. Apart from their main 
activity, which decreases atherogenic lipoproteins, statins reveal various pleiotropic effects, 
including an augmentation of pro-apoptotic properties of some anticancer drugs, or an 
inhibition of inflammatory cell activity. Possibly, these anti-inflammatory properties of 
statins result from suppression of NF-κB, that is also involved in regulation of MMPs 
expression. Indeed, in vitro studies have demonstrated, that simvastatin and cerivastatin 
may decrease the production of MMPs, especially MMP-9, in VSMC, macrophages and 
neutrophils. A subsequent small clinical study by Nagashima, and a randomized 
prospective trial by Evans group independently showed, that statins were potent inhibitors 
of inflammatory cells in vivo, and they effectively suppressed the MMP-9 production in the 
aortic aneurysm wall (Nagashima et al., 2002; Evans et al., 2007). Also, Wilson and his 
colleagues observed, that simvastatin, pravastatin and atorvastatin decreased local 
concentrations of MMP-3 and MMP-9 in the anterior wall of aortic aneurysms in patients 
undergoing open heart surgery. Furthermore, as shown by Schouten and coauthors, statin 
use resulted in lower aneurysm expansion rate with 2.0 mm/year in statin-treated versus 3.6 
mm/year in the placebo control group (Schouten et al., 2006). Interestingly, in contrast to 
reports mentioned previously, Hurks and coauthors did not observe any statistically 
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other TIMPs are generally less selective. However, a direct interaction between TIMPs and 
active MMPs may be difficult to observe in vivo, mainly due to a presence of α2-
macroglobulin, a common MMP-neutralizing agent (Fu et al., 2008). On the other hand, as 
clearly shown for TIMP-2, as well as for other TIMPs, their binding to the hemopexin 
domain of pro-MMP-2 is actually necessary for the activation of this enzyme by MT1-MMP 
(Hadler-Olsen et al., 2011). 
It is plausible, that functional polymorphisms in genes encoding for TIMPs could influence 
the activity of MMPs in the aneurysm wall. Thus, several SNPs supposed to affect the level 
of TIMP transcription, were assessed in patients with aortic aneurysms. It is noteworthy, 
that the genotyping results were analyzed for male and female patients separately due to 
the fact, that TIMP-1 gene is located on the X chromosome. To date, the association with 
aortic aneurysm has been suggested for two polymorphisms in gene for TIMP-1 (434 C/T 
and rs2070584 T/C) (Ogata et al., 2005) and two in TIMP-2 (a promoter SNP -479 C/T, and 
573 G/A, but in male patients group only) (Wang et al., 1999; Hinterseher et al., 2007). 
Nevertheless, since the mentioned analyses concerned relatively small groups, this issue still 
requires additional investigation (Sandford et al., 2007; Saratzis et al., 2011). 
3.5.2 Pharmacological modulation of MMPs 
Since the modulation of MMPs activity by endogenous inhibitors in pathology seems to be 
inefficient, several strategies with exogenous MMP modulators have been developed. It is 
noteworthy, that some of these modulators are already used in clinical practice, although 
the primary indication for their application did not concern inhibition of MMPs. 
An interesting approach may be the use of MMP-specific antibody-based inhibitors. The 
experimental model with neutralizing antibodies directed against MMP-2 has shown their 
protective influence on a heart exposed to ischemia/reperfusion injury (Cheung et al., 2000). 
However, the verification, whether this procedure would be useful in management of aortic 
aneurysms, needs further studies. Apart from endogenous inhibitors, various 
pharmacological agents may reveal inhibitory activity against MMPs. The small 
hydroxamate-based zinc-chelating synthetic agents, such as batimastat, marimastat or 
ilomastat (galardin), were first used in oncology, to suppress MMPs-dependent metastasis 
and tumor invasion. However, due to non-selective, generalized inhibition of MMPs activity 
with numerous adverse events, accompanied by relatively poor effectiveness, their clinical 
career was ended very soon (Baxter, 2004). 
3.5.2.1 Tetracyclines 
Tetracyclines are natural antibiotics derived from Streptomyces. They are known for many 
non-antibiotic properties, including inhibition of proteolysis, or anti-apoptotic and anti-
inflammatory activity. The most intensively tested representative of tetracyclines – 
doxycycline, has been shown to prevent formation of aortic aneurysm in several animal 
models. Also, the results of three small clinical trials in humans have shown that 
doxycycline in a well tolerated dose 150-200 mg/day significantly reduced aneurysm 
expansion rate. It has been suggested, that doxycycline inhibits MMPs directly, by binding 
to their catalytic site. Furthermore, it may reduce the MMP expression attenuating the 
inflammatory cascade. However, the results of the studies on putative effects of tetracyclines 
on MMP-9 are not fully consistent. The first published study by Cruci and coauthors has 
shown that doxycycline treatment in a dose 200 mg/day resulted in a 2.5-fold reduction of 
MMP-9 protein levels and 82% reduction of MMP-9 mRNA expression (Cruci et al., 1998). 
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Surprisingly, in a subsequent placebo-controlled study Ding and colleagues did not observe 
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expression level (p=0.206). The authors have concluded, that the beneficial effect of 
doxycycline on aneurysm progression might be due to the reduction of aneurysm wall 
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thus, indirect MMPs modulation (also discussed in chapter 2.2). This concept led to the 
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The mechanism of anti-aneurysm protective action of macrolides remains unclear. 
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of inflammatory cells in vivo, and they effectively suppressed the MMP-9 production in the 
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significant differences in MMP-9 level between patients treated with statins and a control 
group. Moreover, they have found, that a level of active MMP-9 in patients treated with 
pravastatin was higher, than in control subjects (Hurks et al., 2010). This may suggest, that a 
pleiotropic actions profile of these drugs may differ among the various statins. 
Unfortunately, the issue concerning statins influence on aortic aneurysm progression seems 
unlikely to be resolved in the near future, because of two reasons at least. Firstly, the 
prevalence of statin use in aortic aneurysm-suffering patients is very high, mainly due to 
other concomitant cardiovascular diseases. Therefore, it may be difficult to assemble a 
control group for a large randomized study. Secondly, according to current 
recommendations, statins should be used as perioperative protection during open surgical, 
as well as endovascular aneurysm repair (Diehm et al. 2007). Thus, such a study, 
additionally to being difficult to design, appears to be ethically controversial. 
3.5.2.4 Low molecular weight heparin 
As was discussed previously (chapter 2.1), the aortic aneurysm is usually accompanied by 
an intraluminal thrombus, that is always associated with more or less clinically overt 
coagulation abnormalities. It has been shown, that these coagulopathies may be successfully 
treated with small doses of low molecular weight heparin (LMWH) (Jelenska et al., 2004). 
Moreover, our subsequent studies revealed, that in addition to the attenuation of 
coagulation abnormalities, a LMWH treatment resulted in statistically significant decrease 
of circulating MMP-9 plasma activity. Interestingly, the in vitro studies did not show any 
direct influence of LMWH on MMP-9 production by activated leucocytes, or enzyme 
activity, either. Therefore, the most plausible explanation seems to be an indirect mechanism 
of LMWH action. According to our concept, the stabilized thrombus does not capture any 
new leukocytes. In such circumstances the number of MMP-9-producing cells, which are 
already entrapped in fibrin clot, decreases slowly. Finally, theses conditions lead to the 
decrease of MMP-9 amounts, released from intraluminal thrombus to the circulating blood. 
However, the verification of this hypothesis, as well as further clinical studies, concerning 
LMWH influence on aneurysm progression, are necessary. 
3.5.2.5 JNK inhibitor 
Based on results of studies focused on molecular aspects of aortic aneurysm 
pathophysiology, the c-Jun N-terminal kinase (JNK) has been selected as a new target for 
therapy. Using pharmacological JNK inhibitor Yoshimura and coauthors prevented the 
development, or induced the regression of already formed aneurysm in calcium-, or 
angiotensin II-induced aortic aneurysm mouse models. This effect was associated with 
decreased MMP-9 activity, but also with restoration of aortic tissue architecture, mainly due 
to the upregulation of various extracellular matrix proteins synthesis. Obviously, the results 
of further studies are expected highly impatiently (Yoshimura et al., 2005; Miyake & 
Morishita, 2009). 
3.5.2.6 Renin-angiotensin system modulators 
Recently, it has been suggested, that the renin-angiotensin system and its main effector 
molecule – angiotensin II, may also be involved in the initiation of inflammatory reaction in 
the aortic wall and, thus, it significantly contributes to the development of aneurysm. 
Therefore, antagonists of the angiotensin II receptor were tested for their presumable 
protective effect on aneurysm progression. Indeed, it was shown, that losartan and 
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valsartan, two representatives of the group, were effective in preventing aneurysm 
formation. Interestingly, although they do not appear to influence MMPs activity directly, 
their beneficial influence was associated with decrease of MMPs expression in aneurismal 
tissue, possibly due to the suppression of NF-κB-controlled inflammatory reaction (Fujiwara 
et al., 2008; Miyake & Morishita, 2009). However, since the career of angiotensin II receptor 
antagonists in a management of cardiovascular diseases is rather short, their value in aortic 
aneurysm treatment still remains to be verified. 
The next group of pharmaceuticals, addressed to interfere with the renin-angiotensin system 
are angiotensin converting enzyme (ACE) inhibitors. In contrast to the previously described 
angiotensin II receptor antagonists, they bind to the active site of MMPs and directly block 
their enzymatic activity in a dose dependent manner. Using animal models, it has been shown, 
that ACE inhibitors, including captopril, enalapril, lisinopril and perindopril, reduced the 
aortic wall degeneration and aneurysm progression. Surprisingly, data provided by several 
clinical trials are highly inconsistent. Reports by Lederle and Taylor, or Hackam group 
suggested independently, that patients with aortic aneurysms, which received ACE inhibitors, 
displayed lower aneurysm expansion rate and were better protected from aneurysm rupture, 
as compared to individuals treated without convertase inhibitors (Hackam et al., 2006; Lederle 
& Taylor, 2006). On the other hand, Schouten and colleagues did not find any correlation 
between aneurysm dilatation rate and ACE inhibitors (Schouten et al., 2006; Baxter et al., 2008; 
Miyake & Morishita, 2009). Moreover, the abdominal aortic aneurysm screening program in 
UK revealed an increasing aneurysm growth rate, that was apparently associated with ACE 
inhibitors intake (Sweeting et al., 2010). Therefore, this approach urgently needs further 
elucidation in multicenter prospective randomized trials, although, due to the common use of 
ACE inhibitors in cardiovascular diseases, the study design will possibly meet similar 
obstacles, as in statins case. 
3.5.2.7 Decoy oligodeoxynucleotides 
Recently, the novel strategy based on targeting transcription factors, which are known to be 
involved in regulation of inflammatory reaction and MMPs expression, appears to be highly 
promising approach in the management of aortic aneurysm. A principle of this strategy is 
the use of synthetic oligodeoxynucleotides (ODNs), referred as “decoy” ODNs, which 
specifically recognize and bind to respective transcription factors and thus competitively 
block their binding to promoter of gene of interest. 
This decoy strategy was used to inhibit two transcription factors – NF-κB and ets-1, which 
are suggested to control gene expression of several MMPs, including MMP-1, -2, -3 and -9. 
Using elastase-induced aneurysm rat and rabbit models, and chimeric anti-NF-κB/ets-1 
decoy ODNs, Miyake and colleagues have analyzed the effects of the simultaneous 
suppression of both, NF-κB and ets-1. They found, that this approach resulted in marked 
decrease of aortic aneurysm progression, that was accompanied by significant decrease of 
MMP-1 and MMP-9 expression in the aneurysm wall. Moreover, in the rabbit model the 
application of the mentioned decoy system onto already formed aneurysms led to their 
significant regression, which in addition to MMPs inhibition, was possibly due to induction 
of collagen and elastin synthesis, that is negatively controlled by ets-1. Hopefully, this 
strategy will be effective also in human, since the anti-NF-κB/ets-1 ODNs decreased MMPs 
expression in ex vivo experiments with cultured human aortic tissue (Miyake & Morishita, 
2009). It is noteworthy, that the decoy ODNs-based therapy has some limitations, too. The 
main problem is the rapid degradation and relatively short half-life of therapeutic ODNs, 
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significant differences in MMP-9 level between patients treated with statins and a control 
group. Moreover, they have found, that a level of active MMP-9 in patients treated with 
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an intraluminal thrombus, that is always associated with more or less clinically overt 
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treated with small doses of low molecular weight heparin (LMWH) (Jelenska et al., 2004). 
Moreover, our subsequent studies revealed, that in addition to the attenuation of 
coagulation abnormalities, a LMWH treatment resulted in statistically significant decrease 
of circulating MMP-9 plasma activity. Interestingly, the in vitro studies did not show any 
direct influence of LMWH on MMP-9 production by activated leucocytes, or enzyme 
activity, either. Therefore, the most plausible explanation seems to be an indirect mechanism 
of LMWH action. According to our concept, the stabilized thrombus does not capture any 
new leukocytes. In such circumstances the number of MMP-9-producing cells, which are 
already entrapped in fibrin clot, decreases slowly. Finally, theses conditions lead to the 
decrease of MMP-9 amounts, released from intraluminal thrombus to the circulating blood. 
However, the verification of this hypothesis, as well as further clinical studies, concerning 
LMWH influence on aneurysm progression, are necessary. 
3.5.2.5 JNK inhibitor 
Based on results of studies focused on molecular aspects of aortic aneurysm 
pathophysiology, the c-Jun N-terminal kinase (JNK) has been selected as a new target for 
therapy. Using pharmacological JNK inhibitor Yoshimura and coauthors prevented the 
development, or induced the regression of already formed aneurysm in calcium-, or 
angiotensin II-induced aortic aneurysm mouse models. This effect was associated with 
decreased MMP-9 activity, but also with restoration of aortic tissue architecture, mainly due 
to the upregulation of various extracellular matrix proteins synthesis. Obviously, the results 
of further studies are expected highly impatiently (Yoshimura et al., 2005; Miyake & 
Morishita, 2009). 
3.5.2.6 Renin-angiotensin system modulators 
Recently, it has been suggested, that the renin-angiotensin system and its main effector 
molecule – angiotensin II, may also be involved in the initiation of inflammatory reaction in 
the aortic wall and, thus, it significantly contributes to the development of aneurysm. 
Therefore, antagonists of the angiotensin II receptor were tested for their presumable 
protective effect on aneurysm progression. Indeed, it was shown, that losartan and 
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valsartan, two representatives of the group, were effective in preventing aneurysm 
formation. Interestingly, although they do not appear to influence MMPs activity directly, 
their beneficial influence was associated with decrease of MMPs expression in aneurismal 
tissue, possibly due to the suppression of NF-κB-controlled inflammatory reaction (Fujiwara 
et al., 2008; Miyake & Morishita, 2009). However, since the career of angiotensin II receptor 
antagonists in a management of cardiovascular diseases is rather short, their value in aortic 
aneurysm treatment still remains to be verified. 
The next group of pharmaceuticals, addressed to interfere with the renin-angiotensin system 
are angiotensin converting enzyme (ACE) inhibitors. In contrast to the previously described 
angiotensin II receptor antagonists, they bind to the active site of MMPs and directly block 
their enzymatic activity in a dose dependent manner. Using animal models, it has been shown, 
that ACE inhibitors, including captopril, enalapril, lisinopril and perindopril, reduced the 
aortic wall degeneration and aneurysm progression. Surprisingly, data provided by several 
clinical trials are highly inconsistent. Reports by Lederle and Taylor, or Hackam group 
suggested independently, that patients with aortic aneurysms, which received ACE inhibitors, 
displayed lower aneurysm expansion rate and were better protected from aneurysm rupture, 
as compared to individuals treated without convertase inhibitors (Hackam et al., 2006; Lederle 
& Taylor, 2006). On the other hand, Schouten and colleagues did not find any correlation 
between aneurysm dilatation rate and ACE inhibitors (Schouten et al., 2006; Baxter et al., 2008; 
Miyake & Morishita, 2009). Moreover, the abdominal aortic aneurysm screening program in 
UK revealed an increasing aneurysm growth rate, that was apparently associated with ACE 
inhibitors intake (Sweeting et al., 2010). Therefore, this approach urgently needs further 
elucidation in multicenter prospective randomized trials, although, due to the common use of 
ACE inhibitors in cardiovascular diseases, the study design will possibly meet similar 
obstacles, as in statins case. 
3.5.2.7 Decoy oligodeoxynucleotides 
Recently, the novel strategy based on targeting transcription factors, which are known to be 
involved in regulation of inflammatory reaction and MMPs expression, appears to be highly 
promising approach in the management of aortic aneurysm. A principle of this strategy is 
the use of synthetic oligodeoxynucleotides (ODNs), referred as “decoy” ODNs, which 
specifically recognize and bind to respective transcription factors and thus competitively 
block their binding to promoter of gene of interest. 
This decoy strategy was used to inhibit two transcription factors – NF-κB and ets-1, which 
are suggested to control gene expression of several MMPs, including MMP-1, -2, -3 and -9. 
Using elastase-induced aneurysm rat and rabbit models, and chimeric anti-NF-κB/ets-1 
decoy ODNs, Miyake and colleagues have analyzed the effects of the simultaneous 
suppression of both, NF-κB and ets-1. They found, that this approach resulted in marked 
decrease of aortic aneurysm progression, that was accompanied by significant decrease of 
MMP-1 and MMP-9 expression in the aneurysm wall. Moreover, in the rabbit model the 
application of the mentioned decoy system onto already formed aneurysms led to their 
significant regression, which in addition to MMPs inhibition, was possibly due to induction 
of collagen and elastin synthesis, that is negatively controlled by ets-1. Hopefully, this 
strategy will be effective also in human, since the anti-NF-κB/ets-1 ODNs decreased MMPs 
expression in ex vivo experiments with cultured human aortic tissue (Miyake & Morishita, 
2009). It is noteworthy, that the decoy ODNs-based therapy has some limitations, too. The 
main problem is the rapid degradation and relatively short half-life of therapeutic ODNs, 
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that require their local application. This in turn raises the problem with an effective delivery 
system. In experiments by Miyake and coauthors the cellulose-based ODNs delivery system 
was applied intraoperatively on the outer surface of dilated aorta. In clinical practice this 
could be done using low-invasive procedures, such as laparoscopy, or more likely by 
endovascular access. However, this issue remains to be resolved.  
3.6 Methods of MMP detection and analysis 
The increasing evidence concerning the involvement of MMPs in various pathologies, 
including aortic aneurysm, results in the necessity to develop methods of analysis that 
would be sufficiently sensitive and specific enough to detect minute amounts of MMPs. 
3.6.1 ELISA 
The above mentioned main requirements are met by an enzyme-linked immunosorbent 
assay (ELISA). Despite its high sensitivity (picograms per ml) and availability for all known 
MMPs, the ELISA method provides data reflecting only the specific protein amount, 
without any information about its enzymatic activity. This obstacle is partially resolved by a 
new generation of ELISA kits, that can discriminate between full length pro-enzyme and 
proteolytically activated MMP (Fig. 3A). Obviously, similar data could be obtained using 
the western-blot method with respective anti-MMP antibodies. Nevertheless, the previously 
mentioned non-proteolytic activation of full-length molecules may result in false negative, 
or at least, underestimated results of MMP measurement. Thus, the studies focusing on 
MMPs require another method that would enable convenient analysis of their enzymatic 
activity.  
3.6.2 Substrate-specific zymography 
Currently, the standard method used for the analysis of MMPs activity is a substrate-specific 
zymography with sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis 
(PAGE). The method is based on a molecular size-dependent electrophoretic separation of 
tested samples in a polyacrylamide gel, containing substrate specific for MMP being 
analyzed, e.g. gelatin for MMP-2 and MMP-9, casein for MMP-1, -3, -7, -10, -12 and -13 or 
collagen for MMP-1 and -13 (Kupai et al., 2010). Then, the gel is incubated in zinc- and 
calcium-rich reaction buffer to re-activate enzyme particles separated in the gel. The high 
local concentration of enzyme molecules results in a substrate digestion, that is restricted to 
the area close to the position of respective MMP in the gel. The visualization of enzymatic 
activity of assayed samples occurs after incubation of the whole gel with the staining 
solution, e.g. Coomassie blue. The presence of an unstained area in a gel corresponds to a 
substrate cleavage, due to enzymatic activity of respective MMP, whereas the size of this 
area directly correlates with amount and/or activity of the enzyme. Thus, the standard SDS-
PAGE zymography allows a semi-quantitative comparison of respective MMP amount, or 
more precisely – activity between various samples. When used with known amounts of 
recombinant MMP, as a reference, the method permits the quantitative assessment of 
respective MMP. Furthermore, due to the gel electrophoresis of analyzed samples, this 
method enables the molecular size-based identification and individual measurement of 
both, full length pro-MMP and its short processed form, too (Fig. 3D, also Fig.2). It has been 
proven that sensitivity of standard SDS-PAGE zymography is sufficient to detect similar 
amounts of active MMP, as those using ELISA method (Table 1). 
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Substrate Enzyme Detection limit 
gelatin MMP-2 10 pg 
casein MMP-7 1 ng 
collagen MMP-1 0.1 pg 
Table 1. Examples of SDS-PAGE zymography detection limits (Kupai et al., 2010) 
It is noteworthy, that the standard SDS-PAGE zymography is not free of some problems, 
either. The important issue is the unspecific, SDS-mediated activation of pro-MMP, that may 
occur during electrophoresis. Obviously, this event affects the results, and is usually 
associated with an overestimation of MMP activity. Additional difficulty with the use of this 
method is the long, time-consuming procedure. Therefore, although the SDS-PAGE 
zymography is sensitive enough and relatively inexpensive, in some circumstances the 
better choice for a fast MMP assessment could be the fluorescent zymography. 
3.6.3 Fluorescent zymography 
The fluorescent zymography is based on a technology known as the fluorescence resonance 
energy transfer (FRET). Briefly, the tested sample is incubated in small volume (10-20 μl) of 
reaction mixture containing the substrate, that is labeled with fluorochrome and quencher 
tags. When a substrate remains intact, the energy emitted by fluorochrome is entirely absorbed 
by the quencher, therefore no fluorescence is detected. The substrate degradation abolishes the 
suppressive effect of the quencher on fluorochrome, thus resulting in increase of fluorescence 
in the reaction mixture. The intensity of fluorescence corresponds to the amount of digested 
substrate, that, in turn, reflects the amount of active enzyme in a sample (Fig. 3B). 
 
 


























MMP reactivation and  
substrate cleavage 
 
Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture 
 
44
that require their local application. This in turn raises the problem with an effective delivery 
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could be done using low-invasive procedures, such as laparoscopy, or more likely by 
endovascular access. However, this issue remains to be resolved.  
3.6 Methods of MMP detection and analysis 
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including aortic aneurysm, results in the necessity to develop methods of analysis that 
would be sufficiently sensitive and specific enough to detect minute amounts of MMPs. 
3.6.1 ELISA 
The above mentioned main requirements are met by an enzyme-linked immunosorbent 
assay (ELISA). Despite its high sensitivity (picograms per ml) and availability for all known 
MMPs, the ELISA method provides data reflecting only the specific protein amount, 
without any information about its enzymatic activity. This obstacle is partially resolved by a 
new generation of ELISA kits, that can discriminate between full length pro-enzyme and 
proteolytically activated MMP (Fig. 3A). Obviously, similar data could be obtained using 
the western-blot method with respective anti-MMP antibodies. Nevertheless, the previously 
mentioned non-proteolytic activation of full-length molecules may result in false negative, 
or at least, underestimated results of MMP measurement. Thus, the studies focusing on 
MMPs require another method that would enable convenient analysis of their enzymatic 
activity.  
3.6.2 Substrate-specific zymography 
Currently, the standard method used for the analysis of MMPs activity is a substrate-specific 
zymography with sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis 
(PAGE). The method is based on a molecular size-dependent electrophoretic separation of 
tested samples in a polyacrylamide gel, containing substrate specific for MMP being 
analyzed, e.g. gelatin for MMP-2 and MMP-9, casein for MMP-1, -3, -7, -10, -12 and -13 or 
collagen for MMP-1 and -13 (Kupai et al., 2010). Then, the gel is incubated in zinc- and 
calcium-rich reaction buffer to re-activate enzyme particles separated in the gel. The high 
local concentration of enzyme molecules results in a substrate digestion, that is restricted to 
the area close to the position of respective MMP in the gel. The visualization of enzymatic 
activity of assayed samples occurs after incubation of the whole gel with the staining 
solution, e.g. Coomassie blue. The presence of an unstained area in a gel corresponds to a 
substrate cleavage, due to enzymatic activity of respective MMP, whereas the size of this 
area directly correlates with amount and/or activity of the enzyme. Thus, the standard SDS-
PAGE zymography allows a semi-quantitative comparison of respective MMP amount, or 
more precisely – activity between various samples. When used with known amounts of 
recombinant MMP, as a reference, the method permits the quantitative assessment of 
respective MMP. Furthermore, due to the gel electrophoresis of analyzed samples, this 
method enables the molecular size-based identification and individual measurement of 
both, full length pro-MMP and its short processed form, too (Fig. 3D, also Fig.2). It has been 
proven that sensitivity of standard SDS-PAGE zymography is sufficient to detect similar 
amounts of active MMP, as those using ELISA method (Table 1). 
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Substrate Enzyme Detection limit 
gelatin MMP-2 10 pg 
casein MMP-7 1 ng 
collagen MMP-1 0.1 pg 
Table 1. Examples of SDS-PAGE zymography detection limits (Kupai et al., 2010) 
It is noteworthy, that the standard SDS-PAGE zymography is not free of some problems, 
either. The important issue is the unspecific, SDS-mediated activation of pro-MMP, that may 
occur during electrophoresis. Obviously, this event affects the results, and is usually 
associated with an overestimation of MMP activity. Additional difficulty with the use of this 
method is the long, time-consuming procedure. Therefore, although the SDS-PAGE 
zymography is sensitive enough and relatively inexpensive, in some circumstances the 
better choice for a fast MMP assessment could be the fluorescent zymography. 
3.6.3 Fluorescent zymography 
The fluorescent zymography is based on a technology known as the fluorescence resonance 
energy transfer (FRET). Briefly, the tested sample is incubated in small volume (10-20 μl) of 
reaction mixture containing the substrate, that is labeled with fluorochrome and quencher 
tags. When a substrate remains intact, the energy emitted by fluorochrome is entirely absorbed 
by the quencher, therefore no fluorescence is detected. The substrate degradation abolishes the 
suppressive effect of the quencher on fluorochrome, thus resulting in increase of fluorescence 
in the reaction mixture. The intensity of fluorescence corresponds to the amount of digested 
substrate, that, in turn, reflects the amount of active enzyme in a sample (Fig. 3B). 
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Oppositely to standard SDS-PAGE zymography, this method is very fast and enables the 
measurement of proteolytic activity in analyzed samples within several minutes. In contrast 
to the previously mentioned ELISA and SDS-PAGE zymography, the fluorescent 
zymography allows an assessment of the direct influence of various factors on MMP 
activity. However, the outcome of the analysis is highly sensitive to sample preparation and 
the reaction conditions. The samples should be prepared without addition of EDTA or other 
metal-ion chelators, and without addition of protease inhibitors. This step may be of great 
importance for final results of analysis, especially since the extraction procedures 
themselves may induce MMPs activation or lead to release of natural MMP inhibitors. After 
tissue disruption during sample preparation, these inhibitors, although initially localized in 
different compartments, can interact with active enzymes, and thus, may affect the results of 
assay. Another important issue may be the concentration of non-ionic detergents in the 
reaction mixture, which may “neutralize” small molecules that potentially could interfere 
with MMP activity (Kupai et al., 2010). 
The most significant disadvantage of the fluorescent zymography is, that it does not 
determine MMP, that directly contributes to the observed substrate degradation. This 
obstacle may be omitted by the use of respective, MMP-specific, monoclonal antibodies, 
which block the proteolytic activity of the selected enzyme. With a panel of blocking 
antibodies, this modification allows the quantitative assessment of each constituent of 
MMP-mediated proteolytic activity in the analyzed sample. 
Another solution to this problem may be the method that combines the idea of both, ELISA 
and fluorescent zymography. Briefly, the plate is coated with specific anti-MMP antibodies, 
which capture molecules of the respective enzyme from the sample being assessed. Then, non-
captured, unspecific proteins are washed out and the fluorochrome/quencher-labeled 
substrate is added to the plate followed by incubation. Finally, since the intensity of MMP-
mediated fluorescence corresponds to the activity of specific MMP, it may be measured using 
the fluorescence plate reader. This solid-phase, or immunocapture fluorescent zymography 
represents the key advantages of both, ELISA and “normal” fluorescent zymography (Fig. 3C). 
It enables a measurement of enzymatic activity of individual MMPs, is specific, sensitive, rapid 
and lacks the previously mentioned main deficiencies of both methods. 
3.6.4 In situ zymography 
In studies concerning distribution of MMPs in affected tissues, the use of in situ 
zymography may be very advantageous. This test allows the detection of MMPs activity in 
histological specimens, directly on the place of their production or activation. Similarly to 
previously mentioned fluorescent zymography, this method also exploits FRET technology. 
The fluorochrome/quencher-labeled substrate is applied on the surface of a specimen, and 
is incubated. Then, the specimen can be assessed with a fluorescent microscope, or using a 
confocal laser scanning microscope. 
The main disadvantage of this method is that it does not allow precise measurement of the 
amount of active MMP. Moreover, similarly to “normal” fluorescent zymography, it is 
necessary to use neutralizing antibodies, to determine MMPs that contribute to substrate 
cleavage. 
3.6.5 Reverse zymography - detection of MMP inhibition 
The studies concerning the role of MMP in pathogenesis of aortic aneurysm include also a 
method that enables assessment of the natural tissue inhibitors of MMP (TIMPs). This 
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method, known as reverse zymography, utilizes polyacrylamide gel with specific 
substrate, that is additionally supplemented with respective MMP. After electrophoresis 
of tested samples the gel is subjected to the same processing as in routine zymography. 
Then, the MMP, which is equally distributed in the whole gel, cleaves the substrate with 
the exception of those places, where TIMPs inhibit its proteolytic activity. Those places are 
visible as Coomassie blue-stained bands, whereas the other parts of the gel remain 
unstained. 
In addition to reverse zymography, the expected interaction between MMPs and their tissue 
inhibitors can also be analyzed using a modified western blotting (SDS-PAGE and 
immunoblotting) method. The formation of higher molecular weight complex by interacting 
molecules results in its slower migration during polyacrylamide gel electrophoresis, and 
thus reveals a band shift of specific MMP or its inhibitor, depending on the antibody used 
for detection. 
3.6.6 Possible applications 
Currently, the methods of MMPs analysis in aortic aneurysm clinics described above  
are predominantly used for research purpose. However, due to an increasing interest in 
the monitoring of MMPs level and/or activity in aneurysm-suffering patients, it is 
plausible that some of these methods will become the standard diagnostic tools in the 
near future. 
The first postulated indication for clinical use could be the screening of plasma MMPs 
activity in patients with newly recognized aortic aneurysm. Although there is no consent, 
whether low plasma levels of MMPs may be considered as a low risk indicator of aneurysm 
progression and/or rupture, it is nevertheless widely accepted that the higher 
concentration, or more precisely, their higher activity should at least encourage more 
frequent monitoring of aneurysm diameter. The second, important clinical application for 
MMP assessment seems to be the periodic monitoring of MMPs activity in patients with 
small aneurysms and subjected to pharmacological treatment. Obviously, the method 
selected for monitoring should depend on the mechanism of action of controlled MMP 
modulator. Thus, the monitoring of pharmacological treatment of aortic aneurysm using 
compounds displaying indirect influence on MMP amount and/or activity, including 
statins, heparins or ODNs, may engage a broad spectrum of methods mentioned above. 
However, in regimens using potent direct MMP inhibitors, e.g. tetracycline-derivatives, or 
angiotensin converting enzyme-inhibitors, the fluorescent zymography rather, than other 
methods, including substrate-specific SDS-PAGE zymography, should be used 
preferentially. 
It has been found that open aneurysm repair leads to transient (usually within first 3 moths)  
MMP-9 increase, followed by its later significant reduction. Nevertheless, in some patients 
high levels of MMPs may still persist even a very long time after surgery (Kadoglou & 
Liapis, 2004). An interesting example of this condition may by the case of a 50-year old men 
with an abdominal aortic aneurysm, subjected to successful open aneurysm repair. 
Surprisingly, after 4 years the patient was qualified again for surgical treatment due to the 
significant enlargement of the thoracic aorta, remaining suprarenal part of abdominal aorta 
and common iliac arteries. The plasma level of MMP-2 was similar to those observed in 
other aortic aneurysm-suffering individuals. However, his MMP-9 plasma activity was 
extraordinarily (almost 10-fold) higher, than mean MMP-9 level, observed in other patients 
bearing an aortic aneurysm. 
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Oppositely to standard SDS-PAGE zymography, this method is very fast and enables the 
measurement of proteolytic activity in analyzed samples within several minutes. In contrast 
to the previously mentioned ELISA and SDS-PAGE zymography, the fluorescent 
zymography allows an assessment of the direct influence of various factors on MMP 
activity. However, the outcome of the analysis is highly sensitive to sample preparation and 
the reaction conditions. The samples should be prepared without addition of EDTA or other 
metal-ion chelators, and without addition of protease inhibitors. This step may be of great 
importance for final results of analysis, especially since the extraction procedures 
themselves may induce MMPs activation or lead to release of natural MMP inhibitors. After 
tissue disruption during sample preparation, these inhibitors, although initially localized in 
different compartments, can interact with active enzymes, and thus, may affect the results of 
assay. Another important issue may be the concentration of non-ionic detergents in the 
reaction mixture, which may “neutralize” small molecules that potentially could interfere 
with MMP activity (Kupai et al., 2010). 
The most significant disadvantage of the fluorescent zymography is, that it does not 
determine MMP, that directly contributes to the observed substrate degradation. This 
obstacle may be omitted by the use of respective, MMP-specific, monoclonal antibodies, 
which block the proteolytic activity of the selected enzyme. With a panel of blocking 
antibodies, this modification allows the quantitative assessment of each constituent of 
MMP-mediated proteolytic activity in the analyzed sample. 
Another solution to this problem may be the method that combines the idea of both, ELISA 
and fluorescent zymography. Briefly, the plate is coated with specific anti-MMP antibodies, 
which capture molecules of the respective enzyme from the sample being assessed. Then, non-
captured, unspecific proteins are washed out and the fluorochrome/quencher-labeled 
substrate is added to the plate followed by incubation. Finally, since the intensity of MMP-
mediated fluorescence corresponds to the activity of specific MMP, it may be measured using 
the fluorescence plate reader. This solid-phase, or immunocapture fluorescent zymography 
represents the key advantages of both, ELISA and “normal” fluorescent zymography (Fig. 3C). 
It enables a measurement of enzymatic activity of individual MMPs, is specific, sensitive, rapid 
and lacks the previously mentioned main deficiencies of both methods. 
3.6.4 In situ zymography 
In studies concerning distribution of MMPs in affected tissues, the use of in situ 
zymography may be very advantageous. This test allows the detection of MMPs activity in 
histological specimens, directly on the place of their production or activation. Similarly to 
previously mentioned fluorescent zymography, this method also exploits FRET technology. 
The fluorochrome/quencher-labeled substrate is applied on the surface of a specimen, and 
is incubated. Then, the specimen can be assessed with a fluorescent microscope, or using a 
confocal laser scanning microscope. 
The main disadvantage of this method is that it does not allow precise measurement of the 
amount of active MMP. Moreover, similarly to “normal” fluorescent zymography, it is 
necessary to use neutralizing antibodies, to determine MMPs that contribute to substrate 
cleavage. 
3.6.5 Reverse zymography - detection of MMP inhibition 
The studies concerning the role of MMP in pathogenesis of aortic aneurysm include also a 
method that enables assessment of the natural tissue inhibitors of MMP (TIMPs). This 
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method, known as reverse zymography, utilizes polyacrylamide gel with specific 
substrate, that is additionally supplemented with respective MMP. After electrophoresis 
of tested samples the gel is subjected to the same processing as in routine zymography. 
Then, the MMP, which is equally distributed in the whole gel, cleaves the substrate with 
the exception of those places, where TIMPs inhibit its proteolytic activity. Those places are 
visible as Coomassie blue-stained bands, whereas the other parts of the gel remain 
unstained. 
In addition to reverse zymography, the expected interaction between MMPs and their tissue 
inhibitors can also be analyzed using a modified western blotting (SDS-PAGE and 
immunoblotting) method. The formation of higher molecular weight complex by interacting 
molecules results in its slower migration during polyacrylamide gel electrophoresis, and 
thus reveals a band shift of specific MMP or its inhibitor, depending on the antibody used 
for detection. 
3.6.6 Possible applications 
Currently, the methods of MMPs analysis in aortic aneurysm clinics described above  
are predominantly used for research purpose. However, due to an increasing interest in 
the monitoring of MMPs level and/or activity in aneurysm-suffering patients, it is 
plausible that some of these methods will become the standard diagnostic tools in the 
near future. 
The first postulated indication for clinical use could be the screening of plasma MMPs 
activity in patients with newly recognized aortic aneurysm. Although there is no consent, 
whether low plasma levels of MMPs may be considered as a low risk indicator of aneurysm 
progression and/or rupture, it is nevertheless widely accepted that the higher 
concentration, or more precisely, their higher activity should at least encourage more 
frequent monitoring of aneurysm diameter. The second, important clinical application for 
MMP assessment seems to be the periodic monitoring of MMPs activity in patients with 
small aneurysms and subjected to pharmacological treatment. Obviously, the method 
selected for monitoring should depend on the mechanism of action of controlled MMP 
modulator. Thus, the monitoring of pharmacological treatment of aortic aneurysm using 
compounds displaying indirect influence on MMP amount and/or activity, including 
statins, heparins or ODNs, may engage a broad spectrum of methods mentioned above. 
However, in regimens using potent direct MMP inhibitors, e.g. tetracycline-derivatives, or 
angiotensin converting enzyme-inhibitors, the fluorescent zymography rather, than other 
methods, including substrate-specific SDS-PAGE zymography, should be used 
preferentially. 
It has been found that open aneurysm repair leads to transient (usually within first 3 moths)  
MMP-9 increase, followed by its later significant reduction. Nevertheless, in some patients 
high levels of MMPs may still persist even a very long time after surgery (Kadoglou & 
Liapis, 2004). An interesting example of this condition may by the case of a 50-year old men 
with an abdominal aortic aneurysm, subjected to successful open aneurysm repair. 
Surprisingly, after 4 years the patient was qualified again for surgical treatment due to the 
significant enlargement of the thoracic aorta, remaining suprarenal part of abdominal aorta 
and common iliac arteries. The plasma level of MMP-2 was similar to those observed in 
other aortic aneurysm-suffering individuals. However, his MMP-9 plasma activity was 
extraordinarily (almost 10-fold) higher, than mean MMP-9 level, observed in other patients 
bearing an aortic aneurysm. 
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In contrast to open repair, patients subjected to endovascular aneurysm exclusion usually 
reveal a gradual decrease of circulating MMP-3 and -9, whereas the persisting high 
concentration and/or activity of circulating MMP-9 actually correlates with some 
postoperative complications. They include graft migration, or presence of endo-leak, where 
both conditions are accompanied by the contact of circulating blood with the thrombus still 
existing in the aneurysm lumen (Kadoglou & Liapis, 2004). Therefore, the temporary 
monitoring of MMP activity may be an important diagnostic procedure also in patients after 
both, open surgical, but also endovascular intervention. 
4. Conclusion 
Despite numerous studies, the role of MMPs in pathogenesis of aortic aneurysm remains 
unclear. Also, the question, whether they are “executors”, or “executioners”, is still 
unanswered. Since MMPs are obviously engaged in all stages of the aneurysm development, 
from the beginning, till the fatal aneurysm rupture, they are very attractive targets in 
approaches, concerning pharmacological treatment of this pathology. However, due to some 
discrepancies between results of experimental, as well as clinical studies conducted so far, 
this issue still requires intensive research. Nevertheless, it is plausible that in the near future 
the majority of patients with aortic aneurysms might simply require regular drug intake, 
without the necessity for surgical intervention, which would be reserved for particular cases 
only. Since it is very similar to the history of management of gastric ulcers, this vision seems 
to be quite realistic in the near future… 
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In contrast to open repair, patients subjected to endovascular aneurysm exclusion usually 
reveal a gradual decrease of circulating MMP-3 and -9, whereas the persisting high 
concentration and/or activity of circulating MMP-9 actually correlates with some 
postoperative complications. They include graft migration, or presence of endo-leak, where 
both conditions are accompanied by the contact of circulating blood with the thrombus still 
existing in the aneurysm lumen (Kadoglou & Liapis, 2004). Therefore, the temporary 
monitoring of MMP activity may be an important diagnostic procedure also in patients after 
both, open surgical, but also endovascular intervention. 
4. Conclusion 
Despite numerous studies, the role of MMPs in pathogenesis of aortic aneurysm remains 
unclear. Also, the question, whether they are “executors”, or “executioners”, is still 
unanswered. Since MMPs are obviously engaged in all stages of the aneurysm development, 
from the beginning, till the fatal aneurysm rupture, they are very attractive targets in 
approaches, concerning pharmacological treatment of this pathology. However, due to some 
discrepancies between results of experimental, as well as clinical studies conducted so far, 
this issue still requires intensive research. Nevertheless, it is plausible that in the near future 
the majority of patients with aortic aneurysms might simply require regular drug intake, 
without the necessity for surgical intervention, which would be reserved for particular cases 
only. Since it is very similar to the history of management of gastric ulcers, this vision seems 
to be quite realistic in the near future… 
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1. Introduction 
Atherosclerosis exhibits many inflammatory characteristics, in which macrophages and  
T-lymphocytes are found at the shoulder region of atherosclerotic plaque, and are associated 
with its rupture and thrombosis (Libby et al. 2010).  On the other hand, abdominal aortic 
aneurysm (AAA) shows distinct histological features; inflammatory cell infiltration was 
observed predominantly at the outer media and adventitia (Michel et al. 2010).  Several 
experimental studies have suggested important roles of inflammatory cells (macrophages, 
T-lymphocytes and neutrophils) in AAA development (Longo et al. 2002; Xiong et al. 2004; 
Eliason et al. 2005).  Mast cell, unique effector components of the immune system, play a 
critical role in defending hosts against pathogens by releasing a number of 
immunoregulatory mediators (Marshall & Jawdat 2004).  Mast cells synthesize a number of 
substances, which include histamine, heparin, tryptase, chymase, carboxypeptidase, 
cathepsin G, leukotriene C4, prostaglandin D2, tumor necrosis factor-α and interleukin (IL)-
4,-5,-6,-13, some of which are stored in secretory vesicles (Krishnaswamy et al. 2006).  
Recently, mast cells have been recognized not only to be involved in host defense but also to 
initiate the inflammatory response by recruiting macrophages and T-lymphocytes (von 
Stebut et al. 2003; Henz et al. 2001) and by releasing pro-inflammatory cytokines, growth 
factors, angiogenic mediators and proteases (Krishnaswamy et al. 2006).  Specifically, 
tryptase and chymase have been examined for their unique biological actions to modulate 
extracellular matrix formation and induce apoptosis of vascular smooth muscle cells (Cairns 
& Walls 1997; Leskinen et al. 2001; Tchougounova et al. 2005).  In this chapter, we 
characterize mast cell density and distribution in the human aneurysmal abdominal aorta, 
compared with atherosclerotic abdominal aorta, and discuss the potential role of this type of 
cell to understand the pathophysiology of AAA.     
2. Materials and methods 
This study was approved by the Human Investigation Review Committee of the University 
of Miyazaki (No. 99) and conformed with the principles outlined in the Declaration of 
Helsinki (World Medical Association Declaration of Helsinki. 1997).   
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2.1 Human tissue preparation 
Aneurysmal tissues were obtained from the anterior side of aortic walls of 60 Japanese 
suffering from AAA associated with atherosclerosis during elective repair surgery. AAA 
tissues were fixed in 10 % formalin or frozen in liquid nitrogen immediately after resection. 
Aortic tissues with various degrees of atherosclerosis were collected from the anterior side of 
the aorta at autopsy performed within 6 hours postmortem: 26, early stage atherosclerosis 
including diffuse intimal thickening or fatty streak; 30, advanced atherosclerosis formed by an 
extracellular lipid core (Stary et al. 1995). Hypertension was defined as a blood pressure 
>140/90 mm Hg or the need for antihypertensive medication. Diabetes mellitus was defined 
as fasting plasma glucose 126 mg/dL or higher and/or two-hour postprandial plasma glucose 
readings of 200 mg/dL or higher and/or the need for medicine in the medical records.   
2.2 Immunohistochemistry   
Single Staining: Aortic tissues fixed in 10% formalin were embedded in paraffin wax.  The 
tissue sections (3 μm thick) were microwaved at 95 oC for one hour in 10 mmol/L citrate 
buffer (pH 6.0) to stain mast cell tryptase, prior to incubation with the primary antibody.  
The sections were incubated at 4 oC overnight with the monoclonal antibody against 
tryptase (80 μg/mL, Clone AA1; DAKOcytomation), followed by incubation with 
horseradish peroxidase-labeled polymer conjugated secondary antibody (Dako Envision+ 
System) for 30 min at room temperature.  Immunoreactivity was visualized with 3,3’-
diaminobenzidine (Dako), counterstained with Mayer’s hematoxylin.  For IL-4 staining, 
frozen sections of AAA tissues were fixed in acetone and incubated with the monoclonal 
antibody against human IL-4 (10 μg/mL, clone 3007.11; R&D Systems, Inc.).   
Double Staining: To identify the phenotype of mast cells in aortic tissues, double staining was 
performed using a Histofine kit (Nichirei, Tokyo, Japan) according to the manufacturer’s 
instructions.  In double staining of tryptase (80 μg/mL, Clone AA1; DAKOcytomation) and 
chymase (1:100, Clone CC1; abcam), enzymatic activity of alkaline phosphatase for tryptase 
was visualized with new fuchsin in red (New Fuchsin Kit; Nichirei) and for chymase with 3, 3’, 
5, 5’-tetramethylbenzidine in blue (TMB substrate kit; Vector Laboratories).  
2.3 Morphometric analysis 
Mast cell numbers in at least 10 microscopic fields were counted at a magnification of x400 
and expressed as a density (cells per mm2) in the intima, outer media and adventitia of early 
(diffuse intimal thickening and fatty streak), advanced atherosclerotic abdominal aorta and 
AAA. In counting the cell number, the intima was defined as the region of the arterial wall 
from the endothelial surface to the luminal margin of the media;(Stary et al. 1992) however, 
the internal elastic lamina becomes unclear or absent in the advanced atherosclerotic aorta, 
so we counted mast cells located on the luminal side of atheromatous plaques. On the other 
hand, the adventitia was defined as the area outside the external elastic lamina and inside 
the border of inner dense and outer loose connective tissues, and the number of cells in the 
outer media and adventitia was combined because the external elastic lamina was mostly 
unclear in AAA specimens. Capillary vessel number positive for CD34 antigen was also 
evaluated in the outer media and adventitia, and was expressed as a density (/mm2). 
2.4 Western blot 
Denatured protein extract (30 μg) from the AAA and non-dilated atherosclerotic aorta was 
subjected to sodium dodecyl sulfate-polyacrylamide gel as described (Tsuruda et al. 2008).  
 
Mast Cell Density and Distribution in Human Abdominal Aortic Aneurysm 
 
57 
The separated proteins electrically transferred onto polyvinylidene difluoride (PVDF) 
membranes were incubated with anti-mouse monoclonal IL -4 antibody (2 μg/mL, clone 
3007.11; R&D Systems, Inc.), followed by incubation with horseradish peroxidase-coupled 
second antibody.  Immunoreactive bands were visualized by the ECL Plus detection kit 
(Amersham), and intensities of the bands were analyzed densitometrically (Chemi DocTM 
Documentation System; BIO-RAD).  
3. Statistical analysis 
All data were analyzed with JMP 7.0.1 and GraphPad prism 5.  Comparisons between 
groups were assessed with the chi-square test or Kruskal-Wallis test, and the mast cell 
density and capillary number were correlated with the Spearman rank correlation 
coefficient test.  Protein expression between the two groups was analyzed with Student’s t-
test.  The data are expressed as the mean ± SEM or as the median with the quartile range, 1.5 
interquartile and outlying values.  Statistical significance was accepted at p<0.05.   
4. Results 
4.1 Patients’ characteristics 
Clinical parameters of the patients enrolled in this study are shown in the Table 1.  The 
advanced atherosclerosis and AAA groups were significantly older than the early stage 
atherosclerosis group, but there was no difference in age between AAA patients and those 
with advanced atherosclerosis.  The AAA group showed a significantly higher rate of 
hypertension than the early or advanced atherosclerosis group, whereas the ratio of diabetes 































Table 1. Patients’ characteristics.  Data are expressed as the mean ±SEM.  *p<0.01, **p<0.0001 
vs. early stage of atherosclerosis, ##p<0.0001 vs. advanced atherosclerosis 
4.2 Mast cell density in atherosclerotic abdominal aorta and AAA 
Figure 1 shows representative pictures of tryptase-positive mast cells at the intima and outer 
media and adventitia of early atherosclerosis (diffuse intimal thickening, DIT), advanced 
atherosclerosis and AAA.  As shown in Figure 2A, the density of mast cells at the intima 
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tended to decrease according to the degree of atherosclerosis, and was further diminished in 
AAA.  On the other hand, the cell number significantly increased at the outer media and 
adventitia of the AAA group, compared with those in the early or advanced atherosclerotic 
aorta (Figure 2B).   
 
 
Fig. 1. Representative pictures of tryptase-positive mast cells at intima and outer media and 
adventitia of early atherosclerosis (diffuse intimal thickening, DIT), advanced 
atherosclerosis and AAA.  Scale bar, 200 μm. 
 
 
Fig. 2. Mast cell density in early or advanced atherosclerosis and AAA.  Number of tryptase-
positive mast cells was counted at intima (A) and outer media and adventitia (B), respectively 
in early (n=26) or advanced (n=30) atherosclerosis and AAA (n=60). Data are expressed as the 
median with the quartile range, 1.5 interquartile and outlying values. *p<0.05, **p<0.01 vs. 
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4.3 Phenotype of mast cells in AAA 
Figure 3A-C illustrate the representative pictures of the mast cell phenotype in the AAA 
specimens.  As shown in Figure 3D, most of the mast cells distributed at the outer media 
and adventitia of AAA were positive both for tryptase and chymase (97.9%), while the 
remainder of the mast cell subtypes, tryptase-positive/chymase-negative (0.27%) or 
tryptase-negative/chymase-positive (1.9%) were a minor population.  The proportion of 
mast cell phenotypes was similar in early or advanced atherosclerotic aortae. 
 
 
Fig. 3. Phenotype of mast cells in early or advanced atherosclerosis and AAA.  
Representative pictures of tryptase-positive/chymase-negative (A), tryptase-
negative/chymase-positive (B) and tryptase-positive/chymase-positive mast cells (C).  Scale 
bar, 20 μm.  D, Percentage of mast cell phenotype in early (n=10) or advanced (n=5) 
atherosclerosis and AAA (n=26).   
4.4 Expression and distribution of IL-4 in AAA 
Figure 4A illustrates that the protein expression of IL-4 was significantly increased in AAA 
compared to the atherosclerotic aorta.  The immunoreactivity of IL-4 was widely distributed 
in the endothelial cells of microvessels and fibroblast-like cells at the outer media and 
adventitia of AAA (Figure 4B).   
4.5 Correlation between numbers of capillary vessel and mast cell  
Figure 5A shows that the number of capillary vessels distributed at the outer media and 
adventitia (so called “vasa vasorum”) was significantly increased in the advanced 
atherosclerotic aorta group compared with the early stage of atherosclerosis; however, the 
number did not change significantly between advanced atherosclerosis and AAA.  As 
shown in Figure 5B, mast cell density correlated with the capillary vessel number at the 
outer media and adventitia of all cases (n=116, r=0.349, p=0.0001). 
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Figure 5A shows that the number of capillary vessels distributed at the outer media and 
adventitia (so called “vasa vasorum”) was significantly increased in the advanced 
atherosclerotic aorta group compared with the early stage of atherosclerosis; however, the 
number did not change significantly between advanced atherosclerosis and AAA.  As 
shown in Figure 5B, mast cell density correlated with the capillary vessel number at the 
outer media and adventitia of all cases (n=116, r=0.349, p=0.0001). 
  




Fig. 4. Protein expression of IL-4 and its distribution in AAA specimen.  A, Western blot for 
IL-4 in non-dilated atherosclerotic aorta (n=5) and AAA (n=6). Arrows indicate the mono-
form (18 kDa) and dimer (36 kDa) of IL-4, respectively.  The two forms of IL-4 expression 
were combined to present the data.  Data are expressed as the mean ± SEM.  *p<0.05 vs. 


























































































Fig. 5. A, Capillary vessel number determined by CD34-positive staining in the outer media 
and adventitia of early or atherosclerosis and AAA.  Data are expressed as the median with 
the quartile range, 1.5 interquartile and outlying values.  B, Correlation between numbers of 
mast cells and capillary vessels in the outer media and adventitia in early or advanced 
atherosclerosis and AAA (n=116, r=0.3494, p=0.0001).   
 




Up to 8 % of men older than 65 years harbor AAA, and it is associated with several risk factors, 
such as smoking and hypertension (Nordon et al. 2010).  AAA progresses asymptomatically 
and patients with AAA eventually die due to rupture.  At the tissue level, inadequate 
remodeling of the extracellular matrix in aortic walls appears to be involved in the 
development, progression or rupture of AAA (Kadoglou & Liapis 2004; Choke et al. 2005; 
Longo et al. 2002; Xiong et al. 2004; Daugherty & Cassis 2004; Brown & Powell 1999; Singh et 
al. 2001; Freestone et al. 1995); however, to date, the underlying mechanism is not fully 
understood and there is no effective pharmacological therapy to inhibit/reverse enlargement 
of the aneurysmal aorta in humans.  The immune system is assumed to participate because of 
the inflammatory infiltration of macrophages and T lymphocytes that can produce enzymes 
degrading the extracellular matrix at the outer media and adventitia of human and 
experimental AAA (Longo et al. 2002; Ocana et al. 2003; Xiong et al. 2004).  
As a component of the immune system, mast cells are widely distributed throughout the body 
and have an important role in defending hosts against pathogens.  In the cardiovascular 
tissues, this type of cell is present at the intima of normal/fatty streak (Kaartinen et al. 1994), 
whereas it is more prominent at the adventitia of atherosclerotic aorta (Atkinson et al. 1994) 
and in the vulnerable plaques of atherosclerotic coronary and carotid arteries (Kaartinen et al. 
1998; Jeziorska et al. 1997).  Our data support a previous study (Kaartinen et al. 1994) which 
shows that mast cells at the intima decreased according to the degree of atherosclerosis, 
assuming that a loss of endogenous heparin production by mast cells stimulates pro-coagulant 
activity on atherosclerotic plaques.  More importantly, we demonstrated that the cell number 
was significantly increased at the outer media and adventitia of AAA, compared with either 
the early or advanced stage of atherosclerosis.  The proportion of activated mast cells (seen as 
“degranulation”) has been reported to be frequently observed in the adventitia of AAA 
compared to in advanced atherosclerosis (15±2 % vs. 0.4±0.3% total number of mast cells) 
(Tsuruda et al. 2008).  Thus, mast cells distributed “outside of aortic wall” appear to be 
associated with the AAA pathogenesis.   
Mast cells mature with tissue-specific phenotypes from circulating multipotent haematopoietic 
progenitor cells in response to signals communicated by quiescent microvascular environment 
cells where they become resident (Krishnaswamy et al. 2006).  Stem cell factor (SCF), a ligand 
for the proto-oncogene c-kit, is widely produced in various types of cells, such as fibroblasts 
(Nocka et al. 1990), endothelial cells and stromal cells (Heinrich et al. 1993), and is the main 
factor for the growth and differentiation of mast cells (Zsebo et al. 1990).  Circulating mast cell 
precursor has been reported to mature in tissues by SCF (Zsebo et al. 1990) and other cytokines 
such as IL-4 (Conti et al. 2003; Yanagida et al. 1995).  In accordance with the report (de Paulis et 
al. 1999), we have shown that the immunoreactivity of SCF was detected in the cytoplasm of 
mast cells (Tsuruda et al. 2008), suggesting autocrine or paracrine regulation of differentiation 
and maturation of cells in aortic tissues.  Schönbeck et al. (2002) showed the augmented 
expressions of IL-4 and IL-10 in inflammatory cells of AAA tissues.  Importantly, these 
cytokines enhanced the growth-promoting effect of SCF on mast cells (Conti et al. 2003; 
Yanagida et al. 1995), and we further demonstrated that IL-4 was widely present in the 
endothelial cells of microvessels and fibroblast-like cells in AAA specimens.  In contrast, we 
could not detect IL-10 expression in AAA tissues in this study (data not shown).  It seems 
likely that mast cells can mature or differentiate in the aneurysmal aortic wall, at least partly 
through SCF and IL-4 stimulation.   
  




Fig. 4. Protein expression of IL-4 and its distribution in AAA specimen.  A, Western blot for 
IL-4 in non-dilated atherosclerotic aorta (n=5) and AAA (n=6). Arrows indicate the mono-
form (18 kDa) and dimer (36 kDa) of IL-4, respectively.  The two forms of IL-4 expression 
were combined to present the data.  Data are expressed as the mean ± SEM.  *p<0.05 vs. 


























































































Fig. 5. A, Capillary vessel number determined by CD34-positive staining in the outer media 
and adventitia of early or atherosclerosis and AAA.  Data are expressed as the median with 
the quartile range, 1.5 interquartile and outlying values.  B, Correlation between numbers of 
mast cells and capillary vessels in the outer media and adventitia in early or advanced 
atherosclerosis and AAA (n=116, r=0.3494, p=0.0001).   
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Human mast cells exhibit tissue-specific functional heterogeneity; they are divided 
conventionally into two different phenotypes depending on the proteases in their secretory 
vesicles.  In this study, the majority of mast cells distributed at the outer media and 
adventitia of AAA were positive both for tryptase and chymase.  One of the 
histopathological features of AAA is the degeneration of the media by apoptosis of smooth 
muscle cells (Lopez-Candales et al. 1997) and fragmentation of elastic fibers digested by 
matrix metalloproteinase (MMP) (Baxter et al. 1994), resulting in loss of integrity to maintain 
the architecture of the aortic wall.  Mast cell tryptase stimulates fibroblast proliferation 
(Cairns & Walls 1997) as well as MMP-1,-3 activation (Johnson et al. 1998).  On the other 
hand, mast cell chymase may have a wide range of actions in AAA tissues: induction of 
apoptosis of smooth muscle cells (Leskinen et al. 2001), conversion of angiotensin I to 
angiotensin II (Takai et al. 1999) and of pro-MMP-2 and -9 to the mature forms 
(Tchougounova et al. 2005), whereas mast cells themselves are found to express MMPs-2 
and 9 (Fang et al. 1999).  We have reported that interferon-γ produced from mast cells 
stimulated MMP-9 synthesis by macrophages in the co-culture (Tsuruda et al. 2008).  
Angiogenesis appears to be another important histopathological characteristic of AAA (Paik 
et al. 2004; Reeps et al. 2009).  Mast cells are capable of synthesizing factors associated with 
angiogenesis (Hiromatsu & Toda 2003), and indeed, are often positioned around capillary 
vessels.  We found a positive correlation between mast cell density and capillary number at 
the adventitial layer, speculating that mast cells might contribute to initiate the 
inflammatory response by stimulating the growth of the vasa vasorum, and thereby recruit 
macrophages and T-lymphocytes from outside the aortic wall (Satta et al. 1998; Reeps et al. 
2009).  However, it remains to be elucidated whether angiogenesis itself is relevant to AAA 
development, because the vessel number was statistically insignificant between AAA and 
advanced atherosclerosis in this study.  Based upon the observation in human tissues, we 
propose that mast cells infiltrating at the outer media and adventitia of the AAA wall 
contribute to the development or progression of aneurysm formation, coordinating with 
other inflammatory cells.  Furthermore, the inhibition of mast cell accumulation, maturation 
and activation in the aortic wall with a mast cell stabilizer would be a potential 
pharmacological target for preventing/attenuating the development of AAA (Tsuruda et al. 
2008; Sun et al. 2007).   
6. Conclusion 
Mast cells are predominantly present at the outer media and adventitia, and are susceptible 
to maturation/activation by interaction with cytokines in AAA tissues.  In addition, the 
mediators expressed by mast cells and neovascularization might contribute to enhance the 
inflammatory response in AAA.  These results underline the pathophysiological role of this 
type of immune cell in the development/progression of aneurysm formation.   
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Aneurysm is an abnormal widening or ballooning of a portion of an artery due to weakness 
in the wall of the blood vessel. Although venous aneurysms do occur, arterial aneurysms are 
much more common and severe than venous aneurysms. Aneurysmal degeneration of the 
abdominal aortic and iliac arteries is a common and frequently lethal age-related disease 
process (Baxter et al., 2008; Weintraub, 2009). Arterial aneurysm is a potentially lethal 
vascular disorder, much more common in older men with estimates of prevalence ranging 
up to 10 percent (Thompson et al., 2002). Death from a ruptured aneurysm accounts for 
about 1 percent of all the deaths in the Western world (Collin et al., 1988). Extensive 
evidence indicates that mediators of immunity and inflammation participate in the 
development of aneurysm formation (Duftner et al., 2006; Shimizu et al., 2006). However, 
the pathogenesis of the aneurysm formation and rupture remains unclear.  Recent results 
obtained from clinical and experimental studies suggest that complement, an important 
mediator for immune and inflammatory responses may contribute to the pathogenesis of 
artery aneurysms.  Here, we will extensively review the potential roles of complement in 
artery aneurysm formation and rupture.   
2. Artery aneurysms 
Artery aneurysms such as aortic, cerebral and ventricular aneurysms develop as a result of 
weakening of the vascular wall in response to the initiation of a complex extracellular matrix 
remodeling process that culminates in alterations in artery compliance and resilience 
(Powell and Greenhalgh, 1989; Schneiderman et al., 1995). Aortic aneurysm is located within 
the wall of the aorta. Typically, the widened part of the aorta is considered to be an 
aneurysm when it is more than 1.5 times its normal size. Cerebral aneurysm, also known as 
a berry aneurysm, occurs in the wall of a blood vessel in the brain. Ventricular aneurysm is a 
ballooning out of part of the wall of the heart. Most aneurysms are asymptomatic and 
undiagnosed and the rupture of aneurysms is associated with a systemic inflammatory 
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response and multiple organ dysfunctions, which remain a primary cause of death in 
patients who survive the initial surgery (Harkin et al., 2004). Aneurysm rupture has an 
overall mortality rate of 80–90 percent, and an operative mortality rate of 50 percent. Other 
than relatively high risk and costly open surgical repair, few interventional modalities are 
available to treat patients with AAA (Baxter et al., 2008; Krishna et al., 2010). This mainly 
stems from little understanding of the underlying mechanism of aortic aneurysms. 
Therefore, better understanding of the pathogenesis of artery aneurysms and developing 
more effective therapies for the treatment and prevention of artery aneurysms is imperative. 
Extensive evidence indicates that the mediators of immunity and inflammation participate in 
the development of aneurysm formation (Duftner et al., 2006; Shimizu et al., 2006). The 
aneurysm is characterized by chronic adventitial and medial inflammatory cell infiltration, 
extracellular matrix degeneration, and apoptosis of smooth muscle cells, which lead to vessel 
wall weakening, aortic dilatation and aneurysm formation (Jagadesham et al., 2008). 
Inflammatory cells accumulate in aortic aneurysm lesions with a predominance of CD4+ T ,B 
cells and macrophage, which secrete various inflammatory factors, including cytokines, 
chemokines, leukotrienes, reactive oxygen species, and immunoglobulins, contributing to the 
immune response in aneurysm lesions (Shimizu et al., 2006). Macrophages promote aneurysm 
development by secreting collagenases and elastases, which could degrade elastic lamellae 
and extracellular matrix (ECM) proteins, constituting the underlying characteristics of the 
aneurysm (Kadoglou and Liapis, 2004). Consistently, extensive evidence indicates that MMP2 
and MMP9 play critical roles in the pathogenesis of artery aneurysms, and macrophages are 
the primary source of MMP-9 production in human and mouse aneurysm tissues (Longo et al., 
2002; Thompson et al., 1995). The excessive local production of the matrix metalloproteinases 
(MMPs), which are mainly secreted from macrophages, results in the damaging of smooth 
muscle cells (SMC) and thinning of the artery wall (Allaire et al., 1998; Caird et al., 2006; 
Eliason et al., 2005; Hannawa et al., 2009; Newman et al., 1994; Palombo et al., 1999; Tanaka et 
al., 1995). Moreover, the development of aneurysms is suppressed by pharmacologic inhibition 
of MMPs, such as the use of tetracycline derivatives, or genetic alterations that eliminate the 
expression of either MMP 9 or MMP 2 (Curci et al., 2000; Mosorin et al., 2001; Pyo et al., 2000). 
Elastolytic cysteine proteases, including cathepsin,  also play a critical role in the development 
of aneurysms (Shi et al., 1999). In addition, endothelial and smooth muscle cells in aneurysm 
lesions may release an array of growth factors and cytokoines to attract inflammatory cells 
recruitment, which contributes to aneurysm development (Nicholson-Weller and Halperin, 
1993). Nevertheless, the exact underlying mechanism and cause of aneurysms are unclear. The 
risk factors for aneurysms include advanced age, male gender, smoking, hypertension, 
diabetes, obesity, high cholesterol, genetic predisposition, and atherosclerosis (Wassef et al., 
2007). Among these factors, the most common culprits are atherosclerosis and high blood 
pressure (Daugherty and Cassis, 2004; Wassef et al., 2007). Most of the abdominal aortic 
aneurysms (AAA) in humans are associated with atherosclerosis (Daugherty and Cassis, 2004; 
Wassef et al., 2007).   
Although both atherosclerosis and aneurysm are immune and inflammatory diseases, they 
have different pathogeneses. The hallmark pathologic feature of atherosclerosis is foam-cell 
formation, whereas aneurysms are typified by intense oxidative stress, inflammation, matrix 
degradation, and apoptosis of smooth-muscle cells (Miller et al., 2002; Weintraub, 2009). In 
aneurysm development, first, inflammatory leukocytes play an important role in the 
degradation of elastin and collagen in the vessel wall. Subsequent dilation of the vessel will 
trigger the vascular cells to remodel and repair to prevent vessel rupture (de Waard et al., 
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2010). Most aortic aneurysms occur in association with advanced atherosclerosis (Nordon et 
al., 2009). Atherosclerosis may induce AAA formation by causing mechanical weakening of 
the aortic wall with loss of elastic recoil, along with degenerative ischemic changes, through 
obstruction of the vasa vasorum. Many patients with advanced atherosclerosis do not 
develop artery aneurysms, while some patients for which there is having no evidence of 
atherosclerosis do develop artery aneurysms. The observed association between 
atherosclerosis and aneurysm is probably not causative; however, atherosclerosis may 
represent a nonspecific secondary response to vessel wall injury that is induced by multiple 
factors. These facts clearly indicate that aneurysm has a different pathogenesis and 
consequences for aortic walls vs. atherosclerosis. Although increasing emerging evidence 
obtained from clinical and experimental studies indicates that complement system plays a 
critical pathogenic role in the development of atherosclerosis (An et al., 2009; Halas et al., 
2005; Hansson et al., 1984; Lewis et al., 2009; Meuwissen et al., 2006; Niculescu et al., 1999b; 
Nijmeijer et al., 2003; Ross, 1999; Seifert and Kazatchkine, 1988; Vlaicu et al., 1985; Wu et al., 
2009; Yun et al., 2008), the role of complement system in the pathogenesis of aneurysm 
remains unclear. 
3. Complement activation and regulation 
3.1 Complement activation 
The complement system consists of about 30 soluble and membrane-bound proteins, and is 
activated by three distinct pathways: classical, mannose-binding lectin (MBL) and 
alternative pathways, either on pathogen surfaces or in plasma (Yu et al., 2010; Zhou et al., 
2008). Activation of these pathways depends on different molecules for their initiation (Qin 
and Gao, 2006; Zhou et al., 2008). All three activation pathways converge at the level of C3 
to form C5 convertase such as the C4bC2bC3b from classical and MBL pathways and 
(C3b)2Fbb from alternative pathway. The C5 convertase then cleaves C5 to form C5b and 
C5a. The terminal complement activation pathway is induced initially by C5b, followed by 
the sequential condensation of C6 form to C5b6, and then C7, C8, and C9. Polymerization of 
C9 bound to the C5b-8 complex forms the MAC, an end-product of the complement 
activation pathway. The MAC forms a lytic pore in the lipid bilayer membrane that allows 
the free passage of solutes and water across the membrane and destroys membrane 
integrity, followed by killing of foreign pathogens and cells (Mayer, 1984).  
The liver (mainly hepatocytes) is the main source of complement proteins, accounting for 
80%~90% of plasma complement components and their soluble regulators (Qin and Gao, 
2006). Many other non-hepatic cells including macrophage, endothelial, neutrophil and 
lymphocytes could produce complement proteins. This local synthesis of complement 
occurs in the brain, heart, lung, joints, intestine, skeletal muscle and bone marrow (Morgan 
and Gasque, 1997). It has been demonstrated that the absence of locally synthesized 
complement component C3 is capable of modulating the rejection of renal allografts in vivo 
and regulating T-cell responses in vivo and in vitro (Pratt et al., 2002). The result indicates 
that the local complement production also plays a critical role in the pathogenesis of human 
diseases such as organ rejection.   
3.2 Biological functions of complement activation byproducts 
The byproducts produced in complement activation, such as C1q, C3b, iC3b, and C4b, are 
critical opsonins for host defense against pathogen and for disposal of immune complexes 
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and dead cell debris by the phagocytosis/lysis effect of the immune cells (macrophages, 
neutrophils, natural killer [NK] cells, etc.) through their surface receptor binding to these 
byproducts. On the other hand, the small fragment byproducts such as C3a, C4a, and C5a, 
termed anaphylatoxins, also play an important role in inflammation and especially in host 
defense against parasites. These anaphylatoxins can cause mast cell and basophil 
degranulation, with the release of histamine and other substances that increase vascular 
permeability and stimulate smooth muscle constriction. C3a and C5a are potent leukocyte 
chemoattractants, and can also activate these immune effector cells by binding to cell surface 
receptors  (Haas and van Strijp, 2007). Among these anaphylatoxins, C5a has the most 
potent biological activity (Guo and Ward, 2005). 
3.3 MAC function 
The cellular response to MAC formation can be classified into two groups along a response 
continuum: lytic and sublytic. Lytic MAC formation results in colloidoosmotic swelling and 
lysis of the target (Mayer, 1984; Yu et al., 2010). Normally, MAC attacks homologous 
nucleated cells mainly through sublytic MAC because nucleated cells possess several 
protective mechanisms against the cytolytic effect of the MAC, including CD59, anti-
apoptotic genes and endocytosis/shedding of MAC (Haskard et al., 2008; Zhou et al., 2008). 
The sublytic MAC can mediate non-lethal physiological and/or pathological responses in 
autologous cells (Nicholson-Weller and Halperin, 1993).  
Biological functions of sublytic MAC include insertion into the membrane of endothelial 
cells resulting in the release of: a) bFGF and PDGF (Benzaquen et al., 1994; Halperin et al., 
1993; Shankland et al., 1999); b) interleukin-1, which stimulates the expression of pro-
inflammatory adhesion molecules such as VCAM-1 and E-selectin, and of prothrombotic 
tissue factor (Acosta et al., 1996); and c) MCP-1, which attracts monocytes and macrophages 
that contribute to the pathogenesis of the atherosclerotic plaque (Fosbrink et al., 2006; 
Torzewski et al., 1996). Consistently, we have demonstrated that sublytic MAC up-regulated 
the transcripts of these growth factors and cytokines in the plaques of the deficient CD59 
mice as well as of targeted macrophages and endothelial cells. However, the role of MAC-
induced growth factors and cytokines in the aneurysms is unclear.  
In vitro studies have shown that sublytic MAC induces following cellular signaling 
pathways (Niculescu et al., 1999a; Niculescu and Rus, 1999, 2004), which may contribute to 
the increase of the release of these growth factors and cytokines. These cellular signaling 
pathways include 1) elevated Ca2+ via Ca2+ influx through transient pore in cells, which 
partially activates PKC and other cellular signaling pathways (Carney et al., 1990; 
Papadimitriou et al., 1991); 2) G protein coupled-activation of Ras, Raf-1, MEK, ERK-1 
pathway and increased activities of ERK-1, c-jun NH2-terminal kinase JNK1 and p38 MAPK 
in many cells including endothelial cells and smooth muscle cells (Niculescu et al., 1999a; 
Niculescu and Rus, 1999; Niculescu et al., 1997); 3) activation of the PI3/Akt kinase pathway 
(Fosbrink et al., 2006; Hila et al., 2001; Niculescu et al., 1999a; Soane et al., 2001); 4) activation 
of the nuclear factors NF-κB and activator protein-1 (AP-1), which may be responsible for 
MAC-induced release of IL-6 in smooth muscle cells and IL-8 and MCP-1 in endothelial cells 
(Viedt et al., 2000) (Kilgore et al., 1996; Kilgore et al., 1997); and 5) activation of the 
JAK1/STAT3 pathway (Niculescu and Rus, 1999). These in vitro experimental results 
strongly suggest that MAC is an important mediator of cellular signals that may trigger cell 
mitogenic effects, which could explain MAC-mediated growth factor and cytokine release. 
Their activations may result from the secondary effects from the released inflammatory 
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mediators by transiently sublytic MAC and/or the direct effect from sublytic MAC, which 
have not been addressed so far.  
3.4 Complement regulation 
To prevent the potentially harmful effect of complement activation on autologous cells, 
about 10 plasma- and membrane-bound inhibitory proteins have evolved to restrict 
complement activation at different stages of activation pathways (Yu et al., 2010; Zhou et al., 
2008). The soluble plasma complement regulatory proteins include C1 inhibitor, which 
regulates C1; factor H and factor I, which regulate the cleavage of C3b and C3/C5 
convertases; C4 binding protein, which splits C4 convertase and assists factor I in the 
cleavage of C4b; and S-protein, clusterin, and serum lipids, which compete with membrane 
lipids to react with nascent C5b67 (Yu et al., 2010; Zhou et al., 2008). Moreover, three 
membrane proteins that are expressed on the surface of almost all cell types inhibit 
autologous complement activation, thereby protecting self cells from complement-mediated 
injury (Morgan, 1999). These regulators include decay-accelerating factor (DAF or CD55), 
membrane cofactor protein (MCP or CD46), and membrane inhibitor of reactive lysis 
(CD59). DAF inactivates the C3 (C4b2a and C3bBb) and C5 (C4b2a3b and C3bBb3b) 
convertases by accelerating the decay of these enzymes (Davitz et al., 1986; Medof et al., 1987; 
Nicholson-Weller et al., 1985). MCP acts as a cofactor for the cleavage of cell-bound C4b and 
C3b by the serum protease factor (Brodbeck et al., 2000). CD59 restricts MAC formation by 
preventing C9 incorporation and polymerization (Sugita et al., 1989). 
3.4.1 Anti-MAC regulator CD59 
Several lines of evidence indicate that CD59 is much more relevant than DAF, MCP and 
other complement regulators in protecting cells from MAC formation and MAC-induced 
phenomena (reviewed in (Acosta et al., 2004; Fisicaro et al., 2000)): 1) an isolated deficiency 
of DAF has been described in four families that had an unusual blood group phenotype 
termed Inab (Lin et al., 1988; Telen and Green, 1989). Although DAF was completely absent 
from all circulating cells (Reid et al., 1991), none of the propositi had symptoms suggestive 
of paroxysmal nocturnal hemoglobinuria (PNH), a complement-mediated hemolytic disease 
due to the deficiency of complement regulators such as CD59 and DAF; 2) a mDAF 
knockout mouse did not show any evidence of intravascular hemolysis (Sun et al., 1999); 
and 3) an index case report from Japan described a man who had a global deficiency of 
hCD59 due to single nucleotide deletions in the CD59 gene, which placed the gene product 
out of frame and introduced a premature stop codon. This subject expressed a severe PNH 
phenotype from the unusually young age of thirteen and also had a stroke that left him with 
permanent neurological damage (Yamashina et al., 1990). Not only does the Cd59 knockout 
out mouse exhibit a full PNH-like anemia as well as platelet activation, but it also exhibits 
progressive loss of fertility (Holt et al., 2001; Qin et al., 2009; Qin et al., 2003). Also, although 
the role of S-protein as an inhibitor of MAC formation in tissues has been suggested, the S-
protein knockout mouse did not show any detectable phenotype and instead developed 
normally and was fully fertile (Zheng et al., 1995). This indicates that, at least in mice, the S-
protein is not essential for survival nor does it play a major role in restricting complement 
activation or MAC formation. In addition to the anti-MAC role, CD59 has a complement-
independent function in regulating NK, B, and T cell activities (Longhi et al., 2007; 
Sivasankar et al., 2007). 
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3.4.2 The delicate balance between complement activation and regulation 
There is a delicate balance between complement activation and regulation on autologous 
cells, which is subject to perturbation by either increased complement activation or 
decreased regulation. The perturbation may cause a variety of immune diseases and chronic 
diseases (Yu et al., 2010). It is very likely that this delicate balance between complement 
activity and regulation differs in the different tissues because of differential expression of 
complement regulatory proteins and focal activation of complement proteins (Acosta et al., 
2004). Indeed, extensive study has shown an offset balance between complement activation 
and complement regulation, which contributes to the pathogenesis of inflammatory or 
immune diseases, such as systemic lupus erythematosus (Abe et al., 1998), rheumatoid 
arthritis (Breitner et al., 1995),Alzheimer’s disease (Gasque et al., 1995), and acute renal 
transplant rejection (Pratt et al., 2002). In the case of the development of aneurysms, there 
may be an offset balance between complement activation and regulation in the vascular 
walls, thereby leading to the development of aneurysm formation and rupture, which will 
be discussed below.   
4. Clinical evidence indicates that complement may contribute to the 
development of aneurysms 
There are a few clinical studies examining the role of complement and MAC in the 
pathogenesis of aneurysms. The results obtained from human studies only provide indirect 
evidence supporting the role of complement and highlighting the possible involvement of 
each complement activation pathway in the development and rupture of artery aneurysms 
like cerebral and aortic aneurysms.   
4.1 Complement activation and complement deposition in autoimmune disease-
associated aneurysms 
The potential role of complement in the artery aneurysms was first recognized by the study 
of autoimmune disease-associated aneurysms. Early demonstration that there is a negative 
correlation between serum immunoglobin level and complement activity in the Kawasaki 
disease patients with aneurysm provides the clinical evidence to link the potential role of 
complement to the formation of artery aneurysms (Miyata et al., 1984). Kawasaki disease 
(KD), is an autoimmune disease that manifests as a systemic necrotizing medium-sized 
vessel vasculitis and is largely seen in children under five years of age (Ozkan et al., 2007). It 
affects many organ systems, mainly those including the blood vessels, skin, mucous 
membranes and lymph nodes; however, its most serious effect is on the heart, where it can 
cause severe coronary artery aneurysms in untreated children. In 1984, Miyata et al (Miyata 
et al., 1984) conducted a study to measure the serum immunoglobin level and complement 
activity in 32 Kawasaki disease patients with or without coronary aneurysm. They (Miyata 
et al., 1984) demonstrated that the group of patients with coronary aneurysm showed 
relatively higher levels of IgG. Regardless of the presence of coronary aneurysm, the level of 
IgE in the acute phase was higher than that in the convalescent phase. In addition, the level 
of immune complexes was higher in the group of patients with coronary aneurysm. There 
was a low negative correlation between immune complexes and CH50, a clinical 
measurement for total complement activity.  
Another clinical study demonstrates that there is an extensive complement deposition in 
Behcet’s disease-related aneurysm (Yamana et al., 1988). Behçet's disease is a multisystem 
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disorder of probable autoinflammatory etiology with manifestations that can affect many 
organ systems (Gul, 2005). Its classical presentation includes recurrent oral and genital 
ulcers and skin inflammatory reactivity. Neurologic involvement is rare, as is the 
development of peripheral arterial aneurysms (1990). In 1988, Yamana et al (Yamana et al., 
1988) reported two patients with vasculo-Behçet's disease who had femoral and popliteal 
aneurysms. They found that the most interesting histological features in these patients were 
prominent fibrosis of the adventitia, including the surrounding tissue, venous occlusion, 
perivasculitis and deposits of C3, C4 and immunoglobulins (IgA, IgG and IgM) in the 
arterial wall and surrounding tissue. These findings indicate that the formation of aneurysm 
in vasculo-Behçet's disease is caused by destruction of the intimal and outer side of the 
arterial wall. Complement may participate in this destruction. Therefore, the complement 
activation/consumption from increased immune complexes in the circulation of 
autoimmune diseases may be involved in the development of aneurysms associated with 
autoimmune diseases.  
Extensive clinical and experimental evidence indicates that inflammatory aortic aneurysm is 
associated with increased incidence of autoimmune disease (Haug et al., 2003; Jagadesham 
et al., 2008). Complement plays a critical role in the pathogenesis of a variety of autoimmune 
diseases. However, the role of complement in the autoimmune-associated aneurysms 
remains unclear and requires further investigation.  
4.2 Immunoglobins and C3 deposition in aneurysms 
Gregory et al used immunoblotting techniques to compare the reactivity of IgG (detected 
with secondary goat antihuman antibody) from fourteen patients with abdominal aortic 
aneurysm (AAA) with soluble proteins extracted from normal and aneurysmal aortas 
(Gregory et al., 1996). Immunoglobulins G purified from extracts obtained from nine 
patients with no AAA were used for control experiments. They demonstrated that a unique 
band at approximately 80 kd was visualized when the filters were probed with IgG from 
eleven (79 percent) of fourteen patients with AAA compared with only one (11 percent) of 
nine control subjects. Immunoglobulins G from patients with AAA co-distributed with 
matrix fibers in normal aortic sections, particularly in the adventitia (suggestive of a 
microfibrillar component). These findings suggest that these IgGs may participate in the 
development and progression of AAA because these IgGs binding to the matrix fibers in 
artery may initiate local classical pathway activation and mediate complement attack on the 
artery wall, leading to initiation of the formation of artery aneurysms associated with 
autoimmune disease.  
This prediction was further confirmed by increased C3 deposition, along with IgG content 
in the AAA (Capella et al., 1996).  In 1996, Capella et al further demonstrated that compared 
to the amounts of IgG by subclass in normal aorta, AAA had increases of 193-fold in IgG1, 
160-fold in IgG2, 389-fold in IgG3, and 627-fold in IgG4. There was a 125-fold increase in 
immunoreactive C3 by ELISA in AAA vs normal aorta. Western immunoblotting techniques 
revealed the presence of multiple C3 degradation products in AAA. Increases in IgG1, 2, 
and 3 may be responsible for activation of complement in AAA by the classical pathway 
(Capella et al., 1996). Consistent with this finding, Stella et al (Stella et al., 1991) 
demonstrated that the interstitial matrix contained deposits of IgG, IgM and C3c together 
with an increase in type III collagen and a reduction in elastin which appeared fragmented 
and swollen. The degree of activation shown by these cell elements and the activation of 
complement suggest that the relevant antigen may have been localized in the aneurysm wall 
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disorder of probable autoinflammatory etiology with manifestations that can affect many 
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activation/consumption from increased immune complexes in the circulation of 
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at the time of observation. Taken together, the presence of complement-fixing IgG 
subclasses along with increased C3 in the aneurysm wall may be an important mechanism 
promoting matrix proteolysis in AAA.  
Moreover, in addition to C3 and IgG deposits in aneurysm, C9 were also found to deposit in 
aneurysm (Chyatte et al., 1999). Chyatte et al. conducted immunohistochemistry studies 
with aneurysm tissue collected at the time of microsurgical repair from 23 unruptured and 
two ruptured aneurysms (25 patients) and compared with 11 control basilar arteries 
harvested at autopsy. Immunohistochemistry revealed the localization of complement (C3c, 
C9) and immunoglobulins (IgG, IgM) with inflammatory cells such as macrophages and 
monocytes (CD68), T lymphocytes (CD3), and B lymphocytes (CD20). Complement (C3c), 
immunoglobulin (IgG), macrophages (CD68), and T lymphocytes (CD3) were all frequently 
present in the wall of aneurysm tissue but were rarely identified in control basilar arteries. A 
few B lymphocytes (CD20) were found in aneurysm tissue, but none were found in the 
basilar arteries. Extensive inflammatory and immunological reactions are common in 
unruptured intracranial aneurysms and may be related to aneurysm formation and rupture. 
These results strongly suggest that the IgM and/or C3 and MAC deposits located in the 
endothelium of intracranial arteries may play a role in aneurysm-associated neurological 
complications. 
4.3 Complement activation in ruptured aneurysm associated with hemorrhage 
The roles of complement and complement activation in ruptured aneurysms were further 
investigated by several independent groups. In 1987, Ostergaard et al, (Ostergaard et al., 1987) 
monitored circulating immune complexes and complement activation (plasma C3d levels) 
during a two week period in patients with ruptured cerebral aneurysms and also in patients 
with cerebral hematoma unrelated to saccular aneurysms. They found that thirteen of eighteen 
aneurysm patients were found to have immune complexes on admission as compared to three 
of 21 healthy blood donors. The presence of immune complexes in aneurysm patients was 
associated with a poor prognosis. Patients with vasospasm showed a twofold increase in 
plasma C3d levels at the time when the spasm occurred, whereas no significant changes in the 
C3d concentration could be demonstrated in aneurysm patients without spasm or in patients 
with hematoma unrelated to aneurysm rupture. These findings suggest that complement-
activation mediated by immune complex are involved in the pathogenesis of cerebral 
vasospasm following rupture of saccular aneurysms (Ostergaard, 1989).  
Kawano et al. investigated serum complements (CH50, C3, C4) after aneurysmal 
subarachnoid hemorrhage in 21 patients over a two to three week period (Kawano and 
Yonekawa, 1990). Preoperative grading was well correlated with the C4 level but not the C3 
level. C4 levels in patients without symptomatic vasospasm did not change markedly after 
subarachnoid hemorrhage over investigation. There were no remarkable changes of serum 
complements in the control patients. C3 and C4 levels of the patients without symptomatic 
vasospasm did not change markedly after subarachnoid hemorrhage, while they decreased 
severely in patients with severe vasospasm and majorneurological deficit. The patients with 
mild symptomatic vasospasm without major neurological deficit showed transient decrease 
of C3 and C4 levels within a period of five to ten days after subarachnoid hemorrhage. 
These results show that sequential determinations of serum complement (C3 and C4) levels 
after subarachnoid hemorrhage is a useful method for the choice of therapy and for the 
prognosis of aneurysmal patients after subarachnoid hemorrhage. The reduction of plasma 
C3 and C4 in patients with aneurysmal vasospasm indicates that complement have been 
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activated before rupture of the aneurysm. These results further support the role of 
complement activation in the pathogenesis of aneurysmal hemorrhage (Kawano and 
Yonekawa, 1990). 
4.4 Complement including MAC deposits in ruptured aneurysm associated with 
hemorrhage  
Complement including MAC deposition in ruptured intracranial aneurysm has been 
extensively investigated in clinical samples.  An intracranial aneurysm is an important 
acquired cerebrovascular disease that can cause a catastrophic subarachnoid hemorrhage. 
Despite modern therapy, most patients die or are left disabled as a direct result of a severe 
initial hemorrhage. The development of more effective treatment strategies depends on 
understanding the fundamental biology of cerebral aneurysms. The presence of IgM and/or 
C3 in the endothelium of intracranial aneurysms was demonstrated in five out of six 
patients with subarachnoid hemorrhage (SAH) (Ryba et al., 1992). In none of them were the 
immune deposits found in the gyrus rectus. Cortical tissue of four epileptic patients which 
served as a control gave negative results. 
Complement activation associated with the rupture and subarachnoid hemorrhage of 
sacculare cerebral artery aneurysm (SCAA) was also examined by electromicroscopy and 
immunoelectron microscopy. Tulamo et al recently demonstrated that MAC localized 
consistently in a decellularized layer in the outer SCAA wall, and was found in all SCAA 
samples (Tulamo et al., 2006). The percentage of MAC-positive area relative to the total 
SCAA wall surface area was greater in ruptured than in unruptured SCAAs. It was also 
associated significantly with SCAA wall degeneration, de-endothelialization, and CD163+ 
macrophage and T-lymphocyte infiltrations. Apoptotic terminal deoxynucleotidyl 
transferase-mediated deoxyuridine triphosphate nick end-labeling-positive nuclei and MAC 
were located at the same wall areas in four out of 14 double-stained samples, but no double-
positive cells were found. Electromicroscopy and immunoelectron microscopy of an 
unruptured SCAA showed cell death in the MAC-positive layers in the outer SCAA wall. 
These results suggest that complement activation and MAC formation are involved in 
SCAA wall degeneration and rupture (Tulamo et al., 2006).   
4.5 Local classical complement activation may be involved in aneurysm formation 
and rupture  
Tulamo et al further investigated initiators and the pathway of complement activation in 
unruptured and ruptured intracranial aneurysms (Tulamo et al., 2010a). Unruptured and 
ruptured intracranial aneurysm wall samples were studied in parallel sections by 
immunohistochemical and immunofluorescence stainings. Classical pathway components 
such as C1q, C3b/iC3b, C3d, C4b/iC4b and MAC were seen in all intracranial aneurysms, 
and they were located mostly in the extracellular matrix. The early pathway complement 
components co-localized with each other, but were present in larger areas than C5b-9. The 
areas positive for complement component accumulation were significantly broader in 
ruptured than in unruptured intracranial aneurysms. The potential complement activators 
IgG, IgM, CRP and OxLDL were found mostly in the extracellular matrix and in partial 
overlap with MAC. These results indicate that immunoglobulins, CRP, and OxLDL may 
locally activate classical complement pathway, thereby leading to complement and MAC 
deposits in the intracranial aneurysms wall, which participates in the formation and rupture 
of aneurysms  (Tulamo et al., 2010a).  
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at the time of observation. Taken together, the presence of complement-fixing IgG 
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Furthermore, Tulamo et al also reported that the complement regulatory capacity of the 
complement system thus appears disturbed in the outer part of the intracranial aneurysms 
(IA) wall (Tulamo et al., 2010b). The outer part of the IA walls, where MAC is mainly 
localized in, lacked CD59 and cellular parts in comparison to normal controls. In contrast, 
complement inhibitors factor H, C4b binding protein, and CD59 as well as 
glycosaminoglycans were sufficient in the luminal part of the IA wall where MAC was 
lacking from (Tulamo et al., 2010b). Thus, these human studies indicate that dysregulation 
of the complement system, such as loss of CD59 in the outer intracranial aneurysm walls 
leads to an increased susceptibility to complement activation and MAC formation which 
may associate with inflammation and aneurysm formation.  The insufficiency of 
complement regulation may be due to matrix remodeling and cell loss by mechanical 
hemodynamics and/or inflammatory stress (Tulamo et al., 2010b). Therefore, there is an 
imbalance between complement activation and regulation in the outer part of the 
intracranial aneurysms wall, which results from more complement activation and less 
complement regulation. This imbalance may allow full pro-inflammatory complement 
activation to occur before aneurysm rupture.  
In contrast, whether alternative and lectin pathways are involved in the aneurysm formation 
and rupture remains unclear. Recently, Bradley et al (Bradley et al., 2010) demonstrated that 
there was no evidence for significant association between presence or size of aneurysm with 
49 single nucleotide polymorphisms, including common putatively functional 
polymorphisms, in the genes of the alternative complement cascade (CFH, CFB, CFD, CFI, 
properdin, CR1, CR1L, CR2, CD46, vitronectin, C3, C5, C6, C7, C8A, C8B, C8G and C9). This 
study suggests that variation in the genes of the alternative pathway is not an important 
cause of AAA development. However, the relative role of each of the  complement 
activation pathways in the pathogenesis of artery aneurysms still warrants further 
investigation. This is because 1) complement system is a critical mediator of the 
inflammatory process; and 2) the complement-mediated inflammatory process results from 
imbalance between complement activation and regulation, which highly depends on the 
sites and tissues of complement activation.  
4.6 Complement participates in the ischemia-reperfusion injury of the patients 
undergoing the surgery for aneurysm repair   
Although open surgical repair is highly costly and has high mortality rate, it still is a 
common approach for the treatment of aortic aneurysm because few interventional 
modalities are available to treat patients with aortic aneurysm (Baxter et al., 2008; Krishna et 
al., 2010). Since complement activation contributes to ischemia-reperfusion injury, it is 
conceivable that patients undergoing thoracoabdominal aortic aneurysm repair suffer 
extensive ischemia-reperfusion and considerable systemic inflammation. Consistent with 
this prediction, Odegard et al (Odegard et al., 2007) reported that preoperatively, the 
thoracic aortic aneurysms patients had significantly elevated concentrations of 
myeloperoxidase, neopterin and complement activation products compared to controls. 
Myeloperoxidase and lactoferrin increased after the first contrast dose and peaked at 8 h 
postoperatively. Platelet counts decreased, while soluble MAC increased from 8 h 
postoperatively. This result indicates that stent graft treatment induces further activation, 
and markers of endothelial, platelet, and complement activation were increased for several 
days after the procedure. 
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4.6.1 Lectin pathway activation participates in the ischemia-reperfusion injury of 
patients undergoing surgery for aneurysm repair  
Norwood et al reported that there is the consumption of MBL during AAA repair (Norwood 
et al., 2006). They demonstrated that 23 patients undergoing AAA repair experienced a 
mean decrease in plasma MBL levels of 41 percent representing significant lectin pathway 
activation (p = 0.003). In contrast, no lectin pathway activation could be demonstrated in 
eight control patients. The consumption of MBL occurs during AAA repair and is indicative 
of an important role for the lectin pathway in the ischemia-reperfusion injury associated 
with aortic aneurysm repair.  
The degree and mechanism of complement activation and its role in inflammation were 
further investigated in the patients undergoing thoracoabdominal aortic aneurysm (TAAA) 
repair by Fiane et al (Fiane et al., 2003). Substantial complement activation was seen in 
TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, 
whereas C4bc, C3bBbP, C3bc, and the soluble C5b9 (MAC) increased markedly after 
reperfusion, reaching a maximum at eight hours after reperfusion. Interleukin (IL)-1, tumor 
necrosis factor α (TNF-α), and IL-8 increased significantly in TAAA patients but not in 
controls, peaking at 24 hours postoperatively and correlating closely with the degree of 
complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in 
the TAAA patients, were not correlated with complement activation, and increased 
moderately in the control subjects. Furthermore, no increase was observed in complement 
activation products, IL-1, TNF-α, or IL-8 in a MBL–deficient TAAA patient, whereas IL-6 
and IL-10 increased as in the controls. Two other MBL-deficient TAAA patients receiving 
plasma attained significant MBL levels and showed complement and cytokine patterns 
identical to the MBL-sufficient TAAA patients. These results strongly suggest that 
complement activation during TAAA repair is MBL mediated, amplified through the 
alternative pathway, and responsible in part for the inflammatory response (Fiane et al., 
2003). 
Altogether, these clinical results suggest that complement contributes to the formation and 
rupture of artery aneurysm and plays a critical role in ischemia-reperfusion injuries 
associated with aortic aneurysm repair.  However, the underlying molecular and cellular 
mechanisms, through which complement participates in the pathogenesis of artery 
aneurysm still remains unclear. Therefore, there is a strong need to experimentally dissect 
the mechanisms in animal models.  
5. Animal studies 
5.1 Current animal model of aneurysms 
Experimental models of artery aneurysms played an important role in understanding  
the underlying mechanism of artery aneurysms. A number of chemically induced AAA 
mouse models have been used extensively for the study of aneurysm pathogenesis 
(Daugherty and Cassis, 2004). These chemical approaches include intraluminal infusion of 
elastase, periaortic incubations of calcium chloride, and subcutaneous infusion of 
angiotensin II (Ang II) in Apoe-/-background (Daugherty and Cassis, 2004). These mouse 
models can recapitulate some pathological features of human aneurysms, including medial 
degeneration, inflammation, thrombus formation, and rupture (Daugherty and Cassis, 
2004). 
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5.2 Complement-dependent neutrophil recruitment is critical for the development of 
elastase-induced AAA in mice  
Transient perfusion of the abdominal aorta with a porcine elastase solution reproducibly 
leads to the formation of AAA in all C57BL/6 WT mice.  In this elastase-induced model of 
AAA, Pagano, M.B et al reported that mice that were treated with cobra venom factor(CVF, 
a potent complement inhibitor with the ability to deplete serum C3),  before or 24 hours 
after elastase perfusion, were resistant to elastase-induced AAA, characterized by smaller 
aortic dilatation, well-preserved elastic fibers, significantly less smooth muscle cell 
depletion, reduced numbers of macrophages, and activity of mast cells (Pagano et al., 2009). 
These results indicate that complement activation was involved in elastase-induced AAA 
development. Examination of mice deficient in factor B further indicated that the alternative 
pathway of complement played a major role in this process. Activation of the alternative 
pathway led to generation of the anaphylatoxins C3a and C5a, which recruited neutrophils 
to the aortic wall. Moreover, antagonism of both C3a and C5a activity was required to block 
AAA, which suggests that each can independently promote the aneurysmal phenotype. In 
addition, Pagano, M.B et al demonstrated that complement alternative-pathway 
involvement was not restricted to this experimental model, but was instead also evident in 
human AAA (Pagano et al., 2009). These results indicate that complement dependent 
neutrophile recruitment is critical for the development of AAA. 
5.3 Complement may play a role in canine subarachnoid hemorrhage models  
Gao et al (Gao et al., 2009) investigated the correlation between sympathetic nerve 
activation and inflammatory response in the acute stage of subarachnoid hemorrhage 
(SAH) in a canine perforating model. SAH was induced by perforation of the basilar 
artery with the use of a microcatheter via the femoral artery in twenty mongrel dogs. They 
demonstrated that the peak values of C3a and soluble MAC in plasma correlated 
positively with the peak value of noradrenaline. The peak values of IL-6 and IL-8 also 
correlated positively with the peak values of noradrenaline. These results suggest that a 
pronounced activation of the sympathetic nervous system and the inflammatory response 
occur in the acute stage of SAH and highlight that sympathetic activation and immune 
responses such as complement activation are quantitatively linked in the early stage after 
SAH (Gao et al., 2009). These results further support the potential role of complement 
activation in the aneurysm rupture.  
5.4 C5a receptor antagonist attenuates multiple organ injury in a model of ruptured 
AAA in rats   
The C5a-C5a receptor pathway may also play a critical role in multiple organ injuries after 
aneurysm rupture. Harkin et al (Harkin et al., 2004) examined the role of a novel 
complement factor 5a (C5aR) receptor antagonist, the cyclic peptide AcF-(OpdChaWR), in 
attenuation of pathologic complement activation and tissue injury in a model of AAA 
rupture. They demonstrated that C5aR antagonist AcF treatment significantly reduced lung 
and intestinal permeability index and myeloperoxidase activity and down-regulated lung 
TNF-alpha levels. These results indicate that a potent antagonist of C5a receptor protects the 
rat intestine and lung from neutrophil-associated injury in a model of AAA rupture. These 
data suggest that complement-mediated inflammation can be modulated at the C5a receptor 
level, independent of pro-inflammatory TNF-alpha production, and can prevent acute local 
and remote organ injury (Harkin et al., 2004). 
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5.5 Protective role of CD59 and potential pathogenic role of MAC in the AAA model  
Extensive evidence from human and animal studies indicates a protective role of CD59 and an 
atherogenic role of MAC in the pathogenesis of atherosclerosis (Wu et al., 2009). In a well-
accepted rabbit model of atherosclerosis induced by a 3 percent cholesterol diet, the deficiency 
of C6, a necessary complement for formation of MAC, protected against the development of 
atherosclerosis (Schmiedt et al., 1998; Seifert et al., 1989; Seifert and Kazatchkine, 1988). 
Recently, four independent groups defined the anti-atherogenic role of CD59 using mCd59 
deficient mice (An et al., 2009; Lewis et al., 2009; Wu et al., 2009; Yun et al., 2008). Furthermore, 
we (Wu et al., 2009)* and Lewis et al (Lewis et al., 2009) have recently documented the in vivo 
atherogenic roles of MAC using anti-mouse C5 antibody (Ab) to block the formation of MAC 
in mCd59 deficient mice and using mC6 deficient mice to block the formation of MAC 
respectively. Moreover, MAC mediated endothelial damage and promoted foam cell 
formation (Wu et al., 2009). These combined results highlight the atherogenic role of MAC 
(Wu et al., 2009). Although atherosclerosis and AAA have different pathogeneses, they are all 
immune and inflammatory diseases. Atherosclerosis is considered to be a main cause of AAA, 
thus the atherogenic role of MAC shed light on its possible role in aortic aneurysm. 
Moreover, human studies have suggested that MAC may play a role in the formation and 
rupture of aorta aneurysms as we discussed above. Taken together, this evidence prompted 
us to explore the role of MAC in the pathogenesis of AAA with our recent generation of 
both anti-MAC inhibitor CD59 deficient and overexpressing mice (Qin et al., 2009; Wu et al., 
2010). In an angiotensin (Ang) II-induced AAA model, deficiency of both mouse Cd59a and 
Cd59b (mCd59ab-/-) in ApoE-null mice accelerated the disease development, while 
transgenic over-expression of human CD59 in the endothelial and circulating 
cells(macrophages and platelets) (hCD59ICAM-2+/-) attenuated AAA progression (Wu et al., 
2010), these results suggest a protective role of CD59 in AAA development. Staining of the 
aneurysm sections with anti–C9-specific antibodies revealed that mCd59ab-/-/ApoE-/- mice 
had significantly more extensive deposits of C9 than ApoE-/- mice and that ApoE-/- mice 
have significantly more deposits of C9 than hCD59ICAM-2+/-/ApoE-/-mice. The fact that 
deposition of MAC in the AAA Lesions correlated with the severity of AAA strongly 
supports a pathogenic role of MAC in the development of AAA (Wu et al., 2010). 
Macrophage plays a critical role in the development of aorta aneurysms. Macrophages are the 
primary source of MMP-9 production in human and mouse AAA (Longo et al., 2002; 
Thompson et al., 1995). Consistent with the pathogenic role of MMPs, AAA aortic extracts 
from mCd59ab-/-/ApoE-/- mice exhibited significantly higher MMP2 and MMP9 activities, 
whereas extracts from hCD59ICAM-2+/-/ApoE-/- mice showed lower activities than ApoE-/- 
mice. Meanwhile, in the AAA lesions of mCd59ab-/-/ApoE-/- mice, the macrophage content is 
significantly increased, which is consistent with higher levels of MMP2 and MMP9 and the 
severity of AAA in this model (Wu et al., 2010). Furthermore, in vitro study demonstrated that 
sublytic MAC treatment in mouse endothelial, macrophage, and smooth muscle cells (SMC) 
increased MMP2 and MMP9 activities (Wu et al., 2010). Twelve hours after MAC treatment on 
these cells, activities of MMP2 or MMP9 from the cell extracts significantly increased. Further 
studies demonstrate that MAC upregulates MMP2 and MMP9 activities through AP-1 and 
NF-κB signaling pathways. Western blot assay revealed significantly increased 
phosphorylation of c-Jun, c-Fos, IKK-a/b and p65 in lesions of mCd59ab-/-/ApoE-/- mice, 
whereas decreased phosphorylation in hCD59ICAM-2-/-/ApoE-/-. Firefly luciferase reporter gene 
assay and RNA interference assay confirmed that MAC-activated c-Jun and NF-κB signaling 
pathways participate in the upregulation of MMP2 and MMP9, which may in turn contribute 
to the pathogenesis of AAA in Ang-II-induced AAA model.  
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5.2 Complement-dependent neutrophil recruitment is critical for the development of 
elastase-induced AAA in mice  
Transient perfusion of the abdominal aorta with a porcine elastase solution reproducibly 
leads to the formation of AAA in all C57BL/6 WT mice.  In this elastase-induced model of 
AAA, Pagano, M.B et al reported that mice that were treated with cobra venom factor(CVF, 
a potent complement inhibitor with the ability to deplete serum C3),  before or 24 hours 
after elastase perfusion, were resistant to elastase-induced AAA, characterized by smaller 
aortic dilatation, well-preserved elastic fibers, significantly less smooth muscle cell 
depletion, reduced numbers of macrophages, and activity of mast cells (Pagano et al., 2009). 
These results indicate that complement activation was involved in elastase-induced AAA 
development. Examination of mice deficient in factor B further indicated that the alternative 
pathway of complement played a major role in this process. Activation of the alternative 
pathway led to generation of the anaphylatoxins C3a and C5a, which recruited neutrophils 
to the aortic wall. Moreover, antagonism of both C3a and C5a activity was required to block 
AAA, which suggests that each can independently promote the aneurysmal phenotype. In 
addition, Pagano, M.B et al demonstrated that complement alternative-pathway 
involvement was not restricted to this experimental model, but was instead also evident in 
human AAA (Pagano et al., 2009). These results indicate that complement dependent 
neutrophile recruitment is critical for the development of AAA. 
5.3 Complement may play a role in canine subarachnoid hemorrhage models  
Gao et al (Gao et al., 2009) investigated the correlation between sympathetic nerve 
activation and inflammatory response in the acute stage of subarachnoid hemorrhage 
(SAH) in a canine perforating model. SAH was induced by perforation of the basilar 
artery with the use of a microcatheter via the femoral artery in twenty mongrel dogs. They 
demonstrated that the peak values of C3a and soluble MAC in plasma correlated 
positively with the peak value of noradrenaline. The peak values of IL-6 and IL-8 also 
correlated positively with the peak values of noradrenaline. These results suggest that a 
pronounced activation of the sympathetic nervous system and the inflammatory response 
occur in the acute stage of SAH and highlight that sympathetic activation and immune 
responses such as complement activation are quantitatively linked in the early stage after 
SAH (Gao et al., 2009). These results further support the potential role of complement 
activation in the aneurysm rupture.  
5.4 C5a receptor antagonist attenuates multiple organ injury in a model of ruptured 
AAA in rats   
The C5a-C5a receptor pathway may also play a critical role in multiple organ injuries after 
aneurysm rupture. Harkin et al (Harkin et al., 2004) examined the role of a novel 
complement factor 5a (C5aR) receptor antagonist, the cyclic peptide AcF-(OpdChaWR), in 
attenuation of pathologic complement activation and tissue injury in a model of AAA 
rupture. They demonstrated that C5aR antagonist AcF treatment significantly reduced lung 
and intestinal permeability index and myeloperoxidase activity and down-regulated lung 
TNF-alpha levels. These results indicate that a potent antagonist of C5a receptor protects the 
rat intestine and lung from neutrophil-associated injury in a model of AAA rupture. These 
data suggest that complement-mediated inflammation can be modulated at the C5a receptor 
level, independent of pro-inflammatory TNF-alpha production, and can prevent acute local 
and remote organ injury (Harkin et al., 2004). 
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5.5 Protective role of CD59 and potential pathogenic role of MAC in the AAA model  
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increased MMP2 and MMP9 activities (Wu et al., 2010). Twelve hours after MAC treatment on 
these cells, activities of MMP2 or MMP9 from the cell extracts significantly increased. Further 
studies demonstrate that MAC upregulates MMP2 and MMP9 activities through AP-1 and 
NF-κB signaling pathways. Western blot assay revealed significantly increased 
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pathways participate in the upregulation of MMP2 and MMP9, which may in turn contribute 
to the pathogenesis of AAA in Ang-II-induced AAA model.  
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It was previously demonstrated that MAC induced more severe endothelial dysfunction in 
mCd59ab-/-/ApoE-/- mice than in ApoE-/-, which contributes to atherogenesis (Wu et al., 
2009). MAC also mediates endothelial cell apoptosis in vitro. MAC insertion into endothelial 
and other cell membranes releases an array of growth factors and cytokoines, which may 
participate in the development of aneurysms. 
 
 
Fig. 1. Potential roles of complement in the pathogenesis of artery aneurysms 
MBL: Mannose Binding lection pathway, oxLDL: Oxidized low density lipoprotein, CRP: 
ECM: extracellular matrix and MAC: Membrane attack complex. 
Furthermore, the supernatant obtained from MAC-treated endothelial cells triggers the 
migration of both MAC-treated and non–MAC-treated macrophage in vitro. The increase in 
macrophage migration may result from the release of growth factors and cytokines induced 
by sublytic MAC assembly in endothelial cells. These findings suggest that MAC may 
promote AAA development through different target cells or signal pathways. In Ang-II 
induced AAA model, increased MMP expression in the aorta in AAA could be caused by 
increased macrophage infiltration, upregulation by increased MAC tissue levels, or some 
combination of these two mechanisms. 
Our study strongly supports the hypothesis that MAC may accelerate the initiation and 
development of AAA through mediation of endothelial dysfunction, attraction and 
activation of macrophages, which lead to the secretion of MMP2 and MMP9 that destroy the 
wall of blood vessels and thereby form aneurysm (Fig. 1). Taken together, these results shed 
light on the important pathogenic role of MAC in aneurysms, point towards the molecular 
mechanism of MAC-activated signaling pathways in aneurysm, and suggest inhibition of 
MAC may provide a novel approach for the treatment/prevention of aneurysms.  
 




In this review we summarized an increase in clinical and experimental evidence on the 
potential role of complement system in aortic aneurysms. The role of complement and MAC 
in artery aneurysms has only been suggested in human studies and has not been extensively 
studied in experimental models. Complement activation in the circulation has been 
identified in the course of the formation and rupture of artery aneurysms. Complement and 
MAC extensively deposit in aneurysm walls and more in rupture aneurysms than 
unruptured aneursyms. Complement also plays a critical role in the pathogenesis of 
reperfusion-ischemic injury after aneurysm repair.  Experimental evidence indicates that 
C3a and C5a play a critical role in the development of elastase-induced AAA, CD59 plays a 
critical protective role, and MAC plays a critical pathogenic role in the development of 
AAA. Together, these finding lead us to postulate the following hypothesis that 1) after 
complement is activated by one or three complement activation pathways in the circulation, 
the MAC, a terminal complement activation product, mediates endothelial dysfunction in 
the artery wall. This process will lead to the migration of inflammatory cells such as 
macrophage, the promotion of the interaction with the damaged endothelial cells, and 
deposition of activated complement bioproducts such as C3a and C5a and MAC, and 
complement activators such as immunoglobins, CRP and OxLDL in the artery wall; 2) the 
deposition of immuneglobin and CRP, OxLDL locally activates the classical complement 
activation pathways; 3) complement activation byproducts such as C3a and C5a and MAC 
amplify the inflammatory process in the artery wall through the release of inflammatory 
mediators and the attraction of more inflammatory cells to the artery wall; 4) these 
inflammatory process mediate the release of MMP2 and MMP9, which will degrade the 
elastic lamellae and extracellular matrix and damage the smooth muscle cells, finally 
leading to artery wall weakening and the formation of aneurysm or even aneurysm rupture 
(Fig. 1).  
Although the emerging evidence supports the role of complement in the pathogenesis of 
artery, there are still a number of questions that remain to be further studied.  For example, 
the molecular and cellular mechanisms of C3a, C5a, and MAC, and the relative role of 
complement activation pathways in the pathogenesis of artery aneurysms still require 
further investigation with these different animal models. Whether the early complement 
components play a role in the pathogenesis of aneurysms has not been studied so far.  
Whether the restriction of complement activation and MAC formation serves as a novel 
approach for the treatment/prevention of aneurysm also warrants future studies.  
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1. Introduction 
1.1 The concept of immunoglobulin G4-related sclerosing disease 
Immunoglobulin G4 (IgG4) is the rarest subclass of IgG, which is numbered 1 through 4 in 
the order of their discovery and serum concentration, and normally constitutes only 3 to 
6% of the total IgG fraction (Oxelius, 2008). IgG4 antibody has unique structural and 
functional properties, and the production of IgG4 appears to be driven in part by T helper 
2 (Th2) cytokines that mediate allergic responses and IgE production (Nirula et al., 2011). 
The presence of IgG4 autoantibody in bullous skin diseases and high serum IgG4 
concentration in patients with atopic dermatitis, bronchial asthma and bullous skin 
diseases have indicated that IgG4 plays an important role in these diseases (Jones et al., 
1988; Jarvis et al., 2007). However, little attention had been paid to IgG4, before Hamano 
et al. revealed that serum IgG4 concentration was markedly elevated in patients with 
sclerosing pancreatitis (also called autoimmune pancreatitis) in 2001 (Hamano et al., 
2001). Moreover, the same group also reported that the lesions of sclerosing pancreatitis 
and retroperitoneal fibrosis had abundant infiltration of IgG4-positive plasma cells 
(Hamano et al., 2002). Since then, many extrapancreatic lesions that share the same 
histopathological and immunohistochemical features as autoimmune pancreatitis have 
been reported in various organs, and the distinct clinicopathological disease entity, 
termed “IgG4-related sclerosing disease”, was established, because irrespective of origin 
of the organ, these lesions show common clinicopathological features (Kamisawa & 
Okamoto, 2008; Cheuk & Chan, 2010).  
1.2 Clinicopathological features of IgG4-related sclerosing disease 
The characteristic clinical features of IgG4-related sclerosing disease are as follows: mostly 
middle-aged and elderly are affected, male predominance, multiple synchronous or 
metachronous lesions can be seen in different organs, and the presentation of the patients 
depend on the involved site(s).  
Laboratory tests show that high serum IgG, IgG4, and IgE concentrations, and usually low 
titers of autoantibodies, such as antinuclear antibodies and rheumatoid factor. In particular, 
high serum IgG4 concentration (>135mg/dL) is the most important diagnostic factor of 
IgG4-related sclerosing disease.  
Dramatic response to steroid therapy is another characteristic clinical finding of IgG4-
related sclerosing disease; a decline in the serum IgG4 level and a reduction of lymphocytes 
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and IgG4-positive plasma cells in the involved tissues are frequently observed (Cheuk & 
Chan, 2010) (Table 1).  
 
Age Mostly middle-aged and elderly 
Gender Male predominance 
Presentation Symptom due to involved site(s) (usually mass formation) 
Laboratory findings Elevated IgG, IgG4 and IgE, especially IgG4 (>135mg/dL) Low titers of autoantibodies (e.g.: ANA, RF) 
Treatment Dramatic response to steroid therapy 
Table 1. Clinical features of IgG4-related sclerosing disease 
 Pathologically, IgG4-related sclerosing disease is usually non-circumscribed and can extend 
into the surrounding tissues. The triad of pathological features of IgG4-related sclerosing 
disease is dense lymphoplasmacytic infiltration, sclerosis and obliterative phlebitis (Cheuk 
& Chan 2010) (Table 2). The variable proportion of the lymphoplasmacytic infiltrates and 
sclerosis in each case is responsible for the spectrum of histopathological patterns, such as 
pseudolymphomatous, mixed and sclerosing types (Cheuk & Chan, 2010).  
In the pseudolymphomatous type, the presence of dense lymphocytes and plasma cells 
without atypia are the predominant features, and reactive lymphoid follicles are commonly 
observed. Eosinophil infiltration is also occasionally seen. The mixed pattern, which is the 
most common histological subtype of IgG4-related sclerosing disease, is characterized by the 
presence of patchy dense lymphoplasmacytic infiltration and sclerosis. Lastly, the sclerosing 
type is characterized by the predominance of sclerosis with patchy aggregates of 
lymphocytes and plasma cells.  
The presence of obliterative phlebitis, which represents veins affected by segmental or 
circumferential transmural lymphoplasmacytic infiltrates, resulting in luminal occlusion, is 
also a characteristic finding of IgG4-related sclerosing disease.  
Immunohistochemical studies revealed abundant IgG4-positive plasma cell infiltration, and 
the ratio of IgG4-/IgG-positive plasma cells is usually up to 40% (Cheuk & Chan 2010).  
 
a) Lymphoplasmacytic infiltration with/without lymphoid 
 follicles and frequent eosinophil infiltration 
b) Sclerosis 
c) Obliterative phlebitis 
d) No myofibroblast proliferation 
e) Abundant IgG4-positive plasma cell infiltration 
f) The ratio of IgG4-/IgG-positive plasma cells >40% 
Table 2. Pathological features of IgG4-related sclerosing disease 
1.3 The spectrum of IgG4-related sclerosing disease 
The concept of IgG4-related sclerosing disease has been expanded to include various 
organs since the first identification in the pancreas (autoimmune pancreatitis). Many 
extrapancreatic organs, such as bile duct (Zen et al., 2004), liver (Zen et al., 2004), salivary 
gland (Kitagawa et al., 2005), lacrymal gland (Sato et al., 2008), lung (Zen et al., 2005), 
breast (Zen et al., 2005), kidney and urinary tract (Watson et al., 2006; Cornell et al., 2007; 
Kim et al., 2011), prostate (Nishimori et al., 2007), retroperitonum (Hamano et al., 2002), 
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central nervous system (Chan et al., 2009; Shimatsu et al., 2009), thyroid (Li et al., 2011), 
nasal cavity (Ishida et al., 2009; Moteki et al., 2010), skin (Cheuk et al., 2009) and lymph 
node (Cheuk et al., 2008; Sato et al., 2010) (Table 3), have been shown to have the same 
histopathological findings and abundant IgG4-positive plasma cell infiltration as 
autoimmune pancreatitis.   
In addition, recently, a part of inflammatory aortic aneurysm has been regarded as a 
spectrum of IgG4-related sclerosing disease (Kasashima et al., 2008, 2009, 2010; Ishida et al., 
2009).  
Multiple synchronous or metachronous lesions can be seen in different organs in the 
patients with IgG4-related sclerosing disease.  
 
Pancreas Autoimmune pancreatitis 



















Sclerosing sialadenitis (Küttner's tumor) 
Sclerosing dacryoadenitis (Mickulicz’s disease) 
Inflammatory pseudotumor, rhinosinusitis 
Inflammatory pseudotumor (plasma cell granuloma), interstitial 
pneumonia 
Sclerosing mastitis 
Tubulointerstitial nephritis, inflammatory pseudotumor 
Prostatitis 
Hypophysitis, sclerosing pachmeningitis 
Hashimoto’s thyroiditis 




Table 3. The spectrum of IgG4-related sclerosing disease 
2. IgG4-related inflammatory aortic aneurysm 
Inflammatory aortic aneurysm (IAA), first described by Walker et al. in 1972, is a distinct 
clinicopathological entity (Walker et al., 1972). They reported that approximately 10% of 187 
patients undergoing resection of abdominal aortic aneurysm was IAA. The key 
distinguishing features of IAA from atherosclerotic aortic aneurysm are as follows: a) 
marked thickening of the aortic wall, b) fibrosis of the adjacent retroperitoneum, and c) rigid 
adherence of the adjacent structures to the anterior aneurysmal wall (Walker et al., 1972). 
Histopathologically, IAA of the abdominal aorta shows a striking fibrosclerotic change in 
the adventitia with dense lymphoplasmacytic infiltration (Hellmann et al., 2007).  
Patients with IAA of the abdominal aorta are younger than patients with atherosclerotic 
abdominal aortic aneurysm (Paravastu et al., 2009). The clinical symptoms are usually non-
specific, such as abdominal and back pain, fever, and general fatigue (Paravastu et al., 2009). 
Laboratory tests reveal that white blood counts and C-reactive protein levels are usually 
elevated (Walker et al. 1972). Elevated serum IgG concentration and the presence of 
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autoantibodies are also frequently observed in the patients with IAA of the abdominal aorta 
(Vaglio A et al., 2003; Jagadesham et al., 2008) 
IAA preferentially develops in the infrarenal abdominal aorta, and their presence in the 
ascending aorta and aortic arch is extremely rare (Ishida et al., 2009).  
 In 2008, Kasashima et al. proposed that IAA of the abdominal aorta can be divided into two 
subgroups: “IgG4-related” and “non-IgG4-related” (Kasashima et al., 2008). They reported 
that 4 of 10 patients with IAA of the abdominal aorta had high serum IgG4 concentration 
and abundant IgG4-positive plasma cell infiltrates in the aneurysmal wall, which are 
identical to the clinicopathological features of IgG4-related sclerosing disease. Henceforth, 
IgG4-related IAA of the thoracic aorta have also been reported (Ishida et al., 2009; 
Kasashima et al., 2010) 
2.1.1 Abdominal aortic aneurysm 
As shown Kasashima et al., there are clinicopathological differences between IgG4-related 
and non-IgG4-related IAA of the abdominal aorta (Kasashima, et al. 2008, 2009). With 
regard to incidence rate, IgG4-related IAA of the abdominal aorta accounts for 5% of all 
surgically resected abdominal aortic aneurysms, and 57% of IAA of the abdominal aorta 
(Kasashima et al. 2009).  
 
Age/Gender No difference 
Aneurysmal diameter No difference 
Symptom More frequency of abdominal or back  pain in non-IgG4-related cases 
History of autoimmune  
and allergic diseases 
More frequent in IgG4-related cases 
(food or drug allergy, bronchial asthma  
and rheumatoid arthritis) 











Markedly higher in IgG4-related cases 
Higher in IgG4-related cases 
Thicker in IgG4-related cases 
Mildly superior in IgG4-related cases 
More numerous in IgG4-related cases 
More higher in IgG4-related cases 
Higher in non-IgG4-related cases 
Higher in IgG4-related cases 
More frequent in IgG4-related cases 
More frequent in IgG4-related cases 
Table 4. Clinicopathological differences between IgG4-related and non-IgG4-related  
inflammatory aortic aneurysms of the abdominal aorta. 
Clinically, there are no differences in patient age, gender and aneurysmal diameter between 
IgG4-related and non-IgG4-related IAAs, however, IgG4-related cases are characterized by 
less frequent association with abdominal or back pain. The history of autoimmune diseases 
(such as rheumatoid arthritis and idiopathic thrombocytopenic purpura), bronchial asthma 
and food or drug allergy are more frequent in IgG4-related cases than non-IgG4-related 
cases. Characteristically, serum IgG4 concentration is significantly elevated in IgG4-related 
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cases (>135 mg/dL), although serum IgG concentration is not different in both groups. In 
addition, IgE concentration is higher in IgG4-related cases. Aneurysmal rupture is more 
common in non-IgG4-related cases, because severe thickening of the aneurysmal wall and 
adhesion to the surrounding tissue may prevent rupture in IgG4-related cases (Kasashima et 
al., 2010) (Table 4).  
Most reported cases of IgG4-related IAA of abdominal aorta have no association with other 
IgG4-related sclerosing diseases, however, some cases of IgG4-related IAA of the abdominal 
aorta with autoimmune pancreatitis have been reported (Ito et al., 2008; Tseng et al., 2009; 
Matsuki et al., 2010).  
Pathologically, IgG4-related IAA fundamentally has the similar histopathological findings 
of IgG4-related sclerosing disease. IgG4-related IAA is characterized by significant 
thickening of the adventitia more so than non-IgG4-related cases (Figure 1), although all 
IAA cases generally have marked thickening of the adventitia (Figure 6). In IgG4-related 
cases, dense lymphoplasmacytic infiltrates with lymphoid follicles are observed in the 
adventitia (Figure 2). Eosinophil infiltration and perineural lymphoplasmacytic 
infiltration are common findings of IgG4-related cases (Figure 3), however, neutrophil 
infiltration is rarely seen. In contrast, neutrophil infiltration is occasionally seen in non-
IgG4-related cases. In most IgG4-related cases, obliterative phlebitis, one of the 
characteristic findings of IgG4-related sclerosing disease, is present in the adventitia 
(Figure 4), although obliterative phlebitis is also observed in some non-IgG4-related cases, 
but at much lower frequency.  
 
 
Fig. 1. Panoramic view of an IgG4-related inflammatory aortic aneurysm (Elastica van 
Gieson stain). Significant thickening of the adventitia is evident.  
Atherosclerotic change is also observed in IgG4-related cases, because both IgG4-related and 
non-IgG4-related IAAs commonly affect middle-aged to elderly persons. However, 
atherosclerotic intimal thickening is more intense in non-IgG4-related cases (Kasashima et 
al., 2010).  
Immunohistochemically, abundant IgG4-positive plasma cell infiltrate is observed in the 
adventitia of IgG4-related IAA (Figure 5), in contrast to non-IgG4-related IAA, which harbor 
only a few IgG4-positive plasma cells (Figure 7). The ratio of IgG4-/IgG-positive plasma 
cells is markedly higher in IgG4-related cases (usually >60%) as compared to non-IgG4-
related cases (Kasashima et al., 2009).  
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Fig. 2. Histopathological findings of IgG4-related inflammatory aortic aneurysm (H.E. stain). 
Lymphoplasmacytic infiltration and sclerosis in the adventitia.  
 
 
Fig. 3. Histopathological findings of IgG4-related inflammatory aortic aneurysm (H.E. stain). 
Perineural lymphoplasmacytic infiltration is occasionally observed.  
 




Fig. 4. Elastica van Gieson stain clearly showing obliterative phlebitis in the adventitia in 
IgG4-related inflammatory aortic aneurysm. 
 
 
Fig. 5. Immunostaining for IgG4 in IgG4-related inflammatory aortic aneurysm.  
Abundant IgG4-positive plasma cell infiltration.  
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Fig. 4. Elastica van Gieson stain clearly showing obliterative phlebitis in the adventitia in 
IgG4-related inflammatory aortic aneurysm. 
 
 
Fig. 5. Immunostaining for IgG4 in IgG4-related inflammatory aortic aneurysm.  
Abundant IgG4-positive plasma cell infiltration.  
  




Fig. 6. Histopathological findings of non-IgG4-related inflammatory aortic aneurysm (H.E. 
stain). Lymphoplasmacytic infiltration and sclerosis are shown in the adventitia.  
 
 
Fig. 7. Immunostaining for IgG4 in non-IgG4-related inflammatory aortic aneurysm.  
Only a few IgG4-positive plasma cells are detected in the adventitia.  
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2.1.2 Thoracic aortic aneurysm 
In 2009, IgG4-related IAA of the aortic arch was first reported, and this report suggested that 
IgG4-related aortic lesion can occur in the thoracic aorta, as a counterpart of IgG4-related IAA 
of the abdominal aorta (Ishida et al., 2009). Since then, subsequent studies have revealed the 
clinicopathological features of IgG4-related lesions of the thoracic aorta. IgG4-related thoracic 
aortic lesions often represent aneurysmal cases, and several cases of lymphoplasmacytic 
aortitis without dilatation of the aorta are included in this entity, which may represent an early 
phase of IgG4-related aortic aneurysm (Kasashima et al., 2010; Stone et al., 2010).  
Kasashima et al. reported that 4% of all surgically resected thoracic aortic lesions (which 
corresponded to 7% of thoracic aortic aneurysm) was IgG4-related. (Kasashima et al., 2010). 
These cases included inflammatory aneurysm, lymphoplasmacytic aortitis, and 
atherosclerotic aneurysms (Kasashima et al., 2010). Stone et al. reported that IgG4-related 
sclerosing lesions of thoracic aorta accounted for 9% of noninfectious thoracic aortitis and 
75% of lymphoplasmacytic aortitis (Stone et al., 2010). These patients show similar clinical 
features to IgG4-related IAA of the abdominal aorta with a predilection for elderly males, 
medical history of bronchial asthma and allergy, and elevated white blood cell count and C-
reactive protein levels. IgG4-related aortic aneurysm of the thoracic aorta develops 
frequently in the aortic arch and saccular form aneurysm (Kasashima et al., 2010). In 
addition, fibrous adherence to the surrounding tissue is more frequent as compared to non-
IgG4-related cases (Kasashima et al., 2010).  
Pathologically, IgG4-related IAA of the thoracic aorta also shows similar findings to IgG4-
related IAA of the abdominal aorta including thickening of the adventitia, dense 
lymphoplasmacytic infiltration, obliterative phlebitis, frequent eosinophil infiltration, 
lymphoid follicle formation, and infrequent neutrophil infiltration. Immunohistochemically, 
abundant IgG4-positive plasma cell infiltration and high ratio of IgG4-/IgG-positive plasma 
cells (>60%) are observed (Ishida et al., 2009; Kasashima et al., 2010).  
Interestingly, aortic dissection has been reported as one manifestation of IgG4-related 
lesions in the thoracic aorta (Stone et al., 2009, 2010). In such case, inflammation is denser in 
the media than in the adventitia, and medial laminar necrosis is also observed (Stone et al., 
2009, 2010).  
Some cases of IgG4-related lesions of the thoracic aorta associated with other IgG4-related 
sclerosing lesions, such as pancreas, submandibular gland and lymph node, have been 
reported (Stone et al., 2010).  
2.2 Diagnostic criteria for IgG4-related IAA 
The diagnostic criteria for IgG4-related IAA of the abdominal aorta have been previously 
outlined (Kasashima et al., 2009), and a recent study have found that these criteria may also 
be appropriate for IgG4-related thoracic aortic aneurysm (Kasashima et al., 2010).  
a. Diffuse fibrous thickening of the adventitia (>4mm) 
b. Abundant lymphoplasmacytic infiltrates 
c. Numerous IgG4-positive plasma cells (60/ high-power fields) 
d. Ratio of IgG4-/IgG-positive plasma cells >60% 
2.3 Differential diagnosis of IgG4-related IAA 
The chief differential diagnosis of IgG4-related IAA is non-IgG4-related IAA, which is not 
difficult due to the distinct features of each type. The clinicopathological differential 
diagnostic considerations are described in 2.1.2.  
  




Fig. 6. Histopathological findings of non-IgG4-related inflammatory aortic aneurysm (H.E. 
stain). Lymphoplasmacytic infiltration and sclerosis are shown in the adventitia.  
 
 
Fig. 7. Immunostaining for IgG4 in non-IgG4-related inflammatory aortic aneurysm.  
Only a few IgG4-positive plasma cells are detected in the adventitia.  
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The chief differential diagnosis of IgG4-related IAA is non-IgG4-related IAA, which is not 
difficult due to the distinct features of each type. The clinicopathological differential 
diagnostic considerations are described in 2.1.2.  
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 Takayasu arteritis must be taken into consideration during diagnosis of IgG4-related IAA of 
the thoracic aorta. Takayasu arteritis is well known as a “pulseless disease”, which chiefly 
strikes young women, especially in Asian and South American countries, and mainly 
involves the ascending aorta, aortic arch, and their main branches, leading to the 
characteristic clinical findings of pulselessness and ophthalmic and/or cerebral disorders 
(Numano et al., 2000). Histopathologically, Takayasu arteritis is characterized by 
involvement of all three layers of the arterial wall, thickened adventitia with lymphocyte 
and histiocyte infiltrates, destruction of smooth muscles and elastic fiber network of the 
medina, occasional medial necrosis and intimal fibrosis and/or atherosclerotic changes 
(Numano, 2000). The inflammatory process appears to begin at the vaso vasorum in the 
adventitia and these inflammatory processes result in stenosis of vessel lumina and 
sometimes induce aneurysmal formation (Numano, 2000). IgG4-related IAA does not show 
vascular stricture and stenosis. Thus, the differential diagnostic features include patient’s 
age, histopathological findings, especially involvement of all three arterial wall layers found 
only in Takayasu arteritis, and immunohistochemical findings for IgG4. In addition, 
epithelioid granuloma, giant cells, and fibrinoid necrosis are extremely rare in IgG4-related 
IAA (Kasashima et al. 2010). 
Syphilitic aortitis is also included in the differential diagnosis, because it is also 
characterized by frequent aneurysmal formation and lymphoplasmacytic infiltration in the 
adventitia. Lymphoplasmacytic infiltration accompanying destruction of the medina and 
endarteritis obliterans of the vasa vasorum are usually observed in syphilitic aortitis 
(Heggtveit 1962), but not in IgG4-related IAA. The serological examination for Treponema 
pallidum agglutination is also useful.  
 
a) Non-IgG4-related IAA 
b) Takayasu areteritis 
c) Syphilitic arteritis 
Table 5. Chief differential diagnoses of IgG4-related IAA 
3. The association with chronic periaortitis 
Chronic periaortitis encompasses idiopathic retroperitoneal fibrosis, IAA and 
perianeurysmal retroperitoneal fibrosis (Jois et al., 2004). The histopathological characteristic 
are identical, which include periaortic fibrosis with extension to involve the adjacent 
structure, and lymphoplasmacytic infiltration in the aortic adventitia. These characteristic 
histopathological findings also correspond to IgG4-related sclerosing disease, and abundant 
IgG4-positive plasma cells infiltration is also observed in chronic periaortitis. Therefore, 
both retroperitoneal fibrosis and IgG4-related IAA of the abdominal aorta are recognized as 
a manifestation of “IgG4-related chronic periaortitis” (Kasashima et al., 2008, 2011), together 
with mediastinal fibrosis and IgG4-related IAA of the thoracic aorta (Ishida et al., 2009; 
Kasashima et al., 2011).  
4. Treatment of IgG4-related IAA 
Dramatic response to steroid therapy is the characteristic clinical finding of IgG4-related 
sclerosing disease. It is speculated that steroid therapy may be also effective in IgG4-related 
IAA, because adventitial thickening and fibrous adhesion to the surround organs may be 
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reduced (Kasashima et al., 2009). However, most of the reported cases of IgG4-related IAA 
were surgically resected cases, therefore, steroid therapy was not administrated and no data 
is available.  
Recently, some cases of IgG4-related IAA in whom steroid therapy could reduce the 
aneurysmal wall thickening and fibrous adhesion of IAA, have been reported (Kasashima et 
al., 2010; Yabe et al., 2010). However, it must be considered that the risk of aneurysmal 
rupture might be elevated by the thinning of the adventitia. Additional clinicopathological 
studies are required to establish the treatment strategy for IgG4-related IAA.  
 Finally, multiple metachronous or synchronous development is one of the characteristic 
findings of IgG4-related sclerosing disease, therefore, systemic surveillance and follow-up 
are required in cases of IgG4-related IAA.  
5. Conclusion 
IgG4-related sclerosing disease is a distinct clinicopathological entity and may manifest as 
IAA of the thoracic and abdominal aorta. IgG4-related IAA shows characteristic clinical 
features, and histopathological diagnostic criteria of IgG4-related IAA have been recently 
proposed. However, further studies are needed to clarify the spectrum of IgG4-related 
vascular lesions and treatment strategy of IgG4-related IAA.  
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1. Introduction 
Abdominal aortic aneurysms (AAAs) are a potentially fatal disorder. Atherosclerotic 
changes followed by accelerated degradation of collagen and elastin, the main components 
of the extracellular matrix (ECM) in the vascular wall, cause the development of AAAs in 
deteriorating aortic walls that dilate progressively and may eventually rupture. Other 
alterations associated with AAAs include marked changes in the cellular composition of the 
aortic wall, especially the infiltration of macrophages and T-lymphocytes into the adventitia 
and a major reduction in the population of vascular smooth muscle cells (SMCs) (Lopez-
Candales et al., 1997; Henderson et al., 1999).  
AAA appear to be a consequence of complex mechanisms involving several potential 
factors: immunological, inflammatory, chemotactic, apoptotic, protease-related, angiogenic 
and fibrinolytic (Ailawadi et al., 2003). Recently, interleukin-8 and monocyte 
chemoattractant protein 1 expression were shown to be raised in the AAA biopsies 
compared to the abdominal aorta of controls, suggesting that pathways involving these 
proteins may be involved in AAA pathologies (Middleton et al., 2009). AAA is a disease 
associated with chronic inflammation in the aortic wall and leukotrienes are powerful lipid 
mediators released by inflammatory cells (Samuelsson, 1983). A recent study showed the 
increased expression of leukotriene C4 synthase together with the predominant formation of 
cysteinyl-leukotrienes in human AAA, linked with matrix metalloproteinases (MMP) 
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production (Di Gennaro et al., 2010). This suggests a mechanism by which leukotrienes may 
promote matrix degradation in the AAA wall. 
Despite reports that major atherosclerotic risk factors are related to AAA (Iribarren et al., 
2007), we still lack the information about the process of aneurysmal degeneration (Wassef et 
al., 2007, Golledge et al., 2008) that we need to develop non-invasive approaches for its early 
detection. In aneurysm formation, collagen degradation exceeds its synthesis and together 
with excessive degradation of other ECM macromolecules, notably elastin, ultimately 
promotes rupture of these aneurysms. Increased local production of proteases, that is, 
enzymes capable of degrading collagen and elastin ECM proteins, have been identified in 
aneurysm sites (Dobrin & Mrkvicka, 1994; Knox et al., 1997; Thompson, 2006). The source of 
these proteases in humans is unclear, however, although many studies have measured their 
expression in cells from biopsies or tissues obtained after surgery (Wilson et al, 2006).  
2. Purpose of the study 
The aim of the study was to conduct a global comparison of the mRNA and protein 
expression profiles in the vascular cells to determine the genes involved in the pathological 
progression of aneurysmal disease by comparing the transcriptomic and proteomic profiles 
of SMCs and macrophages of patients with AAAs and those who have peripheral arterial 
occlusion (PAO) but no AAAs (verified by imaging). Using samples from two groups of 
patients in LILAS (the Lille Anevrysmal Study, described below), those with AAAs and 
others with PAO, we isolated SMCs from aortic tissue and monocytes (that were 
differentiated into macrophages) from blood. Although these diseases have common 
mechanisms, inflammatory cells essentially infiltrate the media and adventitia of the arterial 
wall in AAAs, whereas they are mostly in the intima in PAO. Because the factors that 
influence these distinctions are unknown, we designed a study that would allow us to 
distinguish “pro-aneurysmal” risk factors from those that are associated with atherogenesis 
and stenosis. We choose PAO disease as control diseases as Thompson et al., (Thompson, 
2002) described the separation of AAA disease from other atherosclerotic diseases like 
peripheral vascular disease and carotid disease. 
Following recommendations for large-scale parallel quantitation of proteins (Kingsmore, 
2006), we have constructed a protein microarray that contained on one slide 42 different 
antibodies representing proteins found by transcriptomic and proteomic analysis to be 
differentially modulated in macrophages and SMC from AAA and PAO patients. Finally, we 
performed the same analysis of plasma from the same patients to identify proteins involved in 
the aneurysmal process that are more easily detectable, as hypothesized that circulating 
biomarkers can reflect inflammation and degeneration in the AAA wall (Golledge et al., 2008). 
3. Population study 
The LILle Anevrysmal Study (LILAS) was a case-control study that enrolled 42 men, either 
AAA (case patients) or peripheral arterial occlusion (PAO) (control patients) who needed a 
vascular surgery or endovascular treatment at the Lille University Hospital Centre (Lille, 
France) (Lamblin et al., 2010). The ethics committee of the Lille University Hospital Center 
(France) approved the study (CCPPRB n° CP03/47 of 06 May 2003), and each patient 
provided written informed consent. The protocol required a blood sample (80 ml) to be 
taken at inclusion, before the surgery. All patients underwent the planned surgical 
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treatment and, when possible, surgeons removed the thrombus and took a sample of the 
aneurysm wall in the case patients (n=24) and a sample of the aortic wall during the bypass 
grafting for the control PAO patients (n=18).  
The mean age of subjects was 65.6 ± 6.9 years but AAA patients were older (68.0 ± 6.1 years 
versus 62.3 ± 6.6 years). No other cardiovascular risk factors differed between the groups. In 
both groups, one third of the patients had hypertension and half dyslipidemia. Diabetes 
mellitus was found in 17% of the AAA group and 22% of the PAO group, an insignificant 
difference. Both groups also had similar percentages of family members with a history of 
heart disease (myocardial infarction and/or acute coronary syndrome): 29% in AAA 
patients and 35% in PAO patients. The AAA case patients (n=24) had a mean maximal 
external aortic diameter of 56.1 ± 11.3 [range: 46-95] mm. All the PAO patients had 
undergone recent vascular imaging of the aorta and lower limbs before surgery: none had 
AAAs or iliac, femoral or popliteal aneurysms. The groups did not differ concerning their 
cardiovascular treatment (Table 2, Lamblin et al, 2010). Before surgery, fewer than two 
thirds had antiplatelet treatment. Fewer AAA than PAO patients received ACE inhibitor 
treatment (21% versus 44%). Three of the 18 PAO patients took non-steroidal anti-
inflammatory drugs and no AAA patients.. 
The difference of age between the two groups (AAA and PAO) of patients recruited in this 
study is consistent with literature on the mean age of onset of the disease in patients with 
similar risk factors. Also consistent with the literature is the finding that 30% of AAA 
patients and 50% of PAO patients have family members who have had a myocardial 
infarction or acute coronary syndrome. 
4. Methods 
4.1 Tissue biopsies from AAA and PAO patients 
Aortic samples (Fig. 1) were obtained for 20 of the 24 AAA patients of the LILAS study. 
Because treatment procedures for PAO changed during the study period, from surgical to 
endovascular interventions, tissues were available for only the 4 of the 18 patients who had 
surgical treatment (Fig. 1).  
 
 
Fig. 1. Aneurysmal (AAA) and peripheral arterial occlusion (PAO) tissue used for culture of 
smooth muscle cells and macrophages. Example of biopsy tissue recovered for AAA (n=20) 
and PAO (n=4) patients. 
  
Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture 
 
106 
production (Di Gennaro et al., 2010). This suggests a mechanism by which leukotrienes may 
promote matrix degradation in the AAA wall. 
Despite reports that major atherosclerotic risk factors are related to AAA (Iribarren et al., 
2007), we still lack the information about the process of aneurysmal degeneration (Wassef et 
al., 2007, Golledge et al., 2008) that we need to develop non-invasive approaches for its early 
detection. In aneurysm formation, collagen degradation exceeds its synthesis and together 
with excessive degradation of other ECM macromolecules, notably elastin, ultimately 
promotes rupture of these aneurysms. Increased local production of proteases, that is, 
enzymes capable of degrading collagen and elastin ECM proteins, have been identified in 
aneurysm sites (Dobrin & Mrkvicka, 1994; Knox et al., 1997; Thompson, 2006). The source of 
these proteases in humans is unclear, however, although many studies have measured their 
expression in cells from biopsies or tissues obtained after surgery (Wilson et al, 2006).  
2. Purpose of the study 
The aim of the study was to conduct a global comparison of the mRNA and protein 
expression profiles in the vascular cells to determine the genes involved in the pathological 
progression of aneurysmal disease by comparing the transcriptomic and proteomic profiles 
of SMCs and macrophages of patients with AAAs and those who have peripheral arterial 
occlusion (PAO) but no AAAs (verified by imaging). Using samples from two groups of 
patients in LILAS (the Lille Anevrysmal Study, described below), those with AAAs and 
others with PAO, we isolated SMCs from aortic tissue and monocytes (that were 
differentiated into macrophages) from blood. Although these diseases have common 
mechanisms, inflammatory cells essentially infiltrate the media and adventitia of the arterial 
wall in AAAs, whereas they are mostly in the intima in PAO. Because the factors that 
influence these distinctions are unknown, we designed a study that would allow us to 
distinguish “pro-aneurysmal” risk factors from those that are associated with atherogenesis 
and stenosis. We choose PAO disease as control diseases as Thompson et al., (Thompson, 
2002) described the separation of AAA disease from other atherosclerotic diseases like 
peripheral vascular disease and carotid disease. 
Following recommendations for large-scale parallel quantitation of proteins (Kingsmore, 
2006), we have constructed a protein microarray that contained on one slide 42 different 
antibodies representing proteins found by transcriptomic and proteomic analysis to be 
differentially modulated in macrophages and SMC from AAA and PAO patients. Finally, we 
performed the same analysis of plasma from the same patients to identify proteins involved in 
the aneurysmal process that are more easily detectable, as hypothesized that circulating 
biomarkers can reflect inflammation and degeneration in the AAA wall (Golledge et al., 2008). 
3. Population study 
The LILle Anevrysmal Study (LILAS) was a case-control study that enrolled 42 men, either 
AAA (case patients) or peripheral arterial occlusion (PAO) (control patients) who needed a 
vascular surgery or endovascular treatment at the Lille University Hospital Centre (Lille, 
France) (Lamblin et al., 2010). The ethics committee of the Lille University Hospital Center 
(France) approved the study (CCPPRB n° CP03/47 of 06 May 2003), and each patient 
provided written informed consent. The protocol required a blood sample (80 ml) to be 
taken at inclusion, before the surgery. All patients underwent the planned surgical 
Transcriptomic and Proteomic Profiles of  
Vascular Cells Involved in Human Abdominal Aortic Aneurysm 
 
107 
treatment and, when possible, surgeons removed the thrombus and took a sample of the 
aneurysm wall in the case patients (n=24) and a sample of the aortic wall during the bypass 
grafting for the control PAO patients (n=18).  
The mean age of subjects was 65.6 ± 6.9 years but AAA patients were older (68.0 ± 6.1 years 
versus 62.3 ± 6.6 years). No other cardiovascular risk factors differed between the groups. In 
both groups, one third of the patients had hypertension and half dyslipidemia. Diabetes 
mellitus was found in 17% of the AAA group and 22% of the PAO group, an insignificant 
difference. Both groups also had similar percentages of family members with a history of 
heart disease (myocardial infarction and/or acute coronary syndrome): 29% in AAA 
patients and 35% in PAO patients. The AAA case patients (n=24) had a mean maximal 
external aortic diameter of 56.1 ± 11.3 [range: 46-95] mm. All the PAO patients had 
undergone recent vascular imaging of the aorta and lower limbs before surgery: none had 
AAAs or iliac, femoral or popliteal aneurysms. The groups did not differ concerning their 
cardiovascular treatment (Table 2, Lamblin et al, 2010). Before surgery, fewer than two 
thirds had antiplatelet treatment. Fewer AAA than PAO patients received ACE inhibitor 
treatment (21% versus 44%). Three of the 18 PAO patients took non-steroidal anti-
inflammatory drugs and no AAA patients.. 
The difference of age between the two groups (AAA and PAO) of patients recruited in this 
study is consistent with literature on the mean age of onset of the disease in patients with 
similar risk factors. Also consistent with the literature is the finding that 30% of AAA 
patients and 50% of PAO patients have family members who have had a myocardial 
infarction or acute coronary syndrome. 
4. Methods 
4.1 Tissue biopsies from AAA and PAO patients 
Aortic samples (Fig. 1) were obtained for 20 of the 24 AAA patients of the LILAS study. 
Because treatment procedures for PAO changed during the study period, from surgical to 
endovascular interventions, tissues were available for only the 4 of the 18 patients who had 
surgical treatment (Fig. 1).  
 
 
Fig. 1. Aneurysmal (AAA) and peripheral arterial occlusion (PAO) tissue used for culture of 
smooth muscle cells and macrophages. Example of biopsy tissue recovered for AAA (n=20) 
and PAO (n=4) patients. 
  
Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture 
 
108 
4.2 Primary smooth muscle cells cultures 
Human SMCs were obtained from all of the AAA tissue samples (n=20) and only one of the 
four samples from PAO patients. Individual cultures of human aortic SMCs were 
established for each patient by dissection of a residual segment of abdominal aorta and then 
cutting out the media into 1- to 2-mm3 pieces and culturing them on dishes coated with 
collagen type 1. Cells began to migrate from the explant after 10 days and confluence was 
reached in one month.  
4.3 Primary cultures of human monocytes-derived macrophages 
Primary cultures of human macrophages are the cell models used most often in vitro for 
human macrophages, because only a simple venous blood sample is required to investigate 
qualitative or quantitative macrophage modifications in a case-control study. A highly-
standardized primary culture had to be devised to take into account the individual genetic 
variability of each blood donor, as well as the behavioral and environmental influences, and 
hidden abnormalities (Korke et al., 2002). Primary cultures of human macrophages were 
prepared as previously described (Pinet et al., 2003), with a technique adapted from Boyum 
(Boyum, 1968).  
4.4 Transcriptomic analysis of vascular cells from AAA and PAO patients 
Specific oligonucleotides for 137 genes corresponding to 24 matrix metalloproteinases (MMP), 
4 tissue inhibitors of metalloproteinases (TIMP), 20 ADAMs (a disintegrin and 
metalloproteinase), 20 ADAMTS (ADAMS with thrombospondin motifs), 65 other proteases 
and 4 control genes (hydroxymethylbilane synthase, beta-actin, NADPH oxidase 1, and 
Glyceraldehyde-3-phosphate dehydrogenase (GADPH)) were designed with OLIGOMER 
software (Mediagen, France) as previously described (Lamblin et al., 2010). Data were 
analyzed in comparison to a reference RNA, mixture from brain, colon, heart, placenta and 
testis, chosen for the expression of each protease and anti-protease in at least one of these 
tissues. We performed a self (Cy3)-self (Cy5) hybridization of the reference RNA and observed 
equivalent staining throughout the microarray, except for the renin gene which we excluded 
from the analysis (not shown). RNA samples were extracted from human SMCs and 
macrophages and only RNA with a RIN value >9 was analyzed. Each sample (5 μg) was 
analyzed with two slides according to a dye-swap strategy to account for labeling and 
detection differences between Cy5 and Cy3. Data analysis was performed with the statistical 
language R (v 2.0.1) (Ihaka & Gentelman, 1996), more specifically with the LIMMA library 
(Linear Models for MicroArray data) (Smyth et al, 2003). In accordance with the MIAME 
(Minimum Information About a Microarray Experiment) guidelines, we note the steps 
involved in data processing: 1) each microarray was scanned twice (at high and low intensity) 
for each wavelength of Cy3 and Cy5; 2) two separate normalization steps were conducted : 
first, pin-by-pin and second, a lowess fitness normalization. A moderated t-statistic with 
empirical Bayes shrinkage of the standard error was used to classify the statistically significant 
modulations (Lönnstedt & Speed, 2003). Because of multiple testing, p-values were corrected 
(Benjamini & Hochberg, 1995) to control for the false discovery rate. Genes with an adjusted p-
value < 0.01 in at least three of five replications were considered further. 
4.5 Proteomic analysis of vascular cells from AAA and PAO patients 
Intracellular proteins from macrophages and SMCs of AAA and PAO patients were loaded (5 
μg) on 2D gels. 2D-DIGE was performed as recently described (Dupont et al, 2008). Image 
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analysis was performed with Progenesis SameSpots v2.0 software. The differences in protein 
spots were then analyzed. Spots were considered to have significantly different normalized 
spot volumes if the fold change was greater than 1.5 and the corresponding p value (one-way 
ANOVA analysis) was significant. The last step applied multivariate statistics to the selected 
spots by calculating q values (for the false discovery rate) and power. Spots corresponding to 
proteins differentially expressed between the different groups of samples were identified by 
MALDI-TOF following the protocol previously described (Acosta-Martin et al, 2009).  
4.6 Protein microarray profiling of vascular cells and plasma from AAA and PAO 
patients 
The protein arrays allowed us to monitor 42 protein-antibody pairs and detected the profile 
of differentially expressed proteins in aneurysmal disease. Four differentially expressed 
proteins were selected from 2D analysis of macrophages from the LILAS or an earlier study: 
HSP70, aconitase-1, GRP75 and beta-actin (Dupont et al, 2008). Four others were selected 
from microarray analysis, TIMP-3, ADAMTS10, fibronectin, and tenascin. Finally, four more 
were identified by the 2D-analysis of plasma from patients from LILAS (personal 
communications), apolipoprotein AII, vitronectin, transthyretin and factor H. 
5. Results  
Recently, laser microdissection was used to analyze mRNA expression from macrophages 
and SMCs from aneurysmal tissue of a rat model of AAA created using elastase infusion 
(Sho et al., 2005). They found that modulation of at least 5 mRNAs differed according to cell 
type and flow conditions and thus concluded that a global analysis of aneurysmal tissue 
could mask cellular responses specific to inflammation and flow. These recent data reinforce 
our strategy to quantify mRNA and protein expression in two types of vascular cells from 
patients with different pathologies: macrophages and SMCs from AAA and PAO patients, 
instead of analysing the whole AAA or PAO biopsies. 
5.1 Primary smooth muscle cells cultures 
All the cultured human SMCs had the same elongated, spindle-shaped morphology, and at 
confluence all cultures assumed a hill-and-valley pattern that was maintained throughout 
all subcultures (Fig. 2).  
 
 
Fig. 2. Phase-contrast microscopy of smooth muscle cells obtained by explant from human 
AAA (n=20) and PAO (n=4) biopsies. Western blot analysis of SMC for fibronectin, meta-
vinculin (160 kDa), vinculin (116 kDa) and α-smooth muscle actin. 
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4.2 Primary smooth muscle cells cultures 
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Protein expression profiles determined by western blot analysis showed that all the cultures 
from both patient groups, expressed α-smooth muscle actin, vinculin and metavinculin. This 
finding indicates the presence of differentiated SMCs, as well as fibronectin, a component of 
basement membrane, that is indicative of a proliferative and secretory SMC phenotype (Fig. 2). 
5.2 Primary cultures of human monocytes-derived macrophages 
After, 12 days of culture, monocytes are differentiated into macrophages as shown by phase-
contrast microscopy (Fig. 3). 
 
 
Fig. 3. Phase-contrast microscopy of macrophages prepared from blood samples obtained 
from human patients presenting AAA (n=16) and PAO (n=16). 
The quality of macrophage cultures was evaluated by characterization of two markers,  
ECE-1 (Endothelin converting enzyme-1) mRNA and MMP-9 (Matrix metalloproteinase-9). 
ECE-1 mRNA was detected by RT-PCR on total RNA isolated from macrophages and  
MMP-9 activity was determined in culture medium by gelatin zymography (Pinet et al, 
2003). Sixteen primary MDMs cultures, met these criteria and we observed no differences 
between macrophages obtained from AAA or PAO patients (Fig. 3). 
5.3 Transcriptomic analysis of smooth muscle cells and macrophages from AAA and 
PAO patients 
The importance of proteases as mediators of ECM degradation in vascular disease has been 
proved (Wight, 2005), as the role of other proteases and their inhibitors in AAA (Choke et 
al., 2005). Our global analysis on a dedicated array of proteases and anti-proteases was not 
limited by advance theories or hypotheses, precisely because it was intended to generate 
hypotheses. This technology enables more efficient selection of the possible genes involved 
in AAAs, as shown in two studies that used AAA specimens and a cDNA microarray (Tung 
et al., 2001) or quantitative RT-PCR (Higashikata  et al., 2004). 
We tested mRNA from SMCs of 12 different AAA patients and 2 mRNA samples from one 
PAO patient, and we compared them to the reference RNA. For human macrophages, 
mRNA expression ratio of AAA/PAO genes was tested from 4 different AAA patients and 5 
different PAO patients. 
The microarray analysis indicated that three mRNA sample species appeared to be 
significantly modulated with a q value (moderated p-value) <0.01 in SMCs from AAA 
compared with PAO patients: angiotensin converting enzyme (ACE), ADAMTS5 and 
ADAMTS8. In the AAA patients, ACE (AAA/PAO ratio: - 2.8 fold) was down-regulated, 
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and ADAMTS5 (AAA/PAO ratio: 1.2 fold) and ADAMTS8 (AAA/PAO ratio: 1.3 fold) were 
very slightly but significantly up-regulated (Fig. 4A). The graphs of individual mRNA 
expression (AAA/PAO ratio) for these three genes show the variability between patients 
(Fig. 4B).  Of the 137 genes analyzed first by microarrays and then by Q-PCR for selected 
genes, all showed significant and concordant up- or down-regulation of expression levels 
for CML samples. The down-regulation of ACE mRNA in AAA patients is not surprising as 
a recent meta-analysis showed that ACE I/D polymorphisms are associated with a 
significant risk of AAAs (Thompson et al., 2008), especially in patients with hypertension 
(Korcz et al., 2009). Similarly, we found that ADAMTS5 and ADAMTS8 were up-regulated 
in SMC of AAA compared with PAO patients. These two members of the ADAMTS family 
are involved in vascular lesion development and can degrade different proteoglycans 
present in blood vessels (Yao  et al., 1994). 
 
 
Fig. 4. mRNA expression ratio of AAA/PAO genes from human SMC and macrophages. A:  
mRNA expression of genes in human SMCs from AAA (n=12) and PAO (n=1) patients 
determined by microarray analysis (open box) and by real-time RT-PCR (grey box). B: 
Expression ratio as measured by real-time PCR (displayed in log2) of individual patients 
(open circles) and mean values (closed circles). The horizontal line represents an expression 
level identical to that of PAO (log2(ratio)=0). C: mRNA expression ratio of AAA/PAO genes 
in human macrophages from AAA (n=4) and PAO (n=5) patients determined by microarray 
analysis. Data are expressed in log2(ratio). 
Figure 4C shows that the mRNA samples identified as differentially expressed in 
macrophages from AAA and PAO patients are different from those differentially modulated 
in SMCs. Differential modulation was observed in eight macrophage mRNA samples. Two 
were down-regulated in AAA compared with PAO patients: SCARB1 (scavenger receptor 
class B, member 1) AAA/PAO(ratio: 1.8) and BACE2 (beta-site APP-cleaving enzyme 2) 
(AAA/PAO ratio: 1.2). Six were up-regulated in AAA patients: caveolin 1 (AAA/PAO ratio: 
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1.8), ADAMTS10 (AAA/PAO ratio: 1.7), APP (amyloid precursor protein) (AAA/PAO ratio: 
2.3), MMP-27 (AAA/PAO ratio: 2.3), ADAM12 (AAA/PAO ratio: 1.9) and TIMP3 
(AAA/PAO ratio: 2.3). Microarray analysis of macrophages showed the modulation of other 
proteases and anti-proteases, but we were unable to validate these results by RT-PCR 
because of the limited amount of RNA obtained from cultures. Interestingly, TIMP-3, which 
we found to be up-regulated in macrophages from AAA patients, has been shown to be a 
potent inhibitor of ADAMTS5 (Kashiwagi  et al., 2001). Nonetheless, our results are 
consistent with the data reported (Sho et al., 2005) and thus demonstrate the interest of 
analyzing cell-specific compared with tissue-specific responses.  
5.4 Proteomic analysis of smooth muscle cells and macrophages from AAA and PAO 
patients 
Proteins from macrophages and SMCs of AAA and PAO patients were analysed on 2D gels. 
An average image was established from the scanned gels for macrophages (Fig. 5A) and for 
SMC (Fig. 5B) from AAA and PAO patients.  
 
 
Fig. 5. Representative 2D-DIGE gel analysis of proteome of human macrophages (A) and 
smooth muscle cells (B) from LILAS patients. A : Macrophage proteins  (5 μg) labeled with 
either Cy3 or Cy5 from patients presenting AAA (n=10) or PAO (n=12) were analyzed. B : 
SMC proteins  (5 μg) labeled with either Cy3 or Cy5 from patients presenting AAA (n=10) or 
PAO (n=1) were analyzed. Gels were classified according to the presence of AAA or PAO. 
Polypeptidic spots differentially expressed between patients presenting AAA or PAO are 
indicated by a number and identified by this number in Table 1. The positions of Mr are 
indicated on the left and the pI on the bottom of the gels. 
This differential analysis found twenty-one polypeptidic spots with differential abundance 
levels and a statistically reproducible difference over the series of gels. Four spots were up-
regulated (spots 16, 17, 18 and 19) and 17 down-regulated (spots 1, 2, 3, 4, 5, 6, 7, 8, 9; 10, 11, 
12, 13, 14, 15, 18 and 19) in macrophages from AAA compared with PAO patients (Fig. 5A). 
The intensity of each spot was calculated as the mean ± SD and expressed as a percentage of 
normalized volume. The same approach was used for the SMC proteins, although only two 
2D gels were used for the PAO SMCs (Fig. 5B). This differential analysis found seven 
polypeptidic spots with differential abundance levels and a statistically reproducible 
difference over the series of gels. Two spots were up-regulated (spots 2 and 5) and 5 down-
regulated (spots 1, 3, 4, 6, and 7) in SMC from AAA compared with PAO patients.  
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Table 1 summarizes the identity and factor of variation of proteins differentially expressed 
by macrophages and SMCs from AAA and PAO patients. Of the 21 polypeptidic spots 
differentially expressed for macrophages, 17 were identified by mass spectrometry and 
corresponded to 13 non-redundant proteins. Unfortunately, we were unable to identify 






number Protein name Protein function 
Mean of normalized value 
of a spot* 














0.008 ± 0.004 
 0.047 ± 0.018 0.18 
3 P11142 Heat shock cognate 71 kDa protein Chaperone 
0.032 ± 0.011 
 
0.078 ± 0.010 
 0.41 
4  ND  0.012 ± 0.006 0.089 ± 0.025 0.13 
5 P25705 ATP synthase subunit alpha 
Produces ATP from 
ADP 
0.005 ± 0.002 0.036 ± 0.010 0.14 
6 0.029 ± 0.010 0.063 ± 0.023 0.47 
7 P14618 Pyruvate kinase isozymes M1/M2 Glycolytic enzyme 0.019 ± 0.010 0.066 ± 0.024 0.29 
8  ND  0.019 ± 0.005 0.090 ± 0.027 0.21 
9 P30101 Protein disulfide-isomerase A3 
Catalyzes the 
rearrangement of -
S-S- bonds in 
proteins 








0.072 ± 0.004 0.122 ± 0.016 0.59 
11 P22695 Cytochrome b-c1 complex subunit 2
Part of the 
mitochondrial 
respiratory chain 
0.036 ± 0.018 0.095 ± 0.022 0.38 
12 
P09467 Fructose-1,6-bisphosphatase 1 
Carbohydrate 
biosynthesis 
0.317 ± 0.077 0.771 ± 0.043 0.41 
13 0.122 ± 0.023 0.284 ± 0.032 0.43 
14 0.036 ± 0.013 0.073 ± 0.016 0.50 
15 P40121 Macrophage-capping protein 
locks the barbed 
ends of actin 
filaments 






degradation 0.22 ± 0.051 0.129 ± 0.025 1.71 
17 
18 P60709 Actin, cytoplasmic 1
Involved in various 
types of cell 
motility 
0.266 ± 0.028 
0.266 ± 0.028 
0.145 ± 0.037 
0.266 ± 0.028 
1.83 
0.26 
18 P25774 Cathepsin S Thiol protease 0.049 ± 0.011 0.031 ± 0.008 1.56 
19 Q06830 Peroxiredoxin-1 
Involved in redox 
regulation of the 
cell 
0.260 ± 0.125 0.082 ± 0.011 3.18 
20  ND  0.246 ± 0.05 0.386 ± 0.028 0.63 
* spot number corresponds to spot indicated in Fig. 5. 
Table 1. Detailed list of proteins differentially expressed between AAA and PAO samples. 
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Of the macrophage proteins identified, three are components of cytoskeleton: microtubule-
associated protein tau (spot 2), beta-actin (spots 17 and 18) and macrophage-capping protein 
(spot 15) and cathepsin S (spot 18), has protease activity. 
This dual transcriptomic and proteomic analysis of vascular cells from AAA and PAO 
patients revealed both the differences and the complementarity of microarray and 2D-
electrophoresis technologies. Proteomic analysis identified only one protease, cathepsin S as 
differentially expressed in macrophages from AAA and PAO patients. This is consistent 
with previous reports showing an increase of cathepsin S activation in the wall of AAAs 
(Abisi et al., 2007; Abdul-Hussein et al., 2007). Still more recently, leukocyte cathepsin S was 
shown to be involved in macrophage apoptosis and increased SMC content and collagen 
deposition (De Nooijer  et al., 2009). Interestingly, of the 13 proteins identified overall, three 
(microtubule-associated protein tau, beta-actin and macrophage-capping protein) are 
components of cytoskeleton, while the others are involved in protein metabolism and stress 
response. Unfortunately, we were unable to identify the SMC proteins corresponding to the 
polypeptidic spots differentially expressed.  
Because of the different size of the proteome and transcriptome, we did not conduct a global 
correlation analysis of proteins and mRNA levels of SMCs and macrophages from these 
patients. Our strategy was to use specific and dedicated tools to identify the modulation of 
proteins and mRNAs in SMC and macrophages from AAA and PAO patients and to apply 
the same technology to their plasma samples. 
5.5 Protein microarray profiling of SMCs, macrophages and plasma from AAA and 
PAO patients 
Because of the limited amount of proteins available from macrophages and SMCs of our 
LILAS study, we used protein antibody array technology that has been shown to provide 
protein information in a systematic, reproducible and high-throughput fashion in several 
diseases (Sanchez-Carbayo  et al., 2006; Weber  et al., 2007). 
The AAA/PAO ratio for each protein modulated is presented in detail in Table 2. 
First, we analysed macrophages and SMCs proteins from LILAS patients. The microarray, 
revealed up-regulation in AAA patients of three macrophage proteins and down-regulation of 
six, as well as up-regulation of six SMC proteins and down-regulation of eight. All the proteins 
up-regulated in macrophages from AAA patients were also up-regulated in their SMCs: 
fibronectin, β-actin, tenascin. Five of six proteins down-regulated in AAA macrophages were 
also down-regulated in their SMCs: TIMP-3, ADAMTS5, HSP70, aconitase, GRP75.  
Plasma analysis, of course, restricted the number of proteins available that could be detected 
as differentially modulated between the two groups. Interestingly, analysis of plasma from 
the LILAS patients showed only five proteins differentially expressed in plasma from AAA 
and PAO patients, three already selected from the macrophage and SMC samples, 
ADAMTS8 (AAA/PAO ratio: 0.9), ADAMTS5 (AAA/PAO ratio: 1.11) and TIMP-3 
(AAA/PAO ratio: 1.15) and two only in plasma: ApoCIII (AAA/PAO ratio: 0.78) and 
alpha1-antitrypsin (AAA/PAO ratio: 0.88).  
Of particular interest, however, is the finding that TIMP-3, ADAMTS5 and ADAMTS8 were 
differentially expressed in proteins from macrophages, SMCs and plasma. ADAMTS8 is 
known to degrade ECM proteoglycans and has the highest specific activity for cleaving 
aggrecan (Porter et al., 2005). Our data are in agreement with a report (Theocharis et al.,  
2001), which showed a decrease in the concentration of versican in human AAA. 
Unfortunately, tools to measure ADAMTS activity need to be developed (Wagstäter et al., 
2008). Interestingly, TIMP-3 was shown to be modulated in the two cell types involved in 
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AAA, SMCs and macrophages and also in the plasma of the same patients, as shown with 
the overexpression of TIMP-3 in AAA tissue compared to aortic occlusive disease but they 
did not measure plasma TIMP-3 levels of the same patients as we did (Carell et al., 2002). 
The availability of TIMP assays allowed us to confirm the increased plasma levels of TIMP-3 
in AAA patients (Lamblin et al., 2010). 
 
Protein name                                            AAA                                      PAO
                                                                                         Mean value ± SD                                       Ratio AAA/PAO 
Macrophages 
TIMP-3 521 ± 430 1409 ± 811 0.35 
ADAMTS5 439 ± 501 1000 ± 633 0.43 
ADAMTS10 611 ± 567 1190 ± 596 0.45 
HSP70 3634 ± 1369 6971 ± 2559 0.55 
GRP75 4909 ± 2331 8505 ± 1862 0.55 
ACO-1 4171 ± 1315 7028 ± 2958 0.60 
Tenascin 27566 ± 7751 16493 ± 3000 1.65 
Fibronectin 29278 ± 6686 15586 ± 3607 1.75 
Beta-actin 43479 ± 13524 23892 ± 6088 1.80 
Smooth muscle cells*
GRP75 6393 ± 1651 5126/8207 0.56/0.56 
ADAMTS5 882 ± 403 1479/1431 0.59/0.59 
TIMP-4 1247 ± 438 1977/2537 0.63/0.51 
HSP70 7180 ± 1700 11358/8906 0.63/0.62 
Transferrin 2895 ±  2153 4868/5076 0.67/0.59 
ACO-1 6782 ± 2088 10076/8089 0.67/0.66 
ApoAII 6009 ± 1392 8419/7622 0.71/0.63 
Vitronectin 25237 ± 2568 31398/33481 0.80/0.71 
Factor H 2339 ± 378 1733/1647 1.35/1.35 
Tenascin 21849 ± 3847 14181/13722 1.54/1.49 
Beta-actin 26599 ± 4899 16672/15917 1.59/1.56 
Prealbumin 15339 ± 1272 16175/13780 1.60/1.57 
ADAMTS8 962 ± 300 599/774 1.61/1.58 
Fibronectin 23910 ± 4485 14154/15035 1.69/1.65 
Plasma 
APOCIII 14867 ± 4892 18964 ± 6046 0.78 
Alpha1-antitrypsin 60718 ± 6815 68871 ± 12632 0.88 
ADAMTS8 2470 ± 523 2754 ± 594 0.90 
ADAMTS5 2176 ± 720 1956 ± 754 1.11 
TIMP-3 2448 ± 653 2132 ± 610 1.15 
Macrophages and SMC analysis were performed respectively from 16 and 14 AAA and 16 and 11 PAO 
samples; Plasma analysis was performed from 24 AAA and 18 PAO samples.* Due to the limited 
number of SMC samples tested, we did not calculated SD for PAO patient and gave the value from 2 
independent experiments performed.  
Table 2. Expression ratio of proteins in macrophages. smooth muscle cells and plasma from 
AAA and PAO patients. 
6. Conclusion  
The limitations of this study are the relatively few tissue specimens allowing study of SMCs 
from PAO patients, because of changes in their treatment strategy (endovascular protheses 
rather than surgery). To our knowledge, this is the first study to combine several global 
analyses to assess the changes in the expression of genes and proteins of vascular cells 
involved in aneurysmal disease. Its strengths include the largest and most detailed view of 
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Of the macrophage proteins identified, three are components of cytoskeleton: microtubule-
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The AAA/PAO ratio for each protein modulated is presented in detail in Table 2. 
First, we analysed macrophages and SMCs proteins from LILAS patients. The microarray, 
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6. Conclusion  
The limitations of this study are the relatively few tissue specimens allowing study of SMCs 
from PAO patients, because of changes in their treatment strategy (endovascular protheses 
rather than surgery). To our knowledge, this is the first study to combine several global 
analyses to assess the changes in the expression of genes and proteins of vascular cells 
involved in aneurysmal disease. Its strengths include the largest and most detailed view of 
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changes in proteases and anti-proteases expression in patients presenting AAA. The protein 
array techniques confirmed that the differentially expressed proteins could also be detected 
in plasma. We found a restricted number of proteins differentially expressed between AAA 
and PAO patients: TIMP-3, ADAMTS5 and ADAMTS8that differ significantly in plasma of 
AAA patients compared to PAO approach. Combining transcriptomic and proteomic is a 
valid approach to a better understanding of the pathophysiology of AAA but strengthen the 
need to investigate multiple circulating biomarkers.  
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1. Introduction 
Aortic aneurysms and aortic dissections account for ~16,000 deaths in the United States 
annually (Kuivaniemi, et al., 2008). Recent evidence suggests that enhanced vascular 
inflammation underlies the progression of both abdominal aortic aneurysms and thoracic 
aortic aneurysms (Guo, et al., 2006a). Common pathologic features of vascular inflammation 
and aneurysmal disease include recruitment and activation of immune cells to the vessel 
wall, myofibroblast differentiation and extracellular matrix (ECM) remodeling. Recent 
preclinical work has implicated divergent signaling pathways downstream of the 
vasopressor angiotensin II (Ang II) peptide in controlling these activities.  This work has 
elucidated two important paracrine signaling networks, one mediated by the NF-κB-IL-6 
pathway controlling monocyte activation, and the second mediated by the TGF-β-Smad2 
pathway controlling myofibroblast differentiation and T lymphocyte differentiation.  
Antagonism of Ang II signaling is being evaluated in the clinical management of patients 
with familial thoracic aneurysms. In this chapter, we will review the multifaceted role of 
Ang II in vascular inflammation in aortic aneurysmal disease. 
1.1 Types of aortic aneurysms 
Aortic aneurysms are primarily classified based on anatomic locations (Kuivaniemi, et al., 
2008). Abdominal aortic aneurysms (AAA) primarily develop in the infrarenal segment of the 
abdominal aorta in humans or suprarenal aorta in rodent models. It predominantly affects 
elderly males, and is associated with hypertension, vascular inflammation and/or 
atherosclerosis (Guo, et al., 2006a). Initial pathological events in AAA involve recruitment and 
infiltration of leukocytes into the aortic adventitia and media, which are associated with the 
production of inflammatory cytokines, chemokine, and reactive oxygen species (ROS). 
Expression of macrophage activating cytokines is increased both systemically and locally in 
AAA. Importantly, as a major source of ECM-degrading matrix metalloproteinases (MMPs), 
recruited activated macrophages promote structural remodeling by degrading elastin and 
collagen in the vessel wall (Longo, et al., 2002). Moreover, in expanding aneurysmal tissues, 
increased infiltration of inflammatory cells may amplify MMP production by resident vascular 
cells (Pearce and Koch, 1996), facilitating aortic inflammation and structural remodeling.  
In contrast, thoracic aortic aneurysms (TAA) are etiologically separable from AAA due to 
their strong genetic influence affecting areas including the ascending aorta, aortic arch, 
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In contrast, thoracic aortic aneurysms (TAA) are etiologically separable from AAA due to 
their strong genetic influence affecting areas including the ascending aorta, aortic arch, 
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and/or descending aorta. Common genetic disorders associated with TAAs include 
Marfan’s Syndrome and Loeys-Dietz syndrome. Recent studies have also identified an 
inflammatory component in the etiology of TAA (Ejiri, et al., 2003). In TAA in patients 
undergoing surgical repair, enhanced expression of cytokines, such as interleukin-6 (IL-6) 
and interferon-γ (IFN-γ), as well as enhanced NADPH oxidase and reactive oxygen species 
(ROS) tone are found in aortic tissues. These events are spatially correlated with increased 
monocyte/macrophage accumulation and enhanced MMP production. 
1.2 Cells and molecules implicated in inflammation in aortic aneurysms 
The vascular inflammatory response involves complex interactions between recruited 
inflammatory cells (lymphocytes, monocytes, macrophages, neutrophils), vascular resident 
cells [endothelial cells (ECs), vascular smooth muscle cells (VSMCs) and adventitial 
fibroblasts] and the ECM. The ensuing inflammatory response increases expression of 
adhesion molecules, growth factors, cytokines and chemokines, that facilitates recruitment 
and local activation of inflammatory cells and matrix remodeling. Additionally, immune 
cells (macrophages, mast cells, B- and T- lymphocytes, neutrophils, along with VSMCs and 
adventitial fibroblasts) produce cytokines and enzymes, promoting an inflammatory 
reaction, extracellular matrix degradation, and neovascularization (Table 1).  
Recruited CD68-expressing macrophages are found in both the adventitia and intima of 
aneurysms. They are attracted to the aortic wall by elastin degradation products, CC 
chemokines [e.g. monocyte chemotactic protein (MCP-1), RANTES, etc] and granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Rizas, et al., 2009). MCP-1 produced by 
VSMCs and fibroblasts (Tilson, et al., 2000) induces monocyte chemotaxis by binding to CC-
chemokine receptor 2 (CCR2). MCP-1 is an important mediator in early pathogenesis of 
aortic aneurysms because CCR2 deficiency prevents aneurysm formation in various mouse 
models (Daugherty, et al., 2010; Tieu, et al., 2009). Additionally, macrophages express 5-
lipooxygenase (5-LO), which produces macrophage inflammatory protein 1α (MIP-1α) to 
recruit T-cells in a paracrine fashion. Locally infiltrated T-cells then magnify the 
inflammatory cascade by secreting various CC and CXC chemokines, attracting other 
inflammatory cells to the aneurysmal tissue (Zhao, et al., 2004).  
CD3+ T-cells are abundant immunomodulatory and pro-inflammatory cells recruited to 
aneurysmal tissues, accounting for ~50% of local hematopoietic cells (Kuivaniemi, et al., 
2008). Most T-cell subtypes have been identified, including helper T-cells (Th cells), 
cytotoxic T-cells and natural killer T-cells (NKT) (Kuivaniemi, et al., 2008). Recent studies to 
identify Th cell subtypes, which are predominant in aneurysms, reported controversial 
results. Some suggested Th2 was predominant, while other studies suggested Th1 (Galle, et 
al., 2005; Schonbeck, et al., 2002).  
Aortic resident cells also potentiate inflammation via interactions with recruited immune 
cells. Adventitial fibroblasts produce cytokines and chemokines such as IL-6, MCP-1, VEGF, 
and TNF (Tilson, et al., 2000), contributing to leukocytic chemotaxis and activation. Work 
from our laboratory has found that Ang II stimulates aortic adventitial fibroblasts to recruit 
monocytes via fibroblast-derived MCP-1, and that the recruited monocytes further promote 
fibroblast proliferation, adventitial thickening, and additional cytokine production. This 
fibroblast-monocyte amplification loop may critically mediate adventitial inflammation 
(Tieu, et al., 2010; Tieu, et al., 2009). Upon stimulation with TGF-β, fibroblasts differentiate 
into α-smooth muscle cell actin-expressing myofibroblasts (Desmouliere, et al., 1993).  
Myofibroblasts play a role in wound healing and fibrosis, and are associated with 
development of aneurysmal disease (Sakata, et al., 2007). 
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Cells Molecules Roles in Aortic Aneurysms 
Fibroblasts MMP-1 Collagen degradation
 MMP-2 Elastin and collagen degradation 
 VEGF Angiogenesis
 MCP-1 Monocyte chemotaxis
 
VSMCs MMP-2 Elastin and collagen degradation 
 MMP-13 Collagen degradation
 MT1-MMP Elastin and collagen degradation;  ProMMP-2 activation; facilitate macrophage migration 
 MCP-1 Monocyte chemotaxis
 IL-6 Macrophage differentiation; MCP-1 induction; systemic acute-phase response 
 
Macrophages MMP-3 Elastin and collagen degradation; VEGF activation 
 MMP-9 
Elastin and collagen degradation;  
dominant gelatinase in late pathogenesis;  
TGF-β, VEGF activation; macrophage migration 
 MMP-12 Elastin and collagen degradation 
 MT1-MMP Elastin and collagen degradation;  ProMMP-2 activation; facilitate macrophage migration 
 Cathepsins ECM degradation; angiogenesis 
 MIP-1α T-cell chemotaxis
 IL-8 Neutrophil chemotaxis
 LTD4 MIP-1α induction
 TGF-β Angiogenesis; MMP induction; Th17 differntiation; myofibroblast differntiation 
 IL-6 Macrophage differentiation; MCP-1 induction; systemic inflammatory responses 
 
Mast cells Chymases ProMMP activation; VSMC apoptosis; Ang II induction 
 Tryptases ProMMP activation
 LTD4 MIP-1α induction
 
Netrophils MMP-8 Collagen degradation
 MMP-9 Elastin and collagen degradation; TGF-β, VEGF activation; macrophage migration 
 Cathespins ECM degradation; angiogenesis 
 Netrophil elastase Elastin degradation
 
NKT cells IFN-γ Th1 differentiation; macrophage activation 
 IL-4 Th2 differentiation; humoral immunity 
 
Th Cells IFN-γ Th1 differentiation; macrophage activation 
 IL-4 Th2 differentiation; humoral immunity 
 IL-17 Macrophage chemotaxis
Table 1. Major cell types and secreted molecules involved in vascular inflammatory 
response in aortic aneurysms. 
  
Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture 
 
120 
and/or descending aorta. Common genetic disorders associated with TAAs include 
Marfan’s Syndrome and Loeys-Dietz syndrome. Recent studies have also identified an 
inflammatory component in the etiology of TAA (Ejiri, et al., 2003). In TAA in patients 
undergoing surgical repair, enhanced expression of cytokines, such as interleukin-6 (IL-6) 
and interferon-γ (IFN-γ), as well as enhanced NADPH oxidase and reactive oxygen species 
(ROS) tone are found in aortic tissues. These events are spatially correlated with increased 
monocyte/macrophage accumulation and enhanced MMP production. 
1.2 Cells and molecules implicated in inflammation in aortic aneurysms 
The vascular inflammatory response involves complex interactions between recruited 
inflammatory cells (lymphocytes, monocytes, macrophages, neutrophils), vascular resident 
cells [endothelial cells (ECs), vascular smooth muscle cells (VSMCs) and adventitial 
fibroblasts] and the ECM. The ensuing inflammatory response increases expression of 
adhesion molecules, growth factors, cytokines and chemokines, that facilitates recruitment 
and local activation of inflammatory cells and matrix remodeling. Additionally, immune 
cells (macrophages, mast cells, B- and T- lymphocytes, neutrophils, along with VSMCs and 
adventitial fibroblasts) produce cytokines and enzymes, promoting an inflammatory 
reaction, extracellular matrix degradation, and neovascularization (Table 1).  
Recruited CD68-expressing macrophages are found in both the adventitia and intima of 
aneurysms. They are attracted to the aortic wall by elastin degradation products, CC 
chemokines [e.g. monocyte chemotactic protein (MCP-1), RANTES, etc] and granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Rizas, et al., 2009). MCP-1 produced by 
VSMCs and fibroblasts (Tilson, et al., 2000) induces monocyte chemotaxis by binding to CC-
chemokine receptor 2 (CCR2). MCP-1 is an important mediator in early pathogenesis of 
aortic aneurysms because CCR2 deficiency prevents aneurysm formation in various mouse 
models (Daugherty, et al., 2010; Tieu, et al., 2009). Additionally, macrophages express 5-
lipooxygenase (5-LO), which produces macrophage inflammatory protein 1α (MIP-1α) to 
recruit T-cells in a paracrine fashion. Locally infiltrated T-cells then magnify the 
inflammatory cascade by secreting various CC and CXC chemokines, attracting other 
inflammatory cells to the aneurysmal tissue (Zhao, et al., 2004).  
CD3+ T-cells are abundant immunomodulatory and pro-inflammatory cells recruited to 
aneurysmal tissues, accounting for ~50% of local hematopoietic cells (Kuivaniemi, et al., 
2008). Most T-cell subtypes have been identified, including helper T-cells (Th cells), 
cytotoxic T-cells and natural killer T-cells (NKT) (Kuivaniemi, et al., 2008). Recent studies to 
identify Th cell subtypes, which are predominant in aneurysms, reported controversial 
results. Some suggested Th2 was predominant, while other studies suggested Th1 (Galle, et 
al., 2005; Schonbeck, et al., 2002).  
Aortic resident cells also potentiate inflammation via interactions with recruited immune 
cells. Adventitial fibroblasts produce cytokines and chemokines such as IL-6, MCP-1, VEGF, 
and TNF (Tilson, et al., 2000), contributing to leukocytic chemotaxis and activation. Work 
from our laboratory has found that Ang II stimulates aortic adventitial fibroblasts to recruit 
monocytes via fibroblast-derived MCP-1, and that the recruited monocytes further promote 
fibroblast proliferation, adventitial thickening, and additional cytokine production. This 
fibroblast-monocyte amplification loop may critically mediate adventitial inflammation 
(Tieu, et al., 2010; Tieu, et al., 2009). Upon stimulation with TGF-β, fibroblasts differentiate 
into α-smooth muscle cell actin-expressing myofibroblasts (Desmouliere, et al., 1993).  
Myofibroblasts play a role in wound healing and fibrosis, and are associated with 
development of aneurysmal disease (Sakata, et al., 2007). 
 
Multifaceted Role of Angiotensin II in Vascular Inflammation and Aortic Aneurysmal Disease 
 
121 
Cells Molecules Roles in Aortic Aneurysms 
Fibroblasts MMP-1 Collagen degradation
 MMP-2 Elastin and collagen degradation 
 VEGF Angiogenesis
 MCP-1 Monocyte chemotaxis
 
VSMCs MMP-2 Elastin and collagen degradation 
 MMP-13 Collagen degradation
 MT1-MMP Elastin and collagen degradation;  ProMMP-2 activation; facilitate macrophage migration 
 MCP-1 Monocyte chemotaxis
 IL-6 Macrophage differentiation; MCP-1 induction; systemic acute-phase response 
 
Macrophages MMP-3 Elastin and collagen degradation; VEGF activation 
 MMP-9 
Elastin and collagen degradation;  
dominant gelatinase in late pathogenesis;  
TGF-β, VEGF activation; macrophage migration 
 MMP-12 Elastin and collagen degradation 
 MT1-MMP Elastin and collagen degradation;  ProMMP-2 activation; facilitate macrophage migration 
 Cathepsins ECM degradation; angiogenesis 
 MIP-1α T-cell chemotaxis
 IL-8 Neutrophil chemotaxis
 LTD4 MIP-1α induction
 TGF-β Angiogenesis; MMP induction; Th17 differntiation; myofibroblast differntiation 
 IL-6 Macrophage differentiation; MCP-1 induction; systemic inflammatory responses 
 
Mast cells Chymases ProMMP activation; VSMC apoptosis; Ang II induction 
 Tryptases ProMMP activation
 LTD4 MIP-1α induction
 
Netrophils MMP-8 Collagen degradation
 MMP-9 Elastin and collagen degradation; TGF-β, VEGF activation; macrophage migration 
 Cathespins ECM degradation; angiogenesis 
 Netrophil elastase Elastin degradation
 
NKT cells IFN-γ Th1 differentiation; macrophage activation 
 IL-4 Th2 differentiation; humoral immunity 
 
Th Cells IFN-γ Th1 differentiation; macrophage activation 
 IL-4 Th2 differentiation; humoral immunity 
 IL-17 Macrophage chemotaxis
Table 1. Major cell types and secreted molecules involved in vascular inflammatory 
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Among the different enzymes secreted by immune and stromal cells, MMP-2, MMP-9, 
MMP-12, cathepsins, and neutrophil elastase cause ECM degeneration (Table 1). Chymase 
causes smooth muscle cell apoptosis, and MMP-3, MMP-8, and MMP-13 cause adventitial 
collagen degradation, promoting abdominal aortic aneurysm rupture.  
Cytokines and chemokines such as IL-8, MIP-1α, and MCP-1 facilitate recruitment and 
proliferation of inflammatory cells (Table 1). Cytokines include TNF, interleukins, 
interferons, colony stimulating factors, and transforming growth factors, etc. They are 
produced by diverse cell types including macrophages, T-cells and monocytes, VSMCs and 
fibroblasts. Circulating cytokines interact with specific receptors on various cell types to 
activate JAK-STAT, NF-κB, and Smad signaling pathways, regulating expression of various 
genes controlling inflammatory response involving cell adhesion, permeability and 
apoptosis. Cytokine signaling is also known to increase mitochondrial ROS production, 
induce integrins to facilitate cellular adhesion and activate MMPs to modify ECM 
composition. Further, increased local cytokine expression is implicated in aortic aneurysms. 
Vascular inflammation is an ordered process producing recruitment of activated leukocyte 
subtypes into the vessel wall, initiating complex interaction with vascular residential cells 
and ECM. This process is initiated and amplified by local secretion of adhesion molecules, 
chemotactic factors and cytokines, whose inducible expression are signaled by vascular 
injury and modulated by vasoactive peptides (Ang II), CD40 ligands, oxidized cholesterol, 
and advanced glycation end products.  Of these, the effects of Ang II have been implicated 
in vascular inflammation and have emerged as an important clinical target for the treatment 
of human aneurysms associated with Marfan’s disease. 
2. Ang II-induced vascular inflammation 
Angiotensin II (Ang II) is the major effector peptide of the renin-angiotensin system.  In 
addition to its potent vasoconstrictor actions, Ang II exert pro-inflammatory activity in the 
vascular wall, inducing production of inflammatory cytokines, adhesion molecules, and 
formation of ROS, resulting in macrophage accumulation, myofibroblast differentiation, and 
localized aortic dilation  followed by dissections (Ejiri, et al., 2003).  
Ang II is a potent inducer of vascular inflammation producing acute thoracic and suprarenal 
aortic aneurysms and dissections in many mouse models (Daugherty, et al., 2010; Tieu, et al., 
2009). Chronic subcutaneous infusion of Ang II peptide into atherosclerosis-prone 
hyperlipidemic apolipoprotein E-deficient (ApoE-/-) or LDL receptor (LDLR-/-) deficient 
mice produces thoracic and suprarenal aneurysms (Reiner, 2007) . Also in aged C57BL/6J 
mice, Ang II produces both suprarenal and ascending thoracic aneurysms and dissections, 
albeit at a lower frequency than in the presence of hyperlipidemia (Tieu, et al., 2009). 
Moreover, Ang II type I receptor and ACE polymorphisms are associated with AAA in humans 
(Jones, et al., 2008), suggesting that Ang II is tightly associated with aneurysmal diseases. The 
mouse models of acute Ang II infusion showed significant vascular inflammatory responses in 
aneurysmal tissues, including enhanced aortic cytokine/chemokine production, early 
macrophage recruitment, elastin degeneration, and intramural hematoma formation.  
Ang II stimulates inflammatory chemokine expression and ROS production in EC and VSCMs, 
events implicated in the pathogenesis of aortic aneurysms (Ejiri, et al., 2003; Longo, et al., 
2002). In ECs, Ang II up-regulates expression of the leukocyte adhesion molecules vascular cell 
adhesion molecule (VCAM-1), intercellular adhesion molecule (ICAM-1), and selectins (Pueyo, 
et al., 2000), facilitating monocyte adhesion and recruitment into the vascular wall. Once 
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recruited, monocytes produce MMPs that mediate aortic wall remodeling in aneurysmal 
expansion, and migrate towards gradients of chemotactic cytokines (e.g. MCP-1, KC/Groβ, 
MIP-1α, etc). The actions of Ang II regulate many steps in these processes, inducing expression 
of chemokines MCP-1, KC/Groβ, and the cytokine IL-6 (Chen, et al., 2001; Han, et al., 1999). In 
VSMCs, Ang II is a potent inducer of cytokine and chemokine expression, including MCP-1 
and IL-6. These molecules, in turn, cause more immune cell infiltration, further amplifying the 
inflammatory tone contributing to aneurysmal expansion. 
The ability of Ang II to potently induce vascular inflammation involves the activation of two 
divergent signaling pathways important in the vascular stress response, the first being the 
nuclear factor-κB (NF-κB)-IL-6 signaling pathway, and the second, the transforming growth 
factor (TGF)-β-Smad pathway (Figure 1). 
 
 
Fig. 1. Ang II-induced signaling pathways involved in vascular inflammatory events 
implicated in aortic aneurysms. The actions of Ang II involve cells directly responding to its 
actions schematically diagrammed as generators and downstream affected cells 
(responders) producing vascular inflammation and remodeling  
3. The NF-κB-IL-6 pathway in Ang II-induced aortic aneurysms 
A number of recent studies have demonstrated that NF-κB transcription factors play a 
central role in controlling the process of vascular inflammation. Responsive to vasoactive 
peptides such as Ang II, oxidized LDL, activated CD40 receptor, monocyte released 
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Among the different enzymes secreted by immune and stromal cells, MMP-2, MMP-9, 
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cytokines, or advanced glycation end-products, activated NF-κB is known to control 
leucocyte adherence and chemotaxis, key steps in the process of vascular inflammation. 
Recently, an additional role for NF-κB in controlling monocyte activation via the IL-6 
pathway has also been discovered. Here, locally secreted IL-6 activates vascular monocytes 
and induces cellular protection from ROS-induced stress via signaling through the 
downstream effector signal transducer and activator of transcription 3 (STAT3). In this way, 
the NF-κB –IL-6 signaling pathway plays multiple roles in initiating and sustaining vascular 
inflammation. 
3.1 Mechanism of NF-κB activation by Ang II in VSMCs 
Ang II initiates intracellular signaling by binding to two types of heterotrimeric guanosine 
(G) -protein coupled 7-transmembrane receptors, termed the type I (AT-1) and type II (AT-2) 
Ang II receptors (Griendling, et al., 1997). AT-1 is the major receptor normally expressed on 
ECs, VSMCs, cardiomyocytes and monocytes (Murphy, et al., 1991). These receptors are 
activated by Ang II ligand binding in a G protein-dependent manner. The activation of G 
protein-dependent signals activates phospholipase Cβ to increase intracellular inositol 
trisphosphate and diacylglycerol, leading to increase in calcium and activation of protein 
kinase C (PKC) isoforms.  
In vascular cells, although Ang II activates multiple second messenger pathways including 
phospholipase D, PKC, and the mitogen activated protein kinase/erk kinase (MEK/ERK) 
pathways, recent attention has been drawn to the Rho family of GTPases (Griendling, et al., 
1997). The Rho family is a group of 20-21 kDa GTPases including RhoA, B, C, D and E; Rac1 
and 2; Cdc42Hs and TC10. The three Rho family members primarily expressed in vascular 
tissues in humans include RhoA, Rac1, and Cdc42Hs. Under unstimulated conditions, the 
Rho proteins are cytosolic, bound to GDP and guanine nucleotide dissociation inhibitors 
(Van Aelst and D'Souza-Schorey, 1997). In response to Ang II stimulation, the ligand 
binding of the G-protein-coupled AT-1 activates guanine nucleotide exchange factors 
(GEFs), which in turn catalyze GDP-GTP exchange and activates the Rho GTPases (Figure 
1). Activated RhoA affects ROS production and controls smooth muscle cell contractility by 
phosphorylating myosin light chain kinase (MLCK), enhancing DNA synthesis, inducing 
VSMC migration, stimulating cardiovascular fibrosis (Kobayashi, et al., 2002), and inducing 
hemostatic and inflammatory proteins (Kobayashi, et al., 2002). 
NF-κB is a ubiquitously-expressed, highly inducible transcription factor complex 
composed of both latent cytoplasmic and activated nuclear components. One major 
activation NF-κB pathway that we and others have defined is referred to as the 
“canonical” pathway, a pathway that controls nuclear targeting of latent cytoplasmic Rel 
A•NF-κB1 heterodimeric complexes. Rel A•NF-κB1 is retained in a cytoplasmic location 
by association with the IκBα inhibitor (Beg and Baldwin, 1993). Stimuli inducing the 
canonical NF-κB pathway activate the IKK kinase complex, resulting in IκBα 
phosphorylation at specific N-terminal serine residues, ultimately targeting it for 
proteosomal degradation (Ghosh and Baltimore, 1990). As a result, sequestered Rel 
A•NF-κB1 complexes are then released to enter the nucleus. Nuclear translocated Rel 
A•NF-κB1 then binds to specific regulatory sequences in cytokine and acute phase 
reactant promoters, activating their transcription. 
Although initially the Ang II signaling pathway was thought to induce the canonical NF-κB 
activation pathway in VSMCs, detailed studies have shown that Ang II induces cell type-
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dependent activation of NF-κB pathways (Brasier, 2010). In non-vascular cells such as 
hepatocytes, PKC activation leads to cleavage of the IKK inhibitory TNFAIP3/A20 molecule 
and degradation of IkBα through the mechanisms as in canonical signaling induced by 
TNFα, resulting in activation of NF-κB translocation. In VSMCs, on the other hand, the Ang 
II-induced pathway is quite distinct from other cell types. A novel activation pathway 
independent of the well-recognized canonical pathway described above was identified by us 
and schematically diagrammed in Figure 1. In VSMCs, inactive NF-κB isoforms could be 
identified in unstimulated cells, and no significant changes in NF-κB abundance was 
observed in response to Ang II stimulation. Of importance, we found that Ang II stimulation 
rapidly induces phosphorylation of RelA at serine residue 536 in its COOH-terminal 
transactivating domain. Interestingly, we also found that phospho-Ser-536 RelA formation 
was blocked by RhoA inhibition, suggesting that Ser-536 phosphorylation was mediated 
upstream by RhoA. In addition, RhoA inhibition also blocked Ang II-induced IL-6 
expression, indicating that Ang II-inducible phospho-Ser-536 RelA was required for IL-6 
activation (Cui, et al., 2006).  
Our studies in Ang II-stimulated VSMCs further showed that total RelA binding did not 
change on the native IL-6 promoter in response to Ang II, but fractional binding of 
phospho-Ser-536 RelA to the IL-6 promoter was increased (Choudhary, et al., 2007). These 
studies showed that Ang II induces NF-κB /RelA activation in VSMCs by increasing the 
relative abundance of phospho-Ser-536 RelA in the nucleoplasmic pool. We also 
confirmed Ang II-induced enhanced phospho-Ser-536 RelA formation in rat aortas treated 
with Ang II, establishing relevance to vascular signaling in vivo (Choudhary, et al., 2007; 
Cui, et al., 2006).  
Our group further showed that Ang II-induced RelA Ser-536 phosphorylation is mediated 
by NF-κB-inducing kinase (NIK), the major regulated step controlling non-canonical NF-κB 
signaling. NIK inhibition prevented Ang II-induced Ser-536 phosphorylation and NF-κB-
dependent transcription (Choudhary, et al., 2007), indicating that it is essential for RelA 
activation. We also found that NIK induced the activity of the RelA transactivation domain-
1 and -2 in constitutively nuclear RelA proteins and that RelA formed an inducible nuclear 
complex with NIK in response to Ang II stimulation. The function and mechanism of this 
NIK·RelA complex in Ang II-induced vascular inflammation still requires further 
investigation.  
Taken together, this data indicate that in VSMCs, where inactive NF-κB is constitutively 
nuclear, Ang II induces NF-κB -dependent transcription through an alternative pathway, 
being largely independent of IκB proteolysis, but mediated by the small GTPases 
Rac/RhoA, required for NIK·RelA complex formation and inducible phospho-Ser-536 RelA 
phosphorylation. 
3.2 Vascular inflammatory actions of Ang II-induced NF-κB signaling 
Ang II-induced NF-κB activation plays a central role in the development of aneurysms 
through regulation of gene expression of inflammatory molecules whose function broadly in 
the cascade of leukocyte recruitment and monocyte chemotaxis. These targets include pro-
inflammatory cytokines (e.g. interleukins, etc.), chemokines (e.g. MCP-1, GM-CSF, etc.), 
adhesion molecules (e.g. E-selectin, ICAM-1, VCAM-1, etc.), and ECM-degrading MMPs. 
A major target of Ang II-induced NF-κB activation is to activate expression of IL-6 by 
adventitial fibroblasts, recruited monocytes and VSMCs. Ang II induces rapid activation of 
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IL-6 transcription and translation (Han, et al., 1999). The transcriptional activation of IL-6 
expression is mediated by NF-κB binding to its high affinity binding site in this proximal 
promoter of the IL-6 gene. This site is required for Ang II inducible expression since Ang II 
inducible activity is completely abolished by a promoter containing a point mutation that 
does not bind NF-κB (Han, et al., 1999). Together, these data suggest that NF-κB 
transcription factor is required for inducible expression of the IL-6 by Ang II.  
IL-6 is a 26 kDa glycosylated cytokine that acts in a paracrine manner to signal through two 
distinct mechanisms, termed the classical initiated by membrane receptor binding, and the 
trans-signaling pathway mediated by soluble IL-6 Rα (Hou, et al., 2008). Classical IL-6 
signaling is mediated via ligand binding to the IL-6Rα receptor on the cell membrane. The 
IL-6 trans-signaling pathway, on the other hand, involves circulating IL-6·IL-6Rα 
engagement with gp130 expressed on cells, enabling activation of the IL-6 signaling 
pathway in cells lacking IL-6Rα. In trans-signaling, proteolysis and/or alternative splicing 
lead to the generation of soluble IL-6 receptors (sIL-6R), which binds IL-6. The IL-6/sIL-6R 
complex can stimulate cells that only express gp130 but no IL-6R.  
In IL-6-initiated classical signaling, the IL-6•IL-6Rα complex causes oligomerization with 
the ubiquitously expressed transmembrane gp130 β-subunit, inducing gp130 
homodimerization, and subsequent formation of a hexameric IL-6•IL-Rα•gp130 complex 
(Boulanger, et al., 2003). This induces conformational changes of gp130, that trigger trans-
autophosphorylation and activation of Janus tyrosine kinase JAK1, a specific Janus kinase 
mediating IL-6 signaling. JAK1 in turn induces tyrosine phosphorylation and activation of 
STAT isoforms STAT1 and STAT3 (Figure 1). As transcription factors, they then form homo- 
and heterodimers with each other, translocate to the nucleus, bind specific DNA sequences 
and enhance transcription of target genes via interactions with co-factors and co-activators 
such as p300/CREB-binding protein (CBP) and Positive Transcription Elongation Factor 
(PTEF-b) (Hou, et al., 2008).  
IL-6 plays a major role in inducing systemic responses to the presence of vascular 
inflammation through the hepatic acute-phase response (Brasier, et al., 2002). IL-6 has 
diverse actions in multiple cell types of cardiovascular importance, including ECs, 
monocytes, platelets, hepatocytes and adipocytes. In the vessel, IL-6 promotes Ang II-
induced ROS production because IL-6 deficiency protects against Ang II-induced 
endothelial dysfunction (Schrader, et al., 2007).  
Importantly, a major action of IL-6 is to promote monocyte-to-macrophage differentiation, 
thus contributing to vascular inflammation. IL-6 stimulation increases esterase and 
phagocytic activities and enhances surface expression of Fc receptors, macrophage-colony 
stimulating factor (M-CSF) receptors, and the mature macrophage marker F4/80. 
Additionally, IL-6 induces expression of genes important for macrophage differentiation 
such as c-Jun, jun B, jun D, interferon-regulatory factor 1 (IRF1), JAK3, Egr-1 (Hou, et al., 
2008). Moreover, IL-6 up-regulates MCP-1 expression (Biswas, et al., 1998; Tieu, et al., 2009) 
by vascular monocytic cells. MCP-1/CCR2 interactions are important in monocyte 
recruitment in the development of aneurysms (Boring, et al., 1998; Tieu, et al., 2009). Also, 
cell-cell interaction of monocytes and fibroblasts in cocultures induces IL-6 expression and 
macrophage activation, suggesting a role of IL-6 in monocyte-to-macrophage differentiation 
(Chomarat, et al., 2000; Tieu, et al., 2010). Recent studies demonstrated that IL-6-induced 
downstream gp130-JAK/STAT signaling pathway activation is also important for 
differentiation of monocytes (Hou, et al., 2008).  
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Recent studies indicate that enhanced IL-6 signaling is associated with vascular 
inflammation and aneurysm formation. IL-6 is elevated systemically and locally in patients 
and experimental models of aortic aneurysmal disease. IL-6 deficiency decreases aortic 
chemokine secretion and macrophage recruitment, and prevents aortic aneurysms and 
dissections in Ang II-infused mice (Tieu, et al., 2009). Conversely, in wild type mice, Ang II 
infusion potently induces IL-6 expression in the aorta, making IL-6 the most abundantly 
secreted cytokine that has yet been detected. IL-6 is predominantly expressed by fibroblasts 
and activated macrophages in the adventitia, with lesser amounts in the media and intimal 
layers (Recinos, et al., 2007). IL-6 signaling pathway was locally activated in Ang II-induced 
aortic aneurysms (Tieu, et al., 2009),where its action promotes monocytic activation and 
adventitial macrophage accumulation via a chemokine MCP-1-CCR2-based mechanism 
(Ishibashi, et al., 2004; Tieu, et al., 2009). These activated macrophages in the vessel wall 
produce pro-inflammatory cytokines, chemokines, ROS and MMPs, further facilitating local 
inflammation and remodeling. 
4. The TGF-β-Smad pathway in Ang II signaling 
The second pathway initiated by Ang II involves TGF-β receptor signaling pathway 
important in myofibroblast transition and vascular ECM remodeling, characteristic of 
aneurysmal disease. This cross-talk pathway is mediated by the effect of Ang II to 
upregulate TGF-β. TGF-β, in turn, induces the proliferation of adventitial fibroblasts and 
their phenotypic transition to myofibroblasts, that further promotes vascular remodeling 
with their enhanced mobility and secretory abilities. Additionally, Ang II-induced ECM 
decomposition and remodeling lead to monocytic chemotaxis and the release of latent TGF-
β. TGF-β activation induces aortic Smad signaling, which further contributes to MMP 
production and macrophage recruitment. Finally, in conjunction with IL-6, TGF-β also 
modulates Th lymphocyte subsets by promoting Th17 cell differentiation via activation of 
Smad and STAT signaling.   
4.1 TGF-β-Smad signaling mechanisms 
TGF-β activates cells by binding to one of 7 type I TGF-β receptors (TGF-βRI) or 5 type II 
TGF-β receptors (TGF-βRII). In the cell, TGF-β signals through both Smad-dependent (Jones, 
et al., 2008) and Smad-independent (p38 MAP kinase-mediated) pathways (Funaba, et al., 
2006). In the classic Smad-dependent pathway, ligand binding of TGF-β dimers leads to 
autophosphorylation and activation of a TGF-βRII homodimer, which in turn recruits and 
phosphorylates a TGF-βRI homodimer (Figure 1). TGF-βRI phosphorylates the appropriate 
receptor-activated Smad (R-Smad) (Jones, et al., 2008). Depending on the TGF-βRI that 
phosphorylates and activates them, there are 5 R-Smads in 2 groups (Smads 1, 5, 8; and 
Smads 2, 3). Once phosphorylated, R-Smad dissociates from TGF-βRI to form a complex 
with Smad4 (co-Smad), that translocates to the nucleus and regulates gene expression by 
binding to Smad binding elements. The signaling can also be regulated by inhibitory Smads 
(I-Smads), which attenuate the TGF-β response (Jones, et al., 2008). 
4.2 Ang II and TGF-β interaction in TAAs 
Recent studies have extensively focused on the role of TGF-β in the development of different 
forms of aortic aneurysms.  Studies on TAAs caused by Marfan or Loeys-Dietz syndromes 
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Recent studies indicate that enhanced IL-6 signaling is associated with vascular 
inflammation and aneurysm formation. IL-6 is elevated systemically and locally in patients 
and experimental models of aortic aneurysmal disease. IL-6 deficiency decreases aortic 
chemokine secretion and macrophage recruitment, and prevents aortic aneurysms and 
dissections in Ang II-infused mice (Tieu, et al., 2009). Conversely, in wild type mice, Ang II 
infusion potently induces IL-6 expression in the aorta, making IL-6 the most abundantly 
secreted cytokine that has yet been detected. IL-6 is predominantly expressed by fibroblasts 
and activated macrophages in the adventitia, with lesser amounts in the media and intimal 
layers (Recinos, et al., 2007). IL-6 signaling pathway was locally activated in Ang II-induced 
aortic aneurysms (Tieu, et al., 2009),where its action promotes monocytic activation and 
adventitial macrophage accumulation via a chemokine MCP-1-CCR2-based mechanism 
(Ishibashi, et al., 2004; Tieu, et al., 2009). These activated macrophages in the vessel wall 
produce pro-inflammatory cytokines, chemokines, ROS and MMPs, further facilitating local 
inflammation and remodeling. 
4. The TGF-β-Smad pathway in Ang II signaling 
The second pathway initiated by Ang II involves TGF-β receptor signaling pathway 
important in myofibroblast transition and vascular ECM remodeling, characteristic of 
aneurysmal disease. This cross-talk pathway is mediated by the effect of Ang II to 
upregulate TGF-β. TGF-β, in turn, induces the proliferation of adventitial fibroblasts and 
their phenotypic transition to myofibroblasts, that further promotes vascular remodeling 
with their enhanced mobility and secretory abilities. Additionally, Ang II-induced ECM 
decomposition and remodeling lead to monocytic chemotaxis and the release of latent TGF-
β. TGF-β activation induces aortic Smad signaling, which further contributes to MMP 
production and macrophage recruitment. Finally, in conjunction with IL-6, TGF-β also 
modulates Th lymphocyte subsets by promoting Th17 cell differentiation via activation of 
Smad and STAT signaling.   
4.1 TGF-β-Smad signaling mechanisms 
TGF-β activates cells by binding to one of 7 type I TGF-β receptors (TGF-βRI) or 5 type II 
TGF-β receptors (TGF-βRII). In the cell, TGF-β signals through both Smad-dependent (Jones, 
et al., 2008) and Smad-independent (p38 MAP kinase-mediated) pathways (Funaba, et al., 
2006). In the classic Smad-dependent pathway, ligand binding of TGF-β dimers leads to 
autophosphorylation and activation of a TGF-βRII homodimer, which in turn recruits and 
phosphorylates a TGF-βRI homodimer (Figure 1). TGF-βRI phosphorylates the appropriate 
receptor-activated Smad (R-Smad) (Jones, et al., 2008). Depending on the TGF-βRI that 
phosphorylates and activates them, there are 5 R-Smads in 2 groups (Smads 1, 5, 8; and 
Smads 2, 3). Once phosphorylated, R-Smad dissociates from TGF-βRI to form a complex 
with Smad4 (co-Smad), that translocates to the nucleus and regulates gene expression by 
binding to Smad binding elements. The signaling can also be regulated by inhibitory Smads 
(I-Smads), which attenuate the TGF-β response (Jones, et al., 2008). 
4.2 Ang II and TGF-β interaction in TAAs 
Recent studies have extensively focused on the role of TGF-β in the development of different 
forms of aortic aneurysms.  Studies on TAAs caused by Marfan or Loeys-Dietz syndromes 
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suggested a critical pathogenic role for increased TGF-β signaling in promoting abnormal 
vessel remodeling, dilatation, and aneurysmal expansion. Enhanced TGF-β signaling was 
implicated in aortic dilatation and aneurysm formation in Loeys-Dietz syndrome caused by 
mutations in the genes encoding TGF-βRI and TGF-βRII (Loeys, et al., 2005). In Marfan 
syndrome caused by mutations in the fibrillin-1 gene, bioavailability of TGF-β1is 
dysregulated (Chaudhry, et al., 2007), which contributes to the pathogenesis of TAAs (Dietz, 
et al., 2005; Neptune, et al., 2003). Normally, fibrillin-1 in the extracellular matrix regulates 
TGF-β activation by sequestering it in a complex with latent TGF-binding proteins (LTBPs). 
LTBPs associate matrix microfibrils with latency-associated peptide (LAP), regulating TGF-β 
matrix association and activation (Figure 1). Recent studies of fibrillin-1 deficient (Fbn1-/-) 
mice have shown that several cardiovascular pathologies are caused by abnormal up-
regulation of TGF-β signaling. Enhanced formation of activated TGF-β and phospho-Smad2, 
a downstream signaling protein activated by TGF-β, are detected in cardiovascular tissues. 
Importantly, neutralizing antibodies to TGF-β administered to Fbn1-/- mice reduce 
pathological abnormalities, suggesting a critical role of TGF-β signaling in the development 
and progression of TAA (Neptune, et al., 2003).  
Interestingly, enhanced Ang II signaling, which is a potent inducer of cytokines and 
chemokines, has also been implicated in Marfan syndrome. Aortic Ang II concentration is 
increased in aortas of mice with fibrillin mutations (Nagashima, et al., 2001). Also, the Ang II 
type I receptor antagonist, Losartan, prevents aortic aneurysm formation in patients with 
Marfan syndrome (Habashi, et al., 2006). The ACE inhibitor perindopril reduced aortic 
diameter in Marfan syndrome patients and significantly reduced TGF-β levels and plasma 
levels of MMP-2 and MMP-3. In addition, Ang II enhances TGF-β actions by activating 
Smad pathway in a TGF-β-independent manner (Carvajal, et al., 2008). It also induces the 
production of a potent activator of TGF-β, thrombospondin-1 (Habashi, et al., 2006). These 
data suggest that Ang II activates TGF-β signaling, contributing to aneurysm formation. 
Ang II may activate TGF-β signaling by regulating its transcription and/or its activation 
from the latent form (Habashi, et al., 2006). Previous studies have shown that in renal 
disease, Ang II regulates TGF-β signaling activation by activating tumor necrosis factor 
TNF-α-converting enzyme (TACE), which through the cleavage of vasorin, controls TGF-β-
mediated epithelial-to-mesenchymal transition (Shah and Catt, 2006).  
In a mouse model with fibrillin deficiency (mgR), an inflammatory-fibroproliferative 
response has been described in aneurysm formation. Homozygous mgR mice die between 3 
and 6 months of age of dissecting TAAs, and adventitial inflammation may accelerate 
pathogenesis by stimulating unregulated degradation of elastic matrix. In this mouse model, 
enhanced monocyte/macrophage infiltration is also pronounced at late stages of disease 
progression (Pereira, et al., 1999). Additionally, aortas from these mice secrete a GxxPG-
containing fibrillin-1 fragment that is able to induce macrophage chemotaxis (Guo, et al., 
2006b). Together, these findings suggest that inflammation is important in extracellular 
matrix degradation associated with fibrillin deficiency-induced TAAs. Two recent reports 
by the Dietz's group of Johns Hopkins University suggested that the effects of Ang II on 
aneurysm progression in MFS was mediated through a noncanonical TGF-beta signaling 
pathway involving extracellular signal-regulated kinase (ERK). It was reported that ERK 
activation contributed to aortic aneurysm progression in MFS (Holm, et al., 20111). Using a 
mouse model haplo-insufficient for Fbn-1 (Fbn1C1039G/+), this group found that ERK1/2 was 
activated and that ERK inhibition, but not Smad4 deficiency, eliminated aneurysm 
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development in MFS. It also was reported that AT1 receptor blocker losartan abrogated 
aneurysm progression by inhibiting TGF-beta-mediated ERK activation through AT2 
(Habashi, et al., 2011). 
Increased expression and activation of TGF-β are found in Ang II-induced AAAs. Preliminary 
studies from our group also demonstrated that Ang II induced Smad2/3 phosphorylation in 
mouse aortas. However, the precise role of TGF-β activity in inflammation in aneurysms 
remains contradictory. One study reported that TGF-β neutralizing antibodies afforded 
significant protection from Ang II-induced inflammatory aneurysms after Cxcl10 targeting 
(King, et al., 2009), while other studies showed that TGF-β played a protective role in AAA 
formation and TGF-β neutralization increased Ang II-induced aneurysm and monocyte 
invasiveness in C57BL/6 mice (Dai, et al., 2005; Wang, et al., 2010). Controversial results 
indicating the protective role of TGF-β in AAA formation may be explained by the 
concentration-dependent bipolar actions of TGF-β. With a higher dose of Ang II infusion in 
aged C57BL/6 mice (Tieu, et al., 2009), our preliminary studies showed that TGF-β 
neutralization decreased incidence of Ang II-induced aneurysm and adventitial thickening. 
Emerging evidence highlights the complex and context-dependent biphasic effects of TGF-β in 
the pathogenesis of aneurysm (Jones, et al., 2008), that can be partially explained by interaction 
with different receptors when TGF-β concentration changes (Goumans, et al., 2002). It may 
also be important to consider the variable roles of TGF-β during the dynamic transition from 
predisposition to terminal events. Thus, the detailed role of TGF-β in inflammatory aneurysms 
may be very complex and merits further exploration. 
Also, we have recently demonstrated that co-culture of monocytes with adventitial 
fibroblasts resulted in enhanced expression of IL-6, MCP-1 and IL-6-dependent macrophage 
differentiation (Tieu, et al., 2009). It is interesting to speculate that TGF-β may play a role in 
this process as a paracrine factor (Dietz, 2010). TGF-β is known to induce IL-6 and MCP-1 
expression (Seong, et al., 2009; Zhang, et al., 2009), monocyte recruitment and differentiation 
and myofibroblast formation, which in turn may amplify the process through secretion of 
TGF-β, MMPs, or even MCP-1 (Dagouassat, et al., 2010). 
4.3 Effects of TGF-β-Smad signaling activation in aneurysms 
TGF-β has both angiogenic and antiangiogenic effects (Goumans, et al., 2002), diametric 
actions thought to be controlled by the ratio of TGF-β signals via different receptors.  
Also, TGF-β produces opposing effects on mast cells to inhibit maturation or induce 
apoptosis, depending on their developmental stage and the TGF-β concentration (Rizas, et 
al., 2009).  
Additionally, TGF-β controls both ECM synthesis and degradation (Jones, et al., 2008). TGF-β 
promotes ECM degradation by inducing MMP-2 and MMP-9 production (Kim, et al., 2007). 
On the other hand, TGF-β stimulates both fibroblasts (Varga and Jimenez, 1986) and 
myofibroblasts (Mishra, et al., 2007) to synthesize collagen I, that provides load-bearing 
characteristics, and collagen III, that provides tensile properties to the aortic wall (van Keulen, 
et al., 2000). TGF-β also induces α-smooth muscle actin expression  in fibroblasts and promotes 
myofibroblast transdifferentiation (Vaughan, et al., 2000). The expression of α-smooth muscle 
actin was found to be significantly increased in adventitial fibroblasts of inflammatory aortic 
aneurysms, suggesting inflammatory remodeling in aneurysmal disease may be partly 
mediated by the proliferation of adventitial myofibroblasts (Sakata, et al., 2007).  
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enhanced monocyte/macrophage infiltration is also pronounced at late stages of disease 
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2006b). Together, these findings suggest that inflammation is important in extracellular 
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development in MFS. It also was reported that AT1 receptor blocker losartan abrogated 
aneurysm progression by inhibiting TGF-beta-mediated ERK activation through AT2 
(Habashi, et al., 2011). 
Increased expression and activation of TGF-β are found in Ang II-induced AAAs. Preliminary 
studies from our group also demonstrated that Ang II induced Smad2/3 phosphorylation in 
mouse aortas. However, the precise role of TGF-β activity in inflammation in aneurysms 
remains contradictory. One study reported that TGF-β neutralizing antibodies afforded 
significant protection from Ang II-induced inflammatory aneurysms after Cxcl10 targeting 
(King, et al., 2009), while other studies showed that TGF-β played a protective role in AAA 
formation and TGF-β neutralization increased Ang II-induced aneurysm and monocyte 
invasiveness in C57BL/6 mice (Dai, et al., 2005; Wang, et al., 2010). Controversial results 
indicating the protective role of TGF-β in AAA formation may be explained by the 
concentration-dependent bipolar actions of TGF-β. With a higher dose of Ang II infusion in 
aged C57BL/6 mice (Tieu, et al., 2009), our preliminary studies showed that TGF-β 
neutralization decreased incidence of Ang II-induced aneurysm and adventitial thickening. 
Emerging evidence highlights the complex and context-dependent biphasic effects of TGF-β in 
the pathogenesis of aneurysm (Jones, et al., 2008), that can be partially explained by interaction 
with different receptors when TGF-β concentration changes (Goumans, et al., 2002). It may 
also be important to consider the variable roles of TGF-β during the dynamic transition from 
predisposition to terminal events. Thus, the detailed role of TGF-β in inflammatory aneurysms 
may be very complex and merits further exploration. 
Also, we have recently demonstrated that co-culture of monocytes with adventitial 
fibroblasts resulted in enhanced expression of IL-6, MCP-1 and IL-6-dependent macrophage 
differentiation (Tieu, et al., 2009). It is interesting to speculate that TGF-β may play a role in 
this process as a paracrine factor (Dietz, 2010). TGF-β is known to induce IL-6 and MCP-1 
expression (Seong, et al., 2009; Zhang, et al., 2009), monocyte recruitment and differentiation 
and myofibroblast formation, which in turn may amplify the process through secretion of 
TGF-β, MMPs, or even MCP-1 (Dagouassat, et al., 2010). 
4.3 Effects of TGF-β-Smad signaling activation in aneurysms 
TGF-β has both angiogenic and antiangiogenic effects (Goumans, et al., 2002), diametric 
actions thought to be controlled by the ratio of TGF-β signals via different receptors.  
Also, TGF-β produces opposing effects on mast cells to inhibit maturation or induce 
apoptosis, depending on their developmental stage and the TGF-β concentration (Rizas, et 
al., 2009).  
Additionally, TGF-β controls both ECM synthesis and degradation (Jones, et al., 2008). TGF-β 
promotes ECM degradation by inducing MMP-2 and MMP-9 production (Kim, et al., 2007). 
On the other hand, TGF-β stimulates both fibroblasts (Varga and Jimenez, 1986) and 
myofibroblasts (Mishra, et al., 2007) to synthesize collagen I, that provides load-bearing 
characteristics, and collagen III, that provides tensile properties to the aortic wall (van Keulen, 
et al., 2000). TGF-β also induces α-smooth muscle actin expression  in fibroblasts and promotes 
myofibroblast transdifferentiation (Vaughan, et al., 2000). The expression of α-smooth muscle 
actin was found to be significantly increased in adventitial fibroblasts of inflammatory aortic 
aneurysms, suggesting inflammatory remodeling in aneurysmal disease may be partly 
mediated by the proliferation of adventitial myofibroblasts (Sakata, et al., 2007).  
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It is also noteworthy that TGF-β engages in adaptive immunity by promoting the 
differentiation of naïve CD4+ T helper cells (Th0) to T helper 17 (Th17) cells via activation of 
Smad and STAT signaling, depending on the coinstantaneous presence of IL-6 or IL-21 
(Reiner, 2007). TGF-β activation is critical and required for differentiation of Th17 cells 
(Melton, et al., 2010). It activates signature transcription factor RORγT (retinoic-acid receptor 
related orphan receptor gt) and cytokine IL-17 expression (Oukka, 2008). IL-17 mediates the 
production of inflammatory cytokines by stromal cells, which results in recruitment of 
leukocytes, thus creating a link between innate and adaptive immunity. Th17 cells and IL-
17A have been implicated in the pathogenesis of autoimmune and inflammatory diseases 
(Tesmer, et al., 2008), and only recently in cardiovascular disease (Cheng, et al., 2008). 
Increased circulating Th17 cells and Th17 cell infiltration into the aorta are found in Ang II-
induced hypertension, and IL-17 deficiency blunts these responses and prevents 
hypertension (Madhur, et al., 2010). Further, Th17 cells as well as IL-17 expression in 
atherosclerosis are increased, and blockade of IL-17A reduced aortic macrophage 
infiltration, cytokine secretion, and atherosclerotic plaque formation. Interestingly, IL-6 
expression is induced by IL-17 and reduced by blockade of IL-17A signaling (Smith, et al., 
2010), suggesting the proinflammatory effects of IL-6 could also be mediated by Th17 cells. 
Importantly, IL-17 and, by extension, Th17 cells, may contribute to inflammatory processes 
by promoting monocyte chemotaxis, adhersion and migration. It has recently been found 
that IL-17 mediated monocyte migration partially through MCP-1 induction (Shahrara, et 
al., 2010). IL-17A treatment of aortas from atherosclerotic mice promoted aortic CXCL1 
expression and monocyte adhesion (Smith, et al., 2010). These studies highlight an 
important proinflammatory role for T cells, especially the Th17 subset, in vascular 
inflammation. 
5. Conclusion 
Recent preclinical research has indicated that Ang II influences development and 
progression of aortic aneurysmal disease in two important ways.  First, Ang II affects the 
process of vascular inflammation by promoting macrophage accumulation, activation, local 
ROS production and aortic aneurysms in the suprarenal and thoracic aorta, followed by 
dissections through the NF-κB-IL-6 signaling pathway.  Second, Ang II promotes 
myofibroblast transition and ECM remodeling - both characteristic of aneurysmal disease - 
by a TGF-β1-Smad pathway. Currently, there are still many important unresolved 
questions. For example, 1) the role of NF-κB RelA activation in the development of 
aneurysms; 2) the mechanism through which Ang II activates TGF-β in the vessel wall; 3) 
the precise role of TGF-β signaling in Ang II-induced aortic aneurysms; 4) the role of 
myofibroblast formation in the development of aortic remodeling and aneurysms; 5) the role 
of TGF-β signaling on Th17 cell differentiation and recruitment in the development of Ang 
II-induced aneurysms; and 6) clinical relevance of TGF-β neutralization in aneurysmal 
disease. Further elucidation of these issues will identify new targets for therapeutic 
intervention and biomarker development. 
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expression is induced by IL-17 and reduced by blockade of IL-17A signaling (Smith, et al., 
2010), suggesting the proinflammatory effects of IL-6 could also be mediated by Th17 cells. 
Importantly, IL-17 and, by extension, Th17 cells, may contribute to inflammatory processes 
by promoting monocyte chemotaxis, adhersion and migration. It has recently been found 
that IL-17 mediated monocyte migration partially through MCP-1 induction (Shahrara, et 
al., 2010). IL-17A treatment of aortas from atherosclerotic mice promoted aortic CXCL1 
expression and monocyte adhesion (Smith, et al., 2010). These studies highlight an 
important proinflammatory role for T cells, especially the Th17 subset, in vascular 
inflammation. 
5. Conclusion 
Recent preclinical research has indicated that Ang II influences development and 
progression of aortic aneurysmal disease in two important ways.  First, Ang II affects the 
process of vascular inflammation by promoting macrophage accumulation, activation, local 
ROS production and aortic aneurysms in the suprarenal and thoracic aorta, followed by 
dissections through the NF-κB-IL-6 signaling pathway.  Second, Ang II promotes 
myofibroblast transition and ECM remodeling - both characteristic of aneurysmal disease - 
by a TGF-β1-Smad pathway. Currently, there are still many important unresolved 
questions. For example, 1) the role of NF-κB RelA activation in the development of 
aneurysms; 2) the mechanism through which Ang II activates TGF-β in the vessel wall; 3) 
the precise role of TGF-β signaling in Ang II-induced aortic aneurysms; 4) the role of 
myofibroblast formation in the development of aortic remodeling and aneurysms; 5) the role 
of TGF-β signaling on Th17 cell differentiation and recruitment in the development of Ang 
II-induced aneurysms; and 6) clinical relevance of TGF-β neutralization in aneurysmal 
disease. Further elucidation of these issues will identify new targets for therapeutic 
intervention and biomarker development. 
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1. Introduction 
Vasculitis encompasses a heterogeneous group of disorders characterized by inflammation 
of blood vessels. Inflammation affects vessels of any type and size, and causes a wide range 
of clinical manifestations, depending on the vascular bed involved. The preferential size of 
involved vessels and the targeted tissues determine the clinical presentation and serve as 
key elements for classification (Watts & Scott, 2009). Vasculitis may occur as a primary 
process or may be secondary to an underlying disease such as infection, malignancy or other 
systemic autoimmune or chronic inflammatory diseases. Blood vessel inflammation results 
in abnormal vascular remodelling with the potential of severe clinical consequences. In 
some instances, inflammation leads to intimal hyperplasia resulting in vascular stenoses and 
ischemia of the tributary tissues. In other settings, inflammation causes disruption of the 
vessel wall architecture leading to aneurysm formation and eventual dissection or rupture. 
Aortitis is the term used to define inflammation of one or more layers of the aortic wall and 
may have an infectious or non-infectious origin (Gornik & Creager, 2008). Non-infectious 
aortitis is usually part of the spectrum of vascular involvement occurring in primary large-
vessel vasculitis  including giant-cell arteritis (GCA) of the elderly and Takayasu’s arteritis 
(TAK). Aortitis is a major component of these diseases and may lead to severe complications 
including aortic aneurysm, dissection or stenosis.  
Aortitis may also present as a circumscribed condition named isolated aortitis. This term refers 
to aortitis incidentally found at the time of histopathological examination of aortas obtained 
from necropsy studies or from patients who have undergone surgical repair of aortic 
aneurysm or aortic valve replacement.   Existing studies are retrospective and most patients 
have not been prospectively and systematically evaluated in search for a systemic vasculitis or 
other chronic inflammatory diseases. There is some controversy about whether isolated aortitis 
is a specific condition or represents an incomplete view of a systemic disease. 
Occasionally, aortitis may occur in the setting of other primary systemic vasculitis, 
particularly  antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (Chirinos et 
al., 2004; Lee et al., 2008), and  other autoimmune disorders or chronic inflammatory 
diseases (i.e. sarcoidosis, Crohn’s disease, ankylosing spondylitis, Behçet’s disease, Cogan’s 
disease, and IgG4-related disease) (Domenech et al., 2005; Gluth et al., 2006; Palazzi et al., 
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2010; Stone, 2011; Weiler et al., 2000; Okada  et al., 1997).  The main causes of primary and 
secondary aortitis are summarized in table 1. 
Chronic periaortitis is an additional form of aortic inflammation that encompasses a variety 
of conditions and is characterized by inflammatory involvement of the outer layer of the 
aorta and surrounding tissues.   Chronic periaortitis may occasionally occur in patients with 
small-medium sized vessel vasculitis. 
This chapter will particularly focus on aortic inflammation and its consequences in the 
context of the primary large-vessel vasculitis. 
 
  
NON INFECTIOUS AORTITIS  
 
     Primary vasculitis 
 
 
       Large-vessel vasculitis Giant-cell arteritis
 Takayasu’s arteritis
 
       Other vasculitis Granulomatosis with polyangiitis (Wegener’s ) 
 Microscopic polyangiitis
Vasculitis associated  with 
chronic inflammatory or 
autoimmune conditions
 
      Rheumatoid arthritis
 SarcoidosisSystemic lupus erythematosus 
 Behçet disease 
 Cogan syndrome 
 HLA-B27 associated spondyloarthropaties 
 Crohn’s disease 






       
Chronic periaortitis  
      Retroperitoneal fibrosis 
      Inflammatory abdominal aortic aneurysm  
      Perianeurysmal aortitis 
  
INFECTIOUS AORTITIS  
  
     Bacterial Salmonella spp 
 Staphylococcus spp 
 Streptococcus pneumoniae 
 Treponema pallidum spp 
  
     Mycobacterial  Mycobacterium tuberculosis 
Table 1. Causes of aortic inflammation 
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2. Aortic inflammation in primary systemic vasculitis 
2.1 Vasculitis leading to aortic inflammation 
Primary large-vessel vasculitis encompasses GCA and TAK which represent the most 
common disorders associated with non-infectious aortitis. Although histologically similar, 
GCA and TAK are considered distinct disease entities based on demographic and clinical 
features. While GCA affects aged people and is usually associated with cranial symptoms, 
TAK predominantly affects patients younger than 40 years, primarily involves the aorta and 
its major branches but generally spares the cranial arteries. These features usually allow a clear 
clinical differentiation between these two vasculitides. However the increasing  recognition of  
large-artery involvement in GCA during the  past decade widens the overlap features  
between both entities and some authors suggest that they may be part of the spectrum of a 
single disorder (Maksimowicz-McKinnon & Hoffman, 2009). 
2.1.1 Giant-cell arteritis 
GCA is a systemic vasculitis involving large and medium sized vessels in patients older 
than 50 years. The preferential involvement of the cranial arteries  determines the classical 
symptoms of GCA (headache, jaw claudication, scalp tenderness) and its more frequent 
vaso-occlusive complication (visual loss usually due to anterior ischemic optic neuritis).   
About half of the patients have polymyalgia rheumatica  and the majority have prominent 
systemic symptoms (fever, anemia of chronic disease type, and weight loss)  and elevation 
of acute phase reactants. 
Although early descriptions of GCA identified the cranial arteries as the main target of the 
disease, subsequent reports  indicated more widespread vascular involvement (Hunder, 
2006). First report of aortic involvement was in 1937 (Sproul & Hawthorne, 1937) and 
described post-mortem chronic diffuse inflammation with giant cells in the aorta and iliac 
arteries of  two men without apparent premortem symptoms of vasculitis. Over the 
following years, additional cases were reported (Bonnin & Lander, 1956; Cardell & Hanley, 
1951; Cooke & Cloake, 1946; Heptinstall et al., 1954) confirming the potential of GCA to 
involve large-vessels. 
In 1972 Ostberg (Ostberg, 1972) systematically investigated the aorta and its major branches  
in  necropsies from  13 patients with GCA. Inflammatory involvement of the aorta was 
present in 12 out of the 13 patients (90%). Although the necropsy nature of this survey may 
be biased towards the inclusion of more severe cases, these findings suggest that aortic 
involvement might be frequent in GCA.  
More recently, other authors have investigated the prevalence of aortitis in specimens 
obtained from patients who underwent aortic reconstructive surgery because of aortic 
aneurysm, aortic dissection or aortic valve insufficiency. Table 2 summarizes the main 
findings of these studies (Burke et al., 2008; Gelsomino et al., 2005; Homme et al., 2006; Kerr 
et al., 2000; Liang et al., 2009; Miller et al., 2006; Nesi et al., 2009; Pacini et al., 2008; Rojo-
Leyva et al., 2000). Histopathologic analysis of removed aortic fragments revealed chronic 
inflammation in about 1,7 to 8,7%  of patients subjected to aortic surgery.   Patients with 
aortic inflammation were predominantly women and the age average was 65 years.  Among 
these patients, 5-20% had an underlying chronic inflammatory disease, mainly GCA.  The 
design of these retrospective studies is not aimed to estimate the frequency of aortic 
involvement in GCA but underlines the fact that GCA accounts for a significant proportion 
of complicated inflammatory aortitis. 
In the past decade, the vast development of imaging techniques has facilitated the non-
invasive detection of signs suggestive of aortic inflammation in living individuals in early 
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2010; Stone, 2011; Weiler et al., 2000; Okada  et al., 1997).  The main causes of primary and 
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phases, before the development of clinically relevant aortic complications (Pipitone et al., 
2008) (Figures 1 and 2). In this setting, three prospective studies have been conducted to 
determine the prevalence of aortitis in patients with recent-onset GCA. Blockmans et al. 
performed a systematic 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography 
(FDG-PET) to  35 newly diagnosed GCA patients and found FDG uptake suggestive of 
active inflammation in both the abdominal and the  thoracic aorta in approximatelly half of 
the patients (Blockmans et al., 2006). Agard et al. studied 22 patients with computed 
tomography angiography (CTA) during the first month after GCA diagnosis. Although 
some of these patients had received treatment at the time of the CTA, the authors 
demonstrated radiological signs of aortitis in 45% of patients in the thoracic aorta and in 
23% in the abdominal aorta. Finally, in a prospective study performed by the authors in 40 
newly diagnosed  GCA patients using CTA, radiologic findings suggesting aortitis were 
detected in 65% of patients, which represents the higher prevalence of aortitis found by 
means of imaging techniques (Cid et al., 2009; Prieto-Gonzalez et al., 2009).  
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Table 2. Prevalence of aortitis and associated diseases in surgical specimens. 
 




Fig. 1. Cross-sectional view of a CT angiography of a patient with newly diagnosed GCA 
displaying a marked circumferential thickening of the aortic wall.  
 
 
Fig. 2. 18F-FDG-PET scan of a patient with GCA prior to corticosteroid treatment.  
(A) Markedly abnormal uptake of 18F-FDG in the ascending thoracic aorta and carotid 
arteries. (B) Increased 18F-FDG uptake in the aortic arch, abdominal aorta, iliac, subclavian 
and axillary arteries.  
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2.1.2 Takayasu’s arteritis 
TAK is a rare chronic inflammatory granulomatous disease of unknown aetiology that 
affects predominantly young women. It has a worldwide distribution but higher prevalence 
has been reported among Asian populations. TAK primarily affects the aorta and its major 
branches. Pulmonary arteries can also be involved (Kerr et al., 1994; Mwipatayi et al., 2005). 
Aortitis may affect either an aortic segment or involve the entire aorta. Although there is 
considerable variability in disease expression between different geographical areas, the 
initial vascular lesion frequently occurs in the middle or proximal segment of the left 
subclavian artery close to the aorta. In Japanese patients, aortitis has been described mostly 
in the ascending aorta and the aortic arch whereas in Indian patients inflammation 
apparently occurs firstly in the abdominal aorta, subsequently extending towards the 
thoracic segments. (Hata et al., 1996). Aortic involvement is very common in TAK. In 
different series of patients with TAK who underwent imaging studies, aortic involvement 
had been detected in more than 70% of cases.  
2.1.3 Isolated aortitis 
Vasculitis limited to the aorta has been found in post-mortem studies or has been 
incidentally diagnosed in specimens obtained from surgical repair of aortic aneurysms. The 
prevalence of isolated aortitis in the general population is unknown due to the subclinical 
course of this entity.   
In a retrospective review of 1204 aortic surgical specimens obtained over a 20-year period at 
the Cleveland Clinic, idiopathic aortitis was found in 52 patients (4.3%) (Rojo-Leyva et al., 
2000). Sixty-nine percent of these patients had no previous history of systemic vasculitis and 
only 31% of patients had prior history of systemic illnesses known to be associated with 
aortitis. Indications for surgery in patients with isolated aortitis consisted of manifestations 
related to aortic aneurysm (large aneurysm size or progressive enlargement, aortic 
dissection, or aortic valve dysfunction), or coronary artery disease and only in 1 patient 
aortitis was detected at the time of thymoma ressection. In 96% of patients with aneurysm 
formation and idiopathic aortitis, the disease was only identified within the thoracic aorta 
whereas aortic aneurysms not associated with idiopathic aortitis occurred predominantly in 
the abdominal aorta (67%).  
In another recent retrospective study, noninfectious aortitis was detected in 64 patients of a 
series of 766 patients with ascending thoracic aneurysm who underwent surgical repair, 
representing 8.4% of the series. The majority of patients were asymptomatic or had 
aneurysm-related symptoms only, being aneurysm incidentally discovered in a chest x-ray 
or echocardiography. The majority of aortitis (81.3%) were of the isolated variant, with no 
history of chronic inflammatory diseases. Among the remaining, GCA was the entity more 
frequently associated with aortitis.  Eighty-nine percent of patients with noninfectious 
aortitis (57/64) underwent vascular imaging, and additional vascular abnormalities were 
present in 72% of them. Additional imaging findings included stenoses and/or ectasia of the 
major aortic branches (42.1%), descending thoracic aneurysm (31.6%), descending thoracic 
and abdominal aneurysms (21.1%), and abdominal aneurysms (7%). The median follow up 
in this study was 15.4 months, which was insufficient to determine the outcome of these 
additional vascular abnormalities (Liang et al., 2009). Data from these and other surgical 
series are summarized in table 2.    
Therefore, in the majority but not all patients with apparently isolated aortitis, a more 
widespread involvement  indicating systemic large-vessel vasculitis or an associated 
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condition can be detected. Existing studies assessing potentially associated diseases in these 
patients are retrospective and almost certainly underestimate the prevalence of pre-existing 
conditions because many patients with incidentally discovered aortitis had not been 
systematically subjected to an extensive clinical evaluation or imaging study. 
2.1.4 ANCA-associated vasculitis 
Large-vessel involvement and associated complications such as aortic stenoses, aneurysm, 
or dissection have been occasionally reported in patients with small-medium sized vessels 
such as ANCA- associated vasculitis, particularly granulomatosis with polyangiitis 
(Wegener’s) (GPA).  Reported cases,  have well-sustained diagnosis and have no 
epidemiologic, clinical or histopathologic features of GCA or TAK  that might suggest 
misclassification (Chirinos et al., 2004). These findings suggest that aortitis may be part of 
the spectrum of vascular involvement in ANCA-associated vasculitis.  
2.1.5 Chronic periaortitis 
Chronic periaortitis includes several modalities of aortic inflammatory involvement 
including retroperitoneal fibrosis, inflammatory aortic aneurysm and perianeurysmal 
retroperitoneal fibrosis. The last two conditions convey aortic dilatation.   The abdominal 
aorta is most frequently involved. Retroperitoneal fibrosis is idiopathic in most cases but 
may occur in the context of small and medium sized vessel vasculitis, particularly GPA.  
It has also been described in association with microscopic poliangiitis and its renal limited 
variant, and hepatitis C virus-associated cryoglobulinemia. Idiopathic retroperitoneal 
fibrosis may accompany other autoimmune diseases such as rheumatoid arthritis, 
systemic lupus erythematosus, autoimmune thyroiditis) or may be part of other fibrosing 
disorders including orbital pseudotumor, mediastinal fibrosis, sclerosing cholangitis,  
and Riedel’s thyroiditis.  Histopathologically there is a marked aortic adventitial 
inflammation with inflammatory involvement of vasa vasorum extending towards the 
retroperitoneal small vessels and retroperitoneum itself. Inflammatory changes are 
thought to trigger a fibrotic response of variable intensity (Vaglio et al., 2003; Levine et al., 
2006). 
2.2 Clinical manifestations derived from aortitis 
Aortic inflammation is usually asymptomatic until complications derived from 
inflammation -induced vascular remodelling occur. Clinical manifestations are dominated 
by other components of the associated disease.  In patients with GCA cranial, systemic and 
polymyalgic symptoms dominate the clinical picture.  TAK disease is usually more silent 
and indolent and initial manifestations are frequently derived from involvement of the 
aortic branches (vascular bruits, weak or absent pulses, limb claudication, hypertension, 
dizziness or light-headedness) (Kerr GS  et al., 1994;  Macsimowicz-Mckinnon et al., 2007). 
Aortitis  may contribute to the inflammation-associated  non-specific  signs and symptoms 
such as fever, anemia, weigh loss or malaise highly frequent in GCA and also present in  a 
substantial proportion of TAK patients. Complications derived from aortitis  are usually 
manifest and patients may present with severe symptoms related to aortic aneurysm 
enlargement or rupture (i.e. chest pain, abdominal pain, back pain) or aortic valve 
insufficiency (i.e. dyspnea and heart failure,) (Garcia-Martinez et al., 2008; Nuenninghoff et 
al., 2003a; Nuenninghoff et al., 2003b). 
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2.3 Histopathological features 
Aortitis is characterized by patchy areas of medial necrosis and focal loss of medial smooth 
muscle cells, along with adjacent infiltration of lymphocytes, plasma cells, and histiocytes. 
Multinucleated giant cells, if present, are generally found at the borders of necrotic zones. 
The aorta of TAK patients may show thickening of the aortic wall with fibrotic rindlike 
adventitia, and intense medial and adventitial inflammation with granulomas.  It can be 
indistinghishable from aortitis found in GCA. In general, histological features of non-
infectious aortitis are similar and there are no specific features helpful in distinguishing   
isolated aortitis from GCA or TAK (Kerr et al., 2000; Miller et al., 2006; Gravanis, 2000; Hall 
et al., 1985; miller et al., 2006).  
2.4 Diagnosis and assessment of aortic inflammation 
In GCA, diagnosis is usually obtained by temporal artery biopsy. The detection of aortitis 
may have diagnostic usefulness in patients with suspected GCA when temporal artery 
biopsy is not informative or is unavailable. In TAK, the diagnosis is largely based on the 
combination of clinical information, laboratory evaluation, and diagnostic imaging 
(Mukhtyar et al., 2009). Imaging is an essential tool for the diagnosis of TAK because the 
involved vessels are not routinely available for histopathologic examination and in both 
conditions imaging techniques play a critical role in evidencing aortitis.  Among imaging 
modalities, percutaneous intravascular angiography has been traditionally the gold 
standard investigation for the diagnosis of TAK, providing high-quality images of the 
arterial lumen frequently altered in involved vessels. Typical lesions appear as long, 
smooth, tapered stenoses or sometimes complete occlusions intermingled with areas of 
dilatation. Collateral circulation is often prominent because of the slow progression of the 
disease. Modern non-invasive diagnostic modalities including ultrasonography,  PET-scan, 
computed tomography scanning and magnetic resonance angiography have progressively 
replaced conventional angiography for diagnosis of large vessel involvement  because of 
their reduced risks and the ability to provide information not only about the lumen but also 
about the vessel wall. Specific MRI sequences such as delayed contrast-enhanced MRI may 
allow the detection of edema and arterial wall thickening at a reversible stage, prior to the 
development of luminal stenosis.  MRI/MRA may provide useful information avoiding the 
risks associated with arterial puncture, iodinated contrast load and radiation exposure. 
Currently, conventional angiography is basically used to guide endovascular intervention 
procedures or to combine imaging with the detection of central blood pressure in patients 
with significant limb artery stenoses.  
Systematic evaluation of patients with large-vessel vasculitis with imaging studies such as 
color duplex ultrasonography (US), CTA, FDG-PET, angiography, and magnetic 
resonance imaging (MRI) or MR angiography (MRA) has been performed by several 
investigators (Agard et al., 2008; Andrews et al., 2004; Andrews & Mason, 2007; 
Blockmans et al., 2008; Blockmans et al., 2009; Both et al., 2008; Hautzel et al., 2008; Henes 
et al., 2008; Narvaez et al., 2005; Pipitone et al., 2008; Prieto-Gonzalez et al., 2009; Walter et 
al., 2005; Webb & Al-Nahhas 2006). These techniques offer different but complementary 
information to assess large vessel involvement with relative advantages and 
disadvantages which are summarized in Table 3 (Tso E et al., 2002; Blockmans  et al., 2009; 
Cid et al., 2009; ). 
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2.3 Histopathological features 
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3. Aortic complications in patients with large-vessel vasculitis  
Aortitis may eventually lead to aortic complications in patients with large-vessel vasculitis.  
After the initial inflammatory injury, abnormal vascular remodelling may eventually cause 
aortic structural damage and clinical complications such as aortic aneurysm, dissection, or 
aortic valve insufficiency secondary to aortic root dilatation (Salvarani et al., 2008). Patients 
with GCA tend to develop complications derived from aortic dilatation or dissection 
whereas patients with TAK more commonly develop aortic stenosis but may also develop 
dilatation of the ascending aorta and aortic valve insufficiency.  
3.1 Aortic complications in patients with GCA  
GCA patients are at an increased risk of developing aortic complications. In a retrospective 
population-based study, GCA patients were 17.3 times more likely to develop thoracic aortic 
aneurysms and 2.4 times more likely to develop abdominal aortic aneurysms during follow-
up than individuals of the same age from the general population (Evans et al., 1995). The 
prevalence of aortic complications during follow-up ranged from 9.5 to 18% in three series 
of patients with GCA (Evans et al., 1995; González-Gay et al., 2004; Nuenninghoff et al., 
2003a). Table 4 summarizes the main results of these studies.  
 
 
Fig. 3. (A) Chest x-ray of a 68 -years old woman at the time of GCA diagnosis. (B) Four years 
later the chest radiograph of the same patient showed mediastinum broadening and aortic 
aneurysm was confirmed by CT-scan.  (C) CT scan of another patient wit GCA 
demonstrating an aneurysm with a maximum diameter of  5 cm at the ascending thoracic 
aorta. (D) Aortic dissection at the ascending aortic segment in a patient with GCA 
presenting with chest pain.  
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Patients were treated 
uniformly and those 
with ASD were able 
to withdraw CS in a 
shorter period of 
time 
TAA: thoracic aortic aneurysm; TAD: thoracic aortic dissection; AAA: abdominal aortic aneurysm;  
AAD: abdominal aortic dissection; CAD: coronary artery disease; yr: years; mo: months;.  
ASD: aortic structural damage (aneurysm or dilatation) 
(*) Only scattered small infiltrates were observed. 
Table 4. Studies evaluating aortic complications in patients with GCA 
Overall, these studies suggest that aortic aneurysms are late complications, usually detected 
several years after the diagnosis of GCA, even in patients that have achieved sustained 
remission and have been able to withdraw corticosteroid therapy. Only 10% of patients with 
GCA evaluated by CT angiography imaging exhibit slight dilatation of the aortic wall at the 
time of diagnosis (Prieto-Gonzalez et al., 2009). Apparently, aortic dissection may occur in 
earlier phases even in the absence of aortic aneurysmal disease and sometimes represents 
the initial event leading to the diagnosis of GCA. In this setting, aortic dissection may occur 
in patients with active inflammation which is demonstrated by histopathologic examination 
of the aortic specimen obtained after surgical repair or necropsy (Lie, 1995; Nuenninghoff et 
al., 2003a). Although the entire aorta may be involved, aneurysms and dissections 
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preferentially develop in the thoracic segments, mainly the ascending aorta. Although 
survival rates are not decreased in patients with GCA, the development of aortic rupture is a 
catastrophic event that carries high morbidity and mortality (Evans et al., 1995; 
Nuenninghoff et al., 2003a). 
In a prospective cross-sectional analysis of 54 GCA patients who were screened with a 
defined protocol after a median follow-up of 5.4 years (range 4-10.5 years), García-
Martínez A et al  found significant aortic structural damage (aneurysm or dilatation) in 
22% of patients which was higher than the prevalence observed in previous retrospective 
studies (García-Martínez et al., 2008). Almost half of the patients in this cohort were 
candidates to surgical repair because of the size of the aneurysm. The ascending aorta was 
the segment involved in three quarters of patients. Aortic structural damage was 
significantly more frequent in men and was not associated with the presence of traditional 
cardiovascular risk factors. When these patients were re-screened after longer follow-up 
(median 8.8 years, range 8-10.5) additional aortic aneurysms appeared in few additional 
patients who had non-dilated aortas in the initial study and one of them developed aortic 
dissection. Histopathological study of the aorta of this patient did not evidence 
persistence of active aortic inflammation but there was marked loss and disruption of 
elastic lamelae.  
 
 
Fig. 4. Post-mortem aortic specimen obtained from a patient who died from aortic dissection 
9 years after the diagnosis of GCA.  A) Hematoxylin-eosin staining showing absence of 
inflammation. B) Orcein staining of a serial section disclosing extensive disruption of the 
elastic fibres, probably due to the initial injury. 
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Persistence of inflammatory infiltrates has been described in some aortic specimens 
obtained from necropsies or from patients with aortic aneurysm that have undergone 
surgery years after the diagnosis of GCA (Evans et al., 1995; Lie, 1995; Nuenninghoff et al., 
2003a; Zehr et al., 2005). As a result of these findings, aortic complications are considered to 
be the result of persistent aortic inflammation and the ensuing weakening of the aortic wall. 
However, in a prospective cross-sectional evaluation, persistence of clinically or analytically 
detectable disease activity was not found to be associated with increased risk of aortic 
structural damage (García-Martínez A et al 2008). Patients with aortic dilatation experienced 
less relapses during follow-up, had lower corticosteroid requirements and exhibited lower 
acute-phase reactants than patients without aortic aneurysm or dilatation. Histopathological 
review of the aortic wall in patients who underwent surgery for aneurysm repair evidenced 
only minimal inflammatory infiltrates but important loss and disruption of elastic lamellae 
even in areas devoid of inflammation, probably as a consequence of the initial injury (Figure 
4). The aneurysmal aortic wall exhibited increased expression of matrix metalloproteinase 
(MMP)-2 but not MMP-9 which suggests ongoing remodelling process more than persistent 
aortic inflammation (García-Martínez et al., 2008). Thus, aortic dilatation develops as a 
consequence of complex and probably multifactorial mechanisms.  On the basis of these 
studies it is likely that aortic inflammation and subsequent maladaptative remodelling 
determine the weakening of the aortic wall, which subjected to mechanical stress, may 
eventually undergo dilatation and aneurysm formation over time. 
The life-threatening nature of the potential complications derived from aortic structural 
damage makes mandatory to subject GCA patients to a continuous surveillance by clinical 
examination and imaging, even patients in long-term sustained remission.  The best cost-
benefit screening procedure has not been established but a reasonable approach would 
include performance of a chest X-ray and abdominal US examination every one or two years 
and echocardiogram if aortic bruits are detected.  
3.2 Aortic complications in patients with Takayasu’s arteritis  
As the disease progresses abnormal vascular remodelling   leads to the combination of 
arterial  stenosis/occlusion with arterial aneurysms. However, while stenotic lesions appear 
in almost all patients with TA only 27% of patients develop arterial aneurysms (Kerr GS  et 
al., 1994).  Symptoms derived from involvement of the aortic branches, usually dominate the 
clinical picture and may combine with symptoms derived form aortic involvement. Patients 
may experience symptoms due to vertebrobasilar insufficiency (vertigo, syncope), upper- 
and lower-extremity claudication, transient ischemic attacks or stroke, coronary heart 
disease, or mesenteric ischemia, among others.  
In the aorta stenoses/occlusions are mainly located at the aortic arch, the descending aorta and 
the abdominal aorta, and aortic aneurysms preferentially develop at the ascending thoracic 
aorta (Kerr et al., 1994; Mwipatayi, 2005). More than 70% of patients develop hypertension, 
mainly of renovascular origin but aortic stenosis leading to atypical aortic coarctation may also 
contribute.  Blood pressure treatment and control may be a serious problem in these patients 
since arm blood pressure measurement may not be accurate. TAK patients may also develop 
aortic dilatation or aneurysm with risk of rupture. Aortic valve incompetence has been 
reported in up to one quarter of patients and is generally due to annular or ascending aortic 
dilatation but also as a result of secondary aortic valve changes such as fibrous thickening, 
retraction, and calcification. Congestive heart failure is present in up to one fourth of patients 
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who have TAK and usually occurs as a consequence of uncontrolled hypertension or aortic 
regurgitation (Kerr et al. 1994; Macksimowicz-Mckinnon et al. 2007).  
4. Treatment of aortitis and aortic complications 
Treatment of primary large vessel vasculitis is addressed to eliminate clinical symptoms and 
suppress inflammatory activity wherever it is present, including the aorta and its branches.  
However current therapies are not able to completely abrogate inflammation in most cases 
and are not able to prevent complications derived from inflammation-induced vascular 
remodelling which may need to be addressed with surgery or revascularization procedures. 
High dose glucocorticoids are the mainstay of initial therapy to induce remission in large-
vessel vasculitis which must be combined with immunosuppressive agents in the majority 
of patients with TAK.  
4.1 Giant-cell arteritis 
Prednisone or equivalent is usually given to patients with GCA at 1 mg/Kg/day, up to 60 
mg/day for 1 month with subsequent tapering. Low-dose prednisone is maintained for 2-3 
years until complete discontinuation which is achieved by approximately half of the patients.  
Between 40-60% of patients experience a relapsing course. Methotrexate and azathioprine  
have shown modest corticosteroid sparing effects in clinical trials  (Mahr et al. 2007;  Hoffman 
et al. 2002; Cid et al., 2007) and can be used to reduce glucocorticoid exposure in patients  with 
relapsing outcome or with glucocorticoid-related side effects (Mukhtyar et al., 2009).   A 
randomized clinical trial did not show benefit of infliximab  over placebo in maintaining 
remission in patients with newly-diagnosed GCA (Hoffman et al.,2007). Glucocorticoid 
treatment is usually adjusted according to remission of cranial, systemic or polymyalgic 
symptoms and normalization of acute phase reactants. Response of aortic inflammation has 
not been taken into account because the substantial prevalence of aortitis and its potential 
delayed complications has not been appreciated until very recently.   Imaging techniques may 
have promise in assessing the effect of treatment on large-vessel inflammation but their 
sensitivity and specificity are not fully established and, at present, it is premature to adapt 
therapeutic adjustments to the persistence or resolution of imaging abnormalities. 
Since the discovery that aortitis and aortic complications are frequent in GCA is relatively 
recent, there is no evidence supporting whether the discovery of aortic dilatation may have 
therapeutic implications. It is not clear whether aortic dilatation results from persistent 
subclinical inflammation, previous injury, abnormal remodelling, hemodynamic factors or a 
combination of these.  Surgical aortic repair in GCA patients should be performed according 
to standard current guidelines for the general population with aortic disease and preferably 
in patients in remission (Zehr et al. 2005). Since GCA targets aged people, advanced age or 
co-morbidities may unacceptably increase the risk of elective surgery and convenience of 
surgical repair must be carefully weighted in an individual basis.  Endovascular repair of 
aortic aneurysm may be an interesting option but the experience is limited.  Moreover, most 
of the existing   evidence regarding endovascular repair of aortic aneurysm has been 
obtained from abdominal and thoracic descending aneurysms. Endovascular repair of 
ascending aortic dilatation, common in GCA, is technically more difficult (The United 
Kingdom  EVAR trial investigators, 2010a; The United Kingdom  EVAR trial investigators, 
2010b; Kolvenbach  et al., 2011).   
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4.2 Takayasu  arteritis  
For TAK patients, an initial prednisone dose of 1 mg/Kg/day (max 60 mg/day) maintained 
for 1 month and gradually tapered is recommended. With this treatment, 93% of patients 
achieve disease remission. However, remission is sustained in only 20% of patients.  More 
than 70% of patients need adjuvant therapy and long-term low-dose glucocorticoid is 
frequently required by most patients.   Recommendations about immunosuppressive agents 
are based on open-label studies. Methotrexate, azathioprine and mycophenolate are the 
most frequently used. Open-label studies support the potential usefulness of infliximab for 
refractory patients (Mukhtyar et al., 2009; Molloy et al., 2008)  
TAK is a chronic relapsing disease and flares and anatomic progression of vascular lesions 
occur in the majority of patients during follow-up.  
One of the challenges in TAK is to find better surrogate markers of disease activity and 
ongoing inflammation. Clinical data are often non-specific and acute-phase reactants may be 
unreliable indicators. Previous studies of patients undergoing periodic imaging surveillance 
showed inconsistencies in the relationship between acute-phase reactants and the 
development of new vascular lesions during follow-up. In a review of patients with 
clinically inactive disease, new angiographic changes appeared in 60% of them and surgical 
aortic biopsy specimens revealed histological evidence of persistent inflammatory infiltrates 
in 44% of the samples (Kerr et al., 1994). 
Serial imaging has been used for long in the follow-up of patients with TAK since symptoms 
usually occur when severe disruption of the normal vascular architecture has occurred.   
Serial imaging is very useful in detecting new lesions or changes in the existing ones and 
allows an objective assessment of  disease stability or progression.  MRI angiography may 
reveal early signs of vascular inflammation in patients with TAK and is currently being 
evaluated as a potential tool to assess disease activity and response to treatment in 
prospective clinical studies (Andrews & Mason 2007). However, qualitative changes 
suggestive of active disease versus fibrotic scarring do not always accurately predict 
response to therapy. (Tso et al., 2002) . 
Vascular remodelling and scarring may lead to fixed vascular lesions that will not be 
reversed by pharmacologic therapy. Revascularization or surgical repair should be 
considered if stenotic or occlusive lesions lead to significant haemodynamic effects with 
ischemic symptoms, or if aneurysmal enlargement results in increased risk of rupture, 
dissection or in case of aortic valve regurgitation (Mukhtyar et al., 2009). 
For correction of stenoses and occlusions of the aorta and its branches the largest body of 
experience comes from bypass graft procedures where good long-term outcomes have been 
achieved. On average, a 20 to 30% rate of restenosis or occlusion is reported on long-term 
follow-up. Revascularization can also be achieved by percutaneous transluminal 
angioplasty (PTA). PTA is less invasive than vascular surgery and is currently the 
revascularization procedure of choice. Angioplasty is usually successful but the rate of 
restenosis during follow-up is higher than with vascular surgery. Endovascular angioplasty 
has shown better outcomes for lesions that are short and not already occluded. To prevent 
restenosis, stents are currently used although conventional stents have been associated with 
high rates of failure in long-term follow-up studies. The long-term impact of angioplasty in 
patients with TAK is still uncertain because there have been no reports describing the 
outcome of angioplasty with or without stenting after periods longer than 10 years. 
Encouraging results have been reported with the use of drug-eluting stents in atheromatous 
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prospective clinical studies (Andrews & Mason 2007). However, qualitative changes 
suggestive of active disease versus fibrotic scarring do not always accurately predict 
response to therapy. (Tso et al., 2002) . 
Vascular remodelling and scarring may lead to fixed vascular lesions that will not be 
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vascular disease. Their benefit in the treatment of patients with TAK needs to be determined 
(Liang et al., 2009). 
In patients with hypertension, anatomical correction of lesions such as renal artery or aortic 
stenosis should also be performed. When needed, the most common procedure to repair 
aortic stenosis has been an aortoaortic bypass with the use of a prosthetic graft. Angioplasty 
with or without stenting may also be of use to treat discrete stenosis of the aorta. Aortic 
aneurysm should be repaired according to the current guidelines for general population. 
Aortic valve incompetence with aortic ring expansion may necessitate root and aortic valve 
replacement or valvuloplasty. Complex vascular reconstructions (i.e. complete aortic arch 
replacement) may be need by patients with multiple stenosis. 
Patients with TAK have lower rates of sustained vessel patency for angioplasty and arterial 
bypass procedures than patients undergoing intervention for atherosclerosis or other 
vascular diseases. Failure has been associated with the presence of active disease at the time 
of surgery. Thus, in order to improve the life-span of the revascularized vessel and 
minimize the risk of surgical dehiscence, interventions should ideally be performed during 
inactive disease. However, when an earlier surgical intervention is mandatory it can also be 
successfully accomplished during the acute stage. In this scenario, treatment with steroids 
and/or immunosuppressive agents should be continued after surgery. Some authors 
recommend to carefully select the anastomotic site excluding inflamed vascular areas in 
order to avoid  occlusion of the reconstructed vessel, anastomotic disruption or aneurysm 
development at the site of anastomosis (Ogino et al., 2008). 
Recent advances in immunosuppressive and surgical therapies, including endovascular 
interventions, have improved the outcome of patients with TAK. However, longer follow-
up studies are still necessary to get statistically valid conclusions about the impact of these 
therapies on the natural history of TAK. In addition, patients with TAK may develop 
accelerated atherosclerosis as a consequence of systemic chronic inflammation and long-
term hypertension. Therefore, in order to improve the long-term outcome of these patients, 
a careful control of traditional vascular risk factors is crucial to prevent the potential 
vascular complications associated with atherosclerosis.  
4.3 Isolated aortitis  
Patients with incidentally discovered noninfectious aortitis should be evaluated for 
additional areas of arterial disease and for signs and symptoms of systemic inflammatory 
conditions potentially associated with aortitis. The evaluation should include a full patient 
interview, a complete physical examination with particular focus on the vascular system, 
and appropriate laboratory testing including acute phase reactants. Imaging of the entire 
aorta and its main branches with MRI or CTA to exclude abnormalities in other vascular 
beds should be considered. 
It is not clear at present whether patients with incidentally discovered aortitis in whom a 
systemic vasculitis or systemic disease has been reasonably ruled out should receive therapy 
with glucocorticoids and/or immunosuppressants following resection of the affected aortic 
segment. Data from retrospective studies indicate that the longterm outcome of patients 
with isolated aortitis is generally good.  However, in a retrospective study performed at the 
Cleveland Clinic in which 36 out of the 52 patients with idiopathic aortitis were followed for 
a mean of 3.25 years, 6 out of the 25 patients not receiving therapy after the initial surgery 
developed new aortic aneurysm during follow-up. Conversely, recurrent aneurysms were 
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not identified among 11 corticosteroid-treated patients, in spite that treatment schedule was 
not standardized and some patients received very short courses of corticosteroids (Rojo-
Leyva F., et al 2008). 
Therefore, the decision to treat with glucocorticoids or immunosuppressive agents should 
be individually considered, depending on the clinical presentation and the location and 
extent of inflammation. Patients with idiopathic aortitis require careful and periodic 
surveillance during follow-up because small case series have identified a propensity toward 
aneurysm formation in other vascular beds over time. Prospective follow-up studies of 
patients with isolated aortitis are required to further clarify this point.   
5. Conclusions 
Over the past decade, the improvement and wider use of imaging techniques has motivated 
an increasing appreciation of the relevance of aortic involvement in systemic vasculitis and 
its potential for severe complications.  Persistent aortitis observed in some patients by means 
of imaging or histopathologic examination questions the ability of current therapies to 
completely suppress the inflammatory process in spite of the clinical remission of the initial 
symptoms.  It remains to be determined whether patients with asymptomatic persistent 
signs of aortitis  would benefit  form more intensive therapy since  recent data suggest that 
persistent low-grade subclinical  inflammatory activity is not clearly associated with higher 
frequency of aortic complications.  On the other hand, mechanisms involved in aortic 
dilatation are not completely understood. It is unclear at present whether aortic dilatation 
results from persistent subclinical activity, abnormal vascular remodelling following the 
initial injury, hemodynamic influences or a combination of factors.  The indication and best 
method for elective repair of aortic dilatation or stenosis need to be delimitated. Awareness 
of aortic participation in systemic vasculitis raises a number of important questions and 
opens an exciting research agenda for coming years that will definitely benefit from 
multicenter collaboration 
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1. Introduction 
Both prescription drugs and illicit substances have been associated with the formation of 
aortic aneurysms, ruptures of aortic aneurysms, and acute aortic dissections. Most of the 
clinical information exists as single case reports and case series, but causal relationships 
have for many drug groups been substantiated on the basis of the known mechanisms of 
action of the drugs as well as from experimental studies in animals. 
For abdominal aneurysms, the most important etiologic factors include systemic 
hypertension, hyperlipidemia and atherosclerosis. In theory, all drugs having a negative 
impact of one or more of these factors might increase the risk of aortic aneurysms. On the 
other hand, drugs positively influencing these factors, such as antihypertensives and 
cholesterol-lowering drugs, could, at least in theory, have a potentially protective effect on 
the formation and development of the aneurysms. For aortic dissections, systemic 
hypertension is a central risk factor, and many drugs known to increase systemic blood 
pressure abruptly are associated with aortic dissections. In addition, abrupt discontinuation 
of antihypertensive drugs known to cause rebound hypertension, such as the beta blockers, 
may precipitate aortic dissections.  
The objective of this chapter is to present a comprehensive review of pharmaceutical 
products and illicit substances associated with the formation and ruptures of aortic 
aneurysms. Moreover, drugs implicated in acute aortic dissections are also included. Data 
from case reports and case series are tabulated for completeness. When relevant, these data 
are also synthesised in order to provide aggregate information, attempting to identify 
potential drug-specific risk factors. Results from experimental studies are included to 
provide an understanding of the underlying mechanisms, and treatment options are 
discussed when they deviate from conventional therapy. 
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This chapter is a literature review based upon the author’s research experience with adverse 
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induced”. Such a search strategy revealed 185 articles, which were scrutinised. The reference 
lists in the articles were further checked to identify other studies and reports of interest.  
3. Drugs associated with aortic aneurysms 
3.1 Glucocorticoids 
Ruptures of aortic aneurysms are not unknown in autoimmune disorders affecting connective 
tissue in various organ systems including blood vessels, such as systemic lupus erythematosus 
(SLE) and rheumatoid arthritis (Smith & Hirst, 1979; Sato et al., 2003; Ohara et al., 2000a, 
2000b). In such cases glucocorticoids may have a protective effect by inhibiting the activity of 
the underlying disorder. However, it has also been suspected that glucocorticoid use could 
have a precipitating role by increasing blood pressure, blood cholesterol and blood glucose 
levels, thereby causing atherosclerosis, as well as by increasing the fragility of blood vessels 
due to its negative effects on collagen formation and connective tissue strength (Smith & Hirst, 
1979; Sato et al., 2003; Ohara et al., 2000a, 2000b).  
In the literature, a total of 14 cases have been reported after long-term glucocorticoid use in 
patients with autoimmune disorders affecting connective tissue (Table 1). In these cases, it is 
by no means obvious whether the rupture is caused by the underlying disease, the 
treatment with glucocorticoids, or a combination thereof. There are no reports of ruptured 
aortic aneurysms during long-term treatment with glucocorticoids for disorders and 
conditions not affecting connective tissue, such as glomerulonephritis, or after organ 
transplantations. However, there are in addition two cases of ruptures after short-term 
treatment with glucocorticiods for disorders not causing weakness of connective tissue 
(Mellingsæter et al., 2009), but on the other hand, these patients also had additional risk 
factors, such as advanced age (Table 1).  
The gender distribution of the 16 cases identified in the literature (Table 1), with 50 % males 
and 50 % females, seems to reflect the gender distribution of the underlying disorders. As 
expected, the mean age is also relatively low, 56 years. 
Experimental evidence of an association between the use of glucocorticoids and aortic 
aneurysm rupture is found in an animal study (Reilly et al., 1990). In that study, genetically 
susceptible mice had a higher risk of developing aortic aneurysms, as well as having a 
rupture of the aneurysms, when treated with hydrocortisone. When the genetically 
susceptible mice were given hydrocortisone for 14 days, the mean aortic diameter increased 
to 1.86 mm, as compared to a stable value of 0.93 mm in a control group of genetically 
normal mice. In another experiment presented in the same publication (Reilly et al., 1990), 
nine of the 10 genetically susceptible mice died during the 21-day trial with hydrocortisone 
(6 with proven aortic rupture, 3 with presumed rupture), and also the 10th mouse in this 
group had an aneurysm after 21 days. The death risk was dose-dependent, with an average 
survival of 14 days among mice receiving the two higher hydrocortisone doses, as compared 
to 18-21 days among mice receiving the two lower doses. 
In conclusion, long-term treatment with glucocorticoids has been associated with aortic 
aneurysm ruptures in numerous case reports, but it is not clear whether the ruptures have 
been caused by the underlying disease, the drug treatment, or combinations thereof. 
However, based on the known pharmacological effects of glucocorticoids as well as an 
experimental study, a causal association is not unlikely, although published evidence 
implies that this adverse drug reaction is very infrequent.  
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55, 
male
Prednisolone 10 mg/d 
for 11 years
Descending 
thoracal Rheumatoid arthritis 
Smith  
et al., 1979 
68, 
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Prednisolone 15 mg/d 
for “many years”
Descending 
thoracal Rheumatoid arthritis 
Stehbens  




for 16 years Infrarenal SLE 
Seyama  
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Hussain  









et al., 2009 
77, 
male 
Prednisolone 40 mg/d 










et al., 2009 
82, 
male 
Prednisolone 60 mg/d 
for 9 days and  
30 mg/d for 5 days
Abdominal Bullous pemphigoid/ advanced age 
Abbreviations: NS = not specified; SLE = systemic lupus erythematosus 
1 The same case is also included in the case series by Ohara et al., 2000a 
2 The same case is also included in the case series by Ohara et al., 2000b 
3 Previously treated with a stent graft in the abdominal part of a thoraco-abdominal aortic aneurysm 
Table 1. Published cases of glucocorticoid-associated aortic aneurysm ruptures 
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3.2 Antihypertensive drugs  
Based upon evidence from animal studies, activation of the renin-angoitensin-aldosteron 
system seems to be a central factor in the development of aortic aneurysms (Daugherty et 
al., 2006; Lu et al., 2008; Miyake & Morishita, 2009). In a population-based case-control study 
of more than 15,000 patients with abdominal aortic aneurysms (3,379 with ruptures and 
11,974 without ruptures), treatment with angiotensin converting enzyme (ACE) inhibitors 
before admission was associated with a reduced risk of ruptures (adjusted Odds Ratio [OR] 
0.83; 95 % confidence interval [CI] 0.73-0.95). In contrast, protective effects were not found 
for beta-blockers, calcium antagonists, alpha-blockers or thiazide diuretics. Thus, the 
beneficial effect of ACE inhibitors on the risk of ruptures seems to be independent of the 
antihypertensive effect (Hackam et al., 2006). Those who during the last months had 
discontinued treatment with ACE inhibitors, had on the other hand a marginally higher risk 
of ruptures (adjusted OR 1.39; 95 % CI 1.09-1.77). In contrast to the above findings, 
angiotensin receptor blockers (ARBs), which also inhibit the renin-angoitensin-aldosteron 
system, were not found to have any protective effect (adjusted OR 1.24; 95 % CI 0.71-2.18). 
However, this apparent discrepancy may be caused by a type II error, as only 132 patients in 
the entire material used ARBs (Hackam et al., 2006).  
Inconsistent with the ACE inhibitor findings cited above, a recent prospective cohort study 
of 1,701 patients with small abdominal aortic aneurysms found that the growth rate of the 
aneurysms in fact was higher (3.33 mm/year) in the 169 patients treated with ACE 
inhibitors than in the remaining patients (2.77 mm/year; p=0.009) (Sweeting et al., 2010). No 
such associations were found for other groups of antihypertensive drugs. 
It should also be noted that in a case-control study, use of calcium antagonists was 
significantly associated with the occurrence of aortic aneurysms (adjusted OR 2.6; 95 % CI 
1.5-4.2), whereas no other antihypertensive drug groups showed an increased risk 
(Wilmink et al., 2002). In the same study, patients exposed to calcium antagonists also had 
an increased aortic wall stiffness. Nevertheless, there was no association between calcium 
antagonists (or with any of the other drug groups) and the growth rate of the aneurysms 
after they had been detected. The association between calcium antagonist use and the 
occurrence of aortic aneurysms is consistent with the finding in an animal study in which 
the calcium antagonist amlodipine accelerated the degradation of elastin (Boyle et al., 
1998). 
All observational studies, including those cited above, are inevitably subject to bias and 
confounding. Thus, there is an urgent need for prospective, randomised, controlled trials to 
elucidate the role of both ACE inhibitors, ARBs, calcium antagonists and other groups of 
antihypertensives as to whether they have a protective, neutral or provoking effect on the 
formation and growth of aortic aneurysms and the risk of ruptures. 
4. Drugs assosiated with aortic dissections 
4.1 Phosphodiesterase-5 inhibitors 
The phospodiesterase-5 (PDE-5) inhibitors sildenafil, tadalafil and vardenafil are widely 
used to cause penile erection in patients with impotence. An association between sildenafil 
and acute aortic dissection has been suspected in three case reports (Table 2). Hitherto, no 
cases have been reported for tadalafil and vardenafil.  
As all the three patients reported in the literature had predisposing factors for aortic 
dissection (Table 2), the causal role of sildenafil has been questioned. One patient used 
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isosorbide mononitrate concomitantly. Combinations of PDE-5 inhibitors with nitrates and 
other nitric oxide donors, including nitroglycerin and isosorbide mono- or dinitrate, are 
contraindicated due to the risk of excessive increases in systemic blood pressure. Also sexual 
arousal is associated with increased blood pressure, which could have been a contributing 
factor. However, at least in one of the patients, the aortic dissection appeared before sexual 
intercourse took place. 
 
Reference Age, gender Drug, dose 
Temporal 




et al., 2001 42, male
Sildenafil 
50 mg 
1 hour after 
intake 
Cocaine sniffing 2 hours 
earlier, heavy smoker B 
Nachtnebel 
et al., 2006 61, male
Sildenafil 
50 mg 
30 min after 
intake 
Hypertension, 




et al., 2009 28, male
Sildenafil 
50 mg 
2 hours after 
intake 




1 Stanford type A: All dissections involving the ascending aorta, regardless of the site of origin.  
Stanford type B: All dissections not involving the ascending aorta 
Table 2. Published cases of phosphodiesterase-5-associated aortic dissections 
In addition to the risk of increasing systemic blood pressure, at least when combined with 
nitrates and other nitric oxide donors, sildenafil has vasorelaxant and antiproliferative 
effects on pulmonary vascular smooth muscle cells. Due to these effects it is also used in 
patients with pulmonary hypertension. Although not substantiated experimentally, it has 
been speculated that a similar antiproliferative effect in the aorta as in the pulmonary artery 
might cause a thinner media due to smooth muscle cell loss, rendering the aortic wall more 
vulnerable to dissections (Nactnebel et al., 2006). 
In conclusion, sildenafil and possibly also other PDE-5 inhibitors have the potential to 
increase systemic blood pressure in certain situations, thus being able to provoke aortic 
dissections in vulnerable individuals.  
4.2 Vascular endothelial growth factor inhibitors 
Vascular endothelial growth factor (VEGF) inhibitors are a drug group inhibiting vascular 
proliferation and promoting apoptosis of cells participating in the formation of new blood 
vessels. As VEGF expression is increased in a variety of tumors, VEGF inhibitors are 
primarily used in the treatment of malignant diseases. An association between acute aortic 
dissection and treatment with the VEGF inhibitors sorafenib, sunitinib and bevacizumab has 
been suspected on the basis of three case reports, summarised in Table 3. 
Hypertension is one of the major adverse drug reactions of VEGF inhibitors. For sorafenib 
and sunitinib, overall incidences of 23.4 and 22.5 % have been reported in meta-analyses 
(Wu et al., 2008). For bevacizumab, the incidence of hypertension in studies included in a 
meta-analysis ranged from 2.7 % to 32 % during low-dose treatment and between 17.6 % 
and 36 % during high-dose treatment (Zhu et al., 2007). In most cases, the increased blood 
pressure can be treated with antihypertensive drugs, but a minority of patients will not 
respond to antihypertensive therapy and the VEGF inhibitor has to be discontinued.  
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Hypertension is one of the major adverse drug reactions of VEGF inhibitors. For sorafenib 
and sunitinib, overall incidences of 23.4 and 22.5 % have been reported in meta-analyses 
(Wu et al., 2008). For bevacizumab, the incidence of hypertension in studies included in a 
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Reference Age, gender Drug 
Temporal 













for 21 days 
Hypertension for 25  
years, increased 
considerably after 10 











None; no increase in 
systemic blood pressure 











Advanced age B 
1 Stanford type A: All dissections involving the ascending aorta, regardless of the site of origin.  
Stanford type B: All dissections not involving the ascending aorta 
Table 3. Published cases of vascular endothelial growth factor inhibitor-associated aortic 
dissections 
The pathogenetic mechanism behind VEGF inhibitor-induced hypertension remains 
uncertain. It has been suggested that as VEGF inhibitors also block the effects of other 
growth factors including platelet-derived growth factor (PDGF), and as PDGF plays a role in 
blood vessel tonus regulation and microvascularisation, this could be a possible mechanism 
(Edeline et al., 2010). However, closely related protein kinase inhibitors such as imatinib, 
dasatinib and nilotinib, which inhibits PDGF without inhibiting VEGF, are not particularly 
linked to hypertension. On this basis, a direct effect via VEGF inhibition seems more likely. 
The involvement of VEGF in the formation of normal blood vessels during embryonic 
development and in the carcinogenesis is well studied, but its possible function in normal 
blood vessels in adults is unclear. Suggested mechanisms include impaired angiogenesis at 
the microcirculation level, endothelial dysfunction associated with decreased levels of the 
vasodilator nitric oxide which is normally stimulated by VEGF, and alterations in the renin-
angiotensin-aldosteron system (Sica, 2006).  
Based upon the high incidence of hypertension during treatment with VEGF inhibitors, 
patients treated with these drugs should be closely followed with blood pressure 
measurements. If hypertension develops, it should be treated adequately. Obviously, as 
hypertension is a well-known risk factor for aortic dissection, also VEGF inhibitor-induced 
hypertension will increase the risk of aortic dissection. 
4.3 Antihypertensive drugs 
Antihypertensive drugs are known to protect a vulnerable aorta from dissections, and 
discontinuation of such drugs could therefore be expected to increase the risk of acute 
dissections. In particular antihypertensive drugs for which rebound hypertension occur 
after abrupt discontinuation, such as beta-blockers and clonidine, would be expected to 
increase the risk of aortic dissections.  
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One single case of acute aortic dissection has been reported within a short time interval 
after abrupt discontinuation of antihypertensive drug treatment (Eber et al., 1993). A 60-
year-old man treated with beta-blockers for hypertension for 20 years developed a 
Stanford type A dissection two days after stopping metoprolol. It is not explicitly stated in 
the report whether the drug was tapered down before discontinuation or stopped 
abruptly, but is seems likely that treatment ceased directly from a dose of 50-100 mg/day. 
In such cases rebound effects including increased blood pressure, tachycardia and cardiac 
arrhythmias, and in some cases even cardiac infarction and sudden cardiac death, may 
occur (Houston & Hodge, 1988; Psaty et al., 1990). Therefore, current recommendations 
state that beta-blockers (and clonidine) should be tapered over at least 1-2 weeks before 
discontinuation. 
4.4 Other drugs 
Anticoagulants and fibrinolytic drugs have in two case reports been associated with aortic 
dissections and ruptures of thoracic aortic aneurysms. The first case was an 80-year-old 
woman who developed a Stanford type B aortic dissection during treatment with warfarin 
(Blunt & Impallomeni, 2004). Notably, her International Normalised Ratio (INR) was 4.8, 
indicating a considerably increased bleeding risk. The authors speculate that the underlying 
mechanism was a bleeding into an atheromatous plaque in the thoracic aorta. The second 
case was a 67-year-old man who was treated with the tissue plasminogen activator (t-PA) 
nateplase due to an acute ischemic stroke and who developed a rupture of a thoracic aortic 
aneurysm (Hayashi et al., 2004). The authors suggest that the t-PA infusion caused the 
rupture, based upon some evidence that plasminogen activators are able to degrade 
abdominal aortic aneurysms (Reilly, 1996).  
A single case report of aortic dissection exists in a patient receiving chemotherapy for cancer 
(Golden et al., 1997). The patient was a 42-year-old man treated with cyclophosphamide, 
vincristine, procarbazine, prednisolone, bleomycin and vinblastine for Hodgkin’s disease. 
As many of these agents are known to cause endothelial cell damage, the authors postulate 
that a toxic effect to endothelial cells in the aortic wall was the underlying mechanism. 
However, the patient also had other risk factors, including hypercholesterolemia and 
tobacco smoking. Thus, a causal relationship between the cytotoxic drugs and the aortic 
dissection remains obscure, and, if the suggested underlying mechanism is correct, it is 
remarkable that no more reports are found in the literature.  
Numerous other drugs than those presented earlier in this review have the ability of causing 
hypertension. Consequently, these drugs might, at least in theory, increase the risk of aortic 
dissections. Common for these drugs is that there are no published case reports of aortic 
dissections related to their use. Whether the reason for the lack of such reports is that the 
relationship has not been recognised, or it is that the excess risk is so low that it can be 
considered negligible, is unknown. Drugs known to increase systemic blood pressure 
include sympathomimetic substances like adrenaline, noradrenaline, dopamine, 
metaraminol and phenylephrine, which might cause excessive elevations in blood pressure 
when the dose or, when given as an infusion, the rate of infusion, is not carefully controlled. 
Other drugs known to cause hypertension as an adverse drug reaction include non-steroidal 
antiinflammatory drugs (NSAIDs), ciclosporin and venlafaxine, just to mention a few. 
Moreover, monoamine oxidase inhibitors induce excessive hypertension when indirectly 
acting sympathomimetic drugs or tyramine-rich food or beverages are ingested 
concomitantly (Davies & Davies, 1998).   
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One single case of acute aortic dissection has been reported within a short time interval 
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tobacco smoking. Thus, a causal relationship between the cytotoxic drugs and the aortic 
dissection remains obscure, and, if the suggested underlying mechanism is correct, it is 
remarkable that no more reports are found in the literature.  
Numerous other drugs than those presented earlier in this review have the ability of causing 
hypertension. Consequently, these drugs might, at least in theory, increase the risk of aortic 
dissections. Common for these drugs is that there are no published case reports of aortic 
dissections related to their use. Whether the reason for the lack of such reports is that the 
relationship has not been recognised, or it is that the excess risk is so low that it can be 
considered negligible, is unknown. Drugs known to increase systemic blood pressure 
include sympathomimetic substances like adrenaline, noradrenaline, dopamine, 
metaraminol and phenylephrine, which might cause excessive elevations in blood pressure 
when the dose or, when given as an infusion, the rate of infusion, is not carefully controlled. 
Other drugs known to cause hypertension as an adverse drug reaction include non-steroidal 
antiinflammatory drugs (NSAIDs), ciclosporin and venlafaxine, just to mention a few. 
Moreover, monoamine oxidase inhibitors induce excessive hypertension when indirectly 
acting sympathomimetic drugs or tyramine-rich food or beverages are ingested 
concomitantly (Davies & Davies, 1998).   
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4.5 Illicit drugs 
4.5.1 Cocaine  
The association between cocaine abuse and aortic dissection is well documented. In some 
case series of patients with aortic dissection the proportion caused by cocaine abuse is 
relatively high. For example, in a material from a US urban hospital, 14 of the 38 cases of 
aortic dissection registered between 1981 and 2000 (37 %) were related to cocaine use (Hsue 
et al., 2002). In another US study, (Singh et al., 2007), 13 of 46 cases (28 %) diagnosed 
between 1996 and 2005 were associated with cocaine. Finally, in a chart review for the 
period 1990-2006, 16 of 163 patients (9.8 %) had used cocaine the last 24 hours before 
symptom onset (Daniel et al., 2007). In contrast, only 0.5 % of the cases in the International 
Registry for Aortic Dissection were found to be related to cocaine (Eagle et al., 2002). The 
proportion found to be caused by cocaine abuse will clearly depend on the frequency of 
cocaine use in the population from which the subjects originate. Moreover, cases associated 
with cocaine use will not be revealed if the patients are not explicitly asked about cocaine 
use or preferably tested for the presence of the cocaine metabolite benzoylecgonine in urine.  
In addition to these four more systematic studies (Hsue et al., 2002; Eagle et al., 2002; Daniel 
et al., 2007; Singh et al., 2007), numerous single cases, summarised in Table 4, are reported in 
the literature.  
Based on the 16 cases detailed by Daniel et al. (2007) and the 19 cases presented in Table 4, 
subjects with cocaine-related aortic dissections seem to be younger than average. All were 
younger than 60 years of age, three of four were younger than 50, and the mean age was 44 
years. In total, 77 % were males. Almost all were long-term users, many had a history of 
uncontrolled hypertension, and the dissections occurred shortly after intake of cocaine. In 
some cases, symptoms appeared during or within the first few minutes after ingestion, but 
there could also be a lag-time of up to 24 hours – with one possible exception; an apparent lag-
time of 3 days is reported in one case (Divakaran et al., 2007). In both the studies by Hsue et al. 
(2002) and by Daniel et al. (2007), the mean lag-time was 12 hours. However, based upon the 
19 single cases (Table 4), the median lag-time could be estimated to about 1.5-2 hours, only. 
It has been suggested that Stanford type B dissections are more common among cocaine 
users than in the average population (Singh 2007). However, according to Daniel et al. 
(2007), it was not apparent that type B dissections were more common. Of the 16 cases 
presented by Daniel et al. (2007) plus the 19 case reports (Table 4), 54 % were of type A 
whereas 46 % were of type B. As a comparison, 62 % were of type A and 38 % of type B in a 
general material consisting of 464 patients with acute aortic dissection (Ince et al., 2007).   
It has been claimed that both the recurrence risk and the mortality of aortic dissections could 
be higher among cocaine users than among subjects with dissections unrelated to cocaine use 
(Hsue et al., 2002). The most likely reason for a possibly increased recurrence risk is continued 
cocaine use after discharge; there is no data available indicating that the recurrence risk would 
be increased in patients able to seize cocaine abuse after the first episode of dissection. 
The effects of cocaine on the cardiovascular system are caused by its sympathomimetic 
properties. Cocaine predominantly exerts its pharmacological effects by blocking the 
reuptake of noradrenaline and dopamine from the synaptic cleft into presynaptic neurons. 
Increased levels of noradrenaline in the synaptic cleft activate postsynaptic alpha-adrenergic 
and beta-adrenergic receptors. An enhanced release of noradrenaline into the synaptic cleft 
by cocaine may also take place, causing further receptor activation. Activation of alpha-1 
receptors in blood vessels causes elevation of the systemic blood pressure through 
vasoconstriction. Activation of beta-1 receptors in the heart promotes ventricular 
contractility and increases heart rate, thereby contributing to the effects on blood pressure. 
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1 Stanford type A: All dissections involving the ascending aorta, regardless of the site of origin.  
Stanford type B: All dissections not involving the ascending aorta 
Table 4. Published cases of cocaine-associated aortic dissections 
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et al., 2007; Singh et al., 2007), numerous single cases, summarised in Table 4, are reported in 
the literature.  
Based on the 16 cases detailed by Daniel et al. (2007) and the 19 cases presented in Table 4, 
subjects with cocaine-related aortic dissections seem to be younger than average. All were 
younger than 60 years of age, three of four were younger than 50, and the mean age was 44 
years. In total, 77 % were males. Almost all were long-term users, many had a history of 
uncontrolled hypertension, and the dissections occurred shortly after intake of cocaine. In 
some cases, symptoms appeared during or within the first few minutes after ingestion, but 
there could also be a lag-time of up to 24 hours – with one possible exception; an apparent lag-
time of 3 days is reported in one case (Divakaran et al., 2007). In both the studies by Hsue et al. 
(2002) and by Daniel et al. (2007), the mean lag-time was 12 hours. However, based upon the 
19 single cases (Table 4), the median lag-time could be estimated to about 1.5-2 hours, only. 
It has been suggested that Stanford type B dissections are more common among cocaine 
users than in the average population (Singh 2007). However, according to Daniel et al. 
(2007), it was not apparent that type B dissections were more common. Of the 16 cases 
presented by Daniel et al. (2007) plus the 19 case reports (Table 4), 54 % were of type A 
whereas 46 % were of type B. As a comparison, 62 % were of type A and 38 % of type B in a 
general material consisting of 464 patients with acute aortic dissection (Ince et al., 2007).   
It has been claimed that both the recurrence risk and the mortality of aortic dissections could 
be higher among cocaine users than among subjects with dissections unrelated to cocaine use 
(Hsue et al., 2002). The most likely reason for a possibly increased recurrence risk is continued 
cocaine use after discharge; there is no data available indicating that the recurrence risk would 
be increased in patients able to seize cocaine abuse after the first episode of dissection. 
The effects of cocaine on the cardiovascular system are caused by its sympathomimetic 
properties. Cocaine predominantly exerts its pharmacological effects by blocking the 
reuptake of noradrenaline and dopamine from the synaptic cleft into presynaptic neurons. 
Increased levels of noradrenaline in the synaptic cleft activate postsynaptic alpha-adrenergic 
and beta-adrenergic receptors. An enhanced release of noradrenaline into the synaptic cleft 
by cocaine may also take place, causing further receptor activation. Activation of alpha-1 
receptors in blood vessels causes elevation of the systemic blood pressure through 
vasoconstriction. Activation of beta-1 receptors in the heart promotes ventricular 
contractility and increases heart rate, thereby contributing to the effects on blood pressure. 
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Table 4. Published cases of cocaine-associated aortic dissections 
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The sudden and considerable increase in blood pressure shortly after intake of cocaine 
obviously will increase shear stress in the aorta, sometimes causing a disruption of the 
intima and a dissection. More infrequently, the stress may produce an intramural hematoma 
that subsequently may rupture into the lumen (Scherzoy et al., 1994; Singh et al., 2010). In 
addition, long-term cocaine use may impair the elastic properties of the aorta, thereby 
reducing the ability of the aortic wall to withstand fluctuations in blood pressure and shear 
stress (Bigi et al., 2008).  
As for aortic dissection of other causes, the immediate treatment of cocaine-induced 
dissections is to lower the blood pressure. In general, beta-blockers are most often used for 
this purpose. However, for cocaine-related dissections, beta-blockers should be avoided 
because they do not antagonise the alpha-adrenergic effects and may thus exacerbate, or at 
least not counteract, cocaine-related vasoconstriction of the coronary and visceral arteries 
(Lange et al., 1990; Hollander, 2008; Singh et al., 2010). The combined alpha- and beta-
blocker labetalol would therefore, at least in theory, be a better choice. However, labetalol 
does not reverse the vasoconstriction of the coronary arteries fully, most likely because its 
alpha-antagonistic properties are too weak (Boehrer et al., 1993; Hollander, 2008). 
Nevertheless, some authors still recommend the use of labetalol. Alternative treatments 
include nitroglycerin, which reverse the cocaine-induced vasoconstriction of the coronary 
arteries to a sufficiently high degree, and verapamil (Lange & Hills, 2001). Also 
nitroprusside and hydralazine have been suggested, although these drugs, which do not 
exert beta-blocking properties, in fact may increase the shear stress of the aorta further due 
to reflex tachycardia with a subsequent increase in cardiac output (Hollander, 2008; Singh et 
al., 2010). 
4.5.2 Methamphetamine, amphetamine and 3,4-methylenedioxymethamphetamine 
(MDMA; ecstasy) 
There are numerous case reports of acute aortic dissection related to methamphetamine,  
and a few case reports exist for the closely related agents amphetamine and 3,4-
methylenedioxymethamphetamine (MDMA; ecstasy) (Table 5). For simplicity, these three 
substances are described as “amphetamines” in this chapter. Among the 13 cases published 
in detail in the literature (Table 5), all were males. Their mean age was 38 years, and none 
were older than 52, thus resembling the situation for cocaine users and reflecting the 
characteristics of the population using these illicit drugs. In nine of the 11 cases where the 
type of dissection was reported (81 %), the dissections were Stanford type A. 
In a systematic review of 35 deceased patients with aortic dissection screened for drug use 
in California during the years 1987-1996, seven (20 %) tested positive for methamphetamine 
(Swalwell & Davis, 1999). Whereas the mean age in the total group was 52 years, the mean 
age among those who tested positive for methamphetamine was 41 years. In six of the seven 
cases (86 %), the dissection was of type A. Thus, the characteristics of this group are similar 
to those of the 13 cases published in detail (Table 5). 
In a population-based study of 3,116 aortic dissections in subjects aged 18 to 49 years 
(Westover & Nakonezny, 2010), abuse and dependence of amphetamines were significantly 
associated with aortic dissections (OR 3.33, 95 % CI 2.37-4.69). Interestingly, the OR for 
abuse and dependence of amphetamines was lower than for Marfan syndrome (OR = 374), 
cardiovascular syphilis (OR = 106), bicuspid aorta valve (OR = 45), Takayashu disease  
(OR = 31), Turner syndrome (OR = 22), Ehlers-Danlos syndrome (OR = 13), giant cell 
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arthritis (OR = 6.5), hypertension (OR = 7.7), coarctation of the aorta (OR = 4.6) and motor 
vehicle accidents (OR = 3.6), but higher than for cocaine abuse/dependence (OR = 1.6), 
tobacco use (OR = 1.4), and age (OR = 1.1). The higher risk for the amphetamines than for 
cocaine is somewhat surprising on the basis of the number of published cases in the 
literature. One possible explanation for the increased risk might be that the amphetamines 
most likely have a prolonged effect on the blood pressure increments as compared to 
cocaine, due to a slower elimination from the body.   
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3 Intake identified by drugs-of-abuse screening in urine 
Table 5. Published cases of aortic dissections associated with methamphetamine, ampheta-
mine and 3,4-methylenedioxymethamphetamine (ecstasy) 
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The sudden and considerable increase in blood pressure shortly after intake of cocaine 
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intima and a dissection. More infrequently, the stress may produce an intramural hematoma 
that subsequently may rupture into the lumen (Scherzoy et al., 1994; Singh et al., 2010). In 
addition, long-term cocaine use may impair the elastic properties of the aorta, thereby 
reducing the ability of the aortic wall to withstand fluctuations in blood pressure and shear 
stress (Bigi et al., 2008).  
As for aortic dissection of other causes, the immediate treatment of cocaine-induced 
dissections is to lower the blood pressure. In general, beta-blockers are most often used for 
this purpose. However, for cocaine-related dissections, beta-blockers should be avoided 
because they do not antagonise the alpha-adrenergic effects and may thus exacerbate, or at 
least not counteract, cocaine-related vasoconstriction of the coronary and visceral arteries 
(Lange et al., 1990; Hollander, 2008; Singh et al., 2010). The combined alpha- and beta-
blocker labetalol would therefore, at least in theory, be a better choice. However, labetalol 
does not reverse the vasoconstriction of the coronary arteries fully, most likely because its 
alpha-antagonistic properties are too weak (Boehrer et al., 1993; Hollander, 2008). 
Nevertheless, some authors still recommend the use of labetalol. Alternative treatments 
include nitroglycerin, which reverse the cocaine-induced vasoconstriction of the coronary 
arteries to a sufficiently high degree, and verapamil (Lange & Hills, 2001). Also 
nitroprusside and hydralazine have been suggested, although these drugs, which do not 
exert beta-blocking properties, in fact may increase the shear stress of the aorta further due 
to reflex tachycardia with a subsequent increase in cardiac output (Hollander, 2008; Singh et 
al., 2010). 
4.5.2 Methamphetamine, amphetamine and 3,4-methylenedioxymethamphetamine 
(MDMA; ecstasy) 
There are numerous case reports of acute aortic dissection related to methamphetamine,  
and a few case reports exist for the closely related agents amphetamine and 3,4-
methylenedioxymethamphetamine (MDMA; ecstasy) (Table 5). For simplicity, these three 
substances are described as “amphetamines” in this chapter. Among the 13 cases published 
in detail in the literature (Table 5), all were males. Their mean age was 38 years, and none 
were older than 52, thus resembling the situation for cocaine users and reflecting the 
characteristics of the population using these illicit drugs. In nine of the 11 cases where the 
type of dissection was reported (81 %), the dissections were Stanford type A. 
In a systematic review of 35 deceased patients with aortic dissection screened for drug use 
in California during the years 1987-1996, seven (20 %) tested positive for methamphetamine 
(Swalwell & Davis, 1999). Whereas the mean age in the total group was 52 years, the mean 
age among those who tested positive for methamphetamine was 41 years. In six of the seven 
cases (86 %), the dissection was of type A. Thus, the characteristics of this group are similar 
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associated with aortic dissections (OR 3.33, 95 % CI 2.37-4.69). Interestingly, the OR for 
abuse and dependence of amphetamines was lower than for Marfan syndrome (OR = 374), 
cardiovascular syphilis (OR = 106), bicuspid aorta valve (OR = 45), Takayashu disease  
(OR = 31), Turner syndrome (OR = 22), Ehlers-Danlos syndrome (OR = 13), giant cell 
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arthritis (OR = 6.5), hypertension (OR = 7.7), coarctation of the aorta (OR = 4.6) and motor 
vehicle accidents (OR = 3.6), but higher than for cocaine abuse/dependence (OR = 1.6), 
tobacco use (OR = 1.4), and age (OR = 1.1). The higher risk for the amphetamines than for 
cocaine is somewhat surprising on the basis of the number of published cases in the 
literature. One possible explanation for the increased risk might be that the amphetamines 
most likely have a prolonged effect on the blood pressure increments as compared to 
cocaine, due to a slower elimination from the body.   
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Like cocaine, the amphetamines exert their stimulating effects by increasing available 
noradrenaline and dopamine in the brain synapses. However, in contrast to cocaine, the 
effect is predominantly mediated by enhancing the release of neurotransmitters from 
presynaptic neurons rather than by inhibiting the reuptake. Nevertheless, the final 
common pathway for cocaine and the amphetamines is activation of adrenergic alpha and 
beta receptors, thereby causing elevation of systemic blood pressure through 
vasoconstriction and increased ventricular contractility and heart rate, respectively (see 
also section 4.5.1). 
It has not been stated in the literature whether specific antihypertensive drugs should be 
preferred for dissections caused by amphetamines. However, based on the mechanism of 
action, it seems reasonable to consider the same treatments for amphetamine- as for cocaine-
related dissections. Thus, beta-blockers should be avoided because they would be expected 
to exacerbate, or at least not counteract, the tendency to cause vasoconstriction of the 
coronary and visceral arteries (see also section 4.5.1). The beta-blocker esmolol has 
nevertheless been suggested as the drug of choice in a recent case report (Obioha et al., 
2009), but the authors of this report have, somewhat surprisingly, not discussed the 
potential risks with beta-blocker treatment in these patients.  
5. Conclusions 
The only drug group for which relatively clear-cut evidence of involvement in the formation 
and rupture of aortic aneurysms exists, is the glucocorticoids. In addition, there is 
inconsistent evidence from epidemiological studies regarding whether the various 
antihypertensive drug classes protect against or in fact may precipitate growth and ruptures 
of aortic aneurysms. Prospective controlled clinical trials in this area are urgently needed to 
elucidate this issue. 
Drug groups implicated in aortic dissection include those known to increase systemic blood 
pressure, such as phosphodiesterase-5 inhibitors like sildenafil, and vascular endothelial 
growth factor inhibitors like sorafenib, sunitinib and bevacizumab. Moreover, abrupt 
discontinuation of antihypertensive drugs known to cause rebound hypertension after 
cessation of therapy, such as beta-blockers, may also cause aortic dissection. In addition, 
single case reports exist for a few other drugs. Finally, illicit drugs such as cocaine, 
amphetamine, methamphetamine and ecstasy are associated with acute aortic dissections, 
with relative risk increases in the order of magnitude of about 2-3. Thus, the increased risk 
of aortic dissection for these substances is presumably considerably higher than for legal 
medicines. 
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1. Introduction 
The infrarenal aorta is a region of variable hemodynamics, with low mean and oscillating 
shear stress, variable secondary flow patterns with vortex formations and consequent high 
particle residence time (Tang et al, 2006, Dua & Dalman, 2010). Among the biomechanical 
parameters, wall stress holds a fundamental role, since its distribution and maximum values 
have been associated with the risk of Abdominal Aortic Aneurysms (AAA) rupture 
(Fillinger et al, 2003 and Venkatasubramaniam et al, 2004). Rupture can occur where the 
mechanical forces per unit area of the aortic wall (stress) exceed the local strength, so that 
reliable rupture risk estimation should take into account both the local distribution of stress 
and wall strength. Furthermore, high values of wall stress in transition areas of AAAs, ie 
inflection site between the neck and the AAA sac have been recently reported to 
differentiate those small AAAs with rapid expansion rate, possibly rendering them 
amenable to early intervention (Li et al, 2010a). 
Computer-enhanced geometric modeling and Finite Element Analysis (FEA) have been used 
to study the biomechanical behavior of the aorta and the aortic aneurysms (Steinman et al, 
2003), contributing in the development of measures to assess AAA rupture risk (Malkawi et 
al, 2010) and expansion (Li et al, 2010b). This chapter reviews from the clinical point of view 
the role of wall stress in AAA rupture risk models.   
2. Reconstructing the AAA models 
Many research groups have evaluated AAA rupture risk with estimation of PWS using the 
FEA technique, which utilizes small subsections (elements) of a 3-dimentional AAA model, 
created by segmentation (Figure 1) and meshing (Figure 2). The stress computations rely on 
the principles of conservation of mass and momentum for all finite elements of the model. 
Most researchers acquire information on the 3D AAA realistic geometric configuration using 
contrast-enhanced high-resolution spiral CT angiography. The acquisition of the two-
dimensional CT images for each case is followed in principle by the creation of outlines of 
the outer and the inner surface of the AAA. Consequently, a stack of contours is 
reconstructed including the common iliac arteries and the neck of the AAA as fixation 
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points are required in essential boundary conditions. The latter are needed for the solution 
the conservation laws. The result is a detailed map of the wall stress values throughout the 
aneurysm (Figure 3). 
 
 
Fig. 1. Reconstructed images of the aneurysm are created from contrast enhanced CT images 
using purpose-developed software. 
3. Role of wall stress in AAA rupture and expansion 
Rupture remains the most threatening outcome of an AAA and is related to maximum 
diameter (Brewster et al, 2003) (Table 1).  
 







Table 1. Annual rupture risk according to diameter (Brewster et al, 2003) 
In current clinical practice, aneurysm diameter is one of the primary criteria used to decide 
when to treat a patient with an abdominal aortic aneurysm (AAA). The current threshold for 
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treatment is 5.5 cm; however, many surgeons have come across gigantic AAAs (e.g., 11 or  
12 cm) that have not yet ruptured, as well as small aneurysms <5.5 cm that have. There is 
evidence that the simple association of aneurysm diameter with the probability of rupture is 
not sufficient, and presumably other parameters play a role in causing an aneurysm to 
rupture or protecting it from rupture. This problem has spawned a need for new methods to 
reliably predict the actual risk of AAA rupture in the clinical setting.  
 
 
Fig. 2. Creation of the mesh 
According to the biomechanical approach, rupture occurs when the stress on the aneurysm 
wall exceeds its failure strength. Laplace’s law can estimate the stress values in ideally thin-
walled shapes of simple geometry. However, these assumptions are rarely met in daily 
routine, since the patent-specific AAA models present variable asymmetry. Therefore, 
patient-specific knowledge of the magnitude and distribution of AAA wall stress and failure 
strength are useful measures in assessing the susceptibility to rupture. Stress is a measure of 
the internal forces induced on a material due to blood pressure and flow (Raghavan et al, 
2005). Peak wall stress reflects the mechanical load sustained by the AAA wall during 
maximal systolic pressurization and depends on the mechanical properties and the 
geometric configuration of the wall (Raghavan et al, 2005). Arterial wall stress distributions 
for uniform wall loading, as well as flow-induced non-uniform pressure wall loading, are 
presented using the von Mises stress, a scalar measure of the stress tensor, proportional to 
the strain energy density at each point. Von Mises stress is expressed as σVM:     
 
where σ1, σ2, σ3 are the principal stresses (Papaharilaou et al, 2007). PWS refers to the 
mechanical load sustained by the AAA wall during maximal systolic pressurization. Its 
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value depends on arterial systolic pressure and the mechanical properties and geometric 
configuration of the material under study. Scotti et al (Scotti et al, 2005) studied virtual 
aneurysm models of variable asymmetry and wall thickness distribution. They showed that 
the variability in wall thickness can increase the PWS by 4 times compared with AAA 
models of uniform thickness. Moreover, they showed that variable thickness and 
asymmetry affect not only the magnitude but also the distribution of the stress values.  
Therefore, it is important for modern patient-specific rupture risk assessment to reproduce 
the specific AAA geometry and wall thickness. Decreasing of wall thickness by 25% causes a 
20% increase in PWS and vice versa (Venkatasubramaniam et al, 2004). Therefore, the 
abovementioned observations depict the limitations of Laplace’s law in accurate stress 
estimation. 
Stress analysis has three main components, the study of the geometry under evaluation, the 
material model that characterizes the mechanical behavior of the aneurysmal tissue and the 
study of the boundary conditions under observation, eg blood pressure. Peak Wall Stress 
(PWS) estimation with the Finite element analysis (FEA) technique has been extensively 
used through the last decade, utilizing a well known mathematical model that describes the 
biomechanical properties of the AAA wall (Raghavan & Vorp, 2000). 
 
 
Fig. 3. The detailed map of the wall stress values throughout the aneurysm wall, after Finite 
Element Analysis. Wall stress values representation is based on a color-scaled climax. The 
red color depicts the Peak Wall Stress location, whereas blue color represents the sites of 
lowest wall stress.  
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The possible relation of PWS to the risk and the site of rupture in AAAs have been 
delineated in many studies. PWS has been estimated in ruptured and nonruptured, 
diameter-matched AAAs and was found to be significantly higher in the rupture group near 
the time of rupture (Fillinger et al, 2002, 2003, Heng et al, 2008; Venkatasubramaniam et al, 
2004; Truijers et al, 2007; Vande Geest et al, 2008, Raghavan et al, 2005a). Moreover, a large 
prospective study by Fillinger et al (Fillinger et al, 2003) showed that PWS could 
differentiate AAAs that required urgent repair better than the maximum diameter criterion. 
In this study, Low-stress aneurysms presented a lower rupture rate whether they were small 
or large, with high stress aneurysms having a higher rupture rate regardless of size. The 
PWS values could differentiate more sufficiently than maximum diameter those AAAs 
prone to rupture over time. The conclusion was that the ruptured AAAs had higher values 
than the non-ruptured ones and that the elevated values were not simply an acute or 
incidental event near the time of rupture, but rather a characteristic that could be early 
recognized, thus gaining a predictive value with respect to the risk of rupture. Though the 
computational evaluation of PWS with FEA can be a strenuous and time-consuming effort 
(Leung et al, 2006), the intra- and interobserver variation for PWS is acceptable (Heng et al, 
2008), making reliable in studies the utilization of PWS for rupture risk evaluation. 
The expansion of the small AAAs is a multifactorial process, where biomechanical and 
biological factors interact (Dua & Dalman, 2010). It is well documented that cells along the 
aortic wall can respond biochemically to mechanical stress (Nakahashi et al, 2002). In early 
stages of AAA enlargement the elastin degradation induced by the wall shear stress (ie. the 
tangential force exerted by the movement of blood along the axis of flow) elevates the wall 
stress but accelerates sac enlargement, despite the stress-mediated collagen turnover 
(Sheidaei et al, 2011).  
Slow growth rate in smaller AAAs has been proven to be associated with low stress values, 
whereas a rapid growth rate in this category seems to depend on the amount of intaluminal 
thrombus (ILT) rather than on the level of wall stress, which is decreased (Speelman et al, 
2010). The presence of ILT promotes elastolytic activity with consequent structural 
degradation of the adjacent AAA wall (Kazi at al, 2003 and Wiernicki et al, 2010). These 
findings have been also confirmed recently by Parr et al (Parr et al, 2011), who reported a 
strong correlation of AAA rapid growth rate with the initial AAA diameter (r = 0.44,  
P = .006) and thrombus volume (r = 0.50, P = 0.001). 
4. Evaluating the AAA geometry 
PWS has been clearly associated with the risk of rupture. Wall stress has been found to be 
12% more specific and 13% more sensitive in rupture prediction than maximum diameter 
alone and may differentiate ruptured and symptomatic small AAAs from the asymptomatic 
ones (Truijers et al, 2007; Vande Geest et al, 2008; Fillinger et al, 2003).  Its values depend on 
the mechanical properties and the geometric configuration of the aneurysm wall (Raghavan 
et al, 2005). PWS estimation requires highly experienced personnel in a process that can 
require considerable power to run (Leung et al, 2006). Therefore, a useful adjunct tightly 
related to PWS assessment could provide great help regarding the rupture risk or growth 
rate estimation. The association of certain geometric parameters with high values of PWS 
has been demonstrated in many studies. This paragraph summarizes the most important of 
these studies, underscoring the importance of geometric parameters as potential adjunctive 
parameters along with maximum diameter and elevated PWS in rupture risk assessment.   
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Nathan et al (Nathan et al, 2010) studied the differences between saccular and fusiform 
descending thoracic aortic aneurysms. Although the saccular aneurysms in his study were 
of smaller diameter than the fusiform ones, the mean PWS was equivalent between the two 
groups. Since the elevated rupture risk of saccular aneurysms has been well defined in the 
literature, the abovementioned findings could imply that factors such as aneurysm shape 
influence the PWS values more effectively than maximum diameter, thus predisposing 
smaller AAAs having a rupture risk comparable to that of larger AAAs. Complex geometry 
contributes to equivalently complex stress distribution, with regions of high curvature being 
associated with high stress values (Sacks et al, 1999). The actual, individualized AAA 
geometry is the main reason for the non-uniform distribution of stress in the wall. Local 
anatomy can influence the AAA growth rate 1.5-fold greater than the traditional risk factors 
(e.g. gender, age, hypertension, heart disease, hypercholesterolemia, renal failure, chronic 
obstructive pulmonary disease (COPD), smoking, diabetes mellitus and peripheral disease) 
(Helderman et al, 2010). Furthermore, Pappu et al suggested that an increase in mean 
tortuosity of the centerline correlated better with rupture of small AAA than an increase in 
mean transverse diameter (Pappu et al, 2008).  
Advanced patient-specific computational models can be used to assess the correlation 
between PWS and 3D geometric features. Giannoglou et al (Giannoglou et al, 2006) reported 
a strong relationship between PWS values and the centerline curvature in AAA models, 
whereas Doyle et al (Doyle et al, 2010) advocated a correlation between PWS and centerline 
asymmetry. Both studies were based on computational models without taking into account 
the presence of thrombus. Others have reported a correlation between PWS and centerline 
tortuosity in AAA models with ILT (Georgakarakos et al, 2010). While the major difference 
in the abovementioned studies is whether or not ILT was integrated into the model, they all 
agree that geometric features will play a significant role in prospective studies estimating 
the risk of AAA expansion or rupture. While the correlation of these 3D geometric features 
with maximum diameter (making them dependent variables) reduces the impact of these 
findings, they may be used as adjuncts to diameter. 
Geometric parameters can affect the hemodynamic behavior of AAAs, which in turn could 
have an important implication regarding the prognosis of rupture or the estimation of the 
aneurysm distension rate. Li and Kleinstreuer showed that an AAA neck angle substantially 
impacts flow fields, causing strong irregular vortices in the AAA sac, remarkably 
influencing wall stress distribution (Li & Kleinstreuer, 2006). Furthermore, Xenos et al 
(Xenos et al, 2010a) showed that the peak value of von Mises stress increases as the iliac 
angle increases. Specifically, the increase in the iliac bifurcation angle is associated with 
constantly high stress values of Von Mises stress values in this area; yet, when these blood 
stagnation points were exluded, an overall decrease of the mean stress values in the rest of 
the AAA wall (ie. sac wall) was revealed.     
As small AAAs enlarge, a variety of geometrical changes can take place, including the 
length and angulation of AAA neck, the asymmetry of the centerline, the tortuosity of iliac 
arteries and the angulation of the iliac bifurcation (Georgakarakos et al, 2011b). Certain 
geometric changes, especially in the iliac bifurcation, have been postulated to mirror an 
adaptation response during the aneurysmal progression disease, in an attempt to alter the 
wall stress distribution patterns and decline the stress values, in favor of rupture risk 
attenuation and AAA growth deceleration. The increase in iliac angulation seems to lower 
the stress values in the AAA wall with instantaneous increase in iliac bifurcation stress 
values (blood stagnation site), trying to re-distribute the mechanical load at sites less prone 
to rupture (Figure 4), being the iliac site (Xenos et al, 2010).  
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Fig. 4. The iliac bifurcation is generally assumed to be a site less susceptible to rupture. In 
the early stages of AAA enlargement, accumulation of high stress values in this area by 
certain geometrical adaptations can be considered as an adaptation response, in order to 
reduce stress in other wall areas. 
5. Association of mechanical stress and biomarkers 
Mechanical and biological factors have been implicated in the growth rate of the small 
AAAs, apart from the aforementioned clinical factors. Increased levels of Metalloproteinase-
2 (MMP-2) have been implicated in the degradation of elastine in the small AAAs wall, 
leading to their generation and expansion, whereas the increased expression of MMP-9 
leads to accelerated expansion of the larger AAAs and rupture (Choke et al, 2005).  
AAA wall degeneration or alteration of integral properties induced by biochemical factors 
such as metalloproteinases (MMPs) and mechanical loading constitute a field to focus on, 
since there has been growing evidence of pathogenic correlation between these factors. The 
mechanical loading of the AAA wall, as expressed by PWS, has been implicated in the 
expansion of small AAAs, since a relative low wall stress was associated with a lower 
aneurysm rate, as reported by Speelman et al (Speelman et al, 2010a). The ratio of wall stress 
to  the  maximum  diameter  of  the  AAA  has  been  postulated  to  be  a  valuable  index for 
predicting AAA growth. Interestingly, the latter study reconfirmed also the positive relation 
of MMP-9 to increased growth rate, despite the fact that no correlation between MMP-9 and 
wall stress was found, implying that AAAs in patients with high wall stress/max Diameter 
values may undergo more rapid growth and wall damage than those with low wall 
stress/max Diameter values. AAA growth is most likely a multifactorial phenomenon, 
possibly combining biological and mechanical effects, as well as dynamic flow effects 
through the AAA (Khanafer et al, 2007).   
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Rahman et al studied the levels of MMPs in areas of low and high wall stress values in the 
AAA wall (Rahman et al, 2011). Finite Element Analysis was used to estimate the values and 
distribution areas of low and peak wall stress (PWS) on the wall of AAAs before surgery. 
These areas were accordingly mapped out and excised intraoperatively, providing tissue 
samples for MMPs analysis. Elevated levels of MMP levels were detected at areas of PWS 
compared to areas of low stress, despite that fact that no statistical significance was reached 
(possibly attributed to type 2 statistical error). Moreover, small AAAs with rapid growth 
rate can be differentiated from small ones of slower growth rate by the high values of wall 
stress at the area of inflection between the neck and the AAA sac (Li, 2010a and Li et al, 
2010b). Localized geometric abnormalities correlate with high PWS values (Sacks et al, 1999) 
which can induce an increased inflammatory reaction (Xu et al, 2010) and overexpression of 
MMPs, thus attenuating the structural integrity of the sac wall. The abovementioned 
findings underscore the importance of interconnection between biomechanical factors and 
bioengineering tools for the study, identification and prediction of small AAAs prone to 
rapid growth and/or rupture.  
6. Mechanical properties of the wall 
The computational estimation of PWS with Finite Element Analysis models relies strongly 
on the material properties data input into these models. In most studies the AAA wall has 
been assumed to be hyperelastic, incompressible and isotropic material (Georgakarakos et 
al, 2011a). The values of these parameters represent mean data derived from large-scale 
population tissue mechanical studies. However, there is increasing evidence of the 
anisotropic properties of the AAA wall, ie the preferential stiffness of the wall in one plane 
compared to the other, as a result of heterogeneous mechanical behavior of the structural 
substrate, depended on the orientation of the collagen fibers (Rissland et al, 2009 and 
Rodríguez et al, 2008, 2009). Whether the adaptation of the anisotropic wall properties in the 
computational models yields statistically significant difference in the evaluation of the PWS 
values and distribution, thus affecting the rupture risk computation, remains to be 
delineated in large-scale studies.     
Moreover, rupture risk estimates or expansion-rate predictions should be obtained in a 
patient-specific basis, since mechanical parameters in AAAs such as segmental dilation and 
compliance, stiffness and pressure strain elastic modulus vary among AAAs from different 
patients and variable maximum diameters (Long et al, 2004, 2005; Wilson et al, 2003). AAA 
rupture is associated with aortic wall weakening as a result of discordant repair / 
remodeling mechanisms, mirrored by an increase in thickness and a decrease in stiffness, 
correlated with decreased strength (Di Martino et al, 2006). Since different AAA of the same 
maximum diameter can have different strength levels, it seems that noninvasive techniques 
to estimate mechanical properties of the AAA wall would be a helpful adjunct for prediction 
of AAA rupture risk. 
Strength is calculated from a mathematical type which takes into account the square root of 
the ILT thickness, the presence of positive family history, the gender, smoking status and 
age of the patient and the normalized diameter (Vande Geest et al, 2006a), strength = 71.9 – 
37.9 (ILT1/2 – 0.81) – 15.6 (NORD – 2.46) – 21.3 HIST + 19.3 SEX, where ILT is the local 
attached ILT thickness in cm; NORD is the local diameter normalized to the diameter of the 
non-aneurysmal aorta (infrarenal) estimated form the patient’s age and sex (Raghavan et al, 
2000); HIST is the family history (1/2 with history, -1/2 without history); and SEX is 
patient’s gender (1/2 male, -1/2 female).     
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Since the wall strength presents a spatial distribution along the AAA wall, an accurate method 
to estimate rupture-risk on a patient-specific model should take into account not only PWS, 
but also the local wall strength variation (Vorp et al, 2005). The Rupture Potential Index (RPI) 
estimates the ratio of local PWS to local wall strength, RPI = Local wall stress (N/cm2) / Local 
wall strength (N/cm2). The importance of simultaneous incorporation of the wall strength in 
the rupture risk prediction is underscored in a recent retrospective study, where the rupture 
risk indices between 15 men and 15 women were compared. Taken into account the reported 
higher rupture risk for women, it was interesting to note that though PWS values did not 
differ between the 2 groups, the difference in peak wall rupture risk between the groups 
almost approached statistical significance (P = .06), suggesting also that differences in 
biomechanical properties could contribute to the higher rupture risk reported for women.     
Small patient series have provided promising results regarding the utility of RPI in the 
prediction of rupture as well as the detection of the rupture site (Xenos et al, 2010b). Larger-
scale prospective clinical trials are needed for validation of RPI as a predictive tool for 
rupture, before this tool can be sufficiently incorporated into routine clinical practice. 
7. The intraluminal thrombus 
ILT is generated by activated platelets that aggregate toward the AAA wall. For the 
generation of ILT the following seem to be essential a) a proximal recirculating zone, with b) 
high values of wall shear stress (WSS), so that the platelets can sustain the WSS long 
enough, to get activated and aggregate (Biasetti et al, 2010). The aggregation sites are 
preferably located in areas of low WSS. The frequently observed asymmetric ILT 
distribution (Figure 5A) can be attributed to the asymmetry and complexity of the flow in 
asymmetric AAAs (Figure 5B), (Ekaterinaris et al, 2006 and Bluestein et al, 2009).  
 
 
Fig. 5. A) Aneurysm sac with asymmetric distribution of intraluminal thrombus (eccentric, 
anterior). B) Complex flow ribbons in the AAA lumen. The inferiorly-anteriorly located 
thrombus causes narrowing of the lower sac, which in turn, induces the complex flow 
pattern above.  
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Fig. 5. A) Aneurysm sac with asymmetric distribution of intraluminal thrombus (eccentric, 
anterior). B) Complex flow ribbons in the AAA lumen. The inferiorly-anteriorly located 
thrombus causes narrowing of the lower sac, which in turn, induces the complex flow 
pattern above.  
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The integration of intraluminal thrombus (ILT) on the FEA models plays a crucial role in the 
estimation of wall stress values and stress distribution (Georgakarakos et al, 2009 and Wang 
et al, 2002). ILT consists of 3 layers (abluminal, medial and luminal) with marked differences 
in mechanical properties and structure (Figure 6A). The luminal layer (Figure 6B) consists of 
a network of fibrin fibers, with Young’s modulus values 54 and 57 N/cm2 in the 
longitudinal and circumferential directions, respectively (van 't Veer et al, 2008). The medial 
layer shows some degree of degeneration of the fibrin fibers and presents a 33 and 27 N/cm2 
in the longitudinal and circumferential directions, respectively (Wang et al, 2001). Finally, 
the abluminal layers appear too degenerated (Figure 6C) to be tested on vitro for 
determination of the mechanical properties. Vande Geest et al performed planar biaxial 
testing on the luminal layer of ILT and estimated the maximum tangential modulus to be 
23.1 and 20.1 N/cm2 in the longitudinal and circumferential directions, respectively (Vande 
Geest et al, 2006b). Di Marino et al (Di Marino et al, 1998) estimated the range of ILT 
Young’s modulus to be 5-20 N/cm2, whereas Hinnen et al (Hinnen et al, 2007) 1.3-5.9 
N/cm2. 
It is clear that there is a wide variation in the mechanical properties of ILT. The mechanical 
properties of the thrombus vary not only within the ILT volume of a given AAA but also 
between different ILTs (Ashton et al, 2009; van Dam et al, 2008). Consequently, the 
hemodynamic load on the AAA wall can be modified by the variations in local thickness, 
shear modulus and volume of ILT (Speelman et al, 2010b). Moreover, the varying 
mechanical properties of the thrombus account for the large variability in its compressibility 
(Truijers et al, 2009), which could influence its protective role against AAA rupture or sac 
enlargement. Furthermore, fissures in ILT can breach the ILT “cushion” effect, resulting in 
increase in wall stress in the underlying AAA wall (Polzer et al, In Press).  
 
 
Fig. 6. A) The different layers of intraluminal thrombus (ILT), B) The luminal surface of ILT, 
C) The abluminal surface of ILT.  
8. Conclusion 
AAA rupture is a matter of deficient wall strength and increased hemodynamic loading. 
Therefore, reliable rupture risk estimation should take into account both the local 
distribution of wall stress and wall strength. Refinements in computational methods of 
these parameters could lead to identification of high-risk aneurysms, patient-specific risk 
assessment, detailed geometric characterization of AAAs and precise follow-up of 
aneurysm growth. The development of hybrid models that would take into account the 
geometric, biomechanical and biologic factors in a patient-specific basis is awaited with 
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great interest. Furthermore, advances in ultrasound and dynamic MRI imaging are 
expected to provide us with important information regarding the material properties of 
ILT over the cardiac cycle, the spatial variance of compliance, stiffness and distensibility 
of the AAA wall and, finally a detailed mapping of the AAA wall thickness. The 
aforementioned elements are necessary for improvement of accurate, reliable patient-
specific prediction models of rupture risk.  
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hemodynamic load on the AAA wall can be modified by the variations in local thickness, 
shear modulus and volume of ILT (Speelman et al, 2010b). Moreover, the varying 
mechanical properties of the thrombus account for the large variability in its compressibility 
(Truijers et al, 2009), which could influence its protective role against AAA rupture or sac 
enlargement. Furthermore, fissures in ILT can breach the ILT “cushion” effect, resulting in 
increase in wall stress in the underlying AAA wall (Polzer et al, In Press).  
 
 
Fig. 6. A) The different layers of intraluminal thrombus (ILT), B) The luminal surface of ILT, 
C) The abluminal surface of ILT.  
8. Conclusion 
AAA rupture is a matter of deficient wall strength and increased hemodynamic loading. 
Therefore, reliable rupture risk estimation should take into account both the local 
distribution of wall stress and wall strength. Refinements in computational methods of 
these parameters could lead to identification of high-risk aneurysms, patient-specific risk 
assessment, detailed geometric characterization of AAAs and precise follow-up of 
aneurysm growth. The development of hybrid models that would take into account the 
geometric, biomechanical and biologic factors in a patient-specific basis is awaited with 
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great interest. Furthermore, advances in ultrasound and dynamic MRI imaging are 
expected to provide us with important information regarding the material properties of 
ILT over the cardiac cycle, the spatial variance of compliance, stiffness and distensibility 
of the AAA wall and, finally a detailed mapping of the AAA wall thickness. The 
aforementioned elements are necessary for improvement of accurate, reliable patient-
specific prediction models of rupture risk.  
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1. Introduction 
The current standard for determination of AAA disease progression is external aneurysm 
diameter measurement (Vainas et al., 2003), where the diameter enlargement is an indirect 
cumulative indicator of disease progression. 
Generally, the maximum diameter and expansion rate of the AAAs, obtained from 
ultrasound or CT scans is used to assess the risk of rupture. Surgical treatment is 
recommended when the maximum diameter of AAA measures 55 mm or above (Katz & 
Cronenwett, 1994; Lederle et al., 2002). 
The untreated AAAs, tend to grow and may rupture or dissect upon reaching a diameter of 
6–7 cm (Katz & Cronenwett, 1994). At this stage, it is likely that the arterial wall will no 
longer withstand the blood pressure, and surgical intervention is usually recommended for 
aneurysms 0.5 cm below than the critical diameter (Lederle et al., 2002). 
Various past numerical and experimental studies were conducted to investigate blood flow 
patterns in the AAAs. Disturbance in blood flow influence physiological parameters and 
processes, pressure, wall shear stress (WSS), wall remodelling and inflammation (Fillinger et 
al., 2003). 
In this work we describe the complexity of the blood flow using a time dependent analisys, 
to determine the effects of aneurysm asymmetry, wall shear stress distribution and vortex 
dynamics inside the aneurysm. 
2. Patient and methods 
The study subject was male (62 year old), and the AAA maximum transverse diameter was 
6.4 cm. The total length of the AAA was 11.6 cm. Patient-specific computed tomography 
(CT) scans were obtained, in order to investigate the AAAs’ wall shear stress. 
2.1 Anatomical model reconstruction 
To produce a realistic three-dimensional model of a patient anatomy, spiral CT (Somatom 
Sensation 64 Scanner - Siemens Medical Systems, Erlangen, Germany) data was then used to 
reconstruct the infrarenal section of the aorta. The selected patient had an anterior-posterior 
asymmetric aneurysm in the infrarenal aorta with a maximum diameter of approximately 
6.4 cm (Figure 1). Digital files in Digital Imaging and Communications in Medicine 
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(DICOM) file format, containing cross-sectional information were then imported to CFD 
software package for reconstruction. 
 
 
Fig. 1. CT scan and 3D reconstruction of the investigated section of the abdominal aorta. 
Axial cross-section CT slices are used for the three-dimensional reconstructions (A). 3D 
reconstruction of examined AAA (B). Anterior-posterior asymmetric AAA model result 
from the CT-scan. 
The reconstructed aneurysm model is shown in Figure 2. The asymmetry parameter β 
(Figure 3) is defined as the ratio of the maximum posterior and anterior wall dimensions 
(Kleinstreuer & Vorp, 2006). Asymmetry parameter for the investigated patient are  
β =0.37. 
The corresponding finite-element computational domain is composed of 574,280 hexahedral 
linear elements, for a total of 596,181 nodes. The software Gambit v2.4 (Ansys Fluent, Ansys 
Inc., 2006) was used for the mesh generation (Figure 4). 
A fine resolution near the wall, with the height of the wall boundary cells (y+ < 2) and a 
minimum of at least 7 grid nodes inside the boundary layer was ensured for the geometry 
owing to the requirements of the numerical model. 
Mesh independence study we performed in order to determine the optimum number of 
mesh elements. The optimum mesh size was determined once the peak wall shear stress 
does not increase by more than 2%. 
2.2 Boundary conditions 
At the inlet, a spatial velocity profile was imposed (Figure 5). These waveforms are triphasic 
pulses appropriate for normal hemodynamics conditions in the infrarenal segment of the 
human abdominal aorta first reported by Mills (Mills et al., 1970). The use of an input 
transient velocity based on normal physiology is justified by the fact that the inlet boundary 
condition is applied in the section of undilated segment of the abdominal aorta anterior the 
proximal neck of the aneurysm (Finol et al., 2003). 
 




Fig. 2. Computational domain for asymmetry parameter β =0.37. Geometrical parameters 
used for AAA rupture risk evaluation. 
In order to prevent overestimating the wall shear stress, a zero pressure state AAA has been 
used in present numerical simulations (Marra et al., 2005). No slip condition was applied at 
the fluid-wall interface. The cardiac cycle period was 1 s, with peak systolic flow occurring 
at 0.302s, and peak diastolic flow at 0.7s (Figure 5b). The length of the systolic and diastolic 
periods were 0.32s and 0.68s respectively. Blood was treated as a incompressible Newtonian 
fluid, an acceptable assumption for large arteries (Perktold et al., 1991). 
Hemodynamic parameters are considered to be responsible for aneurysm initiation and 
growth. In majority of the computational studies, non Newtonian viscosity of blood, wall 
elasticity, blood particle composition and temperature effects are neglected, due to their 
secondary importance. The hemodynamic factors play a vital role in regulating the structure 
and functions of the endothelial layer. 
We considered the dynamic viscosity of 0.004 Pas and density of 1050 kg/m3 for the blood 
(Table 1). The shear stress induced by blood flow was neglected in this study (Raghavan et 
al., 2000; Raghavan & Vorp, 2000; Thubricar et al., 2001), although the effects of blood flow 
have been shown to reduce wall stress by 10% in uniformly thick walled ideal models and 
by up to 30% in variable wall thickness models (Scotti et al., 2005). 
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Fig. 3. Artery neck projected onto the plane of maximum aneurysm cross section. 
 
Fig. 4. Computational model for the patient specific reconstructed AAA. Intraluminal fluid 
mesh. Boundary layer contained 7 grid modes. 
Incompressible, Newtonian flow is simulated for average resting conditions at a heart rate 
of 65 bpm. The governing equations are solved with the software Ansys FLUENT v6.3 
(Ansys Inc.), which uses the finite volume method (FVM) for the spatial discretization. The 
workstations used to perform the simulations in this work is TYANPSC 600 (Tyan 
Computer Corporation) personal supercomputer with Intel® Xeon™ 5100 Dual Core, 40.0 
GB RAM memory, and running on Windows® Compute Cluster Server 2003 operating 
system. The run time for a single simulation (on 8 processors) based on 3 consecutive 
pulsatile flow cycles was approximately 5 days real time. 
 








Fig. 5. Pulsatile velocity waveform reproduced from Scotti (Scotti et al., 2005).  Enlarged 
view of the first three cardiac cycle (a). Peak systolic flow occurs at t=0.302 s and diastolic 
phase begins at t=0.52 s (b). In figure (b), we have: a - systolic acceleration, b - systolic 
deceleration, c - early diastole, d - late diastole. 
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Parameters Normal arterya Aneurysmb Current simulation 
Wall thickness 1.5 mm 0.5-2.0 mm 1.5 mm 
Inner diameter 20 mm 40-80 mm 30-64 mm 
Length Inlet: 200 mmOutlet: 60 mm 80 mm 116 mm 











Lβ ≡ ≡  
(See Figure 4) 
aReference (Raghavan & Vorp, 2000), 
bReference (Di Martino et al., 2001). 
Table 1. Parameters used in the numerical simulation 
3. Results 
Based on the AAA pulsatile flow (Figure 5b), the following four flow phases summarize the 
aneurysm’s size and the asymmetry parameter both dependent of the flow dynamics (Finol 
et al., 2003): 
1. Systolic acceleration involves downstream ejection of the residual vortices. 
2. Systolic deceleration is characterized by flow separation in the proximal neck.  
3. Early diastole is characterized by reduced in size of flow recirculation.  
4. Late diastole is characterized by recirculation regions present downstream of the 
aneurysm midsection. 
3.1 Velocity profiles 
Aneurysm sac diameter, aspect ratio, aneurysm shape and parent artery diameter are the 
parametric factors known to influence the nature of blood flow within an aneurysm. In CFD 
as well as in experimental studies, the researchers studied intra aneurismal flow as a 
function of these geometric parameters. For example, the neck size decide the amount of 
flow entering in the aneurysm sac and the volume of the aneurysm deciding on how 
sluggish the flow in the aneurysm sac. 
The investigated AAAs demonstrates complex flow patterns over the cardiac cycle. The 
effect of aneurysm asymmetry in pulsatile flow dynamics is depicted in Figures 6, 7 and 8. 
At peak flow t=0.3s (Figure 6a), a characteristic attached flow pattern is obtained throughout 
the aneurysm with nearly stagnant flow, present along the anterior wall where the diameter 
is the greatest (cross-section B-B). During systolic deceleration, flow separation occurs and 
the vortex begins to travel in the aneurysm sac. 
The complex flow pattern was observed at t=0.7s near the exit of the proximal neck of the 
aneurysm, where the flow is intensified and recirculation zones are present (Figure 7b). This 
stage is depicted with significant and asymmetric flow recirculation near the aneurysm 
proximal neck (Figure 7b, cross-section A-A). 
In Figure 7, we see an internal jet of fluid surrounded by a recirculating vortex. At the end of 
the systolic deceleration phase, a small recirculating vortex develops at the end of the 
proximal neck. During systolic deceleration and early diastole a large recirculating flow 
region fills the aneurysm sac. 
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Figures 6 and 7 illustrates secondary velocity vectors in the cross section of the aneurysm. At 
the time t=0.3s near the proximal neck of the aneurysm exhibits no significant secondary 
flow, but one large secondary vortice is obtained along the proximal neck of the aneurysm 
at the time t=0.7 s (Figure 7b).  
We can see in Figures 6, 7 and 8 the flow in investigated AAA presents two regimes. The 
first regime with no vortex formation is presented in Figures 6 and 8a, and the second 
regime is with vortical structures (Figures 7 and 8b). These flow regimes, depend on the 
different phases of the cardiac cycle and on the aspect ratio of the aneurysm. 
 
 
Fig. 6. Velocity field at the time t=0.3s, peak systole in the AAA. a) longitudinal section, 
velocity magnitude contour plot; b) velocity vector plot in cross-section; A-A in proximal 
neck and B-B in the maximum diameter region 
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The flow in the aneurysm decelerates and becomes unstable. This leads to flow separation, 
recirculation and possible transition to turbulence (Khanafer et al., 2007). Turbulence is 
induced by sudden expansion of the flow in the proximal neck (Figure 8b). This flow 
expansion generates recirculation region which produce additional wall shear stresses, 
increasing the rate of wall dilation (Khanafer et al., 2007). 
 
 
Fig. 7. Velocity magnitude b) Cross-section velocity vectors in proximal neck and maximum 
diameter region at the time t=0.7 s of the cardiac cycle. Vortical flow through the proximal 
neck. 
3.2 Wall shear stress analysis 
Throughout the cardiac cycle the wall shear stress distribution corresponds to the velocity 
gradients. Fluid shear stress is defined as a measure of the tangential forces per unit area 
generated by the flow stream on the walls of the AAA. 
 




Fig. 8. a) 3D flow patern in the investigated AAA. b) Strong recirculation is present in the 
proximal neck and in the end of the distal neck. Helical flow is show inside to the aneurysm 
sac. 
Along the maximum transversal diameter of the aneurysm, a slow recirculating flow exists, 
where the WSS is low. This flow pattern increase the residence time of blood along the 
aneurysm sac resulting in enhanced mass transfer.  
  
Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture  
 
198 
The flow in the aneurysm decelerates and becomes unstable. This leads to flow separation, 
recirculation and possible transition to turbulence (Khanafer et al., 2007). Turbulence is 
induced by sudden expansion of the flow in the proximal neck (Figure 8b). This flow 
expansion generates recirculation region which produce additional wall shear stresses, 
increasing the rate of wall dilation (Khanafer et al., 2007). 
 
 
Fig. 7. Velocity magnitude b) Cross-section velocity vectors in proximal neck and maximum 
diameter region at the time t=0.7 s of the cardiac cycle. Vortical flow through the proximal 
neck. 
3.2 Wall shear stress analysis 
Throughout the cardiac cycle the wall shear stress distribution corresponds to the velocity 
gradients. Fluid shear stress is defined as a measure of the tangential forces per unit area 
generated by the flow stream on the walls of the AAA. 
 




Fig. 8. a) 3D flow patern in the investigated AAA. b) Strong recirculation is present in the 
proximal neck and in the end of the distal neck. Helical flow is show inside to the aneurysm 
sac. 
Along the maximum transversal diameter of the aneurysm, a slow recirculating flow exists, 
where the WSS is low. This flow pattern increase the residence time of blood along the 
aneurysm sac resulting in enhanced mass transfer.  
  
Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture  
 
200 
Low wall shear stress in the range of ± 0.4 Pa plays a vital role in degenerating the 
endothelial layer, and resulting in an inflammatory cell response by initiating vascular wall 
remodeling (Malek 1999). We can see in Figure 9, that the WSS less than 0.4 Pa covered a 
wide area of the aneurysm body. 
High WSS occurres in the proximal aneurysm neck, and low WSS in regions of flow 
separation (Figures 9 and 7). Sudden changes in cross-sectional area or in curvature cause 
local increment and adverse pressure gradient which creates low WSS in the aneurysm body 
(Figure 9). Regions of high WSS are likely to lead to matrix degradation by expression of 
plasmin, matrix-metalloproteinases and smooth muscle cells apoptosis (Ekaterinas et al., 
2006). This may cause degenerative lesions of aneurysmal wall, altering the wall thickness 
and eventually causing rupture (Tan et al., 2008). 
4. Discussion 
Previous numerical studies in the literature, pointed that the flow in an aneurysm is 
complex with presence of vortices, secondary flows and strong amplification of instability 
(Venkatasubramaniam et al., 2004). 
The velocity profiles showed highly disturbed flow and recirculation within the  aneurysm 
sac. At the end of systole, the flow is a combination of rotational and recirculated secondary 
flows (Figures 7 and 8). Cross-sectional velocity profiles showed disturbed flow and 
recirculation in proximal neck region and in the aneurysm sac (Figure 7b). 
During diastole the flow became instable and recirculation occurred almost everywhere in 
the aneurysm sac (Figure 8b). The flow patterns observed here, are characterized by helical 
flow and large recirculation zone. Same results found in literature for the blood flow in 
presence of the aneurysm (Tan et al., 2008; Boutsianis et al., 2009). 
Disturbed flow induced by sudden expansion of the flow stream, results in additional stresses 
acting on the aneurysm wall that may be responsible for further aortic dilation. Dilation results 
in further radial expansion of the flow stream and in intensified turbulence. The latter then 
becomes a self-perpetuating mechanism for aneurysm dilation (Doyle et al., 2007).  
Recirculation presented by the vector plot in aneurysm sac, suggested that certain disturbed 
flow conditions may cause injury to endothelium and induce stimuli for inflammation or 
degradation. 
Consequently, complex flow pattern, by increasing wall tension may induce dilation of an 
aneurysm. Cyclic turbulent stresses are known to alter the structure and integrity of the 
arterial wall. Large eddies induce vibrations at frequencies which cause the dilation of 
arteries (Khanafer et al., 2007). 
Due to the highly three-dimensional nature of blood flow in the abdominal aneurysm, it can 
be a difficult task to keep track of the paths of fluid particles within the flow field.  
An effective way to investigate these fluid motions is to numerically inject a passive or non-
interactive tracer into the flow, and we have carried out such an investigation in the present 
work. We have introduced a tracer, which serves as a visualization tool to analyze the flow 
characteristics. Figure 10 presents the tracer distribution inside to the aneurysm’s body. 
Further, in a large recirculating flow region the particles residence time is large and could be 
a contributing factor for thrombosis in the aneurysm.  
The obtained results for WSS are in agreement with published data from the investigations 
considering the physiological aorta (Doyle et al., 2007) as well as with data from patient-
specific fluid-solid interaction simulations (Leung et al., 2006).  
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Pressure contours at the peak systole (time t=0.3s) and peak diastole (t=0.7s) are  
presented in Figure 9. Pressure gradient generally decreases in the flow direction. Highest 
pressure of about 15.4 kPa (115.5 mmHg)  at the time t=0.3s is found in the exit region of 
the AAA.  
Therefore the highest pressure difference between inlet and outlet is about 1.3kPa (9.75 
mmHg) at the time t=0.3s and about 0.6 kPa (4.5 mmHg) at the time t=0.7s . In diastolic flow, 
the inlet velocity begins to decelerate, reducing the overall pressure gradient.  
As the cardiac cycle continues, pressure drop is expected to decrease and recirculation 
regions dominate of the aneurysm sac (Cheng et al., 2010). 
4.1 Wall shear stress analysis 
The blood flow dynamics in aneurysm models is governed by the compliance of the vessel. 
The velocity vectors illustrate a streamlined profile absent of vortices, a flow path 
customarily associated with a condition of systolic acceleration (Figure 8a).  
The vortices are developed in the proximal neck and are dissipated in the aneurysm (Figure 
8b). Vortex growth inside the AAA sac creates favorable conditions for increased platelet 
deposition rates and an increased risk of rupture (Thubrikar et al., 2003).  
Geometry has been well established as a contributing factor to aneurysm expansion  
and rupture potential, independently of the heterogenity of the wall (Di Martino et al., 
2001). 
Significant gradients occur at the inflection points of the aneurysm curvature. For the 
investigated aneurysm, the changes in curvature lead to higher displacements and increased 
wall shear stress, suggestive for the effect of flow through the gradual expansions and 
contractions of the geometry (Figures 7 and 8).   
Figures 7 and 9 present the area prone to vascular remodeling increases with decrease the 
blood velocity. In this case the flow along the aneurysm body is sluggish and the WSS along 
the maximum transversal diameter of the aneurysm drops, increasing the risk of leukocyte 
adhesion.  
4.2 Study limitation 
The study presented here is not without limitations. Firstly, it is known that calcifications 
occur in almost all AAAs. Intraluminal trombus - ILT and calcification were not included in 
the present study. 
Another important limitation of the present study is the assumed uniform wall thickness. It 
has been shown that ILT can reduce the strain and the rate of dilation by up to 15% 
(Thubrikar et al., 2003). 
The major assumptions used in the present study include the rigid wall approximation. 
These assumptions represent a reasonable first approximation for the blood flow in the 
abdominal aorta.  
5. Conclusion 
Based on a recent article describing how the aneurysm can induce a considerable increase in 
wall shear stress during flow systole in the region of aneurysm sac, we have used the CFD 
technique to investigate the relation between the blood hemodynamics and WSS during the 
cardiac cycle. 
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Fig. 9. Pressure and wall shear stress magnitude distributions on the anterior side of the 
aortic wall for different stages of the cardiac cycle: a) peak systole t=0.3 s and b) peak 
diastole t=0.7 s. 
 





Fig. 10. Particles’ motion inside the aneurysm colored by velocity magnitude at the different 
moment of the cardiac cycle: a) t=0.3 s and b) t=0.7 s. In order to compare the blood velocity 
in the different moment of the cardiac cycle, both velocity fields are represented for the 
same velocity range. 
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Fig. 10. Particles’ motion inside the aneurysm colored by velocity magnitude at the different 
moment of the cardiac cycle: a) t=0.3 s and b) t=0.7 s. In order to compare the blood velocity 
in the different moment of the cardiac cycle, both velocity fields are represented for the 
same velocity range. 
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The virtual AAA models presented in this work provide a fundamental baseline for 
application of the CFD methodology as a non-invasive tool for rupture risk prediction in 
individual patients, outlining the importance of aneurysm asymmetry. This approach takes 
into account blood flow dynamics, which is inherently transient, and its effect on the wall 
mechanics. The present study demonstrates the relationship between the fluid velocity field 
and the flow-induced wall stresses. During the cardiac cycle, the instantaneous fluid forces 
acting on the inner wall will deform and expand the artery. From this study result that a 
complete understanding of the variation of intra aneurysmal hemodynamics with variations 
in the cardiac cycle is a critical tool for physician. 
The fluid dynamics in a asymmetric aneurysm model is characterized by the development 
of vortices during the systolic deceleration phases. The distortion energy stored in the vessel 
as it expands during the cardiac cycle contributes to the early formation of recirculation 
regions in the aneurysm. This yields high velocity gradients at the distal end of the 
aneurysm. These flow patterns, in combination with the geometrical features of the model, 
determine the distribution of flow-induced wall stresses. 
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1. Introduction  
The aorta, acting as the main conduit through which cardiac output is delivered to the 
systemic arterial bed, is continuously exposed to high pulsatile pressure and shear stress, 
making it prone to mechanical injury. It is also more prone to rupture than other vessels, 
particularly with the development of aneurysmal dilation. Fifty percent of patients who 
experience a rupture of a aortic aneurysm die before reaching the hospital (Bengtsson & 
Bergqvist, 1993). The incidence increases with age and has been reported as 6 per 100,000 
person-years (Knowles & Kneeshaw, 2004). Aneurysmal degeneration that occurs in the 
aortic arch is termed a aortic arch aneurysm. Patients who have aortic arch aneurysm have 
multiple aortic lesions or aneurysmal disease which involves segment of aorta (Crawford et 
al., 1984). Aortic arch aneurysms represent only 10% of aneurysms of the thoracic aorta and 
it has higher risk of rupture than other aneurysm (Knowles & Kneeshaw, 2004).  
Blood flow through the aorta is one of the most complex flow situations found in the 
cardiovascular system. Blood flow is pulsatile and pressure inside aortic aneurysm is non-
uniform. The dynamics interaction between blood flow and wall may influence the wall 
stress. Computer modeling has made impressive progress in scientific, engineering, 
biological and medical applications in recent years and it offers the prospect of providing 
both a better insight into a range of biomechanical problems and improved tools for the 
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2001; Gao et al., 2006abc) have been used to simulate the biomechanical problems in arotic 
arch and aortic arch aneurysm.  The aim of this chapter is to describe the numerical 
simulation and computer modeling work in aortic arch aneurysm.  
2. Aorta, aortic arch and structure of aortic wall 
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ascending aorta, the aortic arch, and the descending aorta. Ascending aorta extends upward 
from the aortic root to the point where the innominate artery branches off the aorta, and the 
aorta begins to form an arch. Aortic arch represents the curved portion at the top of the 
aorta. Descending aorta begins just beyond the arch as the aorta bends down into the body. 
It carries and distributes oxygen rich blood to all arteries. 
 
 
Fig. 1. Aorta in the human body. It arises from the left ventricle of the heart, forms an arch, 
and then extends down to the abdomen. 
The aorta is distinguished by their great elasticity. This helps them smooth out the large 
fluctuations in blood pressure created by the heartbeat. In order to understand the 
properties of aorta, the three types of arteries should first be mentioned. These are elastic 
arteries, medium muscular arteries, small arteries and arterioles. For aorta, large arteries and 
small arteries, the typical radius, typical length, and typical numbers are shown in Table 1.  
 
 
Table 1. The typical radius, length, and numbers for aorta, large arteries and small arteries. 
Elastic arteries experience the greatest pressures and are closest to the heart. The aorta is the 
largest elastic artery that delivers blood from the left ventricle of the heart to the rest of the 
body. Aorta is described as arteries that contain more elastin than smooth muscle content in 
the media. The elastin is necessary to allow the vessel to expand and recoil during pulsatile 
flow (Benjamin Cummings, 1996). The current investigation will work with the elastic 
artery, such as the aorta (throracic and abdominal) and carotid arteries (Yamada, 1970). The 
innermost layer is the tunica intima. The middle layer is the tunica media and the outermost 
layer is the tunica adventitia. 
 
Numerical Simulation in Aortic Arch Aneurysm 
 
209 
In general, the overall mechanical properties of the arterial wall are determined by how 
different compositions of collagen, elastin and protein are linked. The general rule is that 
when the elastin ratio is higher than the collagen ratio, the elastic modulus decreases and 
distensibility increases and vice versa (Doublin & Rovick, 1969). The Young's modulus of 
three layers of the aorta wall is different. Xie et al. (1995) did the bending experiments of 
blood vessel wall and found that the Young's modulus of the inner layer (intima and media) 
was three to four times larger than that of the outer layer (adventitia). The elastic modulus 
of arterial wall became a little higher after de-endothelization in Fischer's experiments 
(Fischer et al., 2002) and this means the elasticity of intima is lower than the mean elasticity 
of vessel wall since the intima layer mainly consists of endothelial cells. 
3. Computational geometric reconstruction of aortic arch aneurysm 
The geometric modeling is the fundamental part of the aorta modeling analysis. Owing to the 
complex geometry of the aorta, three-dimensional models of aorta and aortic aneurysm are 
considerably important. Advances in imaging are being introduced initially as research tools 
and subsequently as clinical diagnostic tests. The reconstruction of aorta structures involves 
the use of sets of clinical data (MRI or CT) that are processed to extract the vessel morphology. 
3.1 STL format of aortic arch aneurysm model 
Stereo lithography (STL) describes a raw unstructured triangulated surface by unit normal 
and vertices (ordered by the right-hand rule) of the triangles using a threedimensional 
Cartesian coordinate system. The surface is logically tessellated or broken down into a series 
of small triangles (facets). Each facet is described by a perpendicular direction and three 
points representing the vertices (corners) of the triangle. Point cloud and connectivity matrix 
data written in this format can be imported into a variety of CAD or grid generation 
software. A patient-specific aortic arch aneurysm model in STL format was reconstructed 
from CT medical images (Fig. 3). This model is a surface model in geometry, which cannot 
be used for numerical simulation directly (Fu et al., 2008). Reverse engineering software 
Geomagic and Pro/E were used to process the surface model of STL format to rebuild a 
patient-specific model of aortic arch aneurysm that can be used in numerical simulation. 
 
 
Fig. 3. A patient-specific aortic arch aneurysm model of STL format 
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3.2 Method of aortic arch aneurysm model reconstruction 
3.2.1 Processing STL surface model 
Because the boundaries of the three branches will impact the integration of patch 
arrangement and lead to the failure of creating NURBS (Non-Uniform Rational B-Splines) 
surface, the main purpose of this study is also to find a way to construct the aneurysm 
model, it is necessary to simplify the three branches. 
1. Simplifying surface 
Opening the STL formatted surface model of the aortic arch aneurysm in Geomagic. First, 
cut the three branches using the “section by plane” mode. Then erase red boundaries (the 
boundary line after intersecting) of the incisions using the “sandpaper” and “relax” 
function, thus the simplified surface model is composed of closed areas with only two 
closed boundaries at the ends. 
2. Dividing areas 
To regularly arrange patches, the method of “section by plane” was applied to divide the 
model into several orbicular areas. There are some rules to obey when locating the cutting 
plane: to preserve the changing information of geometry as much as possible; to divide 
more annulus at the place where shapes change sharply; approximately keeping the normal 
vector of the cutting plane and the trend of vessel’s growth in the same direction. 
3. Rectifying arrangement of the patches 
Create triangle patches under the curvature level 0.3 by using “detect curvature” in “detect 
curvature” mode. Delete extra orange boundaries (panel-demarcation line) and rectify 
arrangement of the patches manually to make sure each red boundary with only four 
keypoints. The arrangement of each opposite keypoints must vary with the changed area to 
avoid torsion around the direction of the bloodstream. 
4. Checking and output 
After checking and repairing the arrangement of quadrilateral patches with “repair patches” 
function, NURBS surface fitted with 48 pieces of quadrilateral patches was finally created. 
Then export this NURBS surface model in IGES format. 
3.2.2 Reconstructing solid model 
1. Preprocessing areas 
Open the NURBS surface model in Pro/E. Create planes that are parallel to the former red 
closed boundaries and get intersection lines. Each intersection line is composed of four lines 
connected end to end. 
2. Creating solid part 
Based on the former intersection lines, a solid model was created by blended drawing. 
3. Reconstructing three branches 
Because the shape near the three branches is very complicated and irregular, precise 
measurement is difficult in CAD software. Considering some small differences are not 
important and have little influence on the following works, therefore, it is viable to make 
some hypotheses and simplifications for convenient rebuilding of branches. Branches and 
aortic arch were connected with round chamfer; cross sections were simplified as circle or 
ellipse; and the centers were located through eyeballing. Based on these simplifications, 
three branches were reconstructed using software Pro/E. 
4. Creating boundary layer 
The thickness of the boundary layer is related with the velocity, factor of friction, location, 
shape, etc. Even at the same place, the thickness of the boundary layer may be different at 
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different times. To gradually obtain finer grids in the boundary layer in the following 
meshing procedure, a solid shell was primarily constructed to approximately imitate the 
boundary layer. Because the thickness of the boundary layer is extremely thin and 
uncertain, an assumed layer thickness not less than 10% of the maximal diameter is 
sufficient for the boundary layer and easy to construct. Create circle and ellipse lines in the 
former planes that are parallel to the former red closed boundaries. Place centers near the 
centroid. Choose inner diameter not more than 80% of the maximal distance of the section. 
To avoid the situation where stents cross the boundary layer, properly move some centers 
away from the aneurysm and reduce the inner diameter to about 20%–60% of the maximal 
distance of the section. A shell remained after cutting a hollow by blended drawing (Fig. 4). 
 
 
Fig. 4. Reconstructed solid model of aortic arch aneurysm for numerical simulation 
4. Simulation in aortic arch and aortic arch aneurysm 
4.1 Mathematical modeling on aortic aneurysm 
It was Stephen Hales in his Statistical Essays who considered arterial elasticity and 
postulated its buffering effect on the pulsatile nature of blood flow (Hales, 1733). He likened 
the depulsing effect to the fire engines of his day, in which a chamber with an air-filled 
dome acted to cushion the bolus from the inlet water pump so that “a more nearly equal 
spout” flowed out the nozzle. This analogy became the basis of the first modern 
cardiovascular models. In the translation from English to German, Hales’s inverted globe 
became a windkessel (air kettle); his idea later became known as the Windkessel theory 
when it was more formally developed and propounded by the German physiologist Otto 
Frank near the beginning of our century (Noordergraaf, 1978). 
A short segment of aorta can be modeled by an elastic, isobaric chamber attached to a rigid 
inlet and outlet tube. The ability of the chamber to store fluid depends on its compliance, C, 






where Vc is total segment (chamber) volume and Pc is chamber pressure. Many modelers 
prefer to use the reciprocal of compliance (termed stiffness, S, or elastance, E). Here, 
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where Vc is total segment (chamber) volume and Pc is chamber pressure. Many modelers 
prefer to use the reciprocal of compliance (termed stiffness, S, or elastance, E). Here, 
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viscoelastic (stress relaxation) effects are assumed negligible, so that compliance is not an 
explicit function of time. Thus, compliance becomes an instantaneous variable which can be 
obtained from the experimentally determined, steadystate pressure-volume (P-V) 
relationship of the segment. Furthermore, model order can be reduced, as pressure can be 
mathematically represented as an empirical function of volume, either by a piecewise linear 
approximation, a polynomial quotient, or some other function fit to the P-V relationship. A 
typical P-V curve is illustrated in Fig. 5, along with its piecewise liner approximation. In 
arteries, pressure is usually positive with small oscillations about a nominal operating point 
(point a in Fig. 5). Hence the piecewise linear approximation can be reduced to a single line 








whereVc0 is the unstressed volume (the idealized zero-pressure volume intercept). Of 
course, if pressure fluctuates outside this region, then additional straight-line sections 
should be included. 
 
 
Fig. 5. Pressure-volume relationship of aorta 
Assuming that blood is incompressible and newtonian, that the flow profile is parabolic and 
unchanging with axial distance along a straight rigid tube, then flow (poisenillean) is 
linearly proportional to the pressure gradient across the ends of the tube. Hence, flow into 
and out of the chamber may be calculated given Pin and Pout (the inlet and outlet pressures); 
Pc; Lin and Lout (the inertances due to fluid mass); and Rin and Rout (the resistances due to 
viscous drag)  
 + = −inin in in in c
dfL R f P P
dt
 (3) 
 + = −outout out out c out
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where fin and fout are the flows into and out of the segment. Volume can now be calculated 
from the difference between the inlet and outlet flows: Pc,Vc, fin, and fout can now be uniquely 
determined at any time given Pin,Pout, and the initial conditions of the segment. 
Determination of the parameters L and R are more problematic. They can be derived 
analytically, although probably because the modeling assumptions are not completely 
correct, an empirical fit generally produces better segmental properties. 




The mathematical modeling method has been applied to the cardiovascular system for the 
study of system pathologies (Rideout, 1991; Rupnic & Runvovc, 2002). The aortic aneurysm 
has primarily been probed and the compliance of aortic aneurysms was investigated and the 
effects of the pathology were observed (Long et al., 2004; Morris-Stiff et al., 2005). The 
cardiac pressure-volume loops for aortic aneurysms has been presented by utilizing 
electronic cardiovascular modeling (Abdolrazaghi et al., 2008). The electronic parameters are 
correlated to their mechanical parameters as follows: voltage is analogous to pressure, 
capacitance to compliance, and inductance to inertance. The aortic aneurysm with different 
diameters were applied and left ventricle pressure-volume with aortic aneurysm increased. 
There is significant increase in pressure both in thoracic and abdominal aortic aneurismal 
condition, therefore it can be understood that the hypertension could be principal symptom 
of these disease (Abdolrazaghi et al., 2008). 
4.2 Hemodynamics simulation in aortic arch and aortic aneurysm 
Blood flow through the aorta is one of the most complex flow situations found in the 
cardiovascular system. This is mainly due to the strong curvature effects, irregular 
geometry, tapering and branching. The human aortic arch has a characteristic configuration. 
One of its characteristics is that the centerline of the arch does not lie in a plane. Another is 
that there are major branches at the top of the arch. Kilner et al. (1993) observed a 
characteristic helical blood flow pattern in the human aortic arch using magnetic resonance 
measurements, and showed the qualitative flow structure in the arch. However, it is difficult 
to obtain distribution and transient change in the wall shear stress from measuring clinical 
images. Instead of experimental methods, the detailed flow in human arteries can be studied 
by using computational fluid dynamics methods (Botnar et al., 2000). The highly disturbed 
flow patterns that have been reported in regions of arterial branching and curvature are 
attributable to a large degree to the combined effects of complex arterial geometry and flow 
pulsatility. One vascular site within which the fluid mechanical environment is especially 
complex is the region of the aortic arch and its major branches. The arch is characterized by 
extensive curvature, which would be expected to lead to velocity profile skewness as well as 
to complex secondary flow motion. Furthermore, the three aortic arch branches which 
emerge in different planes are likely to have a large impact on the flow field. 
A few computational studies have been made of steady and unsteady blood flow in the 
human aortic arch (Shahcheraghi et al., 2002; Morris et al., 2005; Tokuda et al., 2008). The 
simulation results demonstrate that the primary flow velocity is skewed towards the inner 
aortic wall in the ascending aorta, but this skewness shifts to the outer wall in the 
descending thoracic aorta. Within the arch branches, the flow velocities were skewed to the 
distal walls with flow reversal along the proximal walls. Extensive secondary flow motion 
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distal walls with flow reversal along the proximal walls. Extensive secondary flow motion 
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was observed in the aorta, and the structure of these secondary flows was influenced 
considerably by the presence of the branches. Within the aorta, wall shear stresses were 
highly dynamic, but were generally high along the outer wall in the vicinity of the branches 
and low along the inner wall, particularly in the descending thoracic aorta. Within the 
branches, the shear stresses were considerably higher along the distal walls than along the 
proximal walls. Wall pressure was low along the inner aortic wall and high around the 
branches and along the outer wall in the ascending thoracic aorta. 
 
 
Fig. 6. Streamline of blood flow at systolic and diastole in aortic arch aneurysm 
For more realistic simulation of patient-specific thoracic aneurysm blood flow, a real vasclar 
model containing ascending aorta, aortic arch and descending thoracic aorta was 
constructed basd on CT images (Qiao et al., 2011). This model also contains the innominat 
artery, left common carotid artery and left subclavian artery. More importantly, there is a 
fusiform aneurysm in the descending thoracic aorta. In arch aneurysm model, the velocity 
vectors illustrate a streamline profile with vortices through the aneurysm. Streamlines in an 
aortic arch aneurysm model at the decreasing phase of systolic and the phase of diastole are 
shown in Fig. 6. There was large vortexes in the descending aortic aneurysm cavity. This 
was the main difference of flow characteristics in the thoracic aorta with aneurysm and 
without aneurysm. In diastolic flow vortex characteristics were more apparent, and there 
were several vortices; especially in the latter half of the diastolic phase, there was a large 
vortex of blood flow in the descending aortic aneurysm. Therefore residence time of blood 
cells and other particles in the cavity of the aneurysm was increased, and the probability 
that these particles were deposited on these positions increased too. Those factors would 
increase the growth of aneurysm. 
4.3 Fluid structure interaction simulation in layered aortic arch and aortic aneurysm 
Although the exactly relationship between the elastic properties of intima layer and that of 
media layer hasn’t been decided, we can deduce from the Fischer’s experiment data (Fischer 
et al., 2002)that the Young’s modulus of intima layer is smaller than that of media layer. In 
this present study, the Young’s modulus of intima layer is assumed three times larger than 
that of media layer, as same as the adventitia layer: 
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 ami EEE 33 ==  (6) 
where iE , mE and aE  are the Young’s modulus of intima layer, media layer and adventitia 
layer, respectively. The mean Young’s modulus of vessel wall is same, based on the 
assumption that the Young’s modulus of layer is in inverse proportion to the volume of 
layer, so: 
 VEVEVEVE aammii ⋅=⋅+⋅+⋅  (7) 
where Vi, Vm, Va, and V are the volume of intima layer, media layer and adventita layer, 
respectively. Using the volume equation, Equation 6 becomes: 
 tEtEtEtE aammii ⋅=⋅+⋅+⋅  (8) 




Fig. 7. Three-layered aortic arch model and aneurysm model 
In cardiovascular biomechanics one of the major topics today is the simulation and analysis 
of the fluid-structure interaction of the cardiovascular system using computational methods 
(Taylor, 1999). Di Martino and colleagues (Di Mrrtino et al., 2001) provided the notion of 
interaction between solid and fluid domains as it contributes to aneurysm rupture potential. 
Fluid-structure interaction (FSI) of the domains allows computation of the flow and pressure 
fields in the aneurysm, simultaneously with the wall stresses. 
We performed the fluid structure interaction simulation in three-layered aortic arch model 
(Gao et al., 2006abc). Fig. 7 shows the three-layered aortic arch model and aneurysm model. 
The velocity in the entrance region of the ascending aorta is blunted and skewed towards 
the inner wall of the aortic arch and the values become higher at the side of inner wall. 
Skewing is more marked in mid ascending portion. Downstream of the top arch, however, 
skewing of the velocity reverses, and the location of maximum velocity shifted towards the 
outer wall of aortic arch, which agrees with previous studies (Shahcheraghi et al., 2002). 
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The variations of stresses along the arch were not uniform, due to the arch structure.  The 
circumferential stress gets first peak at the mid ascending portion and second peak at the 
mid descending portion and it would be unpredictable by using Laplace's Law. Hence, the 
shape of the arch and the hemodynamic forces acting on the vessel wall (Liepsch, 2002) may 
play important roles in aorta mechanics. The longitudinal stress gets its peak values at the 
entrance to the ascending portion and the top of the arch and the distal end of the arch. 
 
 
Fig. 8. Comparisons of wall stress distribution in nonaneurysm model and aneurysm model 
for compose stress (circumferential stress+longitudinal stress). 
The FSI simulation was also performed on aortic arch aneurysm model (Gao et al., 2008). 
Fig. 8 shows composite stress (composition of the circumferential stress vector and the 
longitudinal stress vector) in aneurysm model comparing with nonaneurysm model.  The 
wall stresses on aneurysm model were indicated to be complexly distributed with large 
regional variations at inflection points. The wall stresses on nonaneurysm model was 
relatively low and uniformly distributed. The previous study found that the failure strength 
of aneurysm wall was lower than that of nonaneurysm wall (Vorp et al., 1996) and the peak 
wall stress on aneurysm was from 45% to 69% of its failure strength, whereas the peak wall 
stress of nonaneurysm aorta was less than 10% of its failure strength (Raghavan et al., 2000). 
The maximum stresses occur at the proximal and distal ends of aneurysm. This result 
suggests that maximum stresses do not occur at the location of the maximum diameter but 
at the regions of high curvature that are associated with the proximal and distal ends. It 
agrees with previous studies (Raghavan et al., 2000; Di Martino et al., 2001; Vorp et al., 
1998). Most aneurismal ruptures occur at the posterolateral wall, which correlates to the 
areas of high stress concentrations (Raghavan et al., 2000; Vorp et al., 1998). Also the actual 
propensity for rupture for another surface of aneurysm depends on the comparative local 
value of wall strength, since it was found that the strength of tissue near the neck or 
undilated ends of aneurysm are greater than that in the midsection, where diameter is 
maximum. 
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The arterial stiffness was significantly higher in aneurysm wall compared with healthy 
aortic wall (Di Martino et al., 2001; Sonesson et al., 1997). It has been suggested that 
aneurysms develop as a result of an alteration in the connective tissue metabolism and this 
might change arterial wall stiffness (Sonesson et al., 1997). Our results indicated that wall 
stiffness in aneurysms increase maximum stresses in inflection points. So wall stiffness in 
aneurysm might make the stress more increased in aneurysm. Morris et al. (2005) used the 
photoelastic method to simulate the failures at the proximal end and distal end of aneurysm 
model. It was also reported that aortic dissection originated in a distal aortic arch aneurysm 
(Tsukamoto et al., 2003). Arterial stiffness that increased both with age and certain disease 
may increase cardiovascular risk (Blacher et al., 1999). The main structural alterations at the 
site of the large artery media account for arterial stiffening (Benetos, 2003). The aortic wall 
has multi-layered composite structure and stress can not be assumed uniformly distributed 
through the wall thickness. The non-homogeneous stress distribution through wall 
thickness was showed (Fig. 9) and stresses are found to be higher in the media and reach a 
peak value in the media near the adventitia at inflection points and the medial stiffening 
increased the stress in media and peak value. 
 
 
Fig. 9. Comparisons of wall stress distribution across wall for nona neurysm wall, 
unstiffened aneurysm wall, stiffened aneurysm wall. 
4.4 Simulation in stented aortic arch aneurysm 
The traditional treatment requires open surgical repair, which involves an incision and 
exclusion of the diseased aneurysm with a synthetic graft. An alternative treatment is 
endovascular aneurysm repair. Endovascular stent is commonly used to bridge the 
aneurysmal orifice since the first trial of Parodi (Parodi et al., 1995). Endovascular aneurysm 
repair is a minimally invasive technique to treat aneurysms. An endovascular graft is 
guided from the iliac to the affected aortic segment to shield the aneurysm from blood 
pressure, eliminate blood circulation in the aneurysm intrasac, and hence prevent aneurysm 
rupture. 
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Different numerical studies have focused on the hemodynamic changes in aneurysm with 
and without a stent-graft. Despite of the expansive investigation in the endovascular stent 
for aneurysms, studies of hemodynamics simulation of stented aneurysm at the aortic arch 
with a localized outpouching (bleb) on top of the dome, at which point aneurysms 
frequently rupture, are relatively rare. The hemodynamics in fully stented aortic arch 
aneurysms harboring a bleb has been studied on the dome (Fig. 10) (Qiao et al., 2005). The 
flow near the dome of the aneurysm is more sluggish after stenting, and flow activities deep 
within the blebs of the stented aneurysm models are significantly diminished, which agree 
very well with the studies of Aenis et al. (1997), Lieber et al. (2002) and Liou and Liou (2004). 
Stenting reduces the momentum transfer from the parent vessel to the aneurysm, thus 
reducing intra-aneurysmal flow, which produces thrombosis formation and subsequent 
contraction of the dilated aorta. The simulation results showed that the intra-aneurysmal 
flow in the stented aneurysm was significantly attenuated, and the pressure and WSSs were 
decreased. A high pressure zone at the dome of the aneurysm prior to stenting decreases 
after stent implantation, this phenomenon in the simulation also accords with the results of 
Aenis et al. (1997) and Liou and Liou (2004). The magnitude and pulsatility of the WSSs 
along the aneurysmal wall were reduced by stenting, specifically in the bleb region. 
Considering the widely convinced therapeutic mechanism of endovascular stents, we 
believe that the stent-induced sluggish flow activity, low pressure, low WSS and hence 
embolization in the aortic arch aneurysmal sacs can facilitate the occlusion of aneurysms. 
The hemodynamic characteristics allow us to conclude that we can treat aortic arch 
aneurysm with bare wire-mesh endovasucular stents.  
 
 
Fig. 10. Geometric models of the stented aortic arch aneurysm harboring a bleb on its dome. 
The shape of the stent (e.g., helix-versus mesh-shaped stents) (Liou et al., 2004), the size of 
the orifice, the porosity of a stent (Rhee et al., 2002) and the stent filament size (Lieber et al., 
2002; Bando & Berger, 2003) are important factors that influence the treatment effectiveness 
of stented aneurysms. The hemodynamics simulations concerning the optimization of all 
these factors are still open to question. Other prospective approaches, such as stent-graft 
(Chuter et al., 2003) (covered stent, coated by porous polyurethane) (Ruiz et al., 1995), 
coiling (Asakura et al., 2003), and multiple overlapping stents (Doerfler et al., 2004), are 
emerging as therapeutic alternatives to surgery for the treatment of aneurysms, and are 
under way for clinical trial.  
 




The aorta is continuously exposed to high pulsatile pressure and shear stress, making it 
prone to mechanical injury. Aneurysmal degeneration that occurs in the aortic arch is 
termed a aortic arch aneurysm. It has higher risk of rupture than other aneurysm.  
The computational modeling in aortic arch aneurysm was designed, implemented and 
evaluated using a series of technologies-based tools. These tools modeled the biomechanical 
aspects of aortic arch aneurysm. The computational modeling presented in the chapter 
combined imaging data, geometrical reconstruction, hemodynamics, the interaction 
between blood flow and aortic wall, and the effect of endovascular stent. The developed 
modeling will aid research and ensure that medical professionals benefit through the precise 
information about aortic arch aneurysm. It will also improve the accuracy and efficiency of 
the medical procedures.  
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